=== МЕТАДАННЫЕ ===
{
  "original_filename": "ehad192.pdf",
  "converted_date": "2026-01-31T14:47:18.364214",
  "file_size_bytes": 7391880,
  "original_format": "pdf",
  "document_type": "Guidelines",
  "source_folder": "Guidelines",
  "full_path": "00_RAW_CARDIOLOGY/Guidelines/ehad192.pdf"
}

=== СОДЕРЖАНИЕ ===

ESC GUIDELINES
European Heart Journal (2023) 44, 4043–4140

2023 ESC Guidelines for the management of
cardiovascular disease in patients with diabetes
Developed by the task force on the management of cardiovascular
disease in patients with diabetes of the European Society of
Cardiology (ESC)
Authors/Task Force Members: Nikolaus Marx *†, (Chairperson) (Germany),
Massimo Federici *†, (Chairperson) (Italy), Katharina Schütt ‡, (Task Force
Co-ordinator) (Germany), Dirk Müller-Wieland ‡, (Task Force Co-ordinator)
(Germany), Ramzi A. Ajjan (United Kingdom), Manuel J. Antunes (Portugal),
Ruxandra M. Christodorescu (Romania), Carolyn Crawford (United Kingdom),
Emanuele Di Angelantonio (United Kingdom/Italy), Björn Eliasson (Sweden),
Christine Espinola-Klein (Germany), Laurent Fauchier (France), Martin Halle
(Germany), William G. Herrington (United Kingdom),
Alexandra Kautzky-Willer (Austria), Ekaterini Lambrinou (Cyprus),
Maciej Lesiak (Poland), Maddalena Lettino (Italy), Darren K. McGuire
(United States of America), Wilfried Mullens (Belgium), Bianca Rocca (Italy),
Naveed Sattar (United Kingdom), and ESC Scientific Document Group
* Corresponding authors: Nikolaus Marx, Department of Internal Medicine I, Cardiology, RWTH Aachen University, Aachen, Germany. Tel: +49 241 80-89300, E-mail: nmarx@ukaachen.de;
and Massimo Federici, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, and Center for Atherosclerosis, Policlinico Tor Vergata, Rome, Italy. Tel: +39 06
20902085, E-mail: federicm@uniroma2.it
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA),
and Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council on Hypertension.
Working Groups: Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Thrombosis.
Patient Forum
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford
University Press, the publisher of the European Heart Journal, and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time
of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recommendations or
guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the
ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies;
however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from
taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case
in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and
regulations relating to drugs and medical devices at the time of prescription.
© The European Society of Cardiology 2023. All rights reserved. For permissions please e-mail: journals.permissions@oup.com.
Downloaded
from

by
guest
on
22
January
2026

4044 E S C G u id e l in e s
Document Reviewers: Eva Prescott, (Clinical Practice Guidelines Review Co-ordinator) (Denmark),
Francesco Cosentino, (Clinical Practice Guidelines Review Co-ordinator) (Sweden), Magdy Abdelhamid (Egypt),
Victor Aboyans (France), Sotiris Antoniou (United Kingdom), Riccardo Asteggiano (Italy), Iris Baumgartner
(Switzerland), Sergio Buccheri (Sweden), Hector Bueno (Spain), Jelena Čelutkienė (Lithuania), Alaide Chieffo
(Italy), Christina Christersson (Sweden), Andrew Coats (United Kingdom), Bernard Cosyns (Belgium),
Martin Czerny (Germany), Christi Deaton (United Kingdom), Volkmar Falk (Germany), Brian A. Ference (United
Kingdom), Gerasimos Filippatos (Greece), Miles Fisher (United Kingdom), Heikki Huikuri (Finland), Borja Ibanez
(Spain), Tiny Jaarsma (Sweden), Stefan James (Sweden), Kamlesh Khunti (United Kingdom), Lars Køber
(Denmark), Konstantinos C. Koskinas (Switzerland), Basil S. Lewis (Israel), Maja-Lisa Løchen (Norway), John
William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom),
Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Gianfranco Parati (Italy), Agnes A. Pasquet
(Belgium), Carlo Patrono (Italy), Steffen E. Petersen (United Kingdom), Massimo Francesco Piepoli (Italy),
Amina Rakisheva (Kazakhstan), Xavier Rossello (Spain), Peter Rossing (Denmark), Lars Rydén (Sweden),
Eberhard Standl (Germany), Lale Tokgozoglu (Türkiye), Rhian M. Touyz (Canada/United Kingdom),
Frank Visseren (Netherlands), Massimo Volpe (Italy), Christiaan Vrints (Belgium), and Adam Witkowski (Poland)
All experts involved in the development of these guidelines have submitted declarations of interest. These have
been compiled in a report and simultaneously published in a supplementary document to the guidelines. The
report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary documents that include background information and
evidence tables.
Keywords Guidelines • Aortic and peripheral arterial diseases • Arrhythmias • Atrial fibrillation • Cardiovascular disease •
Cardiovascular risk assessment • Chronic kidney disease • Coronary artery disease • Diabetes mellitus • Heart failure
• Patient-centred care • Pharmacological treatment • Prevention • Risk factors
Table of contents 5.1. Lifestyle and diabetes............................................................................... 4061
5.1.1. Weight reduction .............................................................................. 4062
1. Preamble................................................................................................................. 4050 5.1.2. Change in diet or nutrition ........................................................... 4062
2. Introduction .......................................................................................................... 4050 5.1.3. Increasing physical activity and exercise .................................. 4063
2.1. Central figure.............................................................................................. 4052 5.1.4. Smoking cessation ............................................................................. 4063
2.2. What is new ................................................................................................ 4053 5.2. Glycaemic targets...................................................................................... 4064
3. Diagnosis of diabetes......................................................................................... 4057 5.2.1. Role of glycated haemoglobin ...................................................... 4064
3.1. Laboratory criteria for diagnosing diabetes and pre-diabetes 4057 5.2.2. Additional glycaemic targets ......................................................... 4064
3.1.1. Fasting glucose .................................................................................... 4057 5.2.3. Glycaemic control following vascular events......................... 4064
3.1.2. Two-hour oral glucose tolerance test and random 5.3. Atherosclerotic cardiovascular disease risk reduction by
glucose................................................................................................................ 4057 glucose-lowering medications in diabetes............................................... 4065
3.1.3. Glycated haemoglobin..................................................................... 4058 5.3.1. Glucose-lowering medications with cardiovascular
3.2. Classifying diabetes................................................................................... 4059 efficacy demonstrated in dedicated cardiovascular outcomes
3.2.1. Type 1 diabetes.................................................................................. 4059 trials ..................................................................................................................... 4065
3.2.2. Type 2 diabetes.................................................................................. 4059 5.3.1.1. Sodium–glucose co-transporter-2 inhibitors ................ 4065
3.2.3. Monogenic diabetes.......................................................................... 4059 5.3.1.2. Glucagon-like peptide-1 receptor agonists.................... 4066
3.2.4. Secondary diabetes and stress hyperglycaemia .................... 4059 5.3.1.3. Pioglitazone.................................................................................. 4068
3.2.5. Gestational diabetes ......................................................................... 4059 5.3.2. Glucose-lowering medications with cardiovascular safety
3.2.6. Further sub-group classification of type 2 diabetes............ 4059 but not incremental efficacy demonstrated in dedicated
3.3. Screening for diabetes............................................................................. 4059 cardiovascular outcomes trials................................................................. 4068
4. Cardiovascular risk assessment in patients with type 2 diabetes .. 4060 5.3.2.1. Dipeptidyl peptidase-4 inhibitors....................................... 4068
4.1. Assessing cardiovascular risk in type 2 diabetes.......................... 4060 5.3.2.2. Lixisenatide and exenatide.................................................... 4068
4.1.1. Cardiovascular risk categories in type 2 diabetes................ 4060 5.3.2.3. Insulin ............................................................................................. 4068
4.1.2. SCORE2-Diabetes: estimating 10-year cardiovascular 5.3.2.4. Glimepiride .................................................................................. 4069
disease risk........................................................................................................ 4060 5.3.3. Cardiovascular considerations of older glucose-lowering
5. Cardiovascular risk reduction in patients with diabetes: targets medications not tested in dedicated cardiovascular outcomes
and treatments.......................................................................................................... 4061 trials ..................................................................................................................... 4069
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4045
5.3.3.1. Metformin .................................................................................... 4069 6.2.2.3. Reperfusion strategies in ST-elevation myocardial
5.3.3.2. Sulphonylureas ........................................................................... 4069 infarction....................................................................................................... 4085
5.3.4. Special considerations...................................................................... 4069 6.2.2.4. Optimal timing of invasive strategy in non-ST-
5.3.4.1. Hypoglycaemia and cardiovascular risk ........................... 4069 elevation acute coronary syndrome................................................. 4085
5.3.4.2. Effects on weight....................................................................... 4070 6.3. Ischaemia with no obstructive coronary artery disease in
5.3.5. Implications of results from cardiovascular outcomes diabetes .................................................................................................................. 4086
trials of glucose-lowering medications.................................................. 4070 7. Heart failure and diabetes............................................................................... 4086
5.4. Blood pressure and diabetes................................................................ 4072 7.1. Definition and pathophysiology .......................................................... 4086
5.4.1. Screening and diagnosis................................................................... 4072 7.2. Epidemiology and prognosis................................................................. 4086
5.4.2. Treatment targets ............................................................................. 4072 7.3. Screening and diagnosis .......................................................................... 4087
5.4.3. Management of hypertension....................................................... 4073 7.4. Treatment of heart failure in patients with diabetes................. 4088
5.4.3.1. Effects of lifestyle intervention and weight loss........... 4073 7.4.1. Treatment of heart failure with reduced
5.4.3.2. Pharmacological treatments in patients with diabetes 4074 ejection fraction.............................................................................................. 4088
5.4.3.3. Blood pressure changes with glucose-lowering agents 4074 7.4.1.1. Sodium–glucose co-transporter-2 inhibitors ................ 4089
5.4.4. Sex-specific aspects........................................................................... 4074 7.4.1.2. Angiotensin receptor–neprilysin inhibitor and
5.5. Lipids and diabetes.................................................................................... 4075 angiotensin-converting enzyme inhibitors...................................... 4089
5.5.1. Treatment targets ............................................................................. 4075 7.4.1.3. Mineralocorticoid receptor antagonists.......................... 4089
5.5.2. Lipid-lowering agents ....................................................................... 4075 7.4.1.4. Beta-blockers .............................................................................. 4089
5.5.2.1. Statins............................................................................................. 4075 7.4.1.5. Angiotensin-II receptor blockers........................................ 4089
5.5.2.2. Ezetimibe ...................................................................................... 4075 7.4.1.6. Ivabradine ..................................................................................... 4090
5.5.2.3. Proprotein convertase subtilisin/kexin type 9 7.4.1.7. Hydralazine and isosorbide dinitrate................................ 4090
inhibitors....................................................................................................... 4076 7.4.1.8. Digoxin .......................................................................................... 4090
5.5.2.4. Fibrates and other TG-lowering drugs............................ 4076 7.4.1.9. Diuretics........................................................................................ 4090
5.5.3. Novel cholesterol-lowering drugs.............................................. 4076 7.4.1.10. Device therapy and surgery............................................... 4090
5.5.3.1. Inclisiran......................................................................................... 4076 7.4.2. Treatment of heart failure with mildly reduced ejection
5.5.3.2. Bempedoic acid.......................................................................... 4076 fraction ............................................................................................................... 4090
5.6. Antithrombotic therapy and diabetes.............................................. 4077 7.4.3. Treatment of heart failure with preserved ejection
5.6.1. Patients without a history of symptomatic atherosclerotic fraction ............................................................................................................... 4091
cardiovascular disease or revascularization ........................................ 4077 7.5. Safety profile of glucose-lowering agents in patients with
5.6.2. Patients with atherosclerotic cardiovascular disease and/ heart failure and diabetes ............................................................................... 4091
or revascularization without an indication for long-term oral 7.5.1. Sodium–glucose co-transporter-2 inhibitors......................... 4091
anticoagulation ................................................................................................ 4078 7.5.2. Glucagon-like peptide-1 receptor agonists ............................ 4092
5.6.2.1. Chronic coronary syndromes.............................................. 4078 7.5.3. Dipeptidyl peptidase-4 inhibitors................................................ 4093
5.6.2.2. Acute coronary syndrome.................................................... 4079 7.5.4. Insulin...................................................................................................... 4093
5.6.2.2.1. Peri-procedural management...................................... 4079 7.5.5. Metformin............................................................................................. 4093
5.6.2.2.2. Post-procedural management..................................... 4079 7.5.6. Sulphonylureas.................................................................................... 4093
5.6.2.2.3. Prolonging DAPT post-ACS........................................ 4079 7.5.7. Thiazolidinediones............................................................................. 4093
5.6.2.2.4. Shortening or de-escalating DAPT post-ACS in 7.5.8. Special consideration: hypoglycaemia and risk of heart
diabetes .................................................................................................... 4079 failure hospitalization.................................................................................... 4093
5.6.3. Patients with atherosclerotic cardiovascular disease 8. Arrhythmias: atrial fibrillation, ventricular arrhythmias, and sudden
and/or revascularization requiring long-term cardiac death and diabetes................................................................................... 4096
oral anticoagulation....................................................................................... 4081 8.1. Atrial fibrillation and diabetes.............................................................. 4096
5.6.4. Preventing gastrointestinal bleeding .......................................... 4081 8.1.1. Epidemiology of atrial fibrillation and its association with
5.7. Multifactorial approach to risk-factor management in diabetes 4082 diabetes .............................................................................................................. 4096
6. Management of coronary artery disease and diabetes....................... 4083 8.1.2. Screening and managing atrial fibrillation in patients with
6.1. Chronic coronary syndromes and diabetes .................................. 4083 diabetes .............................................................................................................. 4096
6.1.1. Clinical presentation......................................................................... 4083 8.1.3. Preventing stroke in patients with atrial fibrillation and
6.1.2. Screening and diagnosis................................................................... 4083 diabetes .............................................................................................................. 4098
6.1.3. Management......................................................................................... 4084 8.2. Ventricular arrhythmias and risk of sudden cardiac death and
6.1.3.1. Pharmacotherapy...................................................................... 4084 diabetes .................................................................................................................. 4098
6.1.3.1.1. Glucose-lowering medication ..................................... 4084 9. Chronic kidney disease and diabetes ......................................................... 4099
6.1.3.1.2. Other medications........................................................... 4084 9.1. Chronic kidney disease definitions, staging, and screening...... 4099
6.1.3.2. Revascularization ....................................................................... 4084 9.2. Management of cardiovascular disease risk and kidney failure
6.2. Acute coronary syndromes and diabetes....................................... 4084 in patients with chronic kidney disease and diabetes......................... 4100
6.2.1. Clinical presentation and diagnosis ............................................ 4084 9.3. Blood pressure and glycaemic control in patients with
6.2.2. Management......................................................................................... 4085 diabetes and chronic kidney disease.......................................................... 4103
6.2.2.1. Pharmacotherapy...................................................................... 4085 9.4. Roles for antithrombotic therapy and invasive strategies in
6.2.2.2. Glucose control in patients with acute coronary managing atherosclerotic cardiovascular disease in patients with
syndrome...................................................................................................... 4085 diabetes and chronic kidney disease.......................................................... 4103
Downloaded
from

by
guest
on
22
January
2026

4046 E S C G u id e l in e s
10. Aortic and peripheral arterial diseases and diabetes........................ 4104 Recommendation Table 12 — Recommendations for patients with
10.1. The impact of diabetes on peripheral atherosclerosis........... 4104 diabetes without a history of symptomatic atherosclerotic
10.1.1. Diabetes and lower-extremity artery disease .................... 4104 cardiovascular disease or revascularization............................................................. 4077
10.1.2. Diabetes and carotid artery disease ....................................... 4106 Recommendation Table 13 — Recommendations for
10.2. Diabetes and aortic aneurysm .......................................................... 4106 antithrombotic therapy in patients with diabetes and acute or
11. Type 1 diabetes and cardiovascular disease ......................................... 4107 chronic coronary syndrome without indications for long-term oral
anticoagulation .......................................................................................................... 4080
11.1. Cardiovascular risk assessment in type 1 diabetes .................. 4107
Recommendation Table 14 — Recommendations for
11.2. Managing cardiovascular risk.............................................................. 4107
antithrombotic therapy in patients with diabetes and acute or
11.2.1. Exercise and lifestyle...................................................................... 4108
chronic coronary syndrome and/or post-percutaneous coronary
11.2.2. Lipid lowering ................................................................................... 4108
intervention requiring long-term oral anticoagulation............................. 4081
11.2.3. Blood pressure................................................................................. 4108
Recommendation Table 15 — Recommendations for gastric
11.2.4. Antiplatelet therapy ....................................................................... 4108
protection in patients with diabetes taking antithrombotic drugs ..... 4081
11.3. Glucose-lowering agents beyond insulin ...................................... 4108
Recommendation Table 16 — Recommendations for a
11.4. Renal protection in type 1 diabetes ............................................... 4108
multifactorial approach in patients with type 2 diabetes with and
12. Person-centred care ....................................................................................... 4108
without cardiovascular disease........................................................................... 4082
13. Practical guidance............................................................................................. 4110
Recommendation Table 17 — Recommendations for
14. Key messages ..................................................................................................... 4110
revascularization in patients with diabetes ................................................... 4084
15. Gaps in evidence............................................................................................... 4111 Recommendation Table 18 — Recommendations for glycaemic
16. Sex differences .................................................................................................. 4112 control in patients with diabetes and acute coronary syndrome....... 4085
17. ‘What to do’ and ‘What not to do’ messages from the Guidelines 4113 Recommendation Table 19 — Recommendations for heart failure
18. Quality indicators............................................................................................. 4117 screening and diagnosis in patients with diabetes...................................... 4088
19. Supplementary data......................................................................................... 4117 Recommendation Table 20 — Recommendations for heart failure
20. Data availability statement............................................................................ 4117 treatments in patients with heart failure with reduced ejection
21. Author information......................................................................................... 4117 fraction and diabetes .............................................................................................. 4090
22. Appendix.............................................................................................................. 4118 Recommendation Table 21 — Recommendations for heart failure
23. Acknowledgements ......................................................................................... 4118 treatments in patients with diabetes and left ventricular ejection
24. References........................................................................................................... 4119 fraction over 40% .................................................................................................... 4091
Recommendation Table 22 — Recommendations for
glucose-lowering medications in patients with type 2 diabetes with
Tables of Recommendations and without heart failure...................................................................................... 4094
Recommendation Table 23 — Recommendations for atrial
Recommendation Table 1 — Recommendations for diagnosing fibrillation in patients with diabetes ................................................................. 4098
diabetes ........................................................................................................................ 4060 Recommendation Table 24 — Recommendations for patients with
Recommendation Table 2 — Recommendations for assessing chronic kidney disease and diabetes................................................................ 4103
cardiovascular risk in patients with type 2 diabetes ................................. 4061 Recommendation Table 25 — Recommendations for peripheral
Recommendation Table 3 — Recommendations for reducing arterial and aortic diseases in patients with diabetes............................... 4106
weight in patients with type 2 diabetes with or without Recommendation Table 26 — Recommendations for patients with
cardiovascular disease ............................................................................................ 4062 type 1 diabetes.......................................................................................................... 4108
Recommendation Table 4 — Recommendations for nutrition in Recommendation Table 27 — Recommendations for
patients with type 2 diabetes with or without cardiovascular disease 4063 person-centred care in diabetes........................................................................ 4110
Recommendation Table 5 — Recommendations for physical
activity/exercise in patients with type 2 diabetes with or without List of tables
cardiovascular disease ............................................................................................ 4063
Recommendation Table 6 — Recommendations for smoking Table 1 Classes of recommendations............................................................. 4051
cessation in patients with type 2 diabetes with or without Table 2 Levels of evidence................................................................................... 4051
cardiovascular disease ............................................................................................ 4064 Table 3 New recommendations ....................................................................... 4053
Recommendation Table 7 — Recommendations for glycaemic Table 4 Revised recommendations.................................................................. 4056
targets in patients with diabetes........................................................................ 4064 Table 5 Revised concepts 2023 Guidelines.................................................. 4057
Recommendation Table 8 — Recommendations for Table 6 Biochemical diagnostic criteria for diabetes and pre-diabetes
glucose-lowering treatment for patients with type 2 diabetes and according to the World Health Organization and the American
atherosclerotic cardiovascular disease to reduce cardiovascular risk 4072 Diabetes Association.............................................................................................. 4058
Recommendation Table 9 — Recommendation for Table 7 Cardiovascular risk categories in type 2 diabetes..................... 4060
glucose-lowering treatment for patients with type 2 diabetes Table 8 Blood pressure measurement ........................................................... 4073
without atherosclerotic cardiovascular disease or severe Table 9 Heart failure phenotypes according to ejection fraction
target-organ damage to reduce cardiovascular risk.................................. 4072 distribution.................................................................................................................. 4086
Recommendation Table 10 — Recommendations for blood Table 10 Risk factors for developing heart failure in patients with
pressure management in patients with diabetes........................................ 4074 diabetes ........................................................................................................................ 4086
Recommendation Table 11 — Recommendations for the Table 11 KDIGO staging by glomerular filtration rate
management of dyslipidaemia in patients with diabetes......................... 4076 and urinary albumin-to-creatinine ratio categories with
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4047
colour chart for risk of initiation of maintenance kidney replacement Abbreviations and acronyms
therapy.......................................................................................................................... 4099
2hPG 2 h plasma glucose
Table 12 ‘What to do’ and ‘What not to do’ ............................................. 4113
ABI Ankle–brachial index
ABPM Ambulatory blood pressure monitoring
List of figures
ACCORD Action to Control Cardiovascular Risk in
Diabetes
Figure 1 Management of cardiovascular disease in patients with type
ACE-I Angiotensin-converting enzyme inhibitor
2 diabetes: clinical approach and key recommendations........................ 4052
ACS Acute coronary syndrome
Figure 2 Diagnosis of diabetes and pre-diabetes........................................ 4058
ADA American Diabetes Association
Figure 3 Cardiovascular risk categories in patients with type 2
ADAPTABLE Aspirin Dosing: A Patient-Centric Trial Assessing
diabetes ........................................................................................................................ 4061
Benefits and Long-term
Figure 4 Simple guide to glycaemic targets in patients with type 2
ADDITION Anglo-Danish-Dutch Study of Intensive
diabetes and cardiovascular disease................................................................. 4065
Treatment In People with Screen Detected
Figure 5 Meta-analysis of cardiovascular outcomes trial results of
Diabetes in Primary Care
sodium–glucose co-transporter-2 inhibitors among patients with
ADJUNCT ONE The Efficacy and Safety of Liraglutide as Adjunct
type 2 diabetes with or at high risk for atherosclerotic cardiovascular
Therapy to Insulin in the Treatment of Type 1
disease........................................................................................................................... 4066
Diabetes
Figure 6 Meta-analysis of cardiovascular outcomes trials with
ADVANCE Action in Diabetes and Vascular Disease: glucagon-like peptide-1 receptor agonists (sensitivity analysis
Preterax and Diamicron MR Controlled
removing ELIXA). Risk of major adverse cardiovascular events and
Evaluation
its components ......................................................................................................... 4067
AF Atrial fibrillation
Figure 7 Glucose-lowering treatment for patients with type 2
ARB Angiotensin-II receptor blocker
diabetes to reduce cardiovascular risk based on the presence of
ARNI Angiotensin receptor–neprilysin inhibitor
atherosclerotic cardiovascular disease/severe target-organ damage
ARR Absolute risk reduction
and 10-year cardiovascular disease risk estimation via
ASA Acetylsalicylic acid
SCORE2-Diabetes................................................................................................... 4070
ASCEND A Study of Cardiovascular Events iN
Figure 8 Glucose-lowering treatment for patients with type 2
Diabetes
diabetes and atherosclerotic cardiovascular disease to reduce
ASCVD Atherosclerotic cardiovascular disease
cardiovascular risk.................................................................................................... 4071
ATTACK Aspirin to Target Arterial Events in Chronic
Figure 9 Screening and diagnosis of hypertension in patients with
Kidney Disease
diabetes ........................................................................................................................ 4073
b.i.d. Twice a day
Figure 10 Recommended low-density lipoprotein-cholesterol
b.p.m. Beats per minute
targets by cardiovascular risk categories in patients with type 2
BANTING Evaluation of Evolocumab Efficacy in Diabetic
diabetes ........................................................................................................................ 4075
Adults With Hypercholesterolemia/Mixed
Figure 11 Mechanisms contributing to altered platelet activation and
Dyslipidemia
atherothrombosis in patients with diabetes................................................. 4078
BARC Bleeding Academic Research Consortium
Figure 12 Recommendations for antiplatelet therapy in patients with
BARI 2D Bypass Angioplasty Revascularization
diabetes with acute or chronic coronary syndrome undergoing
Investigation 2 Diabetes
percutaneous coronary intervention or coronary artery bypass
BERSON Safety and Efficacy of Evolocumab in
grafting without indications for long-term oral anticoagulation.......... 4080
Combination With Statin Therapy in Adults
Figure 13 Assessment of lifestyle risk-factor components and
With Diabetes and Hyperlipidemia or Mixed
stepwise lifestyle recommendations in patients with diabetes ............ 4083
Dyslipidemia
Figure 14 Diagnostic algorithm for heart failure in patients with
BMI Body mass index
diabetes ........................................................................................................................ 4087
BNP B-type natriuretic peptide
Figure 15 Absolute risk reduction with sodium–glucose
BP Blood pressure
co-transporter-2 inhibitors in relation to patient risk based on rate
CABG Coronary artery bypass graft
of heart failure-related endpoints in the placebo arm of the
CAC Coronary artery calcium
respective trials......................................................................................................... 4092
CAD Coronary artery disease
Figure 16 Glucose-lowering treatment of patients with heart failure
CANVAS Canagliflozin Cardiovascular Assessment
and type 2 diabetes................................................................................................. 4095
Study
Figure 17 Screening for atrial fibrillation in patients with diabetes.... 4097
CARMELINA Cardiovascular and Renal Microvascular
Figure 18 Pharmacological management to reduce cardiovascular or
Outcome Study With Linagliptin in Patients
kidney failure risk in patients with type 2 diabetes and chronic kidney
With Type 2 Diabetes Mellitus
disease........................................................................................................................... 4101
CAROLINA Cardiovascular Outcome Study of Linagliptin
Figure 19 Absolute benefits and harms of sodium–glucose
Versus Glimepiride in Patients With Type 2
co-transporter-2 inhibitors in patients with and without diabetes.... 4102
Diabetes
Figure 20 Screening for and managing lower-extremity artery
CCB Calcium channel blocker
disease in patients with diabetes....................................................................... 4105
CCS Chronic coronary syndrome
Figure 21 Person-centred care approach for patients with diabetes
CGM Continuous glucose monitoring
with or without cardiovascular disease.......................................................... 4109
Downloaded
from

by
guest
on
22
January
2026

4048 E S C G u id e l in e s
CHA DS -VASc Congestive heart failure, Hypertension, Age ≥75 EDIC Epidemiology of Diabetes Interventions and
2 2
years (2 points), Diabetes mellitus, Stroke or Complications
transient ischaemic attack (2 points), Vascular eGFR Estimated glomerular filtration rate
disease, Age 65–74 years, Sex category (female) ELIXA Evaluation of Lixisenatide in Acute Coronary
CHAP Chronic Hypertension and Pregnancy Syndrome
CHD Coronary heart disease EMMY Impact of EMpagliflozin on cardiac function and
CI Confidence interval biomarkers of heart failure in patients with acute
CKD Chronic kidney disease MYocardial infarction
CKD-EPI Chronic kidney disease epidemiology/CKD EMPA-KIDNEY The Study of Heart and Kidney Protection With
Epidemiology Collaboration Empagliflozin
CKD-MBD Chronic kidney disease–mineral bone disorder EMPA-REG Empagliflozin Cardiovascular Outcome Event
CLEAR Cholesterol Lowering via Bempedoic Acid, an OUTCOME Trial in Type 2 Diabetes Mellitus Patients
ACL-Inhibiting Regimen EMPA-RESPONSE- Empagliflozin on Clinical Outcomes in Patients
CLTI Chronic limb-threatening ischaemia AHF With Acute Decompensated Heart Failure
COMPASS Cardiovascular Outcomes for People Using EMPEROR- EMPagliflozin outcomE tRial in Patients With
Anticoagulation Strategies Preserved chrOnic heaRt Failure With Preserved Ejection
CPG Clinical Practice Guidelines Fraction
CREDENCE Canagliflozin and Renal Events in Diabetes with EMPEROR- Empagliflozin Outcome Trial in Patients with
Established Nephropathy Clinical Evaluation Reduced Chronic Heart Failure with Reduced Ejection
CRT Cardiac resynchronization therapy Fraction
CRT-D Cardiac resynchronization therapy with an EMPULSE A Study to Test the Effect of Empagliflozin in
implantable defibrillator Patients Who Are in Hospital for Acute Heart
CRT-P Cardiac resynchronization therapy-pacemaker Failure
CT Computed tomography EORP EURObservational Research Programme
CTA Computed tomography angiography ER Extended release
CURRENT- Clopidogrel Optimal Loading Dose Usage to ESC European Society of Cardiology
OASIS Reduce Recurrent EveNTs/Optimal Antiplatelet ESH European Society of Hypertension
Strategy for InterventionS EXAMINE Cardiovascular Outcomes Study of Alogliptin in
CV Cardiovascular Patients With Type 2 Diabetes and Acute
CVD Cardiovascular disease Coronary Syndrome
CVOT Cardiovascular outcomes trial EXSCEL Exenatide Study of Cardiovascular Event
DAPA-CKD Dapagliflozin and Prevention of Adverse Lowering
Outcomes in Chronic Kidney Disease FIDELIO-DKD Efficacy and Safety of Finerenone in Subjects
DAPA-HF Dapagliflozin and Prevention of Adverse With Type 2 Diabetes Mellitus and Diabetic
Outcomes in Heart Failure Kidney Disease
DAPT Dual antiplatelet therapy FIGARO-DKD Efficacy and Safety of Finerenone in Subjects
DAT Dual antithrombotic therapy With Type 2 Diabetes Mellitus and the Clinical
DBP Diastolic blood pressure Diagnosis of Diabetic Kidney Disease
DCCT Diabetes Control and Complications Trial FLOW Effect of Semaglutide Versus Placebo on the
DD Double diabetes Progression of Renal Impairment in Subjects
DECLARE-TIMI Dapagliflozin Effect on Cardiovascular Events With Type 2 Diabetes and Chronic Kidney
58 −Thrombolysis In Myocardial Infarction 58 Disease
DELIVER Dapagliflozin Evaluation to Improve the Lives of FOURIER Further Cardiovascular Outcomes Research
Patients with Preserved Ejection Fraction Heart with PCSK9 Inhibition in Subjects with Elevated
Failure Risk
DES Drug-eluting stent FPG Fasting plasma glucose
DEVOTE A Trial Comparing Cardiovascular Safety of GDM Gestational diabetes mellitus
Insulin Degludec vs Insulin Glargine in Patients GFR Glomerular filtration rate
With Type 2 Diabetes at High Risk of GLOBAL- A Clinical Study Comparing Two Forms of
Cardiovascular Events LEADERS Antiplatelet Therapy After Stent
DIAL Diabetes lifetime-perspective prediction Implantation
DIGAMI Diabetes Mellitus Insulin-Glucose Infusion in GLP-1 RA Glucagon-like peptide-1 receptor agonist
Acute Myocardial Infarction GRACE Global Registry of Acute Coronary Events
DiRECT Diabetes Remission Clinical Trial HARMONY Effect of Albiglutide, When Added to Standard
DPP-4 Dipeptidyl peptidase-4 Outcomes Blood Glucose Lowering Therapies, on Major
EACTS European Association for Cardio-Thoracic Cardiovascular Events in Subjects With Type 2
Surgery Diabetes Mellitus
EASD European Association for the Study of Diabetes HAS-BLED Hypertension, Abnormal renal/liver function,
ECG Electrocardiogram Stroke, Bleeding history or predisposition, Labile
EDC Pittsburgh Epidemiology of Diabetes international normalized ratio, Elderly (>65
Complications years), Drugs/alcohol concomitantly
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4049
HbA1c Glycated haemoglobin ODYSSEY Efficacy and Safety of Alirocumab Versus Usual
HBPM Home blood pressure monitoring DM-DYSLIPIDE- Care on Top of Maximally Tolerated Statin
HCP Healthcare professional MIA Therapy in Patients With Type 2 Diabetes and
HDL-C High-density lipoprotein-cholesterol Mixed Dyslipidemia
HF Heart failure ODYSSEY Evaluation of Cardiovascular Outcomes After an
HFmrEF Heart failure with mildly reduced ejection OUTCOMES Acute Coronary Syndrome During Treatment
fraction With Alirocumab
HFpEF Heart failure with preserved ejection fraction OGTT Oral glucose tolerance test
HFrEF Heart failure with reduced ejection fraction OMT Optimal medical therapy
HMOD Hypertension-mediated organ damage OR Odds ratio
HR Hazard ratio ORIGIN Outcome Reduction With Initial Glargine
ICD Implantable cardioverter defibrillator Intervention
IFG Impaired fasting glucose ORION Inclisiran for Participants With Atherosclerotic
IGT Impaired glucose tolerance Cardiovascular Disease and Elevated
IHD Ischaemic heart disease Low-density Lipoprotein Cholesterol
IMPROVE-IT Improved Reduction of Outcomes: Vytorin PA Physical activity
Efficacy International Trial PAD Peripheral arterial diseases
INR International normalized ratio PARAGON-HF Efficacy and Safety of LCZ696 Compared to
IPD Individual participant data Valsartan, on Morbidity and Mortality in Heart
ISAR-REACT 5 Intracoronary Stenting and Antithrombotic Failure Patients With Preserved Ejection
Regimen: Rapid Early Action for Coronary Fraction
Treatment PCI Percutaneous coronary intervention
ISCHEMIA International Study of Comparative Health PCSK9 Proprotein convertase subtilisin/kexin type 9
Effectiveness with Medical and Invasive PEGASUS-TIMI Prevention of Cardiovascular Events in Patients
Approaches 54 With Prior Heart Attack Using Ticagrelor
ISCHEMIA-CKD International Study of Comparative Health Compared to Placebo on a Background of
Effectiveness with Medical and Invasive Aspirin
Approaches–Chronic Kidney Disease PIONEER 6 Trial Investigating the Cardiovascular Safety of
ISTH International Society of Thrombosis and Oral Semaglutide in Subjects With Type 2
Haemostasis Diabetes
i.v. Intravenous PROactive PROspective pioglitAzone Clinical Trial In
J-DOIT3 Japan Diabetes Optimal Integrated Treatment macroVascular Events
Study for 3 Major Risk Factors of Cardiovascular QI Quality indicator
Diseases QTc Correct QT interval
KDIGO Kidney Disease: Improving Global Outcomes RAS Renin–angiotensin system
KRT Kidney replacement therapy RCT Randomized controlled trial
LDL-C Low-density lipoprotein-cholesterol REDUCE-IT Reduction of Cardiovascular Events with
LEAD Lower-extremity artery disease Icosapent Ethyl–Intervention
LEADER Liraglutide Effect and Action in Diabetes: REWIND Researching Cardiovascular Events With a
Evaluation of Cardiovascular Outcome Results Weekly Incretin in Diabetes
LIBERATES Improving Glucose Control in Patients with ROS Reactive oxygen species
Diabetes Following Myocardial Infarction: The RPG Random plasma glucose
Role of a Novel Glycaemia Monitoring Strategy RR Relative risk
Look AHEAD Action for Health in Diabetes SAPT Single antiplatelet therapy
LV Left ventricular SAVOR-TIMI 53 Saxagliptin Assessment of Vascular Outcomes
LVEF Left ventricular ejection fraction Recorded in Patients with Diabetes Mellitus
MACE Major adverse cardiovascular events −Thrombolysis In Myocardial Infarction 53
MI Myocardial infarction SBP Systolic blood pressure
MRA Mineralocorticoid receptor antagonist s.c. Subcutaneous
NNH Number needed to harm SCD Sudden cardiac death
NNT Number needed to treat SCORED Effect of Sotagliflozin on Cardiovascular and
NO Nitric oxide Renal Events in Participants With Type 2
NOAC Non-Vitamin K Antagonist Oral Anticoagulant Diabetes and Moderate Renal Impairment Who
NSTE-ACS Non-ST-elevation acute coronary syndrome Are at Cardiovascular Risk
NT-proBNP N-terminal pro-B-type natriuretic peptide SCORE2- type 2 diabetes-specific 10-year CVD risk score
NYHA New York Heart Association Diabetes
o.d. Once a day SCORE2-OP SCORE2-older persons
OAC Oral anticoagulant SGLT2 Sodium–glucose co-transporter-2
OARS Open-ended questions, Affirmation, Reflective SMART Specific, Measurable, Achievable, Realistic,
listening, and Summarizing Timely
Downloaded
from

by
guest
on
22
January
2026

4050 E S C G u id e l in e s
SOLOIST-WHF Effect of Sotagliflozin on Cardiovascular Events in formulating and issuing ESC Guidelines can be found on the ESC web-
Patients with Type 2 Diabetes Post Worsening site (
Heart Failure The Members of this Task Force were selected by the ESC to re-
STEMI ST-elevation myocardial infarction present professionals involved with the medical care of patients with
STRONG-HF Safety, Tolerability and Efficacy of Rapid this pathology. The selection procedure aimed to include members
Optimization, Helped by NT-proBNP testinG, of from across the whole of the ESC region and from relevant ESC
Heart Failure Therapies Subspecialty Communities. Consideration was given to diversity and in-
SUSTAIN 6 Trial to Evaluate Cardiovascular and Other clusion, notably with respect to gender and country of origin. The Task
Long-term Outcomes With Semaglutide in Force performed a critical evaluation of diagnostic and therapeutic ap-
Subjects With Type 2 Diabetes proaches, including assessment of the risk-benefit ratio. The strength of
T1DM Type 1 diabetes mellitus every recommendation and the level of evidence supporting them were
T2DM Type 2 diabetes mellitus weighed and scored according to pre-defined scales as outlined below.
TAT Triple antithrombotic therapy The Task Force followed ESC voting procedures, and all approved re-
TBI Toe–brachial index commendations were subject to a vote and achieved at least 75%
TcPO Transcutaneous oxygen pressure agreement among voting members.
2
TECOS Trial Evaluating Cardiovascular Outcomes with The experts of the writing and reviewing panels provided declaration
Sitagliptin of interest forms for all relationships that might be perceived as real or
TG Triglyceride potential sources of conflicts of interest. Their declarations of interest
THEMIS Effect of Ticagrelor on Health Outcomes in were reviewed according to the ESC declaration of interest rules and
Diabetes Mellitus Patients Intervention Study can be found on the ESC website (
TIMI Thrombolysis in Myocardial Infarction Guidelines), and have been compiled in a report published in a supple-
TOD Target-organ damage mentary document with the guidelines. The Task Force received its en-
TRACK Treatment of CVD with Low Dose Rivaroxaban tire financial support from the ESC without any involvement from the
in Advanced CKD healthcare industry.
TRL Triglyceride-rich lipoprotein The ESC Clinical Practice Guidelines (CPG) Committee supervises and
TROPICAL-ACS Testing Responsiveness to Platelet Inhibition on co-ordinates the preparation of new guidelines and is responsible for the
Chronic Antiplatelet Treatment for Acute approval process. ESC Guidelines undergo extensive review by the CPG
Coronary Syndromes Committee and external experts, including members from across the
TSAT Transferrin saturation whole of the ESC region and from relevant ESC Subspecialty
TZD Thiazolidinedione Communities and National Cardiac Societies. After appropriate revisions,
UACR Urine albumin-to-creatinine ratio the guidelines are signed off by all the experts involved in the Task Force.
UKPDS United Kingdom Prospective Diabetes Study The finalized document is signed off by the CPG Committee for publica-
VADT Veterans Affairs Diabetes Trial tion in the European Heart Journal. The guidelines were developed after
VALUE Valsartan Antihypertensive Long-term Use careful consideration of the scientific and medical knowledge and the evi-
Evaluation dence available at the time of their writing. Tables of evidence summarizing
VERTIS CV Evaluation of Ertugliflozin Efficacy and Safety the findings of studies informing development of the guidelines are in-
Cardiovascular Outcomes Trial cluded. The ESC warns readers that the technical language may be misin-
VKA Vitamin K antagonist terpreted and declines any responsibility in this respect.
WHO World Health Organization Off-label use of medication may be presented in the current
WIfI Wound, Ischaemia, foot Infection Guidelines if a sufficient level of evidence shows that it can be consid-
ered medically appropriate for a given condition. However, the final de-
cisions concerning an individual patient must be made by the
responsible health professional giving special consideration to:
1. Preamble
• The specific situation of the patient. Unless otherwise provided for
by national regulations, off-label use of medication should be limited
Guidelines evaluate and summarize available evidence, with the aim of as-
to situations where it is in the patient’s interest with regard to the
sisting health professionals in proposing the best diagnostic or therapeut-
quality, safety, and efficacy of care, and only after the patient has
ic approach for an individual patient with a given condition. Guidelines are
been informed and has provided consent.
intended for use by health professionals and the European Society of
• Country-specific health regulations, indications by governmental
Cardiology (ESC) makes its Guidelines freely available.
drug regulatory agencies, and the ethical rules to which health profes-
ESC Guidelines do not override the individual responsibility of health
sionals are subject, where applicable.
professionals to make appropriate and accurate decisions in consider-
ation of each patient’s health condition and in consultation with that pa-
tient or the patient’s caregiver where appropriate and/or necessary. It is 2. Introduction
also the health professional’s responsibility to verify the rules and reg-
ulations applicable in each country to drugs and devices at the time of Patients with diabetes are at increased risk of developing cardiovascular
prescription, and, where appropriate, to respect the ethical rules of disease (CVD) with its manifestations of coronary artery disease (CAD),
their profession. heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and
ESC Guidelines represent the official position of the ESC on a given peripheral artery diseases. In addition, diabetes is a major risk factor for
topic and are regularly updated. ESC Policies and Procedures for developing chronic kidney disease (CKD), which in itself is associated
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4051
Table 1 Classes of recommendations
Definition Wording to use
Class I Evidence and/or general agreement Is recommended or is indicated
that a given treatment or procedure is
beneficial, useful, effective.
Class II Conflicting evidence and/or a divergence of opinion about the usefulness/
efficacy of the given treatment or procedure.
Class IIa Weight of evidence/opinion is in Should be considered
favour of usefulness/efficacy.
Class IIb Usefulness/efficacy is less well May be considered
established by evidence/opinion.
Class III Evidence or general agreement that the Is not recommended
given treatment or procedure is not
useful/effective, and in some cases
may be harmful.
Table 2 Levels of evidence
Level of Data derived from multiple randomized clinical trials
evidence A or meta-analyses.
Level of Data derived from a single randomized clinical trial
evidence B or large non-randomized studies.
Level of Consensus of opinion of the experts and/or small studies,
evidence C retrospective studies, registries.
with developing CVD. The combination of diabetes with these The current Guidelines—in contrast to the previous 2019 ESC
cardio-renal comorbidities enhances the risk not only for cardiovascular Guidelines on diabetes, pre-diabetes, and cardiovascular diseases—
(CV) events but also for CV and all-cause mortality. The current only focus on CVD and diabetes and, given the lack of clear evidence,
European Society of Cardiology (ESC) Guidelines on the management leave aside the aspect of pre-diabetes. In addition, this version of the
of cardiovascular disease in patients with diabetes are designed to guide Guidelines gives recommendations on stratifying CV risk, as well as
prevention and management of the manifestations of CVD in patients on screening, diagnosis, and treatment of CVD in patients with dia-
with diabetes based on data published until end of January 2023. Over betes. For all other aspects concerning the management of patients
the last decade, the results of various large cardiovascular outcome trials with diabetes, we refer to the recommendations from diabetes associa-
(CVOTs) in patients with diabetes at high CV risk with novel glucose- tions, e.g. the European Association for the Study of Diabetes (EASD)
lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhi- or the American Diabetes Association (ADA).1
bitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but These Guidelines offer evidence-based recommendations to manage
also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), CV risk in patients with diabetes and provide guidance for the treatment
such as finerenone have substantially expanded available therapeutic op- of atherosclerotic cardiovascular disease (ASCVD) in patients with dia-
tions, leading to numerous evidence-based recommendations for the betes. To individualize treatment strategies, the current Guidelines
management of this patient population. introduce a novel, dedicated, type 2 diabetes mellitus (T2DM)-specific,
snoitadnemmocer
fo
sessalC
3202
CSE©
3202
CSE©
3202CSE©
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

4052 E S C G u id e l in e s
10-year CVD risk score (SCORE2-Diabetes) for patients with T2DM recommended to reduce CV risk, independent of glucose control and in
without ASCVD or severe target-organ damage (TOD). This score, addition to standard of care, e.g. antiplatelet, anti-hypertensive, or
which now extends the established SCORE2 prediction algorithm for lipid-lowering therapy. A special focus of these Guidelines is on managing
T2DM, provides data on the 10-year risk of fatal and non-fatal CVD HF in diabetes, a field that has been underestimated for years. Based on
events (myocardial infarction [MI], stroke) based on individual patient data from large CVOTs, it is recommended to treat patients with diabetes
characteristics. SCORE2-Diabetes serves as a guide for clinical decision- and chronic HF (independent of left ventricular ejection fraction [LVEF])
making in patients with T2DM at low, moderate, high, or very high risk, with SGLT2 inhibitors to reduce HF hospitalization. Finally, in patients
but without clinically overt ASCVD or severe TOD. with diabetes and CKD, it is recommended to treat with an SGLT2 inhibi-
Given the high prevalence of undetected diabetes in patients with CVD, tor and/or finerenone, since these agents reduce CV and kidney failure risk
as well as the elevated risk and therapeutic consequences if both co- on top of standard of care (Figure 1).
morbidities co-exist, these Guidelines recommend systematic screening Managing patients with diabetes and CVD requires an interdisciplin-
for diabetes in all patients with CVD. In addition, all patients with diabetes ary approach, which should involve healthcare clinicians from different
need to be evaluated for risk and presence of CVD and CKD. Based on disciplines and areas of expertise to support shared decision-making
evidence from large CVOTs, the current Guidelines provide clear recom- and implement a personalized treatment strategy to reduce each pa-
mendations on how to treat patients with diabetes and clinical manifesta- tient’s disease burden. Ultimately, our common goal in managing
tions of cardiovascular-renal disease. As such, in patients with diabetes and CVD in patients with diabetes is to improve patients’ prognosis and
ASCVD, treatment with GLP-1 RAs and/or SGLT2 inhibitors is health-related quality of life.
2.1. Central figure
Cardiovascular disease Type 2 diabetes mellitus
Patient
presentation
Type 2 diabetes mellitus? Cardiovascular disease? Chronic kidney disease?
(Class I) (Class I) (Class I)
Evaluation Confirmed Confirmed Confirmed
CVD and
type 2 diabetes mellitus
Type 2 diabetes mellitus Type 2 diabetes mellitus Type 2 diabetes mellitus
and ASCVD and HF and CKD
Diagnosis
To reduce heart failure
To reduce cardiovascular risk hospitalization in all patients To reduce cardiovascular
independent of glucose control with T2DM and HF and kidney failure risk
(HFpEF, HFmrEF, HFrEF)
Treatment
GLP-1 RAa SGLT2 inhibitorb SGLT2 inhibitorc SGLT2 inhibitord Finerenone
(Class I) (Class I) (Class I) (Class I) (Class I)
All therapies are recommended independent of glucose control and
in addition to standard of care
Figure 1 Management of cardiovascular disease in patients with type 2 diabetes: clinical approach and key recommendations. ASCVD, atherosclerotic
cardiovascular disease; CKD, chronic kidney disease; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HF, heart failure;
HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection
fraction; s.c. subcutaneous; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus. aGLP-1 RAs with proven cardiovascular benefit: lir-
aglutide, semaglutide s.c., dulaglutide, efpeglenatide. bSGLT2 inhibitors with proven cardiovascular benefit: empagliflozin, canagliflozin, dapagliflozin, sotagli-
flozin. cEmpagliflozin, dapagliflozin, sotagliflozin in HFrEF; empagliflozin, dapagliflozin in HFpEF and HFmrEF. dCanagliflozin, empagliflozin, dapagliflozin.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4053
2.2. What is new
Atherosclerotic cardiovascular disease risk reduction by
glucose-lowering medications in diabetes—Section 5.3
Table 3 New recommendations
It is recommended to prioritize the use of
Recommendations Classa Levelb glucose-lowering agents with proven CV benefits
followed by agents with proven CV safety over I C
Cardiovascular risk assessment in diabetes—Section 4
agents without proven CV benefit or proven CV
In patients with T2DM without symptomatic ASCVD safety.
or severe TOD, it is recommended to estimate I B
If additional glucose control is needed, metformin
10-year CVD risk via SCORE2-Diabetes.
should be considered in patients with T2DM and IIa C
Weight reduction in patients with diabetes—Section 5.1.1 ASCVD.
It is recommended that individuals living with If additional glucose control is needed, pioglitazone
overweight or obesity aim to reduce weight and may be considered in patients with T2DM and IIb B
I A
increase physical exercise to improve metabolic ASCVD without HF.
control and overall CVD risk profile. Blood pressure and diabetes—Section 5.4
Glucose-lowering medications with effects on weight
Regular BP measurements are recommended in all
loss (e.g. GLP-1 RAs) should be considered in
IIa B patients with diabetes to detect and treat I A
patients with overweight or obesity to reduce
hypertension to reduce CV risk.
weight.
Lipids and diabetes—Section 5.5
Bariatric surgery should be considered for high and
very high risk patients with BMI ≥35 kg/m2 (≥Class II) A PCSK9 inhibitor is recommended in patients at
very high CV risk, with persistently high LDL-C levels
when repetitive and structured efforts of lifestyle IIa B
above target despite treatment with a maximum I A
changes combined with weight-reducing medications
tolerated statin dose, in combination with ezetimibe,
do not result in maintained weight loss.
or in patients with statin intolerance.
Increasing physical activity and exercise in patients with
If a statin-based regimen is not tolerated at any
diabetes—Section 5.1.3
dosage (even after re-challenge), a PCSK9 inhibitor IIa B
It is recommended to adapt exercise interventions to
added to ezetimibe should be considered.
T2DM-associated comorbidities, e.g. frailty, I B
If a statin-based regimen is not tolerated at any
neuropathy, or retinopathy.
dosage (even after re-challenge), ezetimibe should be IIa C
It is recommended to introduce structured exercise
considered.
training in patients with T2DM and established CVD,
High-dose icosapent ethyl (2 g b.i.d.) may be
e.g. CAD, HFpEF, HFmrEF, HFrEF, or AF to improve I B
considered in combination with a statin in patients IIb B
metabolic control, exercise capacity, and quality of
with hypertriglyceridaemia.
life, and to reduce CV events.
Antithrombotic therapy in patients with diabetes—Section 5.6
The use of behavioural theory-based interventions,
Clopidogrel 75 mg o.d. following appropriate loading
such as goal-setting, re-evaluation of goals,
IIa B (e.g. 600 mg or at least 5 days already on
self-monitoring, and feedback, should be considered
maintenance therapy) is recommended in addition to
to promote physical activity behaviour.
ASA for 6 months following coronary stenting in I A
It may be considered to use wearable activity
IIb B patients with CCS, irrespective of stent type, unless a
trackers to increase physical activity behaviour.
shorter duration is indicated due to the risk or
Smoking cessation in patients with diabetes—Section 5.1.4
occurrence of life-threatening bleeding.
Nicotine replacement therapy, varenicline, and
In patients with diabetes and ACS treated with
bupropion, as well as individual or telephone
IIa B DAPT who are undergoing CABG and do not
counselling, should be considered to improve
require long-term OAC therapy, resuming a P2Y
smoking cessation success rate. 12 I C
receptor inhibitor as soon as deemed safe after
Glycaemic targets—Section 5.2 surgery and continuing it up to 12 months is
Tight glycaemic control should be considered for recommended.
reducing CAD in the long term, preferably using IIa B Adding very low-dose rivaroxaban to low-dose ASA
agents with proven CV benefit. for long-term prevention of serious vascular events
IIa B
Continued should be considered in patients with diabetes and
CCS or symptomatic PAD without high bleeding risk.
Continued
Downloaded
from

by
guest
on
22
January
2026

4054 E S C G u id e l in e s
In patients with ACS or CCS and diabetes Heart failure and diabetes—Section 7
undergoing coronary stent implantation and having
Evaluation for heart failure in diabetes
an indication for anticoagulation prolonging triple
If HF is suspected, it is recommended to measure
therapy with low-dose ASA, clopidogrel, and an IIa C I B
BNP/NT-proBNP.
OAC should be considered up to 1 month if the
Systematic survey for HF symptoms and/or signs of
thrombotic risk outweighs the bleeding risk in the
individual patient. HF is recommended at each clinical encounter in all I C
patients with diabetes.
In patients with ACS or CCS and diabetes
undergoing coronary stent implantation and having Diagnostic tests in all patients with suspected heart failure
an indication for anticoagulation prolonging triple 12-lead ECG is recommended. I C
therapy with low-dose ASA, clopidogrel, and an IIb C Transthoracic echocardiography is recommended. I C
OAC up to 3 months may be considered if the Chest radiography (X-ray) is recommended. I C
thrombotic risk outweighs the bleeding risk in the
Routine blood tests for comorbidities are
individual patient.
recommended, including full blood count, urea,
I C
When clopidogrel is used, omeprazole and
creatinine and electrolytes, thyroid function, lipids,
esomeprazole are not recommended for gastric III B and iron status (ferritin and TSAT).
protection.
Pharmacological treatment indicated in patients with HFrEF
Multifactorial approach in patients with diabetes—Section 5.7
(NYHA class II–IV) and diabetes
Identifying and treating risk factors and comorbidities
I A SGLT2 inhibitors (dapagliflozin, empagliflozin, or
early is recommended. sotagliflozin) are recommended in all patients with
I A
Multidisciplinary behavioural approaches that HFrEF and T2DM to reduce the risk of HF
combine the knowledge and skills of different I C hospitalization and CV death.
caregivers are recommended.
An intensive strategy of early initiation of
Principles of motivational interviewing should be evidence-based treatment (SGLT2 inhibitors, ARNI/
IIa C
considered to induce behavioural changes. ACE-Is, beta-blockers, and MRAs), with rapid
Telehealth may be considered to improve risk up-titration to trial-defined target doses starting I B
IIb B
profile. before discharge and with frequent follow-up visits in
Management of coronary artery disease in patients with the first 6 weeks following a HF hospitalization is
diabetes—Section 6 recommended to reduce re-admissions or mortality.
Myocardial revascularization in CCS is Other treatments indicated in selected patients with HFrEF
recommended when angina persists despite (NYHA class II–IV) and diabetes
I A
treatment with anti-anginal drugs or in patients with Hydralazine and isosorbide dinitrate should be
a documented large area of ischaemia (>10% LV). considered in self-identified Black patients with
Complete revascularization is recommended in diabetes and LVEF ≤35% or with an LVEF <45%
patients with STEMI without cardiogenic shock and I A combined with a dilated LV in NYHA class III–IV IIa B
with multivessel CAD. despite treatment with an ACE-I (or ARNI), a
It is recommended to assess glycaemic status at initial beta-blocker, and an MRA, to reduce the risk of HF
I B
evaluation in all patients with ACS. hospitalization and death.
Complete revascularization should be considered in Digoxin may be considered in patients with
patients with NSTE-ACS without cardiogenic shock IIa C symptomatic HFrEF in sinus rhythm despite
and with multivessel CAD. treatment with sacubitril/valsartan or an ACE-I, a IIb B
Glucose-lowering therapy should be considered in beta-blocker, and an MRA, to reduce the risk of
patients with ACS with persistent hyperglycaemia, IIa C hospitalization.
while episodes of hypoglycaemia should be avoided. Heart failure treatments in patients with diabetes and LVEF
Routine immediate revascularization of non-culprit >40%
lesions in patients with MI and multivessel disease Empagliflozin or dapagliflozin are recommended in
III B
presenting with cardiogenic shock is not patients with T2DM and LVEF >40% (HFmrEF and
I A
recommended. HFpEF) to reduce the risk of HF hospitalization or
Continued CV death.
Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4055
Special considerations for glucose-lowering medications in Aortic and peripheral arterial diseases and diabetes—Section 10
patients with T2DM with and without HF In patients with diabetes and aortic aneurysm, it is
It is recommended to switch glucose-lowering recommended to implement the same diagnostic
I C
treatment from agents without proven CV benefit or I C work-up and therapeutic strategies (medical, surgical,
proven safety to agents with proven CV benefit. or endovascular) as in patients without diabetes.
Atrial fibrillation and diabetes—Section 8.1 Type 1 diabetes and cardiovascular disease—Section 11
Opportunistic screening for AF by pulse taking or In patients with T1DM, it is recommended that
ECG is recommended in patients with diabetes <65 adjustment of glucose-lowering medication follows
years of age (particularly when other risk factors are I C principles of patient self-management under the I C
present) because patients with diabetes exhibit a guidance of the diabetes healthcare multidisciplinary
higher AF frequency at a younger age. team.
Systematic ECG screening should be considered to Avoiding hypoglycaemic episodes is recommended,
I C
detect AF in patients aged ≥75 years, or those at high IIa B particularly in those with established CVD.
risk of stroke. Statins should be considered for LDL-C lowering in
Chronic kidney disease and diabetes—Section 9 adults older than 40 years with T1DM without a IIa B
history of CVD to reduce CV risk.
Intensive LDL-C lowering with statins or a statin/
I A Statins should be considered for use in adults
ezetimibe combination is recommended.
younger than 40 years with T1DM and other risk
A SGLT2 inhibitor (canagliflozin, empagliflozin, or IIa B
factors of CVD or microvascular end-organ damage
dapagliflozin) is recommended in patients with
T2DM and CKD with an eGFR ≥20 mL/min/1.73 m2 I A or 10-year CVD risk ≥10% to reduce CVD risk.
The use of the Scottish/Swedish risk prediction
to reduce the risk of CVD and kidney failure.
model may be considered to estimate 10-year CVD IIb B
Finerenone is recommended in addition to an ACE-I
risk in patients with T1DM.
or ARB in patients with T2DM and eGFR >60 mL/
min/1.73 m2 with a UACR ≥30 mg/mmol (≥300 mg/ ACE-I, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; AF, atrial
I A
g), or eGFR 25–60 mL/min/1.73 m2 and UACR fibrillation; ARB, angiotensin-II receptor blocker; ARNI, angiotensin receptor–neprilysin
inhibitor; ASA, acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; b.i.d.,
≥3 mg/mmol (≥30 mg/g) to reduce CV events and
twice a day; BMI, body mass index; BNP, B-type natriuretic peptide; BP, blood pressure;
kidney failure. CABG, coronary artery bypass graft; CAD, coronary artery disease; CCS, chronic
Low-dose ASA (75–100 mg o.d.) is recommended in coronary syndrome; CKD-MBD, chronic kidney disease–mineral bone disorder; CV,
I A cardiovascular; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; ECG,
patients with CKD and ASCVD.
electrocardiogram; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like
Treatment with intensive medical or an initial invasive peptide-1 receptor agonist; HF, heart failure; HFmrEF, heart failure with mildly reduced
ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart
strategy is recommended in people with CKD,
I B failure with reduced ejection fraction; LDL-C, low-density lipoprotein-cholesterol; LV,
diabetes, and stable moderate or severe CAD, due to left ventricular/ventricle; LVEF, left ventricular ejection fraction; MI, myocardial infarction;
similar outcomes. MRA, mineralocorticoid receptor antagonist; NSTE-ACS, non-ST-elevation acute
coronary syndrome; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA,
Kidney specialist advice may be considered for
New York Heart Association; OAC, oral anticoagulant; o.d., once daily; PAD, peripheral
managing a raised serum phosphate, other evidence IIb C arterial disease; PCSK9, proprotein convertase subtilisin/kexin type 9; T1DM, type 1
of CKD-MBD, and renal anaemia. diabetes mellitus; T2DM, type 2 diabetes mellitus; TOD, target-organ damage; TSAT,
transferrin saturation; SCORE2-Diabetes, type 2 diabetes-specific 10-year CVD risk
Combined use of an ARB with an ACE-I is not
III B score; SGLT2, sodium–glucose co-transporter-2; STEMI, ST-elevation myocardial
recommended. infarction; UACR, urinary albumin-to-creatinine ratio.
aClass of recommendation.
Continued
bLevel of evidence.
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

4056 E S C G u id e l in e s
Table 4 Revised recommendations
2019 Classa Levelb 2023 Classa Levelb
Change in diet and nutrition in patients with diabetes—Section 5.1.2
A Mediterranean diet, rich in polyunsaturated It is recommended to adopt a Mediterranean or plant-based diet
and monounsaturated fats, should be IIa B with high unsaturated fat content to lower CV risk. I A
considered to reduce CV events.
Atherosclerotic cardiovascular disease risk reduction by glucose-lowering medications in diabetes—Section 5.3
Empagliflozin, canagliflozin, or dapagliflozin SGLT2 inhibitors with proven CV benefit are recommended in
are recommended in patients with T2DM and patients with T2DM and ASCVD to reduce CV events,
I A
CVD, or at very high/high CV risk to reduce independent of baseline or target HbA1c and independent of
CV events. I A concomitant glucose-lowering medication.
In patients with T2DM without ASCVD or severe TOD but with
a calculated 10-year CVD risk ≥10%, treatment with an SGLT2 IIb C
inhibitor or GLP-1 RA may be considered to reduce CV risk.
Liraglutide, semaglutide, or dulaglutide are GLP-1 RAs with proven CV benefit are recommended in patients
recommended in patients with T2DM and with T2DM and ASCVD to reduce CV events, independent of
I A
CVD, or at very high/high CV risk to reduce baseline or target HbA1c and independent of concomitant
CV events. I A glucose-lowering medication.
In patients with T2DM without ASCVD or severe TOD but with
a calculated 10-year CVD risk ≥10%, treatment with an SGLT2 IIb C
inhibitor or GLP-1 RA may be considered to reduce CV risk.
Antithrombotic therapy in patients with diabetes—Section 5.6
When low-dose aspirin is used, proton pump When antithrombotic drugs are used in combination, proton
inhibitors should be considered to prevent pump inhibitors are recommended to prevent gastrointestinal I A
gastrointestinal bleeding. bleeding.
IIa A
When a single antiplatelet or anticoagulant drug is used, proton
pump inhibitors should be considered to prevent gastrointestinal IIa A
bleeding, considering the bleeding risk of the individual patient.
Multifactorial approach to risk-factor management in patients with diabetes—Section 5.7
A multifactorial approach to diabetes A multifactorial approach to managing T2DM with treatment
management with treatment targets should targets is recommended.
IIa B I B
be considered in patients with diabetes and
CVD.
Heart failure and diabetes—Section 7
GLP-1 RAs (lixisenatide, liraglutide, GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide ER,
semaglutide, exenatide, dulaglutide) have a dulaglutide, efpeglenatide) have a neutral effect on the risk of HF
neutral effect on the risk of HF hospitalization, IIb A hospitalization, and should be considered for glucose-lowering IIa A
and may be considered for diabetes treatment treatment in patients with T2DM at risk of or with HF.
in patients with HF.
Insulin may be considered in patients with Basal insulins (glargine and degludec) have a neutral effect on the
advanced, systolic HFrEF. risk of HF hospitalization, and should be considered for
IIb C IIa B
glucose-lowering treatment in patients with T2DM at risk of or
with HF.
Atrial fibrillation and diabetes—Section 8.1
Screening for AF by pulse palpation should be Opportunistic screening for AF by pulse taking or ECG is
considered in patients aged >65 years with recommended in patients ≥65 years of age.
diabetes and confirmed by ECG, if any IIa C I B
suspicion of AF, as AF in patients with diabetes
increases morbidity and mortality.
Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4057
Chronic kidney disease and diabetes—Section 9
Treatment with the GLP-1 RAs liraglutide and A GLP-1 RA is recommended at an eGFR >15 mL/min/1.73 m2
semaglutide is associated with a lower risk of to achieve adequate glycaemic control, due to low risk of
renal endpoints and should be considered for IIa B hypoglycaemia and beneficial effects on weight, CV risk, and I A
diabetes treatment if eGFR is >30 mL/min/ albuminuria.
1.73 m2.
AF, atrial fibrillation; ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; ER,
extended release; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; SGLT2, sodium–
glucose co-transporter-2; T2DM, type 2 diabetes mellitus; TOD, target-organ damage.
aClass of recommendation.
bLevel of evidence.
Table 5 Revised concepts 2023 Guidelines 3. Diagnosis of diabetes
Focus of the Guidelines is prevention and management of
Diabetes mellitus, a common metabolic condition, affected 537 million
cardiovascular disease in diabetes individuals worldwide in 2021 (10.5% prevalence), and this is expected
The aspect of pre-diabetes is no longer covered in the current to rise to 783 million cases by 2045 (12.2% prevalence).2
Guidelines. Diabetes is suspected in the presence of specific symptoms, includ-
ing polyuria, polydipsia, fatigue, blurred vision, weight loss, poor
Cardiovascular risk assessment in diabetes
wound healing, and recurrent infections. However, the condition
For patients without ASCVD or severe target-organ damage, a novel
can be asymptomatic and is therefore undiagnosed in over 40% of
T2DM-specific risk score (SCORE2-Diabetes) is introduced. adults worldwide (ranging from 24% to 75% across regions).3
CV risk categories in T2DM are now defined based on the presence of Abnormal glucose metabolism has been divided into two clinical cat-
ASCVD or severe target-organ damage or the 10-year CVD risk using egories: diabetes and pre-diabetes, which are biochemical definitions
SCORE2-Diabetes. (discussed below).
Atherosclerotic cardiovascular risk reduction by
glucose-lowering medications in diabetes
3.1. Laboratory criteria for diagnosing
Based on various meta-analyses including data from CVOTs with SGLT2
diabetes and pre-diabetes
inhibitors and GLP-1 RAs, the current Guidelines give separate
Several biochemical tests are used to diagnose diabetes, including fast-
recommendations for patients with and without ASCVD/severe
ing glucose, 2 h glucose (during the glucose tolerance test), random glu-
target-organ damage.
cose, and glycated haemoglobin (HbA1c).4–7
Special attention is given on the aspect of proven CV benefit and/or
safety of glucose-lowering medications.
Heart failure and diabetes 3.1.1. Fasting glucose
Fasting glucose levels ≥7.0 mmol/L (≥126 mg/dL) is diagnostic of dia-
Detailed recommendations are given on HF screening and diagnosis in
betes, although two tests are usually recommended to diagnose in
patients with diabetes.
the absence of hyperglycaemic symptoms. In patients with typical symp-
Based on data from outcome trials in patients with HF (HFrEF, HFmrEF,
toms, a single test is adequate, and it should be noted that fasting is de-
HFpEF) with and without diabetes, the current Guidelines provide
fined as no caloric intake for at least 8 h.
recommendations for the treatment of HF in patients with diabetes
While international guidelines agree on the cut-off value for diagnos-
across the whole spectrum of left ventricular ejection fraction.
ing diabetes, they are divided on the criteria for diagnosing pre-diabetes.
Detailed recommendations are given for the use of glucose-lowering
The World Health Organization (WHO) defines pre-diabetes as fasting
medications in patients with HF and diabetes. glucose levels 6.1–6.9 mmol/L (110–125 mg/dL) with levels
Arrhythmias and diabetes <6.1 mmol/L (<110 mg/dL) regarded as normal.5However, the ADA
has more stringent criteria, with glucose levels 5.6–6.9 mmol/L (100–
Given that patients with diabetes exhibit a higher AF frequency at a
125 mg/dL) falling into the pre-diabetes range and only those with glu-
younger age, the concept of opportunistic screening for AF by pulse
cose <5.6 mmol/L (<100 mg/dL) classified as having normal glucose
taking or ECG in patients with diabetes <65 years of age (particularly
metabolism.7,8
when other risk factors are associated) is introduced.
Chronic kidney disease and diabetes
3.1.2. Two-hour oral glucose tolerance test and random
A dedicated section on managing CV risk in patients with CKD and
glucose
diabetes is introduced covering aspects of screening (including regular
screening with eGFR and UACR) and treatment. Following an oral glucose load equivalent to 75 g glucose, 2 h glucose
≥11.1 mmol/L (≥200 mg/dL) is diagnostic of diabetes. Two-hour glu-
AF, atrial fibrillation; ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney
cose 7.8–11.0 mmol/L (140–199 mg/dL) indicates impaired glucose tol-
disease; CV, cardiovascular; CVD, cardiovascular disease; CVOT, cardiovascular outcomes
erance, and the individual is diagnosed with pre-diabetes. However, an
trial; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; GLP-1 RA,
glucagon-like peptide-1 receptor agonist; HF, heart failure; HFmrEF, heart failure with oral glucose tolerance test (OGTT) is not routinely performed, as it is
mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; time-consuming and inconvenient, and is therefore usually reserved for
HFrEF, heart failure with reduced ejection fraction; SCORE2-Diabetes, type 2
unclear cases. Of note, OGTT should be performed under resting con-
diabetes-specific 10-year CVD risk score; SGLT2, sodium–glucose co-transporter-2;
T2DM, type 2 diabetes mellitus; UACR, urinary albumin-to-creatinine ratio. ditions, as exercise during the test can invalidate the results.
3202CSE©
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

4058 E S C G u id e l in e s
Following on, a random glucose ≥11.1 mmol/L (≥200 mg/dL) is also Table 6 Biochemical diagnostic criteria for diabetes
diagnostic of diabetes in the presence of symptoms. In the absence of and pre-diabetes according to the World Health
symptoms, two random glucose levels ≥11.1 mmol/L (≥200 mg/dL) Organization and the American Diabetes Association
are required to diagnose diabetes. One-hour OGTT ≥8.6 mmol/L
Glycaemic marker WHO criteria ADA criteria
(≥155 mg/dL) has been suggested as a better predictor of diabetes
(2011, 2019)5,6 (2021)7
than 2 h OGTT ≥11.1 mmol/L (≥200 mg/dL), and is associated with
vascular complications and mortality.9 However, further validation is
Diabetes
required before this new measure is widely adopted.
FPG ≥7.0 mmol/L (≥126 mg/dL)
3.1.3. Glycated haemoglobin
2hPG (OGTT) ≥11.1 mmol/L (≥200 mg/dL)
Following high-quality epidemiological studies, it was suggested that
HbA1c ≥6.5% (≥48 mmol/mol)
HbA1c could be used to diagnose diabetes, and this was subsequently
RPG ≥11.1 mmol/L (≥200 mg/dL)
endorsed by international guidelines.10 It should be noted that epi-
Pre-diabetes
demiological studies have relied on the adult population, though
HbA1c is also used in younger individuals as a diagnostic test.11 FPG 6.1–6.9 mmol/L 5.6–6.9 mmol/L
(110–125 mg/dL) (100–125 mg/dL)
Advantages of HbA1c include ease of measurement, limited
within-individual variability, and the convenience of anytime testing 2hPG (OGTT) 7.8–11.0 mmol/L (140–199 mg/dL)
without the need for fasting or a cumbersome OGTT. HbA1c 6.0–6.4% 5.7–6.4%
However, HbA1c is not accurate in specific groups where the rela- (42–47 mmol/mol) (39–47 mmol/mol)
tionship between HbA1c and glucose levels is altered for any reason
ADA, American Diabetes Association; 2hPG, 2 h plasma glucose; FPG, fasting plasma
(Supplementary data online, Table S1).12,13Moreover, in cases of short-
glucose; HbA1c, glycated haemoglobin; RPG, random plasma glucose; OGTT, oral
er diabetes duration, such as early type 1 diabetes mellitus (T1DM) or glucose tolerance test; WHO, World Health Organization.
Diagnosis of diabetes and pre-diabetes
Fasting glucose ≥5.6 mmol/L (≥100 mg/dL), or
HbA1c ≥39 mmol/mol (≥5.7%), or
OGTT (2 h) glucose ≥7.8 mmol/L (≥140 mg/dL)
Y N
Values indicative of diabetes or pre-diabetes Diabetes ruled out (normal glucose metabolism)
Fasting glucose ≥7.0 mmol/L (≥126 mg/dL), or Fasting glucose 5.6–6.9 mmol/L (100–125 mg/dL), or
HbA1c ≥48 mmol/mol (≥6.5%), or HbA1c 39–47 mmol/mol (5.7–6.4%), or
OGTT (2 h) glucosea ≥11.1 mmol/L (≥200 mg/dL) OGTT (2 h) glucose 7.8–11.0 mmol/L (140–199 mg/dL)
Diabetesb Pre-diabetes (IGT)c
Figure 2 Diagnosis of diabetes and pre-diabetes. HbA1c, glycated haemoglobin; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test. aRule
out stress hyperglycaemia (often manifests as elevated glucose and normal HbA1c). bIn the presence of symptoms, a single test is enough; in the absence of
symptoms, two abnormal tests are required to make the diagnosis. cAmerican Diabetes Association criteria are used in this scheme for the diagnosis of
pre-diabetes.
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4059
acute pancreatic damage, HbA1c can lead to false-negative results. should be suspected in the presence of a strong family history of abnor-
Another practical limitation is the lack of test availability in some parts mal glucose metabolism in an autosomal dominant manner (i.e. succes-
of the world due to financial constraints. sive generations with diabetes at a young age).17
Guidelines agree that HbA1c ≥48 mmol/mol (≥6.5%) is diagnostic of Patients diagnosed with diabetes before the age of 6 months and
diabetes, while the diagnosis of pre-diabetes uses two different cut-off those not fitting the T1DM or T2DM profiles should be suspected of
values. The WHO criteria define pre-diabetes as HbA1c 42–47 mmol/ having monogenic diabetes.
mol (6.0–6.4%), while the ADA recommends a wider range of 39–
47 mmol/mol (5.7–6.4%).5,7 Notably, the combination of HbA1c and 3.2.4. Secondary diabetes and stress hyperglycaemia
fasting glucose in the diabetes range is diagnostic of diabetes and a se-
Diabetes can occur secondary to various conditions and therapies
cond test is not required, even if the individual is asymptomatic.
(Supplementary data online, Table S2). Stress hyperglycaemia is not un-
However, if the two are discordant, the number in the diabetes range
common in hospitalized patients and can occur in individuals with acute
should be repeated or, preferably, an OGTT performed, which remains coronary syndrome (ACS) or HF.18Stress hyperglycaemia without dia-
the gold standard for diagnosing diabetes in unclear cases. The criteria betes is associated with adverse in-hospital outcomes, and should be
used for diagnosing diabetes and pre-diabetes are summarized in
suspected in those with raised glucose levels during admission and nor-
Table 6. It should be noted that data from 73 studies on 294 998 indi- mal HbA1c.19Such individuals are best investigated using OGTT a few
viduals without known diabetes suggest that HbA1c is as good as or
weeks after discharge to rule out diabetes or impaired glucose toler-
better than fasting, random, or post-load glucose levels for predicting ance. Some studies suggest performing OGTT before hospital dis-
CV risk.14 charge but robust data supporting this approach are lacking.20,21
A diagram for the diagnosis of diabetes is shown in Figure 2.
3.2.5. Gestational diabetes
3.2. Classifying diabetes
Gestational diabetes mellitus (GDM) is defined as diabetes diagnosed
After abnormal glucose metabolism is diagnosed, the next step is to as- in the second or third trimester of pregnancy that was not overt dia-
certain the type of diabetes in order to start the appropriate therapies betes before gestation.7While there is still no worldwide consensus
(Supplementary data online, Table S2). regarding the best testing strategy, the ‘one-step’ 75 g OGTT, also
recommended by the WHO, is the preferred test in many coun-
3.2.1. Type 1 diabetes tries.22In women with GDM, repeat testing is required in the post-
Type 1 diabetes constitutes 5–10% of individuals with diabetes and is partum period to rule out persistent abnormal glucose metabolism.
secondary to destruction of pancreatic β-cells by an autoimmune pro- Women with GDM will require lifelong annual diabetes screening gi-
cess, with subsequent insulin deficiency. Recent guidance on diagnosing ven the high risk of developing diabetes.23–25Also, evidence suggests
T1DM has been published.13 that women with a history of GDM are at increased CV risk, even
Briefly, individuals aged <35 years presenting with diabetes should be with normal post-partum glucose levels. Given that GDM is an im-
suspected of having T1DM, although this condition can occur at any portant precursor of future cardiometabolic complications, women
age. A short history of osmotic symptoms accompanied by weight with a history of GDM should regularly be screened not only for dia-
loss and raised glucose levels in a younger individual is highly suggestive betes, but also for CV health.26–29
of T1DM. Antibody testing helps to confirm the diagnosis, although this
can be negative in 5–10% of individuals with T1DM, while C-peptide 3.2.6. Further sub-group classification of type 2
helps to assess endogenous insulin production in unclear cases diabetes
(Supplementary data online, Table S2). For information regarding further sub-group classification of T2DM,
Pancreatic β-cell function can partially recover after the diagnosis of see Supplementary data online, Section 1.1.1.
T1DM, and this can last several years, often referred to as the ‘honey-
moon period’. However, if this persists beyond 5 years, an alternative 3.3. Screening for diabetes
type of diabetes needs to be considered.15Of importance, the combin-
Criteria for diabetes testing differ widely across regions, and a com-
ation of T1DM with insulin resistance, which can be referred to as dou-
prehensive global screening programme is yet to be developed. It is
ble diabetes (DD), increases the risk of vascular complications, although
generally agreed, however, that individuals in high-risk groups (those
the exact definition of DD is yet to be determined.16
living with overweight or obesity, or having markers of insulin resist-
ance, such as acanthosis nigricans or fatty liver disease) should be
3.2.2. Type 2 diabetes
regularly screened, particularly after age 45 years. The ADA devel-
Type 2 diabetes is the most common cause of diabetes (90% of the dia- oped a relatively simple 7-point scoring system based on age, sex,
betes population) and is usually caused by insulin resistance coupled weight, physical activity (PA), history of GDM, presence of hyperten-
with ‘relative’ insulin deficiency, resulting in raised glucose levels. sion, and family history of diabetes; it is advised that those scoring ≥5
Individuals with T2DM can be asymptomatic and can be diagnosed after are screened for diabetes.7
presenting with CV complications (Supplementary data online, The prevalence of diabetes is increased among patients with CVD,
Table S2). Therefore, it is mandatory to screen all patients with CVD with 23–37% of patients with ACS and 10–47% of patients with HF di-
for the presence of diabetes. agnosed with diabetes. This results in worse clinical outcomes com-
pared with individuals with normal glucose metabolism.30–33
3.2.3. Monogenic diabetes Therefore, individuals with ASCVD and/or HF and/or AF, particularly
This comprises many mutations that cause glucose mishandling. A full those admitted to hospital with an acute event, should be tested for dia-
description can be found elsewhere.17 Briefly, monogenic diabetes betes; those with suspected stress hyperglycaemia (raised glucose levels
Downloaded
from

by
guest
on
22
January
2026

4060 E S C G u id e l in e s
during admission with normal HbA1c) should undergo post-discharge 4.1.1. Cardiovascular risk categories in type 2
glucose testing, preferably with OGTT, to rule out persistent abnormal diabetes
glucose metabolism. Individuals with T2DM should be categorized into different CV risk
Although OGTT has been previously advocated for diabetes screen- groups based on the following criteria (Table 7):
ing in individuals with CVD, practicalities and low reproducibility of the
test limited widespread use.34,35 Importantly, evidence indicates that Table 7 Cardiovascular risk categories in type 2
diabetes
HbA1c, or fasting glucose, are stronger predictors of vascular complica-
tions than 2 h OGTT and it is therefore best to adopt these simple Very high CV Patients with T2DM with:
measures for general screening, particularly given their high reproduci- risk • Clinically established ASCVD or
bility.35–38
• Severe TOD or
• 10-year CVD risk ≥20% using SCORE2-Diabetes
Recommendation Table 1 — Recommendations for
diagnosing diabetes High CV risk Patients with T2DM not fulfilling the very high-risk
criteria and a:
Recommendations Classa Levelb • 10-year CVD risk 10 to <20% using
SCORE2-Diabetes
Screening for diabetes is recommended in all
individuals with CVD,c using fasting glucose and/or I A Moderate CV Patients with T2DM not fulfilling the very high-risk
HbA1c.5–7,36,37,39 risk criteria and a:
• 10-year CVD risk 5 to <10% using
It is recommended that the diagnosis of diabetes is
SCORE2-Diabetes
based on HbA1c and/or fasting plasma glucose, or on I B
an OGTT if still in doubt.d,5–8,10,11 Low CV risk Patients with T2DM not fulfilling the very high-risk
criteria and a:
CVD, cardiovascular disease; HbA1c, glycated haemoglobin; OGTT, oral glucose tolerance
• 10-year CVD risk <5% using SCORE2-Diabetes
test.
aClass of recommendation. ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular
bLevel of evidence. disease; eGFR, estimated glomerular filtration rate; SCORE2-Diabetes, type 2
cCardiovascular disease includes atherosclerotic cardiovascular disease, atrial fibrillation, diabetes-specific 10-year CVD risk score; T2DM, type 2 diabetes mellitus; TOD,
and heart failure. target-organ damage; UACR, urinary albumin-to-creatinine ratio.
dStress hyperglycaemia should be suspected in the presence of high glucose levels and Severe TOD defined as eGFR <45 mL/min/1.73 m2 irrespective of albuminuria; or eGFR 45–
normal HbA1c (see text for details). 59 mL/min/1.73 m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or proteinuria
(UACR >300 mg/g; stage A3); or presence of microvascular disease in at least three
different sites [e.g. microalbuminuria (stage A2) plus retinopathy plus neuropathy].43–45
4. Cardiovascular risk assessment
in patients with type 2 diabetes 4.1.2. SCORE2-Diabetes: estimating 10-year
cardiovascular disease risk
Individuals with T2DM are at a two- to four-fold higher risk of develop- In patients aged ≥40 years with T2DM without ASCVD or severe TOD,
ing CVD during their lifetime alongside its manifestations CAD, stroke, it is recommended to estimate 10-year CVD risk using the
HF, and AF, as well as peripheral artery diseases (PAD).40,41In addition, SCORE2-Diabetes algorithm (Figure 3). In these patients, risk factors
many patients with CVD have undiagnosed T2DM. Given that having for ASCVD should be evaluated on an individual basis. In the 2021
diabetes and CVD, especially at a younger age, has a major impact on ESC Guidelines on cardiovascular disease prevention in clinical practice,
prognosis, it is of utmost importance to screen patients with CVD the ADVANCE (Action in Diabetes and Vascular disease: preterAx and
for diabetes and to assess CV risk in individuals with diabetes, and evalu- diamicroN MR Controlled Evaluation) or DIAL (Diabetes lifetime-
ate them for CV and kidney disease.42 perspective prediction) models were suggested for estimating CVD
risk among patients with diabetes.46–48 However, these models have
4.1. Assessing cardiovascular risk in type 2 some limitations for use in Europe, as they do not allow for substantial
diabetes variations of risk across countries, meaning they may misestimate risk
in these circumstances. Furthermore, these models have been developed
When assessing CV risk in individuals with T2DM, it is important to
from a narrow set of studies and have not been systematically ‘recali-
consider medical and family history, symptoms, findings from examin-
brated’ (i.e. statistically adapted) to contemporary CVD rates, meaning
ation, laboratory and other diagnostic test results, and the presence
they are not ideal for use in contemporary European populations. To ad-
of ASCVD or severe TOD. There is not enough robust evidence to
dress these limitations, the current Guidelines recommend use of the
suggest that assessment of coronary artery calcium (CAC) or intima
SCORE2-Diabetes model, which extends the regionally recalibrated
media thickness help reclassify CV risk in people with T2DM. Severe
European SCORE2 10-year risk model to enable use in individuals with
TOD is defined as:
T2DM aged 40–69 years without ASCVD or severe TOD, and to esti-
(i) Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2 mate an individual’s 10-year risk of fatal and non-fatal CVD events (MI,
irrespective of albuminuria, or stroke).49
(ii) eGFR 45–59 mL/min/1.73 m2 and microalbuminuria (urinary SCORE2-Diabetes integrates information on conventional CVD risk
albumin-to-creatinine ratio [UACR] 30–300 mg/g; stage A2), or factors (i.e. age, smoking status, systolic blood pressure [SBP], and total
(iii) Proteinuria (UACR >300 mg/g; stage A3), or and high-density lipoprotein [HDL]-cholesterol) with diabetes-specific
(iv) Presence of microvascular disease in at least three different sites information (e.g. age at diabetes diagnosis, HbA1c, and eGFR).50This
(e.g. microalbuminuria (stage A2) plus retinopathy plus neur- model is calibrated to four clusters of countries (low, moderate, high,
opathy; see Section 9.1for CKD screening).43–45 and very high CVD risk) using the similar methodology of the
3202CSE©
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4061
Patient with ASCVD or severe TODa
Y N
Scoringb
SCORE2-Diabetes
≥20% 10% to <20% 5% to <10% <5%
Very high risk High risk Moderate risk Low risk
Figure 3 Cardiovascular risk categories in patients with type 2 diabetes. ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease risk;
eGFR, estimated glomerular filtration rate; TOD, target-organ damage; UACR, urinary albumin-to-creatinine ratio. aSevere TOD defined as eGFR <45 mL/
min/1.73 m2 irrespective of albuminuria; or eGFR 45–59 mL/min/1.73 m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or proteinuria (UACR
>300 mg/g; stage A3), or presence of microvascular disease in at least three different sites [e.g. microalbuminuria (stage A2) plus retinopathy plus neur-
opathy].43–45bThe thresholds (10-year CVD risk) suggested are not definitive but rather designed to prompt joint decision-making conversations with pa-
tients about intensity of treatment, as well as additional interventions. SCORE2-Diabetes refers to patients aged ≥40 years.
SCORE2 and SCORE2-Older Persons (SCORE2-OP) algorithms In patients with T2DM without symptomatic ASCVD
(Supplementary data online, Section 2; Table S3).49,51 or severe TOD,c it is recommended to estimate I B
The ESC CVD Risk Calculation App includes SCORE2-Diabetes to 10-year CVD risk via SCORE2-Diabetes.d,50
facilitate risk estimation and communication between health profes-
sionals and individuals with T2DM (Supplementary data online, Tables ASCVD, atherosclerotic cardiovascular disease; eGFR, estimated glomerular filtration rate;
SCORE2-Diabetes, type 2 diabetes-specific 10-year ASCVD risk score; T2DM, type 2
S4–6).
diabetes mellitus; TOD, target-organ damage; UACR, urinary albumin-to-creatinine ratio.
Additional risk scores that attempt to estimate lifetime risk in indivi- aClass of recommendation.
duals with diabetes (such as the DIAL2 [DIAbetes Lifetime] model, bLevel of evidence.
cSevere TOD defined as eGFR <45 mL/min/1.73 m2 irrespective of albuminuria; or eGFR
which is calibrated to different European countries) can also be used
45–59 mL/min/1.73 m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or
to aid treatment decisions.52 However, estimation of lifetime risk proteinuria (UACR >300 mg/g; stage A3); or presence of microvascular disease in at
should be adapted as new methods become available in the future. least three different sites (e.g. microalbuminuria (stage A2) plus retinopathy plus
Thresholds for the different risk categories are shown in Table 7and neuropathy).
dSCORE2-Diabetes refers to patients aged ≥40 years. In patients with T2DM without Figure 3. In general, no risk threshold is universally applicable, and the
ASCVD and/or severe TOD, with age <40 years, risk factors for ASCVD should be
risk thresholds suggested in these Guidelines for use with evaluated on an individual basis.
SCORE2-Diabetes should be used to help guide clinicians and patients
to prompt joint decision-making conversations for considering the in- 5. Cardiovascular risk reduction in
tensity of treatment and additional interventions to prevent ASCVD
patients with diabetes: targets and
(such as lipid-lowering therapies [Section 5.5] or SGLT2 inhibitors
and/or GLP-1 RAs [Section 5.3]). However, 10-year risk thresholds treatments
are for guidance only and other patient characteristics may lead to de-
cisions to treat or not treat irrespective of such thresholds. 5.1. Lifestyle and diabetes
Lifestyle changes are recommended as the basic measure for preventing
Recommendation Table 2 — Recommendations for
assessing cardiovascular risk in patients with type 2 and managing T2DM.48Advice should be addressed by a multifactorial
diabetes approach with patient-centred communication adapted to the health
status and health literacy of the patient (Section 5.7). In T2DM, as inves-
Recommendations to assess cardiovascular Classa Levelb tigated in the Action for Health in Diabetes trial (Look AHEAD; 5145
risk in patients with diabetes T2DM patients, 59% female, mean age 58 years, mean body mass index
[BMI] 36 kg/m2), lifestyle intervention by nutritional counselling, meal
It is recommended to screen patients with diabetes
I A replacement, and exercise induced an average of 8.6% weight loss,
for the presence of severe TOD.c,43,44 which was associated with a significant reduction in HbA1c and BP.56
It is recommended to assess medical history and the Effects on weight and risk-factor control diminished after 5 years in
presence of symptoms suggestive of ASCVD in I B those with low adherence to the lifestyle programme.56After 10 years,
patients with diabetes.53–55 CV events (i.e. a composite endpoint of CV death, non-fatal MI, non-
Continued fatal stroke, and hospitalization for angina) were not different to usual
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

4062 E S C G u id e l in e s
care.56 However, microvascular disease complications (i.e. develop- Recommendation Table 3 — Recommendations for
ment of CKD) were significantly reduced (hazard ratio [HR] 0.69; reducing weight in patients with type 2 diabetes with
95% confidence interval [CI], 0.55–0.87; P = 0.002) by lifestyle interven- or without cardiovascular disease
tion, an effect associated with improvements in CV risk factors.57
Recommendations Classa Levelb
Additional analyses 16.7 years after the start of the study (9.6 years
of intervention and then observation) revealed that participants who It is recommended that individuals living with
lost ≥10% of weight at 1 year of intervention had a 21% reduced risk
overweight or obesity aim to reduce weight and
of mortality (HR 0.79; 95% CI, 0.67–0.94; P = 0.007).58The decline in I A
increase physical exercise to improve metabolic
body fat mass was significantly associated with a lower risk of HF control and overall CVD risk profile.56,79
with reduced ejection fraction (HFrEF) and HF with preserved ejection
Glucose-lowering medications with effects on weight
fraction (HFpEF), while a decline in waist circumference was only signifi-
loss (e.g. GLP-1 RAs) should be considered in
cantly associated with a lower risk of HFpEF.59 In addition, baseline IIa B
patients with overweight or obesity to reduce
cardio-pulmonary fitness was associated with reduced risks of mortality
and CV events during follow-up of 9.2 years.60
weight.67
The DiRECT (Diabetes Remission Clinical Trial)—an open-label, Bariatric surgery should be considered for high and
cluster-randomized trial in patients with T2DM—assigned practices very high risk patients with BMI ≥35 kg/m2 (≥Class
to provide either a weight-management programme including exercise IIc) when repetitive and structured efforts of lifestyle IIa B
(intervention group) or best-practice care by guidelines (control changes combined with weight-reducing medications
group). At 12 months, almost half of the participants in the intervention do not result in maintained weight loss.73–77
group achieved remission to a non-diabetic state and were off glucose-
BMI, body mass index; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1
lowering drugs.61 Home-based exercise intervention in patients with receptor agonist.
CAD and T2DM (ARTEMIS study; Finnish randomized controlled trial aClass of recommendation.
[RCT]; n = 127; 2-year controlled, home-based exercise training vs. bLevel of evidence.
cWorld Health Organization classification.
usual care), however, did not significantly improve CV risk factors des-
pite significant improvements in exercise capacity (P = 0.030).62
5.1.2. Change in diet or nutrition
In general, patients with T2DM should follow nutritional recommenda-
5.1.1. Weight reduction tions that reduce body weight and improve metabolic control and out-
In patients with obesity and T2DM, reducing weight is one of the cor- comes.48 A Mediterranean-style eating pattern improves glycaemic
nerstones of treatment.63Weight loss of >5% improves glycaemic con- control, lipids, and BP.80,81If this diet is supplemented with olive oil or
trol, lipid levels, and BP in overweight and obese adults with T2DM.64,65 nuts, as in the non-randomized PREvencion con Dieta MEDiterranea
These effects can be achieved by improving energy balance and/or (PREDIMED) study in individuals at high CV risk (49% T2DM), the risk
introducing obesity medications. Orlistat, naltrexone/bupropion, and of ASCVD was reduced by 28–31%.82Recent data from the Coronary
phentermine/topiramate are each associated with achieving >5% Diet Intervention With Olive Oil and Cardiovascular Prevention
weight loss at 52 weeks compared with placebo.66However, glucose- (CORDIOPREV) study confirmed the benefit of a Mediterranean diet
lowering agents such as GLP-1 RAs, the dual agonist tirzepatide, and by showing that male patients with established CAD benefitted more
SGLT2 inhibitors also significantly reduce body weight.67,68Adding ex- from a Mediterranean diet than from a low-fat diet intervention after
ercise to a GLP-1 RA (liraglutide) had a greater effect on weight reduc- 7 years of follow-up. A shift from a more animal-based to a plant-based
tion and maintenance.69 Comparing the effects on weight reduction food pattern may also reduce ASCVD risk.83–85
between GLP-1 RAs and SGLT2 inhibitors, the former seems to be su- Data from studies on supplementation with n–3 fatty acids do not
perior. Given the additional beneficial effects of GLP-1 RAs and SGLT2 support recommending n–3 fatty acid supplements for secondary pre-
inhibitors on CV outcomes in T2DM (Section 5.3), these agents should vention of CVD in T2DM.86,87 The consumption of sugars,
be the preferred glucose-lowering medication in overweight and obese sugar-sweetened soft drinks, and fruit juices should be avoided.88,89
patients with CVD and T2DM, as obesity medications have, to date, not Moreover, alcohol intake should generally be moderate, as any amount
shown to reduce CV events.70–72 of alcohol uniformly increases BP and BMI.90–92 A high-protein diet
If weight is not managed effectively by lifestyle interventions and (30% protein, 40% carbohydrates, and 30% fat) seems to be superior
medication, bariatric surgery should be considered in patients with to a standard-protein diet (15% protein, 55% carbohydrates, and
T2DM and a BMI ≥35 kg/m2 (≥Class II; WHO classification) to achieve 30% fat) in overweight and obese (mean weight 107.8 ± 20.8 kg) pa-
long-term weight loss, reduce blood glucose, and improve CV risk fac- tients with HF; both diets were equal in reducing body weight (3.6 vs.
tors. Data from the Swedish Obesity Subjects (SOS) study revealed 2.9 kg, respectively) and waist circumference (1.9 vs. 1.3 cm, respective-
that after 24-year follow-up, bariatric surgery was associated with a ly), but the high-protein diet resulted in greater reductions in CV risk
prolonged life expectancy compared with lifestyle and intensive medical factors, e.g. HbA1c, cholesterol, triglycerides, and BP.93
management alone.73,74 The corresponding HR was 0.70 (95% CI, People with CVD and T2DM are encouraged to reduce sodium in-
0.57–0.85) for CV death and 0.77 (95% CI, 0.61–0.96) for death take, as this may reduce systolic BP by, on average, 5.8 mmHg in hyper-
from cancer.75,76 This evidence has been extended to patients with tensive patients and 1.9 mmHg in normotensive patients.94,95 In a
CVD and obesity, as a large case-control study (n = 2638) revealed meta-analysis, in hypertensive and normotensive people, reducing salt
that bariatric surgery was also associated with a lower incidence of ma- intake by 2.5 g/day resulted in a 20% relative reduction of ASCVD
jor adverse cardiovascular events (MACE) in those patients.77Still, po- events.95In addition, salt substitution with reduced sodium levels and
tential adverse events after bariatric surgery should also be increased potassium levels has been shown to reduce stroke, CVD,
considered.78 and overall mortality in patients with high CV risk.96
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4063
Recommendation Table 4 — Recommendations for include in their daily routines, as such activities are more likely to be
nutrition in patients with type 2 diabetes with or without feasible and sustainable.
cardiovascular disease
Recommendation Table 5 — Recommendations for
Recommendations Classa Levelb physical activity/exercise in patients with type 2 diabetes
with or without cardiovascular disease
It is recommended to adopt a Mediterranean or
plant-based diet with high unsaturated fat content to I A Recommendation Classa Levelb
lower cardiovascular risk.82,85
It is recommended to increase any physical activity
aClass of recommendation. (e.g. 10 min daily walking) in all patients with T2DM
bLevel of evidence.
with and without CVD. Optimal is a weekly activity I A
of 150 min of moderate intensity or 75 min of
5.1.3. Increasing physical activity and exercise vigorous endurance intensity.97,98
Regular moderate to vigorous PA has favourable effects on metabolic
It is recommended to adapt exercise interventions to
control and CV risk factors in T2DM.97–100Intervention programmes
T2DM-associated comorbidities, e.g. frailty, I B
reduce HbA1c by 0.6% in patients with T2DM, with the combination neuropathy, or retinopathy.108,115
of endurance and resistance exercise having the most beneficial ef-
It is recommended to introduce structured exercise
fects.101Moreover, compared with low total PA, high total PA is asso-
training in patients with T2DM and established CVD, ciated with a lower CV mortality risk, as well as a reduction in all-cause
e.g. CAD, HFpEF, HFmrEF, HFrEF, or AF to improve I B
mortality (all-cause mortality: HR 0.60 [95% CI, 0.49–0.73], comparing
high vs. low total PA).97 metabolic control, exercise capacity and quality of
life, and to reduce CV events. 108,115,116
Structured exercise intervention is also recommended in patients with
T2DM with established CVD (e.g. CAD, AF, HFpEF; heart failure with It is recommended to perform resistance exercise in
mildly reduced ejection fraction [HFmrEF]; HFrEF).102–104Interval endur- addition to endurance exercise at least twice a I B
ance exercise training of more vigorous intensity (e.g. interval walking, al- week.115,117
ternating between moderate to vigorous intensities) has superior effects The use of behavioural theory-based interventions,
compared with moderate-intensity continuous walking regarding body such as goal-setting, re-evaluation of goals,
weight, waist circumference, and glucose control.105 Before starting a self-monitoring, and feedback, should be considered IIa B
structured exercise programme in patients with T2DM and established to promote physical activity behaviour.112,113
CVD, performing a maximal exercise stress test to assess CV pathologies
It should be considered to perform a maximally
should be considered. Moreover, assessment of aerobic and anaerobic
tolerated exercise stress test in patients with T2DM
thresholds by spiroergometry is particularly useful to provide an indivi- IIa C
and established CVD before starting a structured
dualized endurance exercise prescription including exercise inten- exercise programme.
sity.106–108 Optimal intensity is determined based on an individual’s
It may be considered to use wearable activity
maximum (peak) effort during spiroergometry, e.g. percentage of cardio- IIb B
trackers to increase physical activity behaviour.114
respiratory fitness (% peak oxygen consumption), percentage of
maximum (peak) heart rate (% HR max), or perceived exertion rate ac- AF, atrial fibrillation; CAD, coronary artery disease; CV, cardiovascular; CVD,
cording to the Borg scale.107–109Exercise prescription is recommended cardiovascular disease; HFpEF, heart failure with preserved ejection fraction; HFmrEF,
heart failure with mildly reduced ejection fraction; HFrEF, heart failure with reduced
to be adapted to T2DM-associated comorbidities, e.g. CAD, HF, AF, dia-
ejection fraction; T2DM, type 2 diabetes mellitus.
betic peripheral neuropathy, or retinopathy, as well as age and aClass of recommendation.
frailty.104,107,108Resistance exercise is recommended to be performed bLevel of evidence.
at least twice weekly (intensity of 60–80% of the individual’s
one-repetition maximum). For older or deconditioned adults, less vol-
ume and lower intensities are recommended, particularly during the ini-
tiation phase of 3–6 weeks.106 5.1.4. Smoking cessation
Interventions are based on encouraging an increase in any PA, as Smoking cessation is a key lifestyle intervention in patients with T2DM
even small amounts were shown to have beneficial effects; even an ex- with or without CVD with evidence suggesting a 36% reduction in mor-
tra 1000 steps of walking per day is advantageous and may be a good tality in CVD patients.118–120If advice, encouragement, and motivation
starting point for many patients.98,100Moreover, a gradual increase in are insufficient, then drug therapies should be considered early, includ-
activity level is recommended. Structured exercise should be addition- ing nicotine replacement therapy (chewing gum, transdermal nicotine
ally introduced at the start or after first achievements to increase activ- patches, nasal spray, inhaler, sublingual tablets) followed by bupro-
ity. Patients should perform ≥2 sessions per week of endurance pion.121 In patients with ASCVD, varenicline, bupropion, telephone
exercise and/or resistance exercise training. PA accumulated in bouts therapy, and individual counselling all increase success rates.122
of even <10 min is associated with favourable outcomes, including re- Electronic cigarettes (e-cigarettes) have been addressed as a potential
duced mortality.110,111 smoking cessation aid to bridge transition from smoking to abstention,
Interventions shown to increase PA level or reduce sedentary behav- but—if used at all—should be limited for a short period of time. A con-
iour include behaviour theory-based interventions, such as goal-setting, sensus regarding the efficacy and safety for this approach has yet to be
re-evaluation of goals, self-monitoring, and feedback.112,113 Using a reached.123,124Overall, smoking cessation programmes have low effi-
wearable activity tracker (e.g. smartphones) may help increase PA.114 cacy at 12 months; nonetheless, cessation measures should be repeti-
Most important is to encourage PA that people enjoy and/or can tively addressed for smoking abstention to succeed.125
3202CSE©
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

4064 E S C G u id e l in e s
The assessment of lifestyle risk-factor components and stepwise life- In addition to hypoglycaemia, glycaemic variability is emerging as a
style recommendations in patients with CVD and diabetes is summar- potential vascular risk factor, but studies are limited and more research
ized in more detail in Section 5.7. in this area is warranted.
Post-prandial glucose has been suggested to independently
Recommendation Table 6 — Recommendations for
predict vascular disease, even in individuals without a previous history
smoking cessation in patients with type 2 diabetes with
of diabetes.141However, manipulating prandial glucose levels failed to
or without cardiovascular disease
impact clinical outcome, and therefore, this remains an unresolved
Recommendations Classa Levelb
area.142,143
It is recommended to stop smoking to reduce
I A
cardiovascular risk.118–120
5.2.3. Glycaemic control following vascular events
Nicotine replacement therapy, varenicline, and
Hyperglycaemia following ACS is associated with worse clinical out-
bupropion, as well as individual or telephone
IIa B come.144 The DIGAMI 1 (Diabetes Mellitus Insulin-Glucose Infusion
counselling, should be considered to improve
in Acute Myocardial Infarction) trial demonstrated reduced mortal-
smoking cessation success rate.121
ity with intensive glucose control post-ACS, but DIGAMI 2, which
aClass of recommendation. was underpowered, failed to confirm these findings.145,146
bLevel of evidence. Unexpectedly, DIGAMI 2 showed a numerical increase in mortality
in the intervention arm, particularly in insulin-treated patients, sug-
5.2. Glycaemic targets gesting an adverse role for hypoglycaemia in this population.147
5.2.1. Role of glycated haemoglobin Therefore, large-scale glycaemic studies are required, using continu-
ous glucose monitoring (CGM) to assess glucose levels, to establish
Reducing HbA1c decreases microvascular complications, particularly
when achieving near-normal levels (HbA1c <7%, <53 mmol/mol), whether optimizing glycaemia in patients with CVD and diabetes
but the effects on macrovascular disease are more complex.126–129 improves clinical outcome.
In summary, glucose control in individuals with diabetes at high CV
The DCCT (Diabetes Control and Complications Trial) in T1DM
risk is a complex area and current evidence indicates the need to ad-
and the UKPDS (United Kindom Prospective Diabetes Study) in new-
dress multiple glycaemic measures, including personalizing HbA1c tar-
ly diagnosed T2DM have shown that reducing HbA1c decreases long-
gets, minimizing hypoglycaemic exposure, and limiting glucose
term macrovascular events without having a significant effect in the
medium term of 6.5–10.0 years.130–132 Other studies, such as variability. Figure 4provides a simple guide to glycaemic control in pa-
tients with T2DM and CVD.
ADVANCE (Action in Diabetes and Vascular Disease: Preterax and
Diamicron MR Controlled Evaluation), ACCORD (Action to
Control Cardiovascular Risk in Diabetes), and VADT (Veterans
Affairs Diabetes Trial), including higher-risk T2DM cohorts, have simi- Recommendation Table 7 — Recommendations for
larly failed to show an effect for intensive glycaemic control on short/ glycaemic targets in patients with diabetes
medium-term macrovascular risk (over 3.5–5.6 years). Meta-analyses
of the UKPDS, ADVANCE, ACCORD, and VADT studies, including Recommendations Classa Levelb
27 049 participants, have demonstrated that lowering HbA1c reduces
It is recommended to apply tight glycaemic control
MACE, driven by a reduction in MI (HF and stroke risk were unaffect-
(HbA1c <7%) to reduce microvascular I A
ed), and decreases microvascular complications (renal and retinal but
complications.126–128,133
not neuropathy).133,134
It is recommended to avoid hypoglycaemia,
Of interest, the ACCORD trial, with 35% of participants having a I B particularly in patients with CVD.134–137,147
previous CV event, showed increased mortality (HR 1.22; 95% CI,
1.01–1.46; P = 0.04) in the intensive glycaemic arm (HbA1c 6.5%, It is recommended to individualize HbA1c targets
48 mmol/mol) compared with controls.129Also, observational studies according to comorbidities, diabetes duration, and I C
have shown a U-shaped relationship between HbA1c and clinical out- life expectancy.134,137
come, suggesting that lower HbA1c is not always better.135,136 Tight glycaemic control should be considered for
reducing CAD in the long term, preferably using IIa B
agents with proven CV benefit.c,129–132
5.2.2. Additional glycaemic targets
CAD, coronary artery disease; CVD, cardiovascular disease; GLP-1 RA, glucagon-like
Hypoglycaemia is associated with an increased risk of vascular events, peptide-1 receptor agonist; HbA1c, glycated haemoglobin; s.c. subcutaneous; SGLT2,
explaining recent consensus advocating hypoglycaemic exposure at sodium–glucose co-transporter-2.
<1% (i.e. <15 min/day) in individuals at high CV risk.137,138A causal re- aClass of recommendation.
bLevel of evidence.
lationship between hypoglycaemia and adverse outcomes is not always cSGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, sotagliflozin) or GLP-1 RAs
clear as low glucose levels can be a marker of ill health.139,140 (liraglutide, semaglutide s.c., dulaglutide, efpeglenatide).
3202CSE©
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4065
Short life expectancy Longer life expectancy
Tighten glycaemic targets
Relax glycaemic targets
but AVOID hypoglycaemiab
HbA1c <69 mmol/mol (<8.5%)a
HbA1c <53 mmol/mol (<7.0%)
Give priority to agents with
Proven CV benefitc
Low hypoglycaemic risk
Figure 4 Simple guide to glycaemic targets in patients with type 2 diabetes and cardiovascular disease. CV, cardiovascular; GLP-1 RA, glucagon-like
peptide-1 receptor agonist; HbA1c, glycated haemoglobin, s.c., subcutaneous; SGLT2, sodium–glucose co-transporter-2. aAdjust target in the presence
of hyperglycaemic symptoms (polyuria and polydipsia). bHypoglycaemia is usually a concern only in those on a sulphonylurea and/or insulin. cSGLT2 inhibitors
(empagliflozin, canagliflozin, dapagliflozin, sotagliflozin) or GLP-1 RAs (liraglutide, semaglutide s.c., dulaglutide, efpeglenatide).
5.3. Atherosclerotic cardiovascular disease 5.3.1. Glucose-lowering medications with
risk reduction by glucose-lowering cardiovascular efficacy demonstrated in dedicated
cardiovascular outcomes trials medications in diabetes
5.3.1.1. Sodium–glucose co-transporter-2 inhibitors
T2DM is common among patients with ASCVD or at the highest risk of
The results of six CVOTs with SGLT2 inhibitors and one trial of a dual
CVD. The converse is also true: ASCVD is common in patients with SGLT1/2 inhibitor have been published, comprising the EMPA-REG
T2DM.148Given these relationships, it is key to consider the presence
OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in
of T2DM when deciding strategies to mitigate CV risk. It is imperative
Type 2 Diabetes Mellitus Patients–Removing Excess Glucose) trial,
that the first step in this process is to screen all patients with CVD for
the CANVAS (Canagliflozin Cardiovascular Assessment Study) pro-
T2DM. Many decisions are independent of glucose management, there-
gramme (two trials combined for analyses), the DECLARE-TIMI 58
fore, T2DM status can inform clinical decision-making for mitigating CV
(Dapagliflozin Effect on Cardiovascular Events−Thrombolysis In
risk, as discussed for several other interventions in the current
Guidelines.149Capitalizing on the results of multiple dedicated CVOTs Myocardial Infarction 58) trial, the CREDENCE (Canagliflozin and
of glucose-lowering medications in patients with diabetes and ASCVD Renal Events in Diabetes with Established Nephropathy Clinical
or at high CV risk, there is now a wealth of data to inform the preferential Evaluation) trial, the VERTIS CV (eValuation of ERTugliflozin
use of selected glucose-lowering medications to reduce CV risk, inde- effIcacy and Safety CardioVascular Outcomes) trial, and the
pendent of glucose management considerations. Glucose-lowering med- SCORED (Effect of Sotagliflozin on Cardiovascular and Renal
ications can be prescribed with two parallel, mutually exclusive intentions: Events in Patients with Type 2 Diabetes and Moderate Renal
(i) to improve CV outcomes and safety; and (ii) to control glucose. On this Impairment Who Are at Cardiovascular Risk) trial (Supplementary
basis, in the current Guidelines, we have separated prescribing recom- data online, Table S7).71,150–154
mendations into those intended to improve CV outcomes and those in- A meta-analysis of the six SGLT2 inhibitor trials demonstrated a re-
tended to control glucose. Underpinning these recommendations are duction in the primary ASCVD-based composite of time to first event
results from the key CVOTs delineating the efficacy and safety of glucose- of CV death, MI, or stroke (MACE). This was most apparent in patients
lowering therapies for treating T2DM and their effect on CV outcomes. with established ASCVD (Figure 5).155Of note, neither dapagliflozin nor
Downloaded
from

by
guest
on
22
January
2026

4066 E S C G u id e l in e s
A
Treatment Placebo
Rate/1000 Rate/1000 Hazard ratio
patient-years patient-years (95% CI)
EMPA-REG OUTCOME 37.4 43.9 0.86 (0.74–0.99)
CANVAS Program 26.9 31.5 0.86 (0.75–0.97)
DECLARE-TIMI 58 22.6 24.2 0.93 (0.84–1.03)
CREDENCE 38.7 48.7 0.80 (0.67–0.95)
VERTIS CV 40.0 40.3 0.99 (0.88–1.12)
Pooled estimate 0.90 (0.85–0.95)
(Q statistic P = 0.27; I2 = 23.4%)
0.25 0.5 1.0 2.0
Favours Treatment Favours Placebo
B
Treatment Placebo
Rate/1000 Rate/1000 Hazard ratio
patient-years patient-years (95% CI)
ASCVD EMPA-REG OUTCOME 37.4 43.9 0.86 (0.74–0.99)
CANVAS Program 34.1 41.3 0.82 (0.72–0.95)
DECLARE-TIMI 58 36.8 41.0 0.90 (0.79–1.02)
CREDENCE 55.6 65.0 0.85 (0.69–1.06)
VERTIS CV 40.0 40.3 0.99 (0.88–1.12)
Pooled estimate 0.89 (0.84–0.95)
(Q statistic P = 0.34; I2 = 11.8%)
No ASCVD CANVAS Program 15.8 15.5 0.98 (0.74–1.30)
DECLARE-TIMI 58 13.4 13.3 1.01 (0.66–1.20)
CREDENCE 22.0 32.7 0.68 (0.49–0.94)
Pooled estimate 0.94 (0.83–1.07)
(Q statistic P = 0.10; I2 = 56.5%)
0.25 0.5 1.0 2.0
Favours Treatment Favours Placebo
P interaction = 0.63
Figure 5 Meta-analysis of cardiovascular outcomes trial results of sodium–glucose co-transporter-2 inhibitors among patients with type 2 diabetes with or
at high risk for atherosclerotic cardiovascular disease. (A) Overall major adverse cardiovascular events; (B) Major adverse cardiovascular events by athero-
sclerotic cardiovascular disease status. ASCVD, atherosclerotic cardiovascular disease; CI, confidence interval; Figure adapted from McGuire et al. 2021.This
is an open access article distributed under the terms of the CC-BY-NC-ND License 
ertugliflozin reduced the risk of MACE, but both reduced risk of HF with SGLT2 inhibitors and/or GLP-1 RAs may be considered to re-
hospitalization, with consistency across the class for HF benefits duce CV risk, independent of glucose control considerations. This
(Section 7). Based on these aggregate results, along with the GLP-1 recommendation is a consensus within the Task Force based on the
RAs (see below), SGLT2 inhibitors are a preferred glucose-lowering assumption that some level of predicted CVD risk appears to be
therapy for patients with T2DM with ASCVD, independent of glucose equivalent to ‘severe TOD risk’, acknowledging it is a Level C recom-
control considerations, and independent of background metformin use. mendation. Of note, it is in line with recommendations from EASD
Results from the meta-analysis demonstrated no statistically signifi- and ADA.1,156,157
cant benefit for risk of MACE in the subsets of patients without
ASCVD but with multiple ASCVD risk factors; yet the point estimate
remains favourable in this subset, with no significant interaction by 5.3.1.2. Glucagon-like peptide-1 receptor agonists
ASCVD status (P = 0.63; Figure 5). In patients with T2DM without Eight randomized, placebo-controlled CVOTs have examined the CV
ASCVD or severe TOD but with a calculated 10-year CVD risk safety and efficacy of GLP-1 RAs in patients with T2DM with or at high
≥10% in the SCORE2-Diabetes algorithm (Section 4.1), treatment risk of ASCVD. These trials comprise the ELIXA (Evaluation of
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4067
TRIAL GLP-1 receptor Placebo Hazard ratio NNT
P value
Three-point MACE agonist n/N (%) n/N (%) (95% CI) (95% CI)
LEADER 608/4668(13%) 694/4672(15%) 0.87 (0.78–0.97) 0.01
SUSTAIN-6 108/1648(7%) 146/1649(9%) 0.74 (0.58–0.95) 0.016
EXSCEL 839/7356(11%) 905/7396(12%) 0.91 (0.83–1.00) 0.061
Harmony Outcomes 338/4731(7%) 428/4732(9%) 0.78 (0.68–0.90) 0.0006
REWIND 594/4949(12%) 663/4952(13%) 0.88 (0.79–0.99) 0.026
PIONEER 6 61/1591(4%) 76/1592(5%) 0.79 (0.57–1.11) 0.17
AMPLITUDE-O 189/2717(7%) 125/1359(9%) 0.73 (0.58–0.92) 0.0069
Subtotal (I2 = 14.9%, P = 0.316) 0.85 (0.80–0.90) 61 (46–92) <0.0001
Cardiovascular death
LEADER 219/4668(5%) 278/4672(6%) 0.78 (0.66–0.93) 0.007
SUSTAIN-6 44/1648(3%) 46/1649(3%) 0.98 (0.65–1.48) 0.92
EXSCEL 340/7356(5%) 383/7396(5%) 0.88 (0.76–1.02) 0.096
Harmony Outcomes 122/4731(3%) 130/4732(3%) 0.93 (0.73–1.19) 0.58
REWIND 317/4949(6%) 346/4952(7%) 0.91 (0.78–1.06) 0.21
PIONEER 6 15/1591(1%) 30/1592(2%) 0.49 (0.27–0.92) 0.021
AMPLITUDE-O 75/2717(3%) 50/1359(4%) 0.72 (0.50–1.03) 0.07
Subtotal (I2 = 12.4%, P = 0.335) 0.85 (0.78–0.93) 142 (97–305) 0.0005
Fatal or non-fatal myocardial infarction
LEADER 292/4668(6%) 339/4672(7%) 0.86 (0.73–1.00) 0.046
SUSTAIN-6 54/1648(3%) 67/1649(4%) 0.81 (0.57–1.16) 0.26
EXSCEL 483/7356(7%) 493/7396(7%) 0.97 (0.85–1.10) 0.62
Harmony Outcomes 181/4731(4%) 240/4732(5%) 0.75 (0.61–0.90) 0.003
REWIND 223/4949(5%) 231/4952(5%) 0.96 (0.79–1.15) 0.63
PIONEER 6 37/1591(2%) 35/1592(2%) 1.04 (0.66–1.66) 0.49
AMPLITUDE-O 91/2717(3%) 58/1359(4%) 0.75 (0.54–1.05) 0.09
Subtotal (I2 = 16.2%, P = 0.306) 0.88 (0.81–0.96) 154 (97–463) 0.0048
Fatal or non-fatal stroke
LEADER 173/4668(4%) 199/4672(4%) 0.86 (0.71–1.06) 0.16
SUSTAIN-6 30/1648(2%) 46/1649(3%) 0.65 (0.41–1.03) 0.066
EXSCEL 187/7356(3%) 218/7396(3%) 0.85 (0.70–1.03) 0.095
Harmony Outcomes 94/4731(2%) 108/4732(2%) 0.86 (0.66–1.14) 0.30
REWIND 158/4949(3%) 205/4952(4%) 0.76 (0.62–0.94) 0.010
PIONEER 6 13/1591(1%) 17/1592(1%) 0.76 (0.37–1.56) 0.43
AMPLITUDE-O 47/2717(2%) 31/1359(2%) 0.74 (0.47–1.17) 0.19
Subtotal (I2 = 0.0%, P = 0.903) 0.81 (0.74–0.90) 171 (124–324)<0.0001
0.5 1 1.5
Note: Weights are from random effects analysis Favours GLP-1RA Favours Placebo
Figure 6 Meta-analysis of cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists (sensitivity analysis removing ELIXA). Risk of major
adverse cardiovascular events and its components. CI, confidence interval; GLP-1, glucagon-like peptide-1; MACE, major adverse cardiovascular outcomes;
NNT, number needed to treat. Figure adapted from Sattar et al. 2021.Reprinted from the Lancet with permission from Elsevier.164
Lixisenatide in Acute Coronary Syndrome) trial, the LEADER (Liraglutide Mellitus) trial, the REWIND (Researching Cardiovascular Events With a
Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Weekly Incretin in Diabetes) trial, the PIONEER 6 (Trial Investigating
Results) trial, the SUSTAIN 6 (Trial to Evaluate Cardiovascular and the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2
Other Long-term Outcomes With Semaglutide in Subjects With Type Diabetes) trial, and the AMPLITUDE-O (Effect of Efpeglenatide on
2 Diabetes) trial, the EXSCEL (Exenatide Study of Cardiovascular Event Cardiovascular Outcomes) trial (Supplementary data online,
Lowering) trial, the HARMONY Outcomes (Effect of Albiglutide, Table S8).70,72,158–163
When Added to Standard Blood Glucose Lowering Therapies, on Five of the eight GLP-1 RAs tested demonstrated superior CV out-
Major Cardiovascular Events in Subjects With Type 2 Diabetes comes on the primary composite of time to the first event of CV death,
Downloaded
from

by
guest
on
22
January
2026

4068 E S C G u id e l in e s
MI, and stroke compared with placebo. A meta-analysis of seven of the it is reasonable to consider using pioglitazone to mitigate ASCVD risk in
eight completed GLP-1 RA trials, excluding the ELIXA trial results (due patients with T2DM and prevalent ASCVD.
to a very short pharmacodynamic half-life [3 h] of once a day [o.d.] lix-
isenatide, and the very high-risk population post-ACS differentiating it
5.3.2. Glucose-lowering medications with
from all others), showed that a pooled estimate for GLP-1 RA vs. pla-
cardiovascular safety but not incremental efficacy
cebo for the primary outcome was reduced by 15% (HR 0.85; 95% CI,
demonstrated in dedicated cardiovascular outcomes
0.80–0.90; Figure 6).164Results from pooled analyses of the effects of
trials
GLP-1 RA vs. placebo on individual CV outcomes included CV death
5.3.2.1. Dipeptidyl peptidase-4 inhibitors
(HR 0.85; 95% CI, 0.78–0.93), MI (HR 0.88; 95% CI, 0.81–0.96), stroke
Five randomized CV safety trials in populations with T2DM with or at
(HR 0.81; 95% CI, 0.74–0.90), and hospitalization for HF (HR 0.88; 95%
high risk of ASCVD have assessed the CV effects of dipeptidyl
CI, 0.79–0.98). Notably, the point estimate in the seven trials was lower
peptidase-4 (DPP-4) inhibitors (Supplementary data online, Table S9):
(HR = 0.85) in those with established ASCVD than in those without
saxagliptin, alogliptin, sitagliptin, and linagliptin each vs. placebo, and li-
(HR = 0.94), with P = 0.068, suggesting but not conclusively proving int nagliptin vs. glimepiride.172–175All four of the placebo-controlled trials
that GLP-1 RAs may reduce risks more in those with established
demonstrated statistical non-inferiority but not superiority for the
ASCVD. As absolute risks are greater in those with established CV dis-
DPP-4 inhibitors in the primary MACE endpoint. In the SAVOR-TIMI
ease, the absolute benefits are also expected to be greater.
53 (Saxagliptin Assessment of Vascular Outcomes Recorded in
Based on these aggregate results, along with the SGLT2 inhibitors (see
Patients with Diabetes Mellitus—Thrombolysis in Myocardial
above) GLP-1 RAs are a preferred glucose-lowering therapy for patients
Infarction 53) trial, saxagliptin statistically significantly increased the with T2DM and ASCVD, independent of glucose control considera-
risk of hospitalization for HF vs. placebo.176 Numerically, more HF
tions, and independent of background metformin use. In patients with
events occurred with alogliptin vs. placebo in the EXAMINE
T2DM without ASCVD or severe TOD, but with a calculated 10-year
(Cardiovascular Outcomes Study of Alogliptin in Patients With Type
CVD risk ≥10% in the SCORE2-Diabetes algorithm (Section 4), treat-
2 Diabetes and Acute Coronary Syndrome) trial, though this difference
ment with GLP-1 RAs and/or SGLT2 inhibitors may be considered to re-
was not nominally significant.177
duce CV risk, independent of glucose control considerations. This
These observations led to the development and regulatory filing of
recommendation is a consensus within the Task Force based on the as-
prospective HF analysis plans for the TECOS (Trial Evaluating
sumption that some level of predicted CVD risk appears to be equivalent
Cardiovascular Outcomes with Sitagliptin) and CARMELINA
to ‘severe TOD risk’, acknowledging it is a Level C recommendation. Of
note, it is in line with recommendations from EASD and ADA.1,156,157 (Cardiovascular and Renal Microvascular Outcome Study With
Linagliptin in Patients With Type 2 Diabetes Mellitus) trials, each of
which revealed no increased risk of HF with either sitagliptin or linaglip-
5.3.1.3. Pioglitazone tin compared with placebo.178,179In the CAROLINA (Cardiovascular
The PROactive (Prospective Pioglitazone Clinical Trial in Outcome Study of Linagliptin Versus Glimepiride in Patients With
Macrovascular Events) randomized CVOT assessed the CV effects Type 2 Diabetes) trial, linagliptin was compared with the active com-
of the thiazolidinedione (TZD) pioglitazone vs. placebo, independent parator glimepiride, demonstrating no difference in any assessed CV
of glucose control, in patients with T2DM and ASCVD. It failed to or kidney outcome, though noting a higher risk of hypoglycaemia
achieve statistical significance for its primary composite outcome of with glimepiride.180
all-cause death, MI, stroke, unstable angina, coronary or peripheral re-
vascularization, and amputation (HR 0.90; 95% CI, 0.80–1.02).165
5.3.2.2. Lixisenatide and exenatide
However, for the principal secondary outcome evaluating the gold-
Of the eight GLP-1 RAs evaluated in CVOTs, two have demonstrated
standard, three-point composite outcome of CV death, MI, and
safety but not incremental efficacy. In the ELIXA trial, lixisenatide 10 or
stroke, there was a nominally significant 16% relative risk (RR) reduc-
20 μg o.d. was non-inferior to placebo, but did not significantly affect a tion (HR 0.84; 95% CI, 0.72–0.98).165
four-point MACE (three-point MACE plus hospitalization for unstable
Results from subsequent meta-analyses and observational studies
angina) in patients with T2DM post-ACS.158In the EXSCEL trial of pa-
have supported the suggested efficacy of pioglitazone in persons with
tients with T2DM in whom 73% had experienced a previous CV event,
ASCVD.166–169 Notably, the magnitude of the estimated treatment
exenatide extended-release 2 mg once weekly showed non-inferiority
benefit with pioglitazone across these studies aligns with contemporary
but not superiority to placebo for the primary outcome of CV death,
meta-analyses estimates of the effects of SGLT2 inhibitors and GLP-1
MI, and stroke.159
RAs on the same composite MACE outcome.155,164
TZDs enhance fluid retention and the risk of peripheral oedema, es-
pecially with concomitant insulin use and in the context of kidney dys- 5.3.2.3. Insulin
function. In addition, TZDs increase the risk of HF, with the incremental Two basal insulins have been formally evaluated in dedicated CVOTs. In
risk of HF with pioglitazone at an estimated 0.4% annualized, absolute the ORIGIN (Outcome Reduction With Initial Glargine Intervention)
increase.170HF associated with TZDs appears to be attributable to ex- trial, 12 537 patients (mean age 63.5 years) at high CVD risk with im-
panded plasma volume, with no evidence of myocardial toxicity.171 paired fasting glucose (IFG), impaired glucose tolerance (IGT), or
TZDs induce weight gain due to adipose tissue expansion, but with T2DM were randomized to insulin glargine titrated to a fasting blood
weight redistributed predominantly to less metabolically active adipose glucose level of ≤5.3 mmol/L (≤95 mg/dL) or standard care.86After a
tissue; weight gain may be the greatest concern of patients and clinicians median follow-up of 6.2 years, the incidence of CV outcomes did not
with the TZD class. Based on the data and net benefit-risk assessment, differ between the two groups.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4069
The DEVOTE (A Trial Comparing Cardiovascular Safety of Insulin with metformin. Therefore, in patients already prescribed metformin,
Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes SGLT2 inhibitors and/or GLP-1 RAs should be added, independent of
at High Risk of Cardiovascular Events) trial, a randomized, double-blind the need for additional glucose control. In patients with T2DM and
comparison of the ultra-long-acting, o.d. insulin degludec vs. insulin glar- ASCVD not treated with metformin, an SGLT2 inhibitor and/or GLP-1
gine U100, enrolled 7637 patients with T2DM with ASCVD or at high RA should be given first line, and metformin should be considered for
CV risk.181Over a median follow-up of 1.8 years, there was no signifi- those who thereafter warrant additional glucose control. This Class IIa
cant difference in the primary composite of CV death, non-fatal MI, or recommendation for metformin is based on the weight of opinion rather
non-fatal stroke between groups. A significantly lower frequency of than the weight of evidence; results from meta-analyses of observational
hypoglycaemia was observed in the degludec arm compared with the studies suggest associations with better CV outcome, but this is not sup-
glargine arm.181 ported by results from meta-analyses restricted to randomized trials in
patients with T2DM and ASCVD, where no statistically significant effect
of metformin has been observed for any major CV outcome.184,185
5.3.2.4. Glimepiride
In patients without ASCVD or severe TOD at low or moderate CV
Based on the findings of statistical non-inferiority of linagliptin vs. pla-
risk, treatment with metformin should be considered based on the
cebo in CARMELINA coupled with the non-inferiority of linagliptin
metformin data from the randomized sub-group with overweight or
vs. glimepiride demonstrated in CAROLINA, one might conclude
obesity from the UKPDS.183 For patients without ASCVD or severe
that glimepiride is most likely not different from placebo with regards
TOD at high or very CV high risk, treatment with metformin may be to CV safety.180Thus, the long-lasting uncertainty about the CV safety
considered based on expert consensus of the Task Force.
of sulphonylureas may no longer be clinically relevant for glimeperide, at
least in patients with a shorter duration of diabetes like those enrolled
in the CAROLINA trial (median duration of T2DM ∼6 years).182 5.3.3.2. Sulphonylureas
Excepting glimepiride, which was assessed for CV safety and efficacy
head-to-head against linagliptin in the CAROLINA trial, and gliclazide-
5.3.3. Cardiovascular considerations of older
modified release, which was compared with usual care (that could
glucose-lowering medications not tested in dedicated
have included treatment with a sulphonylurea other than gliclazide) in
cardiovascular outcomes trials
the ADVANCE trial, dedicated CV safety assessments have not been
5.3.3.1. Metformin
conducted for the other sulphonylureas.132,173,174,184 In the UKPDS,
Despite its long history as the recommended first-line treatment of
which enrolled patients with newly diagnosed T2DM, the sulphonylur-
hyperglycaemia for patients with T2DM, there have been no dedicated
eas chlorpropamide and glibenclamide (also known as glyburide) did
randomized trials to rigorously assess the CV safety or efficacy of met-
not have statistically significant effects on CV outcomes, but important-
formin. Randomized trials that have reported CV outcomes with met- ly, no concerning signal of CV risk was observed.127 Likewise, in the
formin are most-commonly limited by small sample sizes and few CV
ADVANCE trial evaluating more intensive glucose control vs. usual tar-
events for analysis, yielding low statistical power and substantially un-
gets, patients randomized to the more intensive arm were randomized
certain statistical precision of the estimates. to treatment with gliclazide-modified release.128While the gliclazide-
The largest randomized trial with the most encouraging CV results
based more intensive control strategy did not significantly improve
for metformin was a nested randomized trial of 753 patients in the
CV outcomes, there were no major CV safety concerns observed.
UKPDS who were overweight or obese at trial entry, comparing con-
The relative CV safety of gliclazide and glimepiride is somewhat sup-
ventional glucose targets with a policy of intensive glucose lowering ported by results of contemporary real-world data analyses.186
with metformin.183In overweight and obese patients with newly diag-
nosed T2DM without previous CVD, metformin reduced MI by 39%,
coronary death by 50%, and stroke by 41% over a median period of 5.3.4. Special considerations
10.7 years. However, with only 39 MIs and 16 coronary deaths in the 5.3.4.1. Hypoglycaemia and cardiovascular risk
metformin arm of the UKPDS, the precision of these efficacy estimates Results from numerous studies have demonstrated associations between
is largely uncertain. Initial randomization to metformin in the UKPDS hypoglycaemia and CV events, with substantial uncertainty about whether
was also associated with a lower incidence of MI and longer survival these relationships are causal or simply associations. Results from rando-
during an additional 8–10 years of passive follow-up.132 mized trials challenge a causal relationship between hypoglycaemia and ad-
In meta-analyses of 13 randomized clinical trials evaluating the CV ef- verse CV outcomes. For example, insulin degludec compared with
fects of metformin vs. placebo or active control, including the data from glargine in the DEVOTE trial reduced the risk of hypoglycaemia, yet this
the UKPDS, none of the differences in assessed CV outcomes was stat- did not translate into any difference in CV risk.181 Likewise, in the
istically significant.184The pooled HRs (95% CIs) were: all-cause mortal- CAROLINA randomized trial, while glimepiride was associated with sig-
ity 0.96 (0.84–1.09); CV death 0.97 (0.80–1.16); MI 0.89 (0.75–1.06); nificantly more hypoglycaemia than the DPP-4 inhibitor linagliptin,
stroke 1.04 (0.73–1.48); and peripheral vascular disease 0.81 (0.50– MACE did not differ between the two randomized groups.180The results
1.31). While failing to demonstrate CV efficacy, the upper confidence of these two trials challenge, to some degree, the premise that avoiding
limits of each of the outcomes analysed provide reassurance on the hypoglycaemia may improve CV risk. In analyses of data from the
CV safety of metformin. TECOS randomized trial, which compared sitagliptin with placebo, hypo-
Given the inconclusive results regarding the CV effects of metformin glycaemia events were independently associated with subsequent CV
outlined above, metformin should not be a prerequisite for considering events, but importantly, the converse was also true.139A non-fatal CV
SGLT2 inhibitor or GLP-1 RA treatment for CV benefits. However, most event was independently associated with subsequent hypoglycaemia.
patients in CVOTs with SGLT2 inhibitors or GLP-1 RAs were treated Similar results were confirmed in other trials.140,187,188
Downloaded
from

by
guest
on
22
January
2026

4070 E S C G u id e l in e s
Therefore, the data suggest that the relationship between hypogly- 5.3.5. Implications of results from cardiovascular
caemia events and risk of CV events (and vice versa) is most likely outcomes trials of glucose-lowering medications
one of association rather than causation, each risk marking vulnerability Beginning with the EMPA-REG OUTCOME trial results in 2015, an ever-
and frailty of high CV risk patients. Still, in certain patients, hypogly- increasing body of evidence has accumulated from many CVOTs of
caemia may directly contribute to CV risk. In addition, avoiding hypogly- glucose-lowering medications for patients with T2DM that indicate CV
caemia remains important given the unpleasant patient experience and, benefits from using selected SGLT2 inhibitors and GLP-1 RAs in patients
for severe events, life-threatening nature if third-party assistance is not with ASCVD. The combined results obtained from CVOTs using GLP-1
available. RAs and SGLT2 inhibitors support the primacy of their recommendation
for all patients with T2DM with prevalent ASCVD, with such considera-
5.3.4.2. Effects on weight tions made independently of decisions about glycaemic management
The choice of glucose-lowering therapy is often influenced by effects on (Figures 7and 8). Just as T2DM informs prescription of statins, antithrom-
weight, when weight loss or avoiding weight gain is a priority. The insu- botic therapy, angiotensin-converting enzyme inhibitors (ACE-Is)/
lins, sulphonylureas, and pioglitazone all cause weight gain; metformin, angiotensin-II receptor blockers (ARBs), and other CV risk-mitigating
acarbose, and the DPP-4 inhibitors are weight neutral or may result therapies independent of glycaemic considerations, the same should
in small amounts of weight loss; and the SGLT2 inhibitors and GLP-1 now apply to prescribing SGLT2 inhibitors and/or GLP-1 RAs.
RAs are associated with clinically meaningful weight loss, with weight The mechanisms of CV benefits of the novel glucose-lowering
effects of GLP-1 RAs being more pronounced than that of SGLT2 medications with proven efficacy remain incompletely understood.
inhibitors. For the GLP-1 RAs, CV efficacy is driven by reduced risk of
Metformin
S G
LT2
inhibitor
GLP-1 RA
(Class IIb)
S G
G L
Metfo (r Clm ai sn
s
IIa ) Moderate ris evk
ere
eT
s
O
<1D
0H %ig h N Sor Ci As OSk C RV E2D -D o ir a bs eev tee sr e � T 1O 0%D AVe Sr Cy hig h ris
k
( CL lT a s2 s Ii )n hP i b- i1 t
o
rR A ba
w
risk
CVD
or
Es 2-Diabet V
D
Lo
No
AS SCOR
Risk assessment for patients with type 2 diabetes based on the presence of
ASCVD/severe TOD and 10-year CVD risk estimation via SCORE2-Diabetes
Figure 7 Glucose-lowering treatment for patients with type 2 diabetes to reduce cardiovascular risk based on the presence of atherosclerotic cardiovas-
cular disease/severe target-organ damage and 10-year cardiovascular disease risk estimation via SCORE2-Diabetes. ASCVD, atherosclerotic cardiovascular
disease; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1 receptor agonist; s.c., subcutaneous; SGLT2, sodium–glucose co-transporter-2;
T2DM, type 2 diabetes mellitus; TOD, target-organ damage. Risk categorization is based on the presence of ASCVD/severe TOD and 10-year CVD risk
estimation via SCORE2-Diabetes. For patients with ASCVD, only the Class I recommendation is shown. Treatment recommendations for patients with
T2DM and severe TOD are described in Section 9. Severe TOD defined as eGFR <45 mL/min/1.73 m2 irrespective of albuminuria; or eGFR 45–59 mL/
min/1.73 m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or proteinuria (UACR >300 mg/g; stage A3); or presence of microvascular disease
in at least three different sites [e.g. microalbuminuria (stage A2) plus retinopathy plus neuropathy]. aGLP-1 RAs with proven CV benefit: liraglutide, semaglu-
tide s.c., dulaglutide, efpeglenatide. bSGLT2 inhibitors with proven CV benefit: empagliflozin, canagliflozin, dapagliflozin, sotagliflozin.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4071
To reduce CV risk independent of glucose controla
GLP-1 RAb SGLT2 inhibitorc
(Class I) (Class I)
Independent of HbA1c
Independent of concomitant glucose-lowering medication
For additional glucose control
Glucose-lowering agents with suggested CV benefit
Metformin
(Class IIa)
Pioglitazoned
(Class IIb)
Glucose-lowering agents with proven CV safety
DPP-4 inhibitors (sitagliptin, alogliptin, linagliptin)e
Ertugliflozinf
Sulfonylureas (glimepiride or gliclazide)
Insulin glargine or insulin degludec
Other GLP-1 RAs (lixisenatide, exenatide ER, oral semaglutide)
Glucose-lowering agents without CV safety evaluation
E.g. short-acting insulins
E.g. other sulfonylureas
Figure 8 Glucose-lowering treatment for patients with type 2 diabetes and atherosclerotic cardiovascular disease to reduce cardiovascular risk. ASCVD,
atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CV, cardiovascular; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration
rate; ER, extended release; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; MACE, major adverse cardiovascular events;
s.c., subcutaneous; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus. aIn patients with ASCVD and T2DM, it is recommended to
treat with a GLP-1 RA and an SGLT2 inhibitor with proven benefit to reduce CV risk, independent of HbA1c and concomitant glucose-lowering medications.
If additional glucose control is needed, treatment with metformin should be considered and treatment with pioglitazone may be considered. bGLP-1 RAs with
proven CV benefit: liraglutide, semaglutide s.c., dulaglutide, efpeglenatide. cSGLT2 inhibitors with proven CV benefit: empagliflozin, canagliflozin, dapagliflozin,
sotagliflozin. dPioglitazone should not be used in patients with heart failure; the use in CKD requires caution as intravascular volume expansion and heart
failure are common at reduced eGFR. eDPP-4 inhibitors should not be used in patients on GLP-1 RAs. fErtugliflozin in the VERTIS CV trial showed safety
with respect to three-point MACE but no benefit.
Downloaded
from

by
guest
on
22
January
2026

4072 E S C G u id e l in e s
Recommendation Table 8 — Recommendations for
In patients with T2DM without ASCVD or severe
glucose-lowering treatment for patients with type 2
TODc at high or very high risk, treatment with IIb C
diabetes and atherosclerotic cardiovascular disease to
reduce cardiovascular risk metformin may be considered to reduce CV risk.
In patients with T2DM without ASCVD or severe
Recommendations Classa Levelb TODc but with a calculated 10-year CVD riskd
IIb C
≥10%, treatment with a SGLT2 inhibitor or GLP-1
It is recommended to prioritize the use of
glucose-lowering agents with proven CV benefitsc,d RA may be considered to reduce CV risk.155,164
I C
followed by agents with proven CV safetye over agents ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular
without proven CV benefit or proven CV safety. disease; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1
receptor agonist; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes
Sodium–glucose co-transporter-2 inhibitors mellitus; TOD, target-organ damage; UACR, urinary albumin-to-creatinine ratio.
SGLT2 inhibitors with proven CV benefitc are aClass of recommendation.
bLevel of evidence.
recommended in patients with T2DM and ASCVD cSevere TOD defined as eGFR <45 mL/min/1.73 m2 irrespective of albuminuria; or eGFR
to reduce CV events, independent of baseline or I A 45–59 mL/min/1.73 m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or
proteinuria (UACR >300 mg/g; stage A3); or presence of microvascular disease in at
target HbA1c and independent of concomitant
least three different sites [e.g. microalbuminuria (stage A2) plus retinopathy plus
glucose-lowering medication.71,150–152,155,189 neuropathy].
Glucagon-like peptide-1 receptor agonists dUsing SCORE2-Diabetes.
GLP-1 RAs with proven CV benefitd are
recommended in patients with T2DM and ASCVD
ASCVD-related events.164While empagliflozin and canagliflozin im-
to reduce CV events, independent of baseline or I A
proved the composite of CV death, MI, and stroke, all of the
target HbA1c and independent of concomitant
glucose-lowering medication.70,72,161,163,164 SGLT2 inhibitors reduce HF-related endpoints (Section 7) and pro-
gression of kidney disease (Section 9).155,190Thus, SGLT2 inhibitors
Other glucose-lowering medications to reduce cardiovascular
are recommended to reduce HF hospitalization in patients with
risk
T2DM with or at risk of HF, or who have CKD. In patients with newly
If additional glucose control is needed, metformin diagnosed T2DM without CVD or other major CV risk factors who
should be considered in patients with T2DM and IIa C are at low or moderate CV risk, factors other than mitigating CV and
ASCVD. kidney risk may play a greater role in selecting glucose-lowering med-
If additional glucose control is needed, pioglitazone ications, such as affordability, accessibility, side effects, weight bene-
may be considered in patients with T2DM and IIb B fits, tolerability, and ease of use.
ASCVD without HF.165
5.4. Blood pressure and diabetes
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular
disease; DPP-4, dipeptidyl peptidase-4; GLP-1 RA, glucagon-like peptide-1 receptor In the most recent ESC/EURObservational Research Programme
agonist; HbA1c, glycated haemoglobin; HF, heart failure; s.c., subcutaneous; SGLT2, (EORP) EUROASPIRE surveys, history of hypertension was present
sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus.
in 80% of men and 87% of women with known diabetes and in 74%
aClass of recommendation.
bLevel of evidence. of men and 81% of women with newly diagnosed diabetes with a his-
cEmpagliflozin, canagliflozin, dapagliflozin, sotagliflozin. tory of coronary heart disease (CHD).191
dLiraglutide, semaglutide s.c., dulaglutide, efpeglenatide.
eMetformin, pioglitazone, DPP-4 inhibitor (sitagliptin, alogliptin, linagliptin), glimepiride,
gliclazide, insulin glargine, insulin degludec, ertugliflozin, lixisenatide, exenatide (extended 5.4.1. Screening and diagnosis
release), oral semaglutide. Regular BP measurements under standardized conditions are manda-
tory in all patients with diabetes (Figure 9; Table 8). Hypertension
should be confirmed in both arms using multiple readings, including
Recommendation Table 9 — Recommendation for
glucose-lowering treatment for patients with type 2 dia- measurements on separate days.48,157In patients with CVD and values
betes without atherosclerotic cardiovascular disease or >180/110 mmHg, it could be reasonable to diagnose hypertension at a
severe target-organ damage to reduce cardiovascular single visit.192Details on BP measurements are comprehensively sum-
risk marized in the 2018 ESC/European Society of Hypertension (ESH)
Guidelines for the management of arterial hypertension and in the
Recommendations Classa Levelb Supplementary data online, Section 2.6.1.193
In patients with T2DM without ASCVD or severe
TODc at low or moderate risk, treatment with IIa C 5.4.2. Treatment targets
metformin should be considered to reduce CV risk.183 Randomized controlled trials have shown the benefit (reduction of
Continued stroke, coronary events, and kidney disease) of lowering SBP to
3202CSE©
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4073
Patient with increased BP
High normal BP
Hypertension
SBP 130–139 mmHg
BP ≥140/90 mmHg
and/or DBP 85–89 mmHg
Consider masked hypertension To confirm diagnosis
Repeated visits for
office BP measurements
Out of office BP
OR
measurement
Out of office BP
(ABPM or HBPM)
measurement
(ABPM or HBPM)
Figure 9 Screening and diagnosis of hypertension in patients with diabetes. ABPM, ambulatory blood pressure monitoring; BP, blood pressure; DBP, dia-
stolic blood pressure; HBPM, home blood pressure monitoring; SBP, systolic blood pressure. Figure adapted from Williams et al. 2018.193
95% CI, 0.83–0.98), whereas more intensive BP control (≤130 mmHg) was
Table 8 Blood pressure measurement
associated with a greater reduction in stroke but did not reduce other
BP measurements at the initial and every follow-up visit (at every routine events.194,195 Similarly, anti-hypertensive treatment significantly reduced
clinical visit). mortality in people with T2DM, CAD, HF, and stroke, with an achieved
Patients should be seated comfortably in a quiet environment for 5 min mean SBP of 138 mmHg, whereas only stroke was reduced significantly,
before beginning BP measurements. with a mean SBP of 122 mmHg compared with higher BP values.196
Three BP measurements should be recorded, 1–2 min apart, and Thus, reducing SBP to <130 mmHg may benefit patients with a particularly
additional measurements if the first two readings differ by >10 mmHg. high risk of a cerebrovascular event, such as those with a history of
BP is recorded as the average of the last two BP readings. stroke.193,194,196–200However, SBP >140 mmHg or <120 mmHg were re-
Measure BP 1 min and 3 min after standing from a seated position in all lated to higher risk of adverse renal outcomes in patients with diabetes
patients on initial visit to exclude orthostatic hypotension; lying and when compared with those without diabetes and with high CV risk.199–202
The 2018 ESC/ESH Guidelines for the management of arterial hyper-
standing BP measurements should also be considered in subsequent
tension recommend that in all patients with diabetes, office BP should
visits.
be targeted to an SBP of 130 mmHg, and lower if tolerated but not
Out-of-office BP measurement with ambulatory and/or home BP
<120 mmHg; DBP should be lowered to <80 mmHg but not
monitoring should be implemented when feasible. <70 mmHg.193In older patients (age ≥65 years), the SBP target range
Masked hypertension should be considered in patients with normal and should be 130–140 mmHg if tolerated.193However, more recent data
high-normal office BP but with HMOD or at high cardiovascular risk.193
challenge these recommendations for all patients with diabetes, and
BP, blood pressure; HMOD, hypertension-mediated organ damage. highlight a potential need for more individualized target levels.157,203,204
The 2021 ESC Prevention Guideline recommends office SBP treat-
ment target ranges of 120–130 mmHg in patients with diabetes, with
<140 mmHg and diastolic blood pressure (DBP) to <90 mmHg in pa-
lower SBP acceptable if tolerated until the age of 69 years.48In patients
tients with diabetes. However, the optimal BP target in patients with
aged ≥70 years, SBP values <140 mmHg, down to 130 mmHg if toler-
diabetes is still a matter of debate. The UKPDS post-trial, 10-year
ated are recommended. DBP treatment target <80 mmHg is recom-
follow-up study reported no benefits persisting from the earlier period
mended for all treated patients.
of tight BP control with respect to macrovascular events, death, and
microvascular complications, while initial between-group BP differ-
ences were no longer maintained.132 RCTs evaluating the benefits
and risks of more intense compared with standard hypertension treat- 5.4.3. Management of hypertension
ment strategies in patients with diabetes are summarized in 5.4.3.1. Effects of lifestyle intervention and weight loss
Supplementary data online, Table S10. Diets rich in vegetables, fruits, and low-fat dairy products, such as the
In a meta-analysis of RCTs involving patients with diabetes or pre- Mediterranean diets and Dietary Approaches to Stop Hypertension-style
diabetes, an SBP reduction to ≤135 mmHg compared with a less intensive eating patterns (including reducing sodium to <100 mmol/day and increas-
control reduced the RR of all-cause mortality by 10% (odds ratio [OR] 0.90; ing potassium intake), improve BP control.205–207
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

4074 E S C G u id e l in e s
Long-term exercise training intervention modestly but significantly pregnancy, where 16% of the pregnant women had diabetes.229 The
reduces SBP (by −7 mmHg) and DBP (by −5 mmHg). Ideally, an exer- strategy targeting a BP of <140/90 mmHg was related with better preg-
cise prescription aimed at lowering BP in individuals with normal BP ancy outcomes without an increase in the number of Small for
or hypertension would include a mix of predominantly aerobic exercise Gestational Age babies.
training supplemented with dynamic resistance exercise training.208 Women usually show greater differences in BP and higher propor-
A marked improvement in CV risk factors (hypertension, dyslipidae- tions of hypertension than men already at diagnosis of T2DM com-
mia, diabetes), associated with marked weight loss, was observed after pared with women and men without T2DM, and worse BP control
bariatric surgery.209 In the Look AHEAD trial, those who lost 5 to thereafter.191,230Moreover sex-specific, hypertension-mediated organ
<10% of body weight had increased odds of achieving a 5 mmHg de- damage was evidenced with a very high risk of HFpEF in women, espe-
crease in SBP and DBP compared with those who lost >10% or cially in the presence of diabetes.231
<5%.210The frequency of CV complications appears to be modulated
by ethnicity or racial identity.193,211,212
5.4.3.2. Pharmacological treatments in patients with diabetes Recommendation Table 10 — Recommendations for
blood pressure management in patients with diabetes
If office SBP is ≥140 mmHg and/or DBP is ≥90 mmHg, drug therapy is
necessary in combination with non-pharmacological treatment. It is re-
Recommendations Classa Levelb
commended to start with a combination therapy.48 All available
BP-lowering drugs can be used, but evidence strongly supports using a Screening for hypertension
renin–angiotensin system (RAS) inhibitor (ACE-I, ARB), particularly in
Regular BP measurementsc are recommended in all
patients with evidence of end-organ damage (albuminuria and left ven-
patients with diabetes to detect and treat I A
tricular [LV] hypertrophy).213–216However, in a recent meta-analysis,
hypertension to reduce CV risk.193,232,233
RAS inhibitors were not superior to other classes of anti-hypertensive
drugs for reducing total or CV mortality and renal events.217 Treatment targets
Controlling BP often requires multiple drug therapy with an RAS inhibi- Anti-hypertensive drug treatment is recommended
tor and a calcium channel blocker (CCB) or diuretic, while the combination for people with diabetes when office BP is ≥140/ I A
of an ACE-I with an ARB is not recommended.218Consider beta-blockers 90 mmHg.196,202,234,235
at any treatment step when specifically indicated, e.g. HF, angina, post-MI,
It is recommended to treat hypertension in patients
AF, or younger women with or planning pregnancy.193A combination of
with diabetes in an individualized manner. The BP goal
two or more drugs at fixed doses in a single pill should be considered to
is to target SBP to 130 mmHg and <130 mmHg if
improve adherence and to achieve earlier control of BP.48,219 I A
tolerated, but not <120 mmHg. In older people (age
In apparent resistant (including MRA-resistant) hypertension in pa-
>65 years), it is recommended to target SBP to 130–
tients with HFpEF (61% diabetes; post-hoc analysis of PARAGON-HF
139 mmHg.196,236–238
[Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity
An on-treatment SBP target of <130 mmHg may be
and Mortality in Heart Failure Patients With Preserved Ejection
considered in patients with diabetes at particularly
Fraction] trial) sacubitril/valsartan helped to better control BP com- IIb B
pared with valsartan.220 high risk of a cerebrovascular event to further reduce
their risk of stroke.194–198,239,240
5.4.3.3. Blood pressure changes with glucose-lowering agents Treatment and evaluation
Trials testing GLP-1 RAs have shown a BP decrease with these drugs, Lifestyle changes (weight loss if overweight, physical
partly due to weight loss. A sustained decrease in BP was observed activity, alcohol restriction, sodium restriction,
with semaglutide therapy (SBP dose dependent: −1.3 to −2.6 mmHg) increased consumption of vegetables, using low-fat I A
with a slight increase in heart rate (+2 to 2.5 beats per minute dairy products) are recommended in patients with
[b.p.m.]).72 Similar effects were seen in other studies of GLP-1 RAs diabetes and hypertension.205–207,210
and derived from meta-analysis.161,221,222
It is recommended to initiate treatment with a
SGLT2 inhibitors induced a larger BP decrease than did GLP-1 RAs
combination of a RAS inhibitor and a CCB or I A
without changing heart rate.223–225A recent meta-analysis including seven
thiazide/thiazide-like diuretic.196,213–216,218,241
RCTs demonstrated that SGLT2 inhibitors were associated with an aver-
Home BP self-monitoring should be considered in
age reduction of 3.6/1.7 mmHg (systolic/diastolic) in 24 h ambulatory BP,
which is comparable with efficacy of low-dose hydrochlorothiazide.224–226 patients with diabetes on anti-hypertensive treatments IIa B
to check that BP is appropriately controlled.242
24 h ambulatory blood pressure monitoring should
5.4.4. Sex-specific aspects
be considered to assess abnormal 24 h BP patterns,
In general, the diagnosis and treatment of hypertension is comparable
including nocturnal hypertension and reduced or IIa B
between sexes, except for women of child-bearing potential or during
reversed nocturnal BP dipping, and to adjust
pregnancy, when some drugs, such as RAS blockers, can have adverse
effects on the foetus, especially in early gestation.227The possible effect anti-hypertensive treatment.243
of oral contraceptives on BP should also be considered.48 There is BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; CV,
some evidence from RCTs that BP targets during pregnancy should cardiovascular; CVD, cardiovascular disease; RAS, renin–angiotensin system; SBP, systolic
range from 110 to 135 mmHg for SBP and 80 to 85 mmHg for blood pressure.
aClass of recommendation.
DBP.228 This is also supported by the recent CHAP (Chronic bLevel of evidence.
Hypertension and Pregnancy) study of mild chronic hypertension in cIdeally at every encounter.
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4075
5.5. Lipids and diabetes 5.5.2. Lipid-lowering agents
5.5.2.1. Statins
A cluster of lipid and apolipoprotein abnormalities accompanies dia-
betes. The core components are moderately elevated plasma triglycer- Statins remain the first-line therapy to reduce LDL-C levels in patients
ide (TG), TG-rich lipoprotein (TRL), and TRL cholesterol levels, with diabetes and dyslipidaemia, due to their efficacy in preventing CV
normal-to-mildly elevated low-density lipoprotein-cholesterol events and reducing CV mortality with no evidence for sex
(LDL-C), and low high-density lipoprotein-cholesterol (HDL-C).
differences.248,249
Other features comprise structure and function of lipoproteins, e.g. High-intensity statins (rosuvastatin and atorvastatin) are indicated in
small dense LDL and HDL particles. The same abnormalities are also patients with diabetes at high or very high CV risk, as they lower LDL-C
reported in patients with T1DM, whose long-lasting exposure to dysli- by 40–63% and significantly reduce the incidence of major cerebral and
pidaemia might induce atherosclerosis as early as in adolescence. In coronary complications.250This beneficial effect outweighs the poten-
T1DM, high LDL-C values are seen in patients with uncontrolled gly- tial diabetogenic effect of these drugs, estimated as a 9% increased risk
caemia, while high levels of HDL-C might be pro-inflammatory and of incident diabetes, especially in older patients and in patients already
therefore atherogenic instead of protective.244 In well-controlled at risk of developing diabetes.251,252Similar benefits were seen in both
T1DM, HDL-C levels tend to be normal (or even slightly elevated), T1DM and T2DM.253–255
as are serum TGs.245 Statins are safe and generally well tolerated. Subjective adverse events
(such as fatigue, myalgias, and nervous system symptoms) are more fre-
quent than objective adverse events due to the nocebo effect, with wo-
5.5.1. Treatment targets men experiencing adverse events more frequently than men.256In most
Epidemiological studies have shown that high levels of LDL-C and cases of myopathy or rhabdomyolysis, there are drug interactions with a
non-HDL-C and low levels of HDL-C are associated with an increased higher-than-standard dose of statin or combination with gemfibrozil.200
risk of CV events and mortality in patients with and without diabetes.246 Evidence indicates that 70–90% of patients who report statin intolerance
Conversely, RCTs with lipid-lowering agents in patients at risk of CV are able to take a statin when re-challenged.257
events (including patients with T2DM) have demonstrated a log-linear
proportional reduction of CV events and mortality for each 1 mmol re-
duction of LDL-C.247 LDL-C is the primary target of lipid-lowering 5.5.2.2. Ezetimibe
therapies. A secondary goal of non-HDL-C should also be considered Lowering of LDL-C can be further intensified by adding ezetimibe to a
in patients with diabetes and combined dyslipidaemias, although there statin, which reduces cholesterol absorption from the ileum.258 The
are limited data from interventional trials. Treatment targets differ IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy
among patients with diabetes based on their CV risk (Section 4; International Trial) trial showed significantly reduced MACE (compos-
Figure 10).48Due to the lack of evidence, no clear recommendations ite of CV death, non-fatal MI, unstable angina requiring re-
can be given for patients with T2DM at low CV risk. hospitalization, coronary revascularization ≥30 days after
CV risk categorization in patients with T2DM based
on ASCVD, severe TOD, or SCORE2-Diabetes
Very high risk High risk Moderate risk
LDL-C <1.4 mmol/L LDL-C <1.8 mmol/L LDL-C <2.6 mmol/L
(<55 mg/dL) (<70 mg/dL) (<100 mg/dL)
(Class I) (Class I) (Class I)
Figure 10 Recommended low-density lipoprotein-cholesterol targets by cardiovascular risk categories in patients with type 2 diabetes. ASCVD, athero-
sclerotic cardiovascular disease; CV, cardiovascular; LDL-C, low-density lipoprotein-cholesterol; TOD, target-organ damage; T2DM, type 2 diabetes mellitus.
Downloaded
from

by
guest
on
22
January
2026

4076 E S C G u id e l in e s
randomization, or non-fatal stroke; HR 0.94; 95% CI, 0.89–0.99) in pa- If TGs remain elevated even with a statin-based regimen, icosapent
tients post-ACS receiving simvastatin plus ezetimibe, with a stronger ethyl, a stable ester of eicosapentaenoic acid, might be preferred
benefit in the sub-group of patients with diabetes (HR 0.85; 95% CI, over other omega–3 fatty acids at the dose of 2 g twice a day (b.i.d.),
0.78–0.94; P <0.001).259,260The combination of ezetimibe with a statin due to its favourable impact on CV outcomes reported in the
is therefore recommended in patients with diabetes and a recent ACS, REDUCE-IT (Reduction of Cardiovascular Events with Icosapent
especially when an LDL-C target <1.4 mmol/L (55 mg/dL) is required Ethyl—Intervention Trial) trial, where benefit was consistent in patients
and not achieved with a statin alone. Young adults with T1DM have in- with (58%) and without diabetes (P = 0.29).274This benefit remained
int
creased cholesterol absorption, as shown in a recent study, suggesting significant even considering a slight increase of LDL-C and high-
greater efficacy of ezetimibe in this population, which remains to be as- sensitivity C-reactive protein due to the effect of mineral oil in the pla-
sessed with dedicated RCTs.261 cebo arm.275,276
5.5.2.3. Proprotein convertase subtilisin/kexin type 9 inhibitors
5.5.3. Novel cholesterol-lowering drugs
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 5.5.3.1. Inclisiran
evolocumab and alirocumab are monoclonal antibodies that strongly Inclisiran inhibits hepatic synthesis of PCSK9 with a long-lasting effect.277
reduce plasma LDL-C, targeting the protein involved in regulating the
Patients on statins with high LDL-C levels and ASCVD or at least one
LDL receptor on the hepatocyte.262 Administered alongside high-
ASCVD risk equivalent were included in the two phase 3 trials
intensity statin therapy (with or without ezetimibe), PCSK9 inhibitors
ORION-10 and ORION-11 (Inclisiran for Participants With
significantly reduced MACE in the sub-groups of patients with diabetes
Atherosclerotic Cardiovascular Disease and Elevated Low-density
with ASCVD enrolled in the FOURIER (Further Cardiovascular
Lipoprotein Cholesterol), and obtained a further 50% reduction of
Outcomes Research with PCSK9 Inhibition in Subjects with Elevated LDL-C with inclisiran.278This benefit was consistent in patients with dia-
Risk) trial and in the ODYSSEY OUTCOMES (Evaluation of
betes in both trials, and CV outcome endpoints are currently being tested
Cardiovascular Outcomes After an Acute Coronary Syndrome in a phase 3 trial enrolling patients with ASCVD (ORION-4 trial).279
During Treatment With Alirocumab) trial, respectively.263,264 In par-
ticular, evolocumab showed a 17% RR reduction of a composite pri-
mary endpoint of CV death, MI, stroke, hospitalization for unstable 5.5.3.2. Bempedoic acid
angina, or coronary revascularization in patients with diabetes included Bempedoic acid is a pro-drug that reduces cholesterol synthesis by in-
in the FOURIER trial (HR 0.83; 95% CI, 0.75–0.93; P = 0.0008).263 hibiting adenosine triphosphate (ATP) citrate lyase, with very limited
Compared with placebo, evolocumab also significantly reduced other musculoskeletal-related side effects.280 In the CLEAR (Cholesterol
atherogenic lipids (i.e. TGs, non-HDL-C, apolipoprotein B-containing Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) Harmony
particles) in patients with diabetes and mixed dyslipidaemia enrolled trial, adding bempedoic acid to statins significantly reduced LDL-C le-
in the BANTING (Evaluation of Evolocumab Efficacy in Diabetic vels (–16.5%) in patients with ASCVD or familial hypercholesterol-
Adults With Hypercholesterolemia/Mixed Dyslipidemia) and aemia, with consistent results in the sub-group of patients with
BERSON (Safety and Efficacy of Evolocumab in Combination With diabetes (–19.1%).267 Bempedoic acid did not induce new-onset dia-
Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed betes or worsen diabetes as shown by a subsequent meta-analysis.281
Dyslipidemia) studies.265,266 High CV risk patients who were unable or unwilling to take statins
Alirocumab significantly reduced the rate of a composite of CV have been included in the CLEAR Outcomes study and randomized
death, MI, stroke, or hospitalization for unstable angina in the sub-group to bempedoic acid or placebo. Among the 6992 patients assigned to
of patients with ACS with T2DM (n = 5444) of the ODYSSEY the active arm of the study 45% had T2DM. Bempedoic acid was asso-
OUTCOMES trial.267 Alirocumab on top of the maximum tolerated ciated with a significantly lower incidence of the four-component com-
statin dose was also more effective than ezetimibe, fenofibrate, or posite primary endpoint of CV death, non-fatal MI, non-fatal stroke, or
non-lipid-lowering therapy in reducing non-HDL-C and other athero- coronary revascularization and a higher incidence of some adverse
genic lipids in patients with diabetes enrolled in the ODYSSEY events (gout and cholelithiasis) at the 40.6 month follow-up. Of note,
DM-DYSLIPIDEMIA (Efficacy and Safety of Alirocumab Versus Usual the data were only released just before finalising these Guidelines and
Care on Top of Maximally Tolerated Statin Therapy in Patients With could thus not be included.282
Type 2 Diabetes and Mixed Dyslipidemia) trial.268
A meta-analysis by Khan et al. did not show a significant association be-
Recommendation Table 11 — Recommendations for
tween PCSK9 inhibitors and new-onset diabetes (HR 1.00; 95% CI, 0.93–
the management of dyslipidaemia in patients with
1.07; P = 0.96; I2 = 0%), while confirming a modest risk of incident diabetes diabetes
with statins only (HR 1.10; 95% CI, 1.05–1.15; P < 0.001; I2 = 0%).269
Recommendations Classa Levelb
5.5.2.4. Fibrates and other TG-lowering drugs
Lipid targets
Potential use of fibrates to reduce TG levels is quite limited, due to the
In patients with T2DM at moderate CV risk, an
risk of myopathy if given with statins and the little benefit demonstrated
LDL-C target of <2.6 mmol/L (<100 mg/dL) is I A
in RCTs, aside from sub-group analysis including subjects with very high
TG levels.200,270,271 Pemafibrate is a new selective peroxisome
recommended.248,249
proliferator-activated receptor-α modulator with a superior In patients with T2DM at high CV risk, an LDL-C
benefit-risk balance compared with conventional fibrates.272 A phase target of <1.8 mmol/L (<70 mg/dL) and LDL-C I A
3 trial determining the efficacy of pemafibrate in preventing MACE in reduction of at least 50% is recommended.248,249
patients with diabetes has been terminated early for futility.273 Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4077
In patients with T2DM at very high CV risk, an LDL-C proportional benefit-risk profile was also observed in the diabetes sub-
target of <1.4 mmol/L (<55 mg/dL) and LDL-C I B group (Supplementary data online, Table S11).
reduction of at least 50% is recommended.248,249 The ASCEND (A Study of Cardiovascular Events iN Diabetes) trial
was the largest, adequately powered, placebo-controlled RCT testing
In patients with T2DM, a secondary goal of a
low-dose ASA in patients with T1DM or T2DM (n = 15 480) with no
non-HDL-C target of <2.2 mmol/L (<85 mg/dL) in
evident CVD.292Over 7.4 years, ASA significantly reduced serious vas-
very high CV risk patients and <2.6 mmol/L I B
cular events vs. placebo (8.5% vs. 9.6%, respectively; RR 0.88; 95% CI,
(<100 mg/dL) in high CV risk patients is
0.79–0.90; P = 0.01; number needed to treat [NNT] 91;
recommended.283–285
Supplementary data online, Table S11), with a relative benefit similar
Lipid-lowering treatment to the previous meta-analysis.291 Bleeding Academic Research
Statins are recommended as the first-choice Consortium (BARC) type 3–5 bleeding (Supplementary data online,
LDL-C-lowering treatment in patients with diabetes Figure S6) occurred in 4.1% vs. 3.2% of patients in the ASA and placebo
and above-target LDL-C levels. Administration of arms, respectively (RR 1.29; 95% CI, 1.09–1.52; P = 0.003; number
I A
statins is defined based on the CV risk profile of the needed to harm [NNH] 111). ASA-associated major bleeding excess
was largely gastrointestinal, without differences in fatal, intracranial,
patients and the recommended LDL-C (or
non-HDL-C) target levels.247–249 and ocular bleeding. The NNT/NNH ratio was 0.8. The pre-specified
sub-group analysis based on vascular risk score at baseline was consist- A PCSK9 inhibitor is recommended in patients at
ent with the overall population (Supplementary data online, Figure S7).
very high CV risk, with persistently high LDL-C levels
The benefit of ASA in the ASCEND trial was observed on top of sta-
above target despite treatment with a maximum I A
tins (75% of patients) and/or anti-hypertensive (∼60% of patients)
tolerated statin dose, in combination with ezetimibe, drugs.292 Consistently, a recent IPD meta-analysis of 18 162 patients
or in patients with statin intolerance.267,286
with multiple CV risk factors and no previous ASCVD (risk 1.7%/
If the target LDL-C is not reached with statins, year) showed a significant benefit of low-dose ASA, incremental to
combination therapy with ezetimibe is I B lipid- and BP-lowering drugs. This was also observed in a diabetes sub-
recommended.259,260 group (Supplementary data online, Table S11).293
If a statin-based regimen is not tolerated at any A 9.2-year follow-up analysis of the ASCEND trial excluded harm of
dosage (even after re-challenge), a PCSK9 inhibitor IIa B ASA on incident dementia, with a trend towards a reduction (HR 0.89;
added to ezetimibe should be considered.287,288 95% CI, 0.75–1.06) confirmed by a meta-analysis of three large primary
If a statin-based regimen is not tolerated at any prevention RCTs (HR 0.92; 95% CI, 0.84–1.01; P = 0.09).294
dosage (even after re-challenge), ezetimibe should be IIa C Large, observational, prospective data suggest CAC as a non-invasive
considered.259,260 biomarker to identify asymptomatic patients at the highest risk of
ASCVD or revascularization, with or without diabetes, who may largely
High-dose icosapent ethyl (2 g b.i.d.) may be
benefit from ASA.295Ongoing trials are testing the relevance of CAC
considered in combination with a statin in patients IIb B
score and related thresholds in improving primary prevention, including
with hypertriglyceridaemiac.274
in asymptomatic patients with diabetes.296–298
b.i.d., twice a day; CV, cardiovascular; HDL-C, high-density lipoprotein-cholesterol; LDL-C, In summary, in patients with diabetes and no history of symptomatic
low-density lipoprotein-cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; ASCVD or revascularization, ASA (75–100 mg o.d.) may be considered
T2DM, type 2 diabetes mellitus.
aClass of recommendation. to prevent the first severe vascular event. However, in patients with
bLevel of evidence. diabetes with asymptomatic ASCVD (including documented CAD con-
cHypertriglyceridaemia: triglycerides 150–499 mg/dL, according to the inclusion of the firmed by imaging) and a higher CV risk, the net benefit of platelet in-
REDUCE-IT trial.
hibition by ASA may be higher and thus, therapy needs to be
individualized.
5.6. Antithrombotic therapy and diabetes
Recommendation Table 12 — Recommendations for
Several mechanisms contribute to platelet activation and coagulation in
patients with diabetes without a history of symptomatic
diabetes (Figure 11). The pharmacology of different antithrombotic
atherosclerotic cardiovascular disease or revascularization
agents can be found in the Supplementary data online, Section 2.7 and
Figures S1–5. Recommendation Classa Levelb
In adults with T2DM without a history of
5.6.1. Patients without a history of symptomatic symptomatic ASCVD or revascularization, ASA (75–
atherosclerotic cardiovascular disease or 100 mg o.d.) may be considered to prevent the first IIb A
revascularization severe vascular event, in the absence of clear
The largest meta-analysis on 95 000 individual participant data (IPD) of contraindications.c,292,293
patients at average CV risk (0.57% MACE/year) from six RCTs, included
ASA, acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; o.d., once daily;
3818 (4%) patients with diabetes. In the whole cohort, low-dose acetyl- T2DM, type 2 diabetes mellitus.
salicylic acid (ASA) significantly reduced MACE vs. control (absolute risk aClass of recommendation.
reduction [ARR] 0.06%/year; P = 0.0001), while increasing major extra- bLevel of evidence.
cHigh risk of bleeding due to gastrointestinal haemorrhage or peptic ulcer within the
cranial bleed (0.10% vs. 0.07%/year; absolute risk increase 0.03%/year;
previous 6 months, active hepatic disease (such as cirrhosis, active hepatitis), or history
P < 0.0001; Supplementary data online, Table S11).291 A similar of ASA allergy.
3202CSE©
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

4078 E S C G u id e l in e s
Hyperglycaemia, insulin resistance or deficiency, metabolic imbalances
Non-enzymatic Endothelial Pro-coagulant and
Inflammation Platelet
protein glycation dysfunction hypofibrinotic
ROS turnover
modifying function NO synthesis milieu
Thrombin
generation
Hypertension
Smoking Activated Fibrin
Obesity platelets network
Dyslipidaemia
Atherothrombosis
Figure 11 Mechanisms contributing to altered platelet activation and atherothrombosis in patients with diabetes. ↑, increase; ↓, decrease; NO, nitric oxide;
ROS, reactive oxygen species.289,290The figure depicts the major determinants contributing to platelet activation leading to atherothrombosis in patients
with diabetes. An inflammatory environment, metabolic changes, endothelial dysfunction and altered platelet turnover result in a platelet population char-
acterized by enhanced activation, increased thrombin generation, and suppression of the fibrinolytic system. Thrombin release by platelets and de novo gen-
eration through activation of the coagulation pathway further amplify platelet activation and result in fibrin network formation, thus playing a pivotal role in
the increased risk of thrombosis in individuals with diabetes.
5.6.2. Patients with atherosclerotic cardiovascular four-fold higher (300–325 mg o.d.) ASA dose in both chronic coronary
disease and/or revascularization without an syndrome (CCS) and ACS.300,301
indication for long-term oral anticoagulation Clopidogrel provides an alternative in ASA-intolerant patients or can
5.6.2.1. Chronic coronary syndromes be combined with low-dose ASA (clopidogrel 75 mg o.d. and ASA 75–
100 mg o.d.) as dual antiplatelet therapy (DAPT) in patients with CCS
Patients with diabetes and documented significant CAD or with prior
revascularization are at very high CV risk, and low-dose ASA (75– undergoing percutaneous coronary intervention (PCI).
100 mg o.d.) is recommended, although ad hoc RCTs are lacking.48,299 The THEMIS (Effect of Ticagrelor on Health Outcomes in Diabetes
Both the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Mellitus Patients Intervention Study) trial tested the efficacy and safety of
Assessing Benefits and Long-term) and CURRENT-OASIS 7 adding the P2Y 12 inhibitor ticagrelor (60 mg b.i.d.) or placebo to ASA
(Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent (75–150 mg o.d.) in 19 220 patients with diabetes and a history of PCI or
EveNTs/Optimal Antiplatelet Strategy for InterventionS) trials showed coronary artery bypass graft (CABG), or a documented stenosis (≥50%)
comparable efficacy of a lower dose (75–100 mg o.d.) and a three- to in at least one coronary artery, and no previous MI or stroke
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4079
(Supplementary data online, Table S11).302 Over a median 3.3 years of inhibitor, preferably ticagrelor over clopidogrel, is recommended for
follow-up, the primary efficacy outcome of CV death, MI, or stroke showed 12 months.314,315
a marginal 10% RR reduction by ticagrelor vs. placebo, while both
Thrombolysis in Myocardial Infarction (TIMI) major and intracranial bleed-
ing were significantly increased. The pre-specified sub-groups of CABG or 5.6.2.2.3. Prolonging DAPT post-ACS. The GLOBAL-LEADERS
previous PCI showed a benefit-risk profile consistent with the entire (A Clinical Study Comparing Two Forms of Antiplatelet Therapy
trial.302,303 The NNT/NNH ratio was 1.5. Thus, an unfavourable After Stent Implantation) trial failed to show superior efficacy or safety
benefit-risk profile is associated with adding ticagrelor to ASA in this setting. of 24 months of ticagrelor monotherapy post-ACS vs. the standard
The COMPASS (Cardiovascular Outcomes for People Using 12-month DAPT followed by 12-month low-dose ASA monotherapy
Anticoagulation Strategies) trial enrolled 27 395 patients with stable in the overall and diabetes (25% of all patients) cohorts.316
ASCVD (previous MI, symptomatic CAD, and/or PAD). Low-dose The PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in
ASA combined with very low-dose rivaroxaban (2.5 mg b.i.d.) was su- Patients With Prior Heart Attack Using Ticagrelor Compared to
perior to ASA and placebo in preventing MACE (4.1% vs. 5.4%, respect- Placebo on a Background of Aspirin) trial compared prolonged ticagre-
ively; HR 0.76; 95% CI, 0.66–0.86; P < 0.001; NNT 77).304International lor therapy (60 or 90 mg b.i.d.) with placebo added to low-dose ASA in
Society on Thrombosis and Haemostasis-defined major bleeding, but patients with an MI 1–3 years before study entry and additional CV risk
not fatal or intracranial bleeding, was increased (1.9% vs. 3.1%, respect- factors.317 Reduced-dose ticagrelor (60 mg) decreased MACE com-
ively; HR 1.70; 95% CI, 1.40–2.05; P < 0.001; NNH 83), with an NNT/ pared with placebo (7.77% vs. 9.04%, respectively; HR 0.84; 95% CI,
NNH ratio of 0.9 (Supplementary data online, Figure S7). The propor- 0.74–0.95; P = 0.004; NNT 79), with no heterogeneity with respect
tional benefit-risk profile of the diabetes sub-group (38% of all patients) to the diabetes sub-group, whereas it significantly increased TIMI major
was similar to the overall population. Based on these data, adding very bleeding (2.3% vs. 1.06%, respectively; HR 2.32; 95% CI, 1.68–3.21;
low-dose rivaroxaban to low-dose ASA for long-term prevention of NNH 81), dyspnoea, serious adverse events, and drug discontinuation
serious vascular events should be considered in patients with diabetes rates.317 Based on these data, DAPT prolonged beyond 12 months
and CCS or symptomatic PAD without high bleeding risk.304,305Data should be considered up to 3 years in patients with diabetes who
are available up to 47 months of ASA plus very low-dose rivaroxaban have tolerated DAPT without major bleeding.63,317,318 The median
exposure; beyond this time, continuation should be determined on follow-up across all trials on prolonging full-dose DAPT was 18 months
an individual basis and with regular evaluation of thrombotic vs. bleeding (interquartile range 12–24 months), with a maximum DAPT exposure
risks. no longer than 36 months.318No sufficient safety and efficacy data are
available for DAPT with reduced-dose ticagrelor beyond 3 years, espe-
cially considering the significant TIMI major bleeding increase of the as-
5.6.2.2. Acute coronary syndrome
sociation (Supplementary data online, Figure S6).317,319
5.6.2.2.1. Peri-procedural management. Peri-procedural management
of patients with ACS or undergoing PCI, which may include glycoprotein
IIb/IIIa inhibitors, cangrelor, heparins, or bivalirudin, is detailed in the 2018
5.6.2.2.4. Shortening or de-escalating DAPT post-ACS in diabetes.
ESC/European Association for Cardio-Thoracic Surgery (EACTS)
No evidence supports shortening or de-escalating DAPT post-ACS specif-
Guidelines on myocardial revascularization.299,306–308
ically in patients with diabetes, since RCTs on shorter DAPT duration fol-
lowed by ASA or a P2Y inhibitor monotherapy are relatively small, often
12
5.6.2.2.2. Post-procedural management. In patients with ACS with non-inferiority design for efficacy, relatively low power, and wide non-
undergoing PCI, 12 months’ DAPT with low-dose ASA and prasugrel inferiority margins. In addition, these RCTs had primary endpoints combin-
or ticagrelor was superior to DAPT with clopidogrel in the diabetes ing minor bleeding with traditional efficacy outcomes, efficacy outcomes
sub-group of the respective RCTs, with a benefit-risk profile similar including not only MACE, and diabetes sub-groups that contain few pa-
to the overall trial populations (Supplementary data online, Tables tients and events, especially on the major hard endpoints
S12–13).309–312 With the limitations of a subgroup analysis, patients (Supplementary data online, Table S13).320,321Moreover, large, superiority
with diabetes on DAPT with low-dose ASA and prasugrel tended to RCTs have failed to show a higher efficacy of routine platelet-function test-
have a more favourable benefit-risk profile.312 The open-label ing in guiding antiplatelet therapy post-PCI.322,322a Of note, the
ISAR-REACT 5 (Intracoronary Stenting and Antithrombotic Regimen: TROPICAL-ACS (Testing Responsiveness to Platelet Inhibition on
Rapid Early Action for Coronary Treatment) trial randomized 4018 pa- Chronic Antiplatelet Treatment For Acute Coronary Syndromes) trial ‘de-
tients with ACS to prasugrel or ticagrelor added to ASA.313Prasugrel escalating’ P2Y inhibition from prasugrel to clopidogrel after 2 weeks of
12
was superior to ticagrelor in reducing MACE without increasing major DAPT based on platelet function testing showed an upper HR limit for
bleeding, with similar effects in the sub-group of patients with diabetes MACE of 1.93 in the diabetes sub-group (HR 1.17; 95% CI, 0.71–1.93).
(n = 892; 22%; Supplementary data online, Table S12).313 Moreover, CV death was significantly increased in sub-groups with dia-
Thus, DAPT, i.e. low-dose ASA with prasugrel or ticagrelor are pre- betes vs. without diabetes in the ‘de-escalating’ arm (HR 2.42; 95% CI,
ferred to DAPT with clopidogrel in patients with diabetes and ACS 0.61–9.67; P = 0.04), thus suggesting harm from de-escalation compared
int
(Supplementary data online, Table S12),309–312 unless the patient is with standard recommended DAPT.321In addition, patients with diabetes
deemed at very high bleeding risk. Of note, patients with T2DM form less of the clopidogrel active metabolite resulting in less platelet inhib-
have a reduced generation of the active metabolite of clopidogrel ition (Supplementary data online, Section 2.7).323,324
compared with patients without diabetes (Supplementary data Thus, shortening or de-escalating DAPT below 12 months is not recom-
online, Section 2.7).323,324Notably, previous intracranial bleeding con- mended in patients with diabetes in the 12 months post-ACS. Current evi-
traindicates patients to both prasugrel and ticagrelor. dence does not support platelet function testing to adjust DAPT.
In patients with diabetes and ACS who do not undergo cardiac revas- Figure 12 summarizes recommendations in patients with diabetes
cularization, DAPT with ASA (75–100 mg o.d.) and a P2Y receptor and ACS or CCS undergoing PCI or CABG.
12
Downloaded
from

by
guest
on
22
January
2026

4080 E S C G u id e l in e s
Revascularization (PCI, CABG) for ACS and CCS in patients with
diabetes and no indication for anticoagulation
ACS CCS
Time
PCI CABG PCI CABG
0 months
DAPT
DAPT DAPT Low dose ASA
Low dose ASA and Low dose ASA and and clopidogrel
prasugrel or ticagrelor prasugrel or ticagrelor (Class I)
6 months
(Class I) (Class 1) Low dose
ASA
12 months
DAPT Low dose (Class I)
Low dose based on Low dose ASA
24 months ASA bleeding ASA (Class I)
(Class I) risk (Class I)
(Class Ila)
36 months
Low dose ASA
(Class I)
Figure 12 Recommendations for antiplatelet therapy in patients with diabetes with acute or chronic coronary syndrome undergoing percutaneous cor-
onary intervention or coronary artery bypass grafting without indications for long-term oral anticoagulation. ACS, acute coronary syndrome; ASA, acetyl-
salicylic acid; CABG, coronary artery bypass graft; CCS, chronic coronary syndrome; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary
intervention.
Recommendation Table 13 — Recommendations for In patients with diabetes and ACS treated with
antithrombotic therapy in patients with diabetes and DAPT who are undergoing CABG and do not
acute or chronic coronary syndrome without indications require long-term OAC therapy, resuming a P2Y
12
for long-term oral anticoagulation I C
receptor inhibitor as soon as deemed safe after
surgery and continuing it up to 12 months is
Recommendations Classa Levelb
recommended.315,334,335
ASA at a dose of 75–100 mg o.d. is recommended in Prolonging DAPT beyond 12 months after ACS
patients with diabetes and previous MI or I A should be considered for up to 3 years in patients
revascularization (CABG or stenting).291,325,326 with diabetes who have tolerated DAPT without IIa A
In patients with ACS and diabetes who undergo PCI, major bleeding complications.c,317,318,336
a P2Y 12 receptor inhibitor (ticagrelor or prasugrel) is I A Adding very low-dose rivaroxaband to low-dose ASA
recommended in addition to ASA (75–100 mg o.d.), for long-term prevention of serious vascular events
maintained over 12 months. 310–312,314 should be considered in patients with diabetes and IIa B
Clopidogrel 75 mg o.d. following appropriate loading CCS or symptomatic PAD without high bleeding
(e.g. 600 mg or at least 5 days already on risk.304,305
maintenance therapy) is recommended in addition to
ACS, acute coronary syndrome; ASA, acetylsalicylic acid; b.i.d., twice a day; CABG,
ASA for 6 months following coronary stenting in I A
coronary artery bypass graft; CCS, chronic coronary syndrome; DAPT, dual antiplatelet
patients with CCS, irrespective of stent type, unless a therapy; MI, myocardial infarction; OAC, oral anticoagulant; o.d., once daily; PAD,
shorter duration is indicated due to the risk or peripheral arterial disease; PCI, percutaneous coronary intervention.
occurrence of life-threatening bleeding.327–332 aClass of recommendation.
bLevel of evidence.
Clopidogrel is recommended as an alternative in case cIn case of ticagrelor, a reduced dose (60 mg b.i.d.) should be used.317
of ASA intolerance.333 I B dRivaroxaban 2.5 mg b.i.d.
Continued
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4081
5.6.3. Patients with atherosclerotic cardiovascular In patients with ACS or CCS and diabetes
disease and/or revascularization requiring long-term undergoing coronary stent implantation and having
oral anticoagulation an indication for anticoagulation, prolonging triple
In patients requiring long-term oral anticoagulants (OACs; e.g. those therapy with low-dose ASA, clopidogrel, and an IIb C
with AF) undergoing PCI for ACS or CCS, DAPT with clopidogrel is OAC up to 3 months may be considered if the
combined with full-dose OACs (triple antithrombotic therapy thrombotic risk outweighs the bleeding risk in the
[TAT]). Combined antithrombotic drugs, while effective, increase individual patient.341–344
major bleeding risk.337,338RCTs have compared TAT with dual an-
ACS, acute coronary syndrome; AF, atrial fibrillation; CCS, chronic coronary syndrome;
tithrombotic therapy (DAT) combining an OAC mostly with clopi-
NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; PCI,
dogrel, in patients with AF and ACS or post-PCI (Supplementary percutaneous coronary intervention; VKA, vitamin K antagonist.
data online, Table S14). These RCTs have some common features: aClass of recommendation.
bLevel of evidence.
a primary outcome of safety comprising moderate-to-major, often
cContraindications to NOACs are prosthetic mechanical heart valve, mitral stenosis, and
BARC-defined, bleeding (Supplementary data online, Figure S7); effi- creatinine clearance below the approved threshold for the specific NOAC.
cacy (including CV death, MI, stroke, as well as revascularization, and/
or stent thrombosis) as a secondary endpoint, often with a non-
inferiority comparison; relatively short follow-up (6–14 months);
and limited sample size with few patients with diabetes (28–37% 5.6.4. Preventing gastrointestinal bleeding
across RCTs; Supplementary data online, Table S14).339–342 Thus, Large observational studies or head-to-head RCTs show similar rates
these RCTs are underpowered to assess both the efficacy of DAT of gastrointestinal and non-gastrointestinal major bleeding for single
and the safety of major bleeding of TAT in patients with diabetes. antiplatelet therapy (SAPT) with low-dose ASA or a P2Y inhibitor
12
Moreover, two meta-analyses suggest significantly higher MI and (clopidogrel or ticagrelor).337,338,346–350Thus, gastrointestinal mucosal
stent thrombosis rates with DAT vs. TAT (Supplementary data bleeding appears to be due to pre-existing mucosal lesions associated
online, Table S14).343,344The lack of high-quality evidence on efficacy, with defective primary haemostasis secondary to platelet inhibition,
meta-analyses suggesting some harm, and the underlying high CV and rather than with a specific antiplatelet drug. A meta-analysis showed
stent thrombosis risk in patients with diabetes, indicate that TAT that gastroprotectant drugs significantly reduce the risk of gastro-
duration should be cautiously and systematically evaluated for intestinal bleeding in patients on single or combined antithrombotic
both thrombotic and bleeding risks in the individual patient with drugs.351 This benefit was also observed in the pre-specified sub-
diabetes. group of 6732 patients with diabetes in the COMPASS trial, consist-
ent with large population studies on proton pump inhibitors and
Recommendation Table 14 — Recommendations for OACs (either vitamin K antagonist [VKA] or non-vitamin K antagonist
antithrombotic therapy in patients with diabetes and oral anticoagulant [NOACs]).352Regarding CV safety, the composite
acute or chronic coronary syndrome and/or post- of MI, stroke, CV death, CHD, and acute limb ischaemia was similar
percutaneous coronary intervention requiring long- between pantoprazole and placebo, as was the rate of new-onset dia-
term oral anticoagulation betes.337,351–355
Recommendations Classa Levelb
In patients with AF and receiving antiplatelet therapy,
eligible for anticoagulation, and without a Recommendation Table 15 — Recommendations for
I A
contraindication,c NOACs are recommended in gastric protection in patients with diabetes taking an-
preference to a VKA.339,340,343 tithrombotic drugs
In patients with ACS or CCS and diabetes
Recommendations Classa Levelb
undergoing coronary stent implantation and having
an indication for anticoagulation, triple therapy with When antithrombotic drugs are used in combination,
low-dose ASA, clopidogrel, and an OAC is I A proton pump inhibitors are recommended to I A
recommended for at least 1 week, followed by dual prevent gastrointestinal bleeding.337,347,348,351–353,355
therapy with an OAC and a single, oral, antiplatelet When a single antiplatelet or anticoagulant drug is
agent.339–342,344,345 used, proton pump inhibitors should be considered
IIa A
In patients with ACS or CCS and diabetes to prevent gastrointestinal bleeding, considering the
undergoing coronary stent implantation and having bleeding risk of the individual patient.338,347,348,351,352
an indication for anticoagulation, prolonging triple When clopidogrel is used, omeprazole and
therapy with low-dose ASA, clopidogrel, and an IIa C esomeprazole are not recommended for gastric III B
OAC should be considered up to 1 month if the protection.356
thrombotic risk outweighs the bleeding risk in the
aClass of recommendation.
individual patient.341–344 bLevel of evidence.
Continued
3202CSE©
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

4082 E S C G u id e l in e s
5.7. Multifactorial approach to risk-factor healthcare professionals and patients.48 This stepwise approach starts
management in diabetes with assessing CVD risk in all patients with diabetes, including glycaemic
state and lifestyle risk-factor profile (Figure 13). CVD risk stratification
Optimal risk factor and lifestyle management, as well as early identification
should be individually adapted according to comorbidities, e.g. CAD,
and treatment of comorbidities, is a cornerstone of treatment for
HF, AF, or PAD, as well as age, frailty, and sex. This includes discussing in-
T2DM.357–359The Swedish National Diabetes Registry revealed a clear im-
dividual preferences with the patient, particularly regarding lifestyle strat-
provement of clinical outcomes by each risk factor within the target range
egies and potential treatment benefits. Particularly in the field of T2DM,
(HbA1c, LDL-C, albuminuria, smoking, and SBP).360In patients with ad-
studies have shown benefits of a stepwise approach to intensify treat-
vanced disease, e.g. T2DM and established microalbuminuria, an intensive,
ment, and it appears that attaining treatment goals is similar, side effects
target-driven, multifactorial therapy (Steno-2 study; targets: HbA1c <6.5%,
are fewer, and patient satisfaction is significantly higher with such an ap-
total cholesterol <4.5 mmol/L [175 mg/dL], and BP <130/80 mmHg) re- proach.369,370Supporting evidence comes from the Italian Diabetes and
sulted in 50% fewer microvascular and macrovascular events after 7.8
Exercise Study 2, which showed that a behavioural intervention strategy
years of follow-up.361 Long-term follow-up (21 years from baseline)
compared with standard care resulted in a sustained increase in physical
showed significantly reduced end-stage renal disease combined with death activity and decrease in sedentary time among patients with T2DM.371
(HR 0.53; 95% CI, 0.35–0.80), and risk of HF hospitalization reduced by
To achieve a high adherence and optimization of target goals, clinician–
70%.362Overall, this resulted in a 7.9 year gain of life expectancy.363
patient communication is crucial and should include a personalized ap-
These positive effects were not observed in the clinical intervention trials
proach explaining background and targets to improve understanding and
of intensified, multifactorial treatment for T2DM in primary care and early
encourage lifestyle changes and drug-therapy adherence. Aside from the
in the disease trajectory. The ADDITION (Anglo-Danish-Dutch Study of disease entity, including symptoms, the patient’s ability to adopt a healthy
Intensive Treatment in People with Screen Detected Diabetes in
lifestyle depends on individual cognitive and emotional factors, educational
Primary Care) trial showed that microvascular or macrovascular events
level, socioeconomic factors, and mental health. Perceived susceptibility to
were not significantly reduced after 5 or 10 years (17% and 13% reduction,
illness and the anticipated severity of the consequences are also prominent
respectively), while intervention only slightly improved HbA1c.364,365In ac- components of patients’ motivation.372Patients can be motivated by mo-
cordance, the J-DOIT3 (Japan Diabetes Optimal Integrated Treatment
tivational interviewing including the Open-ended questions, Affirmation,
Study for 3 Major Risk Factors of Cardiovascular Diseases) trial in patients
Reflective listening, and Summarizing (OARS) and Specific, Measurable,
with T2DM aged 45–69 years revealed a non-significant trend towards a Achievable, Realistic, Timely (SMART) principles.372–374Multidisciplinary
reduced primary composite outcome (non-fatal MI, stroke, revasculariza-
behavioural approaches that combine the knowledge and skills of different
tion, or all-cause death; HR 0.81; 95% CI, 0.63–1.04; P = 0.094) with inten- caregivers are recommended.104Adding exercise intervention combined
sive vs. conventional therapy.366 Post-hoc analyses showed that only
with psychological support to diet recommendations is more effective
cerebrovascular events were reduced (HR 0.42; 95% CI, 0.24–0.74; P = than diet education alone.375Assessing depression and depressive symp-
0.002), while no differences were seen for all-cause death and coronary
toms is important in patients with CVD and T2DM, as adequate treatment
events. In addition, the Look AHEAD trial, introducing lifestyle intervention improves adherence.376,377
in patients with obesity and T2DM with 10 years’ follow-up, did not dem-
Mobile phone applications may improve adherence to both medica-
onstrate a reduction in the composite CV outcome.56
tion and behavioural changes, but more evidence, particularly in pa-
Key problems in optimally treating patients with T2DM and CVD are tients with CVD and T2DM, is needed.378 Regarding the education
the low rate of detection of T2DM in patients with CVD, the low re-
method, individual education is more effective than face-to-face or
ferral rate to diabetes specialists, and the difficulty of prolonged adher- web and mobile phone education.375 Whether a tailored and auto-
ence to medication or lifestyle interventions in this patient group. The
mated text message (SMS) support programme may improve glycaemic
EUROASPIRE V survey reported that many patients with CVD (29.7%) control in adults with poorly controlled diabetes is equivocal.379
had known diabetes, while 41.1% of those with unknown T2DM were
dysglycaemic.367Of patients with known diabetes, 31% had been ad-
vised to attend a diabetes clinic, though only 24% attended. Only Recommendation Table 16 — Recommendations for a
58% of dysglycaemic patients were prescribed all cardio-protective multifactorial approach in patients with type 2 diabetes
drugs, and use of SGLT2 inhibitors or GLP-1 RAs was limited (3% with and without cardiovascular disease
and 1%, respectively).367A BP target <140/90 mmHg was achieved in
Recommendations Classa Levelb
only 61% of patients with newly detected T2DM, and in 54% of patients
with previously known T2DM.34 An LDL-C target <1.8 mmol/L was Identifying and treating risk factors and comorbidities
I A
only achieved in 18% and 28% of patients, respectively. This was ex- early is recommended.357,358
plained by low prescription rates of the combination of all cardio-
A multifactorial approach to managing T2DM with
protective drugs (antiplatelet therapy, beta-blockers, RAS inhibitors, I B
treatment targets is recommended.361
and statins) in only 55% of patients with newly detected T2DM, and
in 60% of patients with previously known T2DM.34The concept of a Multidisciplinary behavioural approaches that
combine the knowledge and skills of different I C
polypill, e.g. containing aspirin, ramipril, and atorvastatin, may even im-
prove clinical events in secondary cardiovascular prevention.368 caregivers are recommended.104,380
Furthermore, adherence to lifestyle intervention fades over time, with Principles of motivational interviewing should be
IIa C
continuously increasing body weight after 1 year.56To overcome adher- considered to induce behavioural changes.372–374
ence failures, the 2021 ESC Guidelines on cardiovascular disease preven- Telehealth may be considered to improve risk
IIb B
tion in clinical practice outlines a stepwise approach to treating risk factors profile.378,379
and intensifying treatment to help physicians and patients pursue risk-
T2DM, type 2 diabetes mellitus.
factor targets, taking into account patient profiles and preferences, ensur- aClass of recommendation.
ing targets are a part of a shared decision-making process involving bLevel of evidence.
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4083
Global CV risk and disease assessment
Assessment of lifestyle risk factor components
Obesity Nutritiona Inactivity Smoking
Body weight Questionnaire
Questionnaire Questionnaire
Body composition Exercise testing
Step 1 General lifestyle recommendations
HFpEF HFrEF AF CAD PAD
Adaption of lifestyle recommendations to
Step 2
comorbidities, age, frailty, sex, patient preference
Individualized multidisciplinary lifestyle intervention programme
Figure 13 Assessment of lifestyle risk-factor components and stepwise lifestyle recommendations in patients with diabetes. AF, atrial fibrillation; CAD,
coronary artery disease; CV, cardiovascular; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction;
PAD, peripheral arterial diseases. aNutrition includes components on quality and quantity of nutritional components, as well as alcohol consumption.
6. Management of coronary artery 10.4 years, typical angina, anginal equivalent, or a combination of
both were observed in 19%, 21%, and 42% of patients, respectively,
disease and diabetes
whereas 18% remained asymptomatic.382,383In 510 asymptomatic
patients with diabetes without prior CVD, computed tomography
6.1. Chronic coronary syndromes and
(CT) revealed calcifications indicating the presence of coronary ath-
diabetes erosclerosis in 46% of patients.384 An even higher prevalence of
6.1.1. Clinical presentation CAD was found in an autopsy study of asymptomatic decedents
Diabetes is a well-established risk factor for ischaemic heart disease with diabetes.385
(IHD), and CAD accounts for 40−80% of deaths in patients with
T2DM.148,359,381 In patients with CCS, T2DM is also associated 6.1.2. Screening and diagnosis
with an increased risk of the combined outcome (CV death, MI, For details about sensitivity, specificity, and pre-test probability of each
or stroke) with an adjusted HR of 1.28.39Studies show that clinical procedure in the assessment of CHD, we refer to the 2019 ESC
symptoms of CAD in patients with diabetes are often less severe Guideline on chronic coronary syndromes.299
and atypical in presentation. In the BARI 2D (Bypass Angioplasty Screening for asymptomatic CAD in diabetes remains controversial.
Revascularization Investigation 2 Diabetes) trial in patients with Various RCTs evaluating the impact of routine screening for CAD in
angiographically confirmed CAD and a mean diabetes duration of asymptomatic patients with diabetes and no history of CAD showed
Downloaded
from

by
guest
on
22
January
2026

4084 E S C G u id e l in e s
no differences in CV outcomes at follow-up in those who underwent the extent of CAD, lesion complexity, and the risk of major surgery
routine screening compared with standard recommendations.386–388 are key points in the decision-making process. Because most of the
Data from a meta-analysis of five RCTs with 3299 asymptomatic pa- trials on revascularization contained patients with T2DM, current
tients with diabetes showed non-invasive CAD screening significantly Guidelines cannot easily be applied to patients with T1DM. It has
reduced the rate of any cardiac event by 27% (RR 0.73; 95% CI, now been demonstrated that CABG is also superior to PCI in patients
0.55–0.97; P = 0.028), driven by a non-significant reduction in non-fatal with T1DM and multivessel CAD.399
MI (RR 0.65; P = 0.062) and hospitalization for HF (RR 0.61; P = 0.1).
Still, given the limitations of this analysis (e.g. different screening modal- Recommendation Table 17 — Recommendations for
ities, heterogenous patient populations), non-invasive, routine screen- revascularization in patients with diabetes
ing for CAD in asymptomatic patients is not recommended.389
Moreover, in a recently published RCT involving men aged 65–74 years, Recommendations Classa Levelb
routine CVD screening did not significantly reduce the incidence of
It is recommended that similar revascularization
death from any cause after a median follow-up of 5.6 years, also in a
pre-specified diabetes sub-group.296 techniques are implemented (e.g. the use of DES and
the radial approach for PCI, and the use of the left I A
internal mammary artery as the graft for CABG) in
6.1.3. Management
patients with and without diabetes.400
The comprehensive management of patients with diabetes and estab-
Myocardial revascularization in CCS is
lished CAD should start with a healthy lifestyle and reducing or elimin-
recommended when angina persists despite
ating modifiable risk factors such as obesity, hypertension, or
treatment with anti-anginal drugs or in patients with I A
dyslipidaemia. The goal of pharmacotherapy should be to substantially
a documented large area of ischaemia (>10%
reduce serious CV events. Targets and pharmacotherapy for glycaemia,
BP, and LDL-C levels are addressed in the respective sections (Section
LV).382,401,402,402a
5.2, 5.4, and 5.5). Complete revascularization is recommended in
patients with STEMI without cardiogenic shock and I A
6.1.3.1. Pharmacotherapy with multivessel CAD.403–405
6.1.3.1.1. Glucose-lowering medication. Based on the results of vari- Complete revascularization should be considered in
ous CVOTs, SGLT2 inhibitors and/or GLP-1 RAs are recommended in patients with NSTE-ACS without cardiogenic shock IIa C
patients with T2DM and CAD to reduce CV events (Section 5.3). and with multivessel CAD.406,407
Routine immediate revascularization of non-culprit
6.1.3.1.2. Other medications. Due to the diffuse nature of CAD, lesions in patients with MI and multivessel disease
III B
some patients with diabetes are not amenable to revascularization. presenting with cardiogenic shock is not
Symptom relief might then be achieved by increasing myocardial oxy- recommended.408
gen supply with long-acting nitrates or CCBs, or by decreasing oxygen
CABG, coronary artery bypass graft; CAD, coronary artery disease; CCS, chronic coronary
demand with the help of beta-blockers, non-dihydropyridine CCBs, ra-
syndrome; DES, drug-eluting stents; LV, left ventricle; MI, myocardial infarction; NSTE-ACS,
nolazine, or ivabradine. Note that none of these medications improves non-ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention;
mortality or the rate of ischaemic events. Beta-blockers with a simultan- STEMI, ST-elevation myocardial infarction.
aClass of recommendation.
eous vasodilatory effect (e.g. carvedilol, nebivolol, labetalol) may be pre-
bLevel of evidence.
ferred due to their neutral or positive metabolic impact.390–392
Ranolazine, a drug that reduces myocardial ischaemia at the cellular le-
For recommendations for revascularization according to the extent
vel, also has the unique effect of reducing HbA1c, especially in patients
with poor metabolic control.393,394In normotensive patients with dia- of CAD, see the 2018 ESC/EACTS Guidelines on myocardial revascu-
larization and the 2019 ESC Guideline on chronic coronary
betes and CAD, ACE-Is or ARBs are also recommended to reduce the
risk of CV events, especially in patients with HF or CKD.395–397
syndromes.299,308
6.1.3.2. Revascularization
6.2. Acute coronary syndromes and
In patients with diabetes, the indications for myocardial revasculariza-
diabetes
tion are the same as those in patients without diabetes, the essential as-
pects of which are reported in the 2018 ESC/EACTS Guidelines on 6.2.1. Clinical presentation and diagnosis
myocardial revascularization and 2019 ESC Guideline on chronic cor- Diabetes is a frequent comorbidity in patients hospitalized for ACS,
onary syndromes.299,308 A detailed description of the evidence from with an increasing prevalence over the last decade and a high mortality
outcome trials on revascularization in patients with diabetes can be rate.409 Among patients presenting with ST-elevation myocardial in-
found in Supplementary data online, Section 3.1.1. In brief, given the cur- farction (STEMI), ∼25% have a history of diabetes and more than
rent knowledge, in patients with diabetes and multivessel disease, 40% show a previously undiagnosed T2DM or pre-diabetes.410
CABG with arterial grafts is preferred over complex PCI, providing Patients with diabetes more often present with non-typical symptoms
that patient characteristics (e.g. frailty, cerebrovascular disease) are compared with those without diabetes, and this impacts prompt diag-
considered.398 PCI with newer-generation drug-eluting stents (DES), nosis and treatment.411 Moreover, patients with diabetes frequently
whenever possible, is acceptable for patients with less-extensive dis- have multivessel disease and multiple coronary lesions, with a higher
ease (i.e. single-vessel disease or two-vessel disease not involving the percentage of highly vulnerable atherosclerotic plaques associated
left anterior descending, and those with SYNTAX Score ≤22). Thus, with impaired microvasculature vasodilation.412,413
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4085
6.2.2. Management Recommendation Table 18 — Recommendations for
6.2.2.1. Pharmacotherapy glycaemic control in patients with diabetes and acute
coronary syndrome
Patients with diabetes and ACS, despite the poor prognosis and high
prevalence of comorbidities, are less likely to receive appropriate treat-
Recommendations Classa Levelb
ment such as revascularization, reperfusion, or adequate DAPT.414,415
One of the reasons may be the lack of typical symptoms.416While few It is recommended to assess glycaemic status at initial
I B
studies have focused exclusively on patients with diabetes, analyses of evaluation in all patients with ACS.141,367,430
studies indicate that guideline-directed pharmacotherapy provides pa- It is recommended to frequently monitor blood
tients with diabetes similar or improved absolute benefits compared glucose levels in patients with known diabetes or
I C
with patients without diabetes, yet the incidence of events remains con-
hyperglycaemia (defined as glucose levels
stantly higher in those with vs. without diabetes.309,312,417
≥11.1 mmol/L or ≥200 mg/dL).
Glucose-lowering therapy should be considered in
6.2.2.2. Glucose control in patients with acute coronary syndrome patients with ACS with persistent hyperglycaemia,
IIa C
Patients with ACS and hyperglycaemia on admission to hospital have a high- while episodes of hypoglycaemia should be
er risk of death than patients with ACS without hyperglycaemia, irrespect-
avoided.423,424
ive of diabetes status.418Mortality correlates more strongly to the blood ACS, acute coronary syndrome.
glucose level than to the presence of diabetes.419,420Thus, early assessment aClass of recommendation.
of blood glucose level is strongly recommended in all subjects, although bLevel of evidence.
there is insufficient evidence that intensive glycaemic control improves
prognosis. The DIGAMI 1 trial showed that early, tight glycaemic control
Antithrombotic medication in patients with ACS is further described
with intravenous (i.v.) insulin–glucose infusion followed by subcutaneous in-
in Section 5.6.
jections significantly reduced 1-year mortality compared with conventional
glucose-lowering treatment.421Conversely, the DIGAMI 2 study, and later
pooled analyses of studies on insulin–glucose infusions did not confirm this 6.2.2.3. Reperfusion strategies in ST-elevation myocardial infarction
observation.146,422Other studies have shown that adequate glycaemic con- The therapeutic strategy in patients with diabetes presenting with
trol improves the prognosis of patients with ACS, while also demonstrating STEMI should not differ from that for patients without diabetes. As
the importance of avoiding hypoglycaemia, which is strongly associated for the general population, prognosis is determined by early and effect-
with worse outcomes.423,424A criticism of previous studies is the inad- ive reperfusion. Since patients with diabetes are more likely to present
equate characterization of glycaemia, with most studies analysing HbA1c with atypical symptoms, reperfusion is often undertaken late.431
as the glycaemic marker, when both hypoglycaemia and glycaemic variability Although, patients with diabetes and STEMI, compared with those
potentially have a role in CV pathology. without diabetes, are older, more often have multivessel disease and
Considering all evidence, it is best to attempt moderately tight gly- concomitant conditions, and are less likely to receive reperfusion ther-
caemic control while avoiding hypoglycaemia in the early hours of apy. Diabetes is regarded as an independent risk factor of early and late
ACS. Continuous insulin infusion should be limited to cases where the mortality.432–436 Primary angioplasty, performed in a timely fashion,
optimal glycaemic control cannot be achieved otherwise; blood glucose also provides the best clinical outcomes in patients with diabetes.437
level should be maintained <11.1 mmol/L (<200 mg/dL) or Several recent studies indicate the clinical benefit of early, single-stage,
<10.0 mmol/L (<180 mg/dL) according to some recommenda- complete revascularization in patients with non-ST-elevation ACS
tions.425–427Frequent blood glucose testing, preferably hourly during (NSTE-ACS) and early complete revascularization in those with
the acute ACS phase, will help to avoid hypoglycaemia. CGM provides STEMI and multivessel disease.403–407,432–435The exception is patients
comprehensive glucose data while being more convenient than blood in cardiogenic shock, where it is recommended to limit the procedure
glucose testing, and the LIBERATES (Improving Glucose Control in to the infarct-related artery.408Adding proton pump inhibitors, limiting
Patients with Diabetes Following Myocardial Infarction: The Role of a use of glycoprotein IIb/IIIa inhibitors, and avoiding heparin in patients on
Novel Glycaemia Monitoring Strategy) RCT in 141 insulin- or OACs if the international normalized ratio (INR) >2.5 are
sulphonylurea-treated patients with T2DM and ACS showed that recommended.308
CGM over 3 months significantly reduced hypoglycaemic exposure
compared with traditional capillary glucose testing, while being equally
effective at reducing HbA1c.428In the EMMY (Impact of EMpagliflozin 6.2.2.4. Optimal timing of invasive strategy in non-ST-elevation acute
on cardiac function and biomarkers of heart failure in patients with acute coronary syndrome
MYocardial infarction) trial, 467 patients were randomized to empagli- In patients with diabetes and NSTE-ACS, the indications and timing of
flozin 10 mg or placebo within 72 h of PCI for acute MI.429The study revascularization should not differ from those for patients without dia-
drug was associated with a significantly greater N-terminal pro-B-type betes.438Multiple studies have indicated that an early invasive strategy is
natriuretic peptide (NT-proBNP) reduction over 26 weeks (primary beneficial in high-risk sub-groups.439–442Since diabetes is one of the risk
outcome) and a significant improvement in echocardiographic LV para- factors of poor prognosis, patients with diabetes may benefit signifi-
meters, without demonstrating any difference in adverse events of spe- cantly more from the early invasive approach than those without dia-
cial interest including metabolic acidosis and diabetic ketoacidosis.429 betes.417,443 In a meta-analysis of eight RCTs in patients with
It should be noted that hyperglycaemia in the acute phase of ACS NSTE-ACS, which compared an early vs. a delayed invasive strategy,
might reflect stress hyperglycaemia and is not enough to diagnose dia- diabetes, elevated troponin, and a Global Registry of Acute Coronary
betes. These patients should be further evaluated after discharge Events (GRACE) risk score >140 predicted lower mortality in the early
(Section 3). invasive arm.444
3202CSE© Downloaded
from

by
guest
on
22
January
2026

4086 E S C G u id e l in e s
According to current guidelines, an immediate invasive strategy Table 10 Risk factors for developing heart failure in
(within 2 h from admission) should be applied to very high-risk patients, patients with diabetes
mostly with electrical or haemodynamic instability.426 These patients
Cardiac risk factors Ischaemic heart disease
were excluded from all major randomized ACS trials. In addition, pa-
Myocardial infarction
tients with severe symptoms, refractory to medical therapy, or those
Hypertension
with electrocardiogram (ECG) signs suggesting the left main stem as
Valvular heart disease
a culprit vessel should be promptly referred for coronary angiography.
Arrhythmias
An early invasive strategy (within 24 h) should be applied to high-risk
patients, especially those with markedly elevated troponins, dynamic Non-cardiac risk factors Age
Chronic kidney disease
ST/T-segment changes, transient ST-segment elevation, or a GRACE
risk score >140. Increased body mass index
Longer duration of diabetes
6.3. Ischaemia with no obstructive Smoking
coronary artery disease in diabetes Alcohol excess
Details on the role of ischaemia with no obstructive CAD are outlined
in the Supplementary data online, Section 3.2.
7. Heart failure and diabetes myocardial dysfunction.449–452Observational data have also identified
that lower-extremity artery disease (LEAD), longer diabetes duration,
7.1. Definition and pathophysiology ageing, increased BMI, and CKD (Section 9) are associated with HF in
patients with diabetes (Table 10).449–452 Complex pathophysiological
Heart failure is not a single pathological disease but a clinical syndrome
mechanisms may be responsible for the development of myocardial
with current or prior symptoms and/or signs caused by a structural and/
dysfunction, even in the absence of IHD or hypertension.453For dec-
or functional cardiac abnormality. It is corroborated by elevated natri-
ades, the concept of diabetic cardiomyopathy has been discussed,
uretic peptides and/or objective evidence of cardiogenic pulmonary or
with mostly experimental and smaller observational studies suggesting
systemic congestion from diagnostic modalities, such as imaging or in-
vasive haemodynamic measurements.445 its presence; however, its existence has so far not been con-
firmed.447,454–458
Heart failure is one of the most common initial manifestations of
CVD in patients with T2DM, and may present as HFpEF, heart failure
with mildly reduced ejection fraction (HFmrEF), or HFrEF (Table 9).446 7.2. Epidemiology and prognosis
Major causes of HF in diabetes are IHD (Section 6), hypertension Diabetes is an important risk factor for HF.459Observational studies have
(Section 5.3), direct or indirect effects of hyperglycaemia, and obesity consistently demonstrated a two- to four-fold increased risk of HF in in-
and related factors on the myocardium.447,448IHD is often accelerated, dividuals with diabetes compared with those without diabetes.460–463
severe, diffuse, and silent, and increases the risk of MI and ischaemic The prevalence of chronic HF increases steadily with age for patients
with and without diabetes. Patients with T2DM develop chronic HF
more often and earlier in life than those without T2DM, with an incre-
Table 9 Heart failure phenotypes according to ejection
fraction distribution445 mental risk inversely associated with age; for example, in one study,
the incident rate ratio was 11.0 (95% CI, 5.6–21.8) for those <45 years,
HF HFpEF HFmrEF HFrEF declining to 1.8 (95% CI, 1.6–2.2) for those aged 75–84 years, reflecting
phenotype the higher absolute HF risk in elderly patients without diabetes.463
Unrecognized HF is frequent in T2DM: a cross-sectional study in patients
Criterion 1 Symptoms and/or Symptoms Symptoms
aged ≥60 years with T2DM without known HF using a standardized diag-
signsa and/or signsa and/or signsa nostic work-up, including medical history, physical examination, ECG,
Criterion 2 LVEF ≥50% LVEF 41–49% LVEF ≤40% and echocardiography, indicated that HF was present in 28% of patients
Criterion 3 Objective evidence of None None (∼25% HFrEF and ∼75% HFpEF).460–464
cardiac structural Vice versa, HF is associated with a diabetes incidence of 20–30 per
and/or functional 1000 person-years in the first 5 years following HF hospitalization,
abnormalities which is substantially higher than for adults in the general population
consistent with the (10.1 per 1000 person-years).465,466 A large, pan-European registry
presence of LV found that ∼36% of all outpatients with stable HF had diabetes, while
in patients hospitalized for acute HF for whom i.v. therapy (inotropes,
diastolic dysfunction
vasodilators, or diuretics) was needed, diabetes was present in up to
or raised filling
50%.467,468In addition, available data from observational studies dem-
pressures, including
onstrate that diabetes prevalence in patients with HF is similar, irre-
raised natriuretic
spective of LVEF category.469,470
peptides
A significant association exists between diabetes and a higher risk of
HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart adverse outcomes in patients with HF, with the greatest incremental risk
failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; associated with diabetes observed in patients with HFrEF.467,471–475
LV, left ventricular; LVEF, left ventricular ejection fraction.
aSymptoms include, for example, breathlessness, ankle swelling, and fatigue. Signs may not However, CV mortality, including death caused by worsening HF, is
be present at an early stage or in patients receiving diuretics. also 50–90% higher in patients with HF and diabetes compared
3202CSE©
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4087
with HF patients without diabetes, regardless of HF phenotype.471,475–477 risk score including high-sensitivity cardiac troponin T ≥6 ng/L,
In patients with acute HF, for whom i.v. therapy (inotropes, vasodi- NT-proBNP ≥125 pg/mL, high-sensitivity C-reactive protein ≥3 mg/L,
lators, or diuretics) was needed, diabetes was associated with higher and LV hypertrophy by ECG (with one point for each abnormal param-
risk of in-hospital death, 1 year all-cause death, and 1 year HF eter) demonstrated good discrimination and calibration for predicting 5-
re-hospitalization.468,478 and 10-year HF risk among patients with diabetes. The highest 5-year risk
of HF was noted among those with scores ≥3.481 The Heart Failure
Association of the ESC reviewed the clinical evidence and value of further
7.3. Screening and diagnosis biomarker testing and currently recommends no further testing.482
Patients with diabetes are at risk of HF but not all patients with diabetes To detect transition from being at risk of HF to developing HF, the
will develop HF.479 Given that the prognosis of patients with both co- following regular evaluation is recommended in patients with diabetes
morbidities is worse, it is of utmost importance to screen all patients (Figure 14):
with diabetes for HF to allow early implementation of life-saving therapies.
To predict the HF risk among outpatients with T2DM, the WATCH-DM • Regularly, a systematic survey for HF symptoms (breathlessness, dys-
(Weight [BMI], Age, Hypertension, Creatinine, HDL-C, Diabetes control pnoea on exertion, orthopnoea, paroxysmal nocturnal dyspnoea,
[fasting plasma glucose], QRS duration, MI, and CABG) risk score has nocturia, fatigue, tiredness, increased time to recover following exer-
been developed.480Each increment of 1 unit in the risk score is associated cise) or signs (weight gain, peripheral oedema, elevated jugular ven-
with a 24% higher HF risk within 5 years. In addition, a biomarker-based ous pulse, rales, hepatojugular reflux, third heart sound, or laterally
Patient with diabetes (at risk for HF)
Symptoms and/or
Repeat evaluation
N signs for HF and/or
regularly
abnormal ECG
Y
Suspected HF
N NT-proBNP ≥125 pg/mL
or BNP ≥35 pg/mL
Y
Echocardiography with
N structural and/or
functional cardiac abnormality
Y
HF confirmed
Define HF phenotype
based on LVEF measurement
≤40% 41%–49% ≥50%
(HFrEF) (HFmrEF) (HFpEF)
Determine aetiology and commence treatment
Figure 14 Diagnostic algorithm for heart failure in patients with diabetes. BNP, B-type natriuretic peptide; ECG, electrocardiogram; HF, heart failure;
HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection
fraction; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
Downloaded
from

by
guest
on
22
January
2026

4088 E S C G u id e l in e s
displaced apical impulse) is recommended. For more details, see the Routine blood tests for comorbidities are
2021 ESC Guidelines for the diagnosis and treatment of acute and recommended, including full blood count, urea,
chronic heart failure.445 creatinine and electrolytes, thyroid function, lipids, I C
and iron status (ferritin and TSAT).
If one or more of the symptoms or signs above is present, HF can be
ECG, electrocardiogram; HF, heart failure; BNP, B-type natriuretic peptide; NT-proBNP,
suspected, and the following diagnostic tests are recommended:
N-terminal pro-B-type natriuretic peptide; TSAT, transferrin saturation.
aClass of recommendation.
• Measurement of natriuretic peptides is recommended, if available. bLevel of evidence.
Values below the following cut-offs make the diagnosis of HF unlikely
and other diagnoses should be considered:483–485
○ B-type natriuretic peptide (BNP) <35 pg/mL (threshold in AF: 7.4. Treatment of heart failure in patients
<105 pg/mL).
with diabetes
○ NT-proBNP <125 pg/mL (threshold in AF: <365 pg/mL).
7.4.1. Treatment of heart failure with reduced
However, natriuretic peptide concentrations may be disproportion- ejection fraction
ately low in patients with obesity or in women, and disproportionately
Treatment of HFrEF encompasses therapeutic lifestyle modifications, as
high in patients with advanced CKD, advanced age, or AF.486,487Still,
well as pharmacological and device therapies with benefits confirmed in
elevated concentrations support the diagnosis of HF and may guide fur-
RCTs, in which 30–40% of patients had diabetes. Treatment effects of
ther cardiac investigation.488
medications and devices for HFrEF have been consistently demon-
• ECG is recommended to detect abnormalities such as AF, signs of LV strated to not differ in patients with vs. without diabetes. Importantly,
hypertrophy, Q waves, or widened QRS, each of which may be a sign while the RR reductions are consistently similar for those with and with-
of HF.489 out diabetes, given the higher absolute HFrEF clinical risk associated with
• Echocardiography is recommended to assess cardiac function includ- diabetes, the ARR in patients with diabetes is typically higher, yielding a
ing LV function, chamber size, LV hypertrophy, regional wall motion lower NNT for benefit among patients with diabetes.
abnormalities (that may suggest CAD), right ventricular function, es- The cornerstone of treatment for HFrEF is pharmacotherapy along-
timated pulmonary pressure, valvular function, and markers of diastol- side lifestyle interventions, which should be implemented before con-
ic dysfunction. Transthoracic echocardiography may be considered to sidering device therapy. The recent 2021 ESC Guidelines for the
detect HF in patients with diabetes if other risk factors arise. diagnosis and treatment of acute and chronic heart failure recommend
• Chest X-ray is recommended to investigate other causes of dys- starting quadruple therapy (angiotensin receptor–neprilysin inhibitor
pnoea (e.g. pulmonary disease). It may provide supportive evidence [ARNI]/ACE-I, MRA, beta-blocker, SGLT2 inhibitor).445 These four
of HF (e.g. cardiomegaly, pulmonary congestion, pleural effusion). foundational treatments should be initiated early, as much of the ben-
• Routine blood tests (including full blood count, urea, creatinine, and efits are seen within 30 days of starting treatment, and adding new
electrolytes, thyroid and liver function, lipids, and iron status (ferritin drugs yields greater benefits than up-titrating existing drug classes. In
and transferrin saturation) are recommended to differentiate HF the STRONG-HF (Safety, Tolerability and Efficacy of Rapid
from other conditions, to obtain prognostic information, and to Optimization, Helped by NT-proBNP testinG, of Heart Failure
guide potential therapy. Additional diagnostic tests should be consid- Therapies) trial, 1078 patients with acute HF, 29% of whom had dia-
ered if other specific diagnoses are suspected (e.g. amyloidosis). betes at baseline, were assigned to either high-intensity care with up-
• If HF is confirmed, additional diagnostic tests are recommended as titration of treatments to 100% of recommended doses within 2 weeks
summarized in the 2021 ESC Guidelines for the diagnosis and treat- of discharge or to usual care.490Safety and tolerability were assessed at
ment of acute and chronic heart failure.445 weeks 1, 2, 3, and 6 by full physical examination and laboratory assess-
ments of NT-proBNP, sodium, potassium, glucose, kidney function, and
haemoglobin measures. The study was stopped early due to a greater
Recommendation Table 19 — Recommendations for than expected between-group difference. The primary endpoint, con-
heart failure screening and diagnosis in patients with sisting of 180-day re-admission to hospital due to HF or all-cause death,
diabetes was significantly reduced in the high-intensity group, with a RR reduc-
tion of 34% (HR 0.66; 95% CI, 0.50–0.86) with similar incidences of ser-
Recommendations Classa Levelb ious adverse events. Of note, no sub-group analysis exists on patients
with diabetes. Based on these data, an intensive strategy of early initi-
Evaluating for heart failure
ation of evidence-based treatment (SGLT2 inhibitors, ARNI/ACE-Is,
If HF is suspected, it is recommended to measure beta-blockers, and MRAs), with rapid up-titration to trial-defined target
I B
BNP/NT-proBNP.485
doses and frequent follow-up visits in the first 6 weeks following dis-
Systematic survey for HF symptoms and/or signs of charge from a HF hospitalization is recommended to reduce
HF is recommended at each clinical encounter in all I C re-admissions or mortality. The sequence of therapy initiation should
patients with diabetes. be based on the individual patient phenotype taking into account BP,
heart rhythm, and heart rate, as well as kidney function and risk of hy-
Diagnostic tests in all patients with suspected heart failure
perkalaemia. While the start dose of SGLT2 inhibitors is the same as the
12-lead ECG is recommended. I C
target dose, ARNI/ACE-Is, beta-blockers, and MRAs should be started
Transthoracic echocardiography is recommended. I C at low dose and up-titrated to the maximum tolerated dose. For more
Chest radiography (X-ray) is recommended. I C details on HFrEF therapy, please refer to the 2021 ESC Guidelines for
Continued the diagnosis and treatment of acute and chronic heart failure.445The
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4089
specific characteristics for patients with diabetes are presented in the for HF, or death at 60 days compared with placebo. In the
following sections. SOLOIST-WHF trial mentioned above, 1222 patients with T2DM re-
ceived sotagliflozin or placebo, with a median follow-up of 9 months (trial
stopped prematurely).189Sotagliflozin therapy, initiated before or shortly
7.4.1.1. Sodium–glucose co-transporter-2 inhibitors after discharge, resulted in significantly fewer deaths from CV causes and
Two randomized placebo-controlled trials have investigated the effect of hospitalizations and urgent visits for HF than placebo, with no increase in
an SGLT2 inhibitor compared with placebo added to optimal medical acute kidney injury. The EMPULSE (A Study to Test the Effect of
therapy (OMT) in patients with HFrEF with and without diabetes. The Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure) trial
DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in randomized 530 hospitalized patients with and without diabetes with a pri-
Heart Failure) trial included patients if they were in New York Heart mary diagnosis of acute de novo or decompensated HF, regardless of LVEF
Association (NYHA) class II–IV, had an LVEF ≤40% despite OMT, and when clinically stable, to receive either empagliflozin or placebo. More pa-
had elevated NT-proBNP (in sinus rhythm ≥600 pg/mL, in AF tients treated with empagliflozin had clinical benefit (win ratio 1.36; 95% CI,
≥900 mg/mL, or ≥400 pg/mL if they had been hospitalized for HF within 1.09–1.68) compared with placebo. This effect was consistent for acute de
the previous 12 months). Patients with T1DM or an eGFR <30 mL/min/ novo and decompensated chronic HF and was observed regardless of LVEF
1.73 m2 were excluded. Therapy with dapagliflozin 10 mg o.d. vs. placebo or the presence of diabetes.499In these trials, very few cases of euglycaemic
reduced the risk of the primary outcome, a composite of worsening diabetic ketoacidosis were reported; still, physicians treating patients with
HF (hospitalization or an urgent visit resulting in i.v. therapy for HF) or diabetes with SGLT2 inhibitors in this setting should be aware of this rare
CV death, by 26% (HR 0.74; 95% CI, 0.65–0.85). In addition, dapagliflozin but potentially serious complication. Of note, misinterpreting eGFR
reduced all-cause mortality (HR 0.83; 95% CI, 0.71–0.97) and improved changes can lead to inappropriate discontinuation of disease-modifying
symptoms, physical function, and quality of life in patients with agents and should be avoided.
HFrEF.491,492 All of the clinical benefits observed were independent of
baseline diabetes status and background glucose-lowering therapy, 7.4.1.2. Angiotensin receptor–neprilysin inhibitor and
and consistent across the spectrum of HbA1c.491,493 The EMPEROR- angiotensin-converting enzyme inhibitors
Reduced (Empagliflozin Outcome Trial in Patients with Chronic Heart
The ARNI sacubitril/valsartan has shown superior efficacy to enalapril in
Failure with Reduced Ejection Fraction) trial evaluated empagliflozin vs.
reducing CV death and HF hospitalization in patients with HFrEF, with
placebo and included patients with HFrEF with and without diabetes, or without diabetes.471Patients were up-titrated to 200 mg b.i.d. sacu-
with NYHA class II–IV, and LVEF ≤40% despite OMT, an eGFR bitril/valsartan within 2–4 weeks.471The beneficial effect of sacubitril/
≥20 mL/min/1.73 m2, and an elevated NT-proBNP (EF ≤30% or EF
valsartan over enalapril was consistent for patients with and without
≤40% and HF hospitalization within 12 months: NT-proBNP ≥600 pg/
diabetes and across the spectrum of baseline HbA1c.
mL; EF 31–35%: NT-proBNP ≥1000 pg/mL; EF 36–40%: NT-proBNP
ACE-Is were the first class of drugs shown to reduce mortality and
≥2500 pg/mL). Empagliflozin 10 mg o.d. reduced the risk of the primary morbidity and improve symptoms in patients with HFrEF.500There is
outcome, a composite of CV death or HF hospitalization, by 25% vs. pla- no difference in efficacy in patients with and without diabetes.501–503
cebo (HR 0.75; 95% CI, 0.65–0.86).494This effect was consistent across
As RAS inhibitors increase the risk of hyperkalaemia and may acutely
patients with and without diabetes at baseline.495Treatment with empa-
compromise kidney function, routine surveillance of serum creatinine
gliflozin improved quality of life.496A meta-analysis of the DAPA-HF and and potassium levels is advised.504,505However, misinterpreting eGFR
EMPEROR-Reduced trials showed a consistent reduction in HF hospital-
changes often leads to inappropriate discontinuation of disease-
ization or CV death, CV death, and all-cause mortality by SGLT2-inhibitor modifying agents and should be avoided.504–506
treatment without significant heterogeneity between trials.497
The combined SGLT1 and -2 inhibitor sotagliflozin was investigated
7.4.1.3. Mineralocorticoid receptor antagonists
in patients with T2DM who were recently hospitalized for worsening
The steroidal MRAs spironolactone or eplerenone reduce death and
HF, irrespective of their LVEF (SOLOIST-WHF [Effect of Sotagliflozin
HF hospitalization in patients with HFrEF, with consistent results in pa-
on Cardiovascular Events in Patients with Type 2 Diabetes Post tients with or without diabetes.507,508Eplerenone is more specific for
Worsening Heart Failure] trial). Patients with an eGFR <30 mL/min/
blocking aldosterone and, therefore, causes less gynaecomastia.
1.73 m2 were excluded. Sotagliflozin significantly reduced the RR of the
Caution should be exercised when using MRAs in patients with im-
composite primary outcome (CV death, HF hospitalization, or urgent visit
paired renal function and in those with serum potassium concentration
for HF) by 33% compared with placebo (HR 0.67; 95% CI, 0.52–0.85). The
>5.0 mmol/L. The non-steroidal MRA finerenone has not been investi-
treatment effect was consistent across the spectrum of LVEF.189
gated in patients with HFrEF (Section 9).
Thus, the SGLT inhibitors dapagliflozin, empagliflozin, and sotagliflo-
zin are recommended, in addition to OMT (with an ARNI/ACE-I, beta-
7.4.1.4. Beta-blockers
blocker, and MRA), in patients with HFrEF and diabetes to reduce CV
death and HF hospitalization. Beta-blockers are effective at reducing all-cause death and hospitaliza-
Three studies have investigated whether SGLT2 inhibitors can be safely tion for HF in patients with HFrEF, with or without diabetes.509–512
started in patients hospitalized for acute HF. The EMPA-RESPONSE-AHF Treatment benefits strongly support using beta-blockers in patients
(Effects of Empagliflozin on Clinical Outcomes in Patients With Acute with HFrEF and diabetes.
Decompensated Heart Failure) trial randomized 80 patients with acute
HF with (approximately one-third) and without diabetes to either empa- 7.4.1.5. Angiotensin-II receptor blockers
gliflozin or placebo for 30 days.498Treatment with empagliflozin did not The place of ARBs in managing HFrEF has changed over the last few
affect visual analogue scale dyspnoea, diuretic response, NT-proBNP le- years. They are now recommended for patients who cannot tolerate
vels, or duration of hospital stay, but was safe, increased urinary output, ARNI or ACE-Is because of serious side effects. ARBs have similar treat-
and reduced a combined endpoint of worsening HF, re-hospitalization ment effects in patients with HFrEF with or without diabetes.513–515
Downloaded
from

by
guest
on
22
January
2026

4090 E S C G u id e l in e s
7.4.1.6. Ivabradine MRAse are recommended in patients with HFrEF and
Ivabradine slows heart rate by inhibiting the I channel in the sinus node diabetes to reduce the risk of HF hospitalization and I A
f
and is therefore only effective in patients in sinus rhythm. Ivabradine re- death.507,529
duced the combined endpoint of CV death or HF hospitalization irre- An intensive strategy of early initiation of
spective of diabetes status.516
evidence-based treatment (SGLT2 inhibitors, ARNI/
ACE-Is, beta-blockers, and MRAs), with rapid
7.4.1.7. Hydralazine and isosorbide dinitrate up-titration to trial-defined target doses starting before I B
discharge and with frequent follow-up visits in the first 6
There is no evidence to support the use of this fixed-dose combination ther-
apy in all patients with HFrEF, but rather limited to self-identified Black pa- weeks following a HF hospitalization is recommended
tients as per product labelling. An RCT in self-identified Black patients with to reduce re-admissions or mortality.490
HFrEF showed that adding the combination of hydralazine and isosorbide di- Recommendations for other treatments indicated in selected
nitrate to conventional therapy (ACE-I, beta-blocker, MRA) reduced mortal- patients with HFrEF (NYHA class II–IV) and diabetes
ity and HF hospitalization in patients in NYHA class III–IV.517The beneficial
Device therapy with an ICD, CRT-P, or CRT-D is
effects were consistent in patients with or without diabetes.518
recommended in patients with diabetes, as in the I A
general population with HFrEF.522–525
7.4.1.8. Digoxin ARBs are recommended in symptomatic patients
Digoxin may reduce the risk of HF hospitalization in patients with with HFrEF and diabetes who do not tolerate I A
HFrEF treated with ACE-Is, irrespective of diabetes status.519 sacubitril/valsartan or ACE-Is, to reduce the risk of
HF hospitalization and CV death.513–515
Diuretics are recommended in patients with HFrEF
7.4.1.9. Diuretics
and diabetes with signs and/or symptoms of fluid
Despite a lack of evidence for the efficacy of either thiazide or loop I C
congestion to improve symptoms, exercise capacity,
diuretics in reducing CV outcomes in patients with HF, diuretics pre-
and HF hospitalization.520
vent and treat symptoms and signs of fluid congestion in patients
with HF.520Importantly, a judicious use of diuretic therapy including al- Ivabradine should be considered to reduce the risk of
ternating dosing over time is warranted.521 HF hospitalization and CV death in patients with
HFrEF and diabetes in sinus rhythm, with a resting
IIa B
heart rate ≥70 b.p.m., who remain symptomatic
7.4.1.10. Device therapy and surgery
despite treatment with beta-blockers (maximum
Device therapies (implantable cardioverter defibrillator [ICD], cardiac tolerated dose), ACE-Is/ARBs, and MRAs.516
resynchronization therapy [CRT], and CRT with an implantable defib-
Hydralazine and isosorbide dinitrate should be
rillator [CRT-D]) have similar efficacies and risks in patients with HFrEF
considered in self-identified Black patients with
with or without diabetes.522–525These therapies should be considered
diabetes and LVEF ≤ 35% or with LVEF <45%
according to treatment guidelines in the HFrEF population. Heart trans-
combined with a dilated left ventricle in NYHA class IIa B
plantation could be considered in end-stage HF, but a large, prospective
III–IV despite treatment with an ACE-I (or ARNI), a
study of transplanted patients indicated a decreased likelihood of
beta-blocker, and an MRA, to reduce the risk of HF
10-year survival in those with diabetes.526
hospitalization and death.517,518
Digoxin may be considered in patients with
Recommendation Table 20 — Recommendations for symptomatic HFrEF in sinus rhythm despite
heart failure treatments in patients with heart failure
treatment with sacubitril/valsartan or an ACE-I, a IIb B
with reduced ejection fraction and diabetes
beta-blocker, and an MRA, to reduce the risk of
Recommendations Classa Levelb
hospitalization.519
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker;
Recommendations for the pharmacological treatment
ARNI, angiotensin receptor–neprilysin inhibitor; CRT-D, cardiac resynchronization
indicated in patients with HFrEF (NYHA class II–IV) and therapy with defibrillator; CRT-P, cardiac resynchronization therapy-pacemaker; CV,
diabetes cardiovascular; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; ICD,
implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MRA,
SGLT2 inhibitors (dapagliflozin, empagliflozin, or mineralocorticoid receptor antagonist; NYHA, New York Heart Association; SGLT2,
sotagliflozinc) are recommended in all patients with sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus.
I A aClass of recommendation.
HFrEF and T2DM to reduce the risk of HF bLevel of evidence.
hospitalization and CV death.189,491,494,497 cSotagliflozin is a dual SGLT1/2 inhibitor.
dSustained-released metoprolol succinate, carvedilol, bisoprolol, and nebivolol.
Sacubitril/valsartan or an ACE-I is recommended in
eSpironolactone or eplerenone.
all patients with HFrEF and diabetes to reduce the I A
risk of HF hospitalization and death.471,501,502,527
Beta-blockersd are recommended in patients with 7.4.2. Treatment of heart failure with mildly reduced
HFrEF and diabetes to reduce the risk of HF I A ejection fraction
hospitalization and death.509–512,528 As in other forms of HF, diuretics should be used to control conges-
Continued tion.520 Results from retrospective analyses of RCTs in patients with
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4091
HFrEF or HFpEF indicate that patients with a LVEF between 40–50% might be useful for managing hypertension. For treating comorbidities
benefitted from similar therapies to those with LVEF ≤40%.445 alongside HFpEF, refer to the 2021 ESC Guidelines for the diagnosis
However, to date, no definitive RCT has evaluated therapies exclusively and treatment of acute and chronic heart failure.445
in patients with HFmrEF. The best evidence so far derives from
SGLT2-inhibitor studies. The EMPEROR-Preserved (Empagliflozin Recommendation Table 21 — Recommendations for
Outcome Trial in Patients with Chronic Heart Failure With heart failure treatments in patients with diabetes and
left ventricular ejection fraction over 40%
Preserved Ejection Fraction) trial included patients with NYHA class
II–IV, an LVEF >40%, and an elevated NT-proBNP (>300 pg/mL in si-
Recommendations Classa Levelb
nus rhythm; >900 pg/mL in AF).530 Patients with an eGFR <20 mL/
min/1.73 m2 were excluded. Compared with placebo, empagliflozin re- Empagliflozin or dapagliflozin are recommended in
duced the risk of the primary outcome, a composite of CV death or patients with T2DM and LVEF >40% (HFmrEF and
I A
hospitalization for HF, by 21%, which was mainly related to a 29% lower HFpEF) to reduce the risk of HF hospitalization or
risk of hospitalization for HF.530This effect was independent of diabetes CV death.530–533
status, and baseline HbA1c did not modify the effects on the primary
Diuretics are recommended in patients with HFpEF
outcome.531 The DELIVER (Dapagliflozin Evaluation to Improve the
or HFmrEF and diabetes with signs and/or symptoms
Lives of Patients with Preserved Ejection Fraction Heart Failure) trial in- I C
of fluid congestion to improve symptoms, exercise
cluded 6263 patients with NYHA class II–IV, an LVEF >40%, an elevated capacity, and HF hospitalization.520
NT-proBNP (>300 pg/mL in sinus rhythm; >600 pg/mL in AF), and an
eGFR ≥25 mL/min/1.73 m2. Compared with placebo, dapagliflozin re- CV, cardiovascular disease; HF, heart failure; HFmrEF, heart failure with mildly reduced
duced the primary outcome, a composite of worsening HF or CV ejection fraction; HFpEF, heart failure with preserved ejection fraction; LVEF, left
ventricular ejection fraction; T2DM, type 2 diabetes mellitus.
death, by 18%, which was mainly driven by a reduction in hospitalization
aClass of recommendation.
for HF. This effect was independent of diabetes status.532 A bLevel of evidence.
meta-analysis including 12 251 participants from DELIVER and
EMPEROR-Preserved showed that SGLT2 inhibitors, compared with
7.5. Safety profile of glucose-lowering
placebo, reduced a composite of CV death and first hospitalization
agents in patients with heart failure and
for HF (HR 0.80; 95% CI, 0.73–0.87), with consistent reductions in
both components: CV death (HR 0.88; 95% CI, 0.77–1.00) and first diabetes
hospitalization for HF (HR 0.74; 95% CI, 0.67–0.83).533 For glycaemic targets in patients with diabetes, please refer to Section
There is no specific trial evaluating ARNI in patients with HFmrEF. 5.2.
The PARAGON-HF trial, which included patients with EF ≥45%, al-
though missing its primary endpoint overall, showed significant
EF-by-treatment interaction. Sacubitril/valsartan, compared with valsar- 7.5.1. Sodium–glucose co-transporter-2 inhibitors
tan, reduced the likelihood of the primary composite outcome of CV Sodium–glucose co-transporter-2 inhibitors (see also Section 7.4.1.1)
death and total HF hospitalization by 22% in those with an LVEF below have been investigated in different populations with diabetes, ranging
or equal to the median of 57%.534 from patients with ASCVD or multiple ASCVD risk factors to patients
recently hospitalized for worsening HF, with increasing ARR for
HF-related outcomes according to higher patient risk (Figure 15;
7.4.3. Treatment of heart failure with preserved Supplementary data online, Table S15).
ejection fraction As outlined above, in dedicated HF trials, dapagliflozin and empagli-
Over the past decade, several large RCTs failed to achieve statistical sig- flozin reduced CV death and HF hospitalization in patients with
nificance with regard to effects on the primary outcomes in patients HFrEF with or without diabetes, and sotagliflozin reduced CV death
with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (can- and HF hospitalization in patients with T2DM and recent hospitalization
desartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG for HF of any aetiology.189,491,494Moreover, empagliflozin and dapagli-
Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsar- flozin reduced the risk of CV death or HF hospitalization in patients
tan).477,534–538As presented above in section 7.4.2, the SGLT2 inhibi- with HFmrEF or HFpEF.530,532
tors empagliflozin and dapagliflozin both reduced the RR of the While the EMPA-REG OUTCOME (empagliflozin) and VERTIS CV
primary composite outcome, CV death or hospitalization for HF, by (ertugliflozin) trials investigated patients with T2DM and established
21% and 18%, respectively.530,532The treatment effect on the incidence ASCVD risk, the CANVAS Programme (canagliflozin) and
of the primary outcome did not differ between LVEF sub-groups nor DECLARE-TIMI 58 trial (dapagliflozin) included patients with
between patients with and without diabetes.531–533 The combined established ASCVD or multiple ASCVD risk factors. In all of these
SGLT1 and -2 inhibitor sotagliflozin was investigated in patients with placebo-controlled CVOTs of SGLT2 inhibitors, only a small proportion
T2DM who were recently hospitalized for worsening HF, irrespective of patients had a baseline history of HF. Empagliflozin reduced the risk of
of their LVEF (SOLOIST-WHF trial); 20.9% of the patients had an HF hospitalization by 35% in patients with and without previous HF.71
LVEF ≥50%. Sotagliflozin reduced the risk of the primary composite Canagliflozin also significantly reduced the risk of HF hospitalization
outcome of CV death, HF hospitalization, and urgent visit for HF by by 33%.151Dapagliflozin significantly reduced the combined endpoint
33%, with a consistent effect across the spectrum of baseline LVEF. of CV death or HF hospitalization, a result driven mainly by lower rates
However, the number of events in the HFpEF group was too small of HF hospitalization.152 This effect was independent of pre-existing
to draw any firm conclusion.189 HF.540Ertugliflozin did not reduce the combined endpoint of CV death
Diuretic therapy should be used to reduce symptoms of conges- or HF hospitalization, although there was a significant reduction in HF
tion.520 Loop diuretics are preferred, but low-dose thiazide diuretics hospitalization and repeated hospitalizations.154,541
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

4092 E S C G u id e l in e s
High risk T2DM CKD Chronic HFpEF Chronic HFrEF Worsening HF
ARR: 0.25–1.04 ARR: 0.80–1.39 ARR: 1.8 ARR: 3.9–5.2 ARR: 10.4
per 100 pt-yrs per 100 pt-yrs per 100 pt-yrs per 100 pt-yrs per 100 pt-yrs
NNT: 96–400 NNT: 72–125 NNT: 59 NNT: 21–36 NNT: 10
RRR: 12%–34% RRR: 29%–31% RRR: 21% RRR: 25% RRR: 129%
Absolute risk reduction with
SGLT2 inhibitors (per 100 pt-yrs)
14
SOLOIST-WHFa
12
10
8
6 EMPA-KIDNEY
EMPEROR-Preserved
VERTIS-CV
4 DECLARE-TIMI-58 DELIVER
EMPA-REG OUTCOME
EMPEROR-Reduced
CANVAS CREDENCE
2
DAPA-HF
0 DAPA-CKD
1 2 4 8 16 32
Rate of first failure hospitalization or cardiovascular death in the placedo arm (per 100 pt-yrs)
Figure 15 Absolute risk reduction with sodium–glucose co-transporter-2 inhibitors in relation to patient risk based on rate of heart failure-related end-
points in the placebo arm of the respective trials. ARR, absolute risk reduction; CKD, chronic kidney disease; HF, heart failure; HFpEF, heart failure with
preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NNT, number needed to treat; pt-yrs, patient-years; RRR, relative risk re-
duction; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus. Bubble plots demonstrate the consistent reductions in time to cardio-
vascular mortality or first HF hospitalization with SGLT2 inhibitors across all trials, with a greater ARR in patients at higher risk. The size of the bubble
represents the sample size of the trial. NNT is estimated from the ARR. aEvent rates of first HF hospitalization or cardiovascular mortality were not reported
in SOLOIST-WHF.189Figure adapted from Butler et al. 2021.539
In addition, four trials investigated the effect of SGLT2 inhibition in pa- 7.5.2. Glucagon-like peptide-1 receptor agonists
tients with CKD: CREDENCE (with canagliflozin) and SCORED (with so- Eight CVOTs have been completed with GLP-1 RAs in patients with
tagliflozin) in patients with T2DM; DAPA-CKD (with dapagliflozin) and T2DM, and the prevalence of established HF in these trials ranged
EMPA-KIDNEY (with empagliflozin) in patients with and without diabetes. from 9% to 24%. Most GLP-1 RAs had a neutral effect on risk of HF
In these patients at high risk of HF, a consistent risk reduction of CV death hospitalization in the placebo-controlled RCTs assessing CV safety of
or HF hospitalization was observed ranging from 23% to 31%.150,153,542,543 glucose-lowering medications in patients with T2DM with or at high
A meta-analysis of six outcome trials of four SGLT2 inhibitors in pa- risk of ASCVD, despite increasing heart rate by 3–5 b.p.m.70,72,158–
tients with T2DM (EMPA-REG OUTCOME, CANVAS Programme 163,544In addition, two meta-analyses including eight trials comprising
[two trials], DECLARE-TIMI-58, CREDENCE, VERTIS CV) demon- 60 080 patients found HF hospitalization to be reduced by 10–11%
strated a 32% reduction in HF hospitalization, with no heterogeneity by GLP-1 RA compared with placebo.164,545
between trials; the effect on HF hospitalization was independent of The AMPLITUDE-O trial, comparing efpeglenatide with placebo,
ASCVD.155 Thus, SGLT2 inhibitors are recommended for patients showed a nominally significant benefit on hospitalization for HF. The
with T2DM and multiple ASCVD risk factors or established ASCVD trial included stratified randomization by baseline or anticipated use
to reduce HF hospitalization. of SGLT2 inhibitors and had the highest prevalence (15.2%) of
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4093
SGLT2 inhibitor use among GLP-1 RA trials. Data from an exploratory neutral in its effect on HF hospitalizations.553 The DEVOTE rando-
analysis of the AMPLITUDE-O trial suggest that the efficacy and safety mized trial, a double-blind comparison of the ultra-long-acting, once-
of efpeglenatide was independent of concurrent SGLT2 inhibitor use, daily insulin degludec vs. insulin glargine U100, enrolled 7637 patients
including HF hospitalization.546 with T2DM with ASCVD or at high CV risk.181Treatment with insulin
Only three small RCTs of GLP-1 RAs have been conducted in pa- degludec vs. insulin glargine did not differ with respect to HF hospital-
tients with HFrEF.547 The LIVE trial randomly assigned 241 patients ization; prior HF was independently associated with future HF
with chronic, stable HFrEF with or without DM to placebo or liraglu- hospitalization.554
tide.548 While no changes in LVEF, quality of life, or functional class
were noted after 24 weeks of treatment, more serious adverse cardiac
7.5.5. Metformin
events (sustained ventricular tachycardia, AF requiring intervention, and
Metformin is suggested to be safe at all stages of HF with preserved or
aggravation of IHD; 12 [10%] vs. 3 [3%] for liraglutide and placebo, re-
stable, moderately reduced kidney function (i.e. eGFR >30 mL/min/
spectively; P = 0.04) occurred in the liraglutide group. The FIGHT trial
1.73 m2). It is associated with a lower risk of death and HF hospitaliza-
(Functional Impact of GLP1 for HF Treatment) randomly assigned 300
tion compared with insulin and sulphonylureas in observational studies,
patients with and without DM with HFrEF and a recent hospitalization
though dedicated randomized, controlled, CVOTs evaluating safety and
for HF to liraglutide or placebo. Following 180 days of treatment, the
efficacy of metformin have not been conducted.555–557Concerns re-
primary outcome (time to death, time to re-hospitalization for HF,
garding lactic acidosis have not been substantiated.558,559
and time-averaged proportional change in NT-proBNP level from base-
line to 180 days) was not different between groups. In addition, there
was a non-significant between-group difference in the number of re- 7.5.6. Sulphonylureas
hospitalizations for HF (63 [41%] in the liraglutide group vs. 50 [34%] Data on the effects of sulphonylureas on HF are inconsistent. Data
in the placebo group; HR 1.30, 95% CI, 0.89–1.88; P = 0.17).549 The from two retrospective cohort studies, including 111 971 patients
third trial was a small (n = 82), randomized study evaluating 12 weeks with diabetes, suggest an adverse safety profile showing ∼20–60% high-
of albiglutide vs. placebo in patients with HFrEF. No significant differ- er death rate and ∼20–30% higher risk of HF compared with metfor-
ences were seen in LVEF, 6 min walk test, myocardial glucose utilization, min.560,561 However, in the UKPDS, NAVIGATOR (Nateglinide And
or oxygen use.550The study was too small and too short to evaluate Valsartan in Impaired Glucose Tolerance Outcomes Research), and
clinical outcomes. ADOPT trials, there were no increased HF signals.127,562–564 In add-
ition, data from the CAROLINA trial comparing linagliptin (shown to
not increase the risk of HF hospitalization vs. placebo in the
7.5.3. Dipeptidyl peptidase-4 inhibitors
CARMELINA trial) vs. glimepiride did not show an elevated risk of
Four DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin, and linagliptin)
HF hospitalization by this sulphonylurea.179
have been examined in dedicated placebo-controlled CV safety trials
in patients with T2DM with or at high risk of ASCVD. Saxagliptin signifi-
cantly increased the risk of HF hospitalization172 and is not recom- 7.5.7. Thiazolidinediones
mended in patients with DM with or at increased risk of HF. Thiazolidinediones increased the risk of HF hospitalization in several
Alogliptin was associated with a non-significant trend towards an in- trials and are not recommended in patients with diabetes and symp-
crease in HF hospitalization.173Sitagliptin and linagliptin had a neutral tomatic HF.165,565–567
effect.174,178–180Vildagliptin, not tested in a CVOT, had no significant
effect on LVEF but led to an increase in LV volumes in a small trial.551
7.5.8. Special consideration: hypoglycaemia and risk
of heart failure hospitalization
7.5.4. Insulin Although severe hypoglycaemic events were associated with higher HF
In patients with T2DM and advanced HF, insulin use is independently hospitalization in some but not all studies, there is no clear evidence for
associated with a significantly worse prognosis.552 Two basal insulins causality.139,140,554,568Recent analyses have demonstrated bi-directional
have been formally evaluated in dedicated CV outcomes trials. In the associations between hypoglycaemia and CV outcomes, including HF,
ORIGIN trial, 12 537 patients (mean age 63.5 years) at high CV risk, suggesting that this is not causal, but rather reflects underlying frailty
with IFG, IGT, or T2DM, were randomized to insulin glargine titrated and risk of adverse outcomes.139,140
to a fasting blood glucose level of ≤5.3 mmol/L (≤95 mg/dL) or stand- Figure 16 summarizes glucose-lowering treatment of patients with
ard care. After a median follow-up of 6.2 years, insulin glargine was HF and T2DM.
Downloaded
from

by
guest
on
22
January
2026

4094 E S C G u id e l in e s
Recommendation Table 22 — Recommendations for glucose-lowering medications in patients with type 2 diabetes
with and without heart failure
Recommendations Classa Levelb
Recommendations for glucose-lowering medications to reduce heart failure hospitalization in patients with type 2 diabetes with or
without existing heart failure
SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, or sotagliflozinc) are recommended in patients with T2DM with
I A
multiple ASCVD risk factors or established ASCVD to reduce the risk of HF hospitalization.71,150–153,541
SGLT2 inhibitors (dapagliflozin, empagliflozin, or sotagliflozinc) are recommended in patients with T2DM and HFrEF to reduce the risk of
I A
HF hospitalization and CV death.189,491,494,497
Empagliflozin or dapagliflozin are recommended in patients with T2DM and LVEF >40% (HFmrEF and HFpEF) to reduce the risk of HF
I A
hospitalization or CV death.530,532,533
Recommendations for additional glucose-lowering agents with safety demonstrated for heart failure hospitalization in patients with
type 2 diabetes if additional glucose control is needed
GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide ER, dulaglutide, efpeglenatide) have a neutral effect on the risk of HF
IIa A
hospitalization, and should be considered for glucose-lowering treatment in patients with T2DM at risk of or with HF.70,158–164,545
DPP-4 inhibitors (sitagliptin and linagliptin) have a neutral effect on the risk of HF hospitalization, and should be considered for
IIa A
glucose-lowering treatment in patients with T2DM at risk of or with HF.174,179,180
Basal insulins (glargine and degludec) have a neutral effect on the risk of HF hospitalization and should be considered for glucose-lowering
IIa B
treatment in patients with T2DM at risk of or with HF.553,554
Metformin should be considered for glucose-lowering treatment in patients with T2DM and HF.d,555,556,558 IIa B
Recommendations for glucose-lowering medications with an increased risk of heart failure hospitalization in patients with type 2
diabetes
Pioglitazone is associated with an increased risk of incident HF in patients with diabetes and is not recommended for glucose-lowering
III A
treatment in patients at risk of HF (or with previous HF).165,566
The DPP-4 inhibitor saxagliptin is associated with an increased risk of HF hospitalization in patients with diabetes and is not recommended
III B
for glucose-lowering treatment in patients at risk of HF (or with previous HF).172
Recommendations for special consideration
It is recommended to switch glucose-lowering treatment from agents without proven CV benefit or proven safety to agents with proven
I C
CV benefit.e
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; DPP-4, dipeptidyl peptidase-4; ER, extended release; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HF, heart failure;
HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular
ejection fraction; MACE, major adverse cardiovascular events; s.c., subcutaneous; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cSotagliflozin is a dual SGLT1/2 inhibitor.
dChronic and stable HF.
eAgents with proven benefit: SGLT2 inhibitors: empagliflozin, canagliflozin, dapagliflozin, sotagliflozinc; GLP-1 RAs: liraglutide, semaglutide s.c., dulaglutide, efpeglenatide. In the VERTIS CV
trial, ertugliflozin did not reduce the primary endpoint (three-point MACE) nor the key secondary endpoint (CV death or HF hospitalization), but reduced HF hospitalization as a secondary
exploratory endpoint.
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4095
To reduce HF-related outcomesa in all patients with T2DM
and HF (HFpEF, HFmrEF, HFrEF)
SGLT2 inhibitorb
(Class I)
Independent of HbA1c
Independent of concomitant glucose-lowering medication
For additional glucose control
Other glucose-lowering agents with neutral effects on HF
in CVOTs should be considered
Sitagliptin Insulin glargine
GLP-1 RAc Metformin
Linagliptin Insulin degludec
(Class lla) (Class lla)
(Class lla) (Class lla)
Other glucose-lowering agents with increased risk for HF
hospitalization in CVOTs are not recommended
Pioglitazone Saxagliptin
(Class III) (Class Ill)
Figure 16 Glucose-lowering treatment of patients with heart failure and type 2 diabetes. CVOT, cardiovascular outcomes trial; DPP-4, dipeptidyl
peptidase-4; GLP-1 RA, glucagon-like peptide-1 receptor agonist; Hb1Ac, glycated haemoglobin; HF, heart failure; HFmrEF, heart failure with mildly reduced
ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; SGLT2, sodium–glucose
co-transporter-2; T2DM, type 2 diabetes mellitus. aThis includes HF hospitalization or CV death. bEmpagliflozin, dapagliflozin, or sotagliflozin in patients
with HFrEF, empagliflozin or dapagliflozin in patients with HFpEF and HFmrEF. cPreferred in patients with atherosclerotic cardiovascular disease and if weight
reduction is needed; do not combine with DPP-4 inhibitors.
Downloaded
from

by
guest
on
22
January
2026

4096 E S C G u id e l in e s
8. Arrhythmias: atrial fibrillation, on controlling diabetes-associated comorbidities (especially weight,
sleep apnoea, and BP).597–600
ventricular arrhythmias, and
Intensive glucose lowering (target HbA1c <6.0%) has been asso-
sudden cardiac death and diabetes ciated with similar incident AF rates than a less-stringent approach
(HbA1c <8.0%).601 The rate of new-onset AF may, however, be af-
Diabetes may increase the risk of cardiac arrhythmias via several fac- fected by diabetes therapy.577 The impact of anti-hyperglycaemic
tors including: associated CV risk factors (e.g. hypertension), CVD agents on the risk of AF is still debated. It has been suggested that met-
(i.e. CAD, prior MI, HF, or stroke), and diabetes-associated factors formin and pioglitazone may reduce the risk of AF.602SGLT2 inhibitors,
such as glucose control or diabetic neuropathy.157,569–572 The risk compared with placebo, were associated with more new-onset AF
of cardiac arrhythmias or sudden cardiac death (SCD) in patients cases in EMPA-REG OUTCOME (empagliflozin vs. placebo), but fewer
with diabetes is most often related to the presence and severity of incident AF cases in CANVAS (canagliflozin vs. placebo) and
underlying CVD, but diabetes-related factors may induce arrhyth- DECLARE-TIMI 58 (dapagliflozin vs. placebo).71,151,153,603 In the
mias independently of CV comorbidities.157,573–577 The risk of con- EMPA-REG OUTCOME trial, empagliflozin, compared with placebo,
duction disturbances and need for pacemaker therapy may also be reduced CV death or HF hospitalization consistently in patients with
higher in patients with T2DM than in controls, although the general diabetes with or without AF (P = 0.56).604 It has recently been re-
int
management for these issues should not differ from that for other ported that finerenone may reduce new-onset AF in patients with
patients.578,579 T2DM and CKD.605This is consistent with results obtained with other
MRAs in HF.508,606
8.1. Atrial fibrillation and diabetes In the ADVANCE study, patients with diabetes and AF (∼8%) had
higher risks of all-cause death, CV death, major cerebrovascular events,
8.1.1. Epidemiology of atrial fibrillation and its
and HF compared with patients with diabetes without AF. Lowering BP
association with diabetes
resulted in similar RR reduction in all-cause and CV death but, due to
Patients with T1DM or T2DM may exhibit atrial electrical and
their higher risk of these events, the absolute benefits from BP control
structural remodelling associated with increased vulnerability for
was much greater in patients with AF.607 In the VALUE (Valsartan
AF.580–583Many epidemiological studies have reported an association
Antihypertensive Long-term Use Evaluation) trial, hypertensive pa-
of diabetes (mainly T2DM) with incident AF.584,585Recent, large ana-
tients with new-onset diabetes had higher rates of new-onset AF com-
lyses confirmed that T1DM was also independently associated with a
pared with patients without diabetes, and were at a higher risk of HF.608
higher incidence of AF.586–588 Diabetes duration has also been asso-
Hence, AF in patients with diabetes should be viewed as a marker of
ciated with AF; each year with diabetes conferred a 3% increase in
adverse outcome, which should prompt aggressive management of all
the risk of AF.589A meta-analysis of 11 studies with 108 703 AF cases
concomitant risk factors.609
in 1 686 097 patients showed a 40% greater risk of AF in the presence
of diabetes. The effect was attenuated but still significant after adjusting
for other risk factors (RR 1.24; 95% CI, 1.06–1.44).590Although men 8.1.2. Screening and managing atrial fibrillation in
have higher absolute rates for incidence of AF, the relative rates of in- patients with diabetes
cident AF associated with diabetes are higher in women than in men for Detecting AF in patients with diabetes has clinical consequences be-
both T1DM and T2DM.586–588 cause the risk of stroke is markedly higher in these patients. In the ab-
Diabetes and AF frequently co-exist, and when this occurs, there is a sence of other comorbidities, the annual risk of stroke can be
substantially higher risk of all-cause death, CV death, stroke, kidney dis- estimated at 2.2% per year in isolated diabetes.610Since asymptomatic
ease, and HF, regardless of diabetes type.541,577,591–596 Risk factors (silent) AF is not uncommon, patients with diabetes should be oppor-
commonly associated with diabetes and AF (and not fully dissociable, tunistically screened for AF by palpating pulse or by ECG.611Patients
e.g. hypertension and obesity) are also likely to worsen prognosis. In with diabetes at high risk of AF would likely benefit from an active
several observational studies, the age-adjusted association of diabetes screening for AF, but more data are needed to define optimal AF
with incident AF was no longer significant after multiple adjustments screening strategies also including modern equipment, such as wear-
for hypertension, CV comorbidity, BMI, or obesity, thus suggesting able digital devices in patients with diabetes (Supplementary data
that strategies for preventing AF in patients with diabetes should focus online, Table S16).612,613Before starting treatment, clinical AF should
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4097
Screening and treatment of AF in patients with diabetes by healthcare professionals
Symptomatic patient
Asymptomatic patient
e.g. palpitations, dyspnoea
Opportunistic screening
(e.g. pulse palpation, ECG)
(Class I)
Yearly
opportunistic
screening
Screening results Positive Suspicion of AF
Negative 12-lead ECG
Positive ECG results
Negative
No definite AF but symptoms or high risk
of AF or high risk of ischaemic stroke
(CHADS-VASc score >1 in men
2 2
or >2 in women with diabetes)
Systematic screening:
repeated surface ECG, Holter ECG,
patient-activated or wearable device
Positive Systematic screening results
Negative
No atrial fibrillation Atrial fibrillation confirmed Consider repeated screening
Start treatment with OAC
(NOACs preferred over VKA)
According to CHADS-VASc score
2 2
Figure 17 Screening for atrial fibrillation in patients with diabetes. AF, atrial fibrillation; CHA DS VASc, Congestive heart failure, Hypertension, Age ≥75
2 2-
years (2 points), Diabetes mellitus, Stroke or transient ischaemic attack (2 points), Vascular disease, Age 65–74 years, Sex category (female); ECG, electro-
cardiogram; OAC, oral anticoagulant; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist.
Downloaded
from

by
guest
on
22
January
2026

4098 E S C G u id e l in e s
be well documented using surface-lead ECG (≥30 s showing heart Recommendation Table 23 — Recommendations for
rhythm with no discernible repeating P waves and irregular R–R inter- atrial fibrillation in patients with diabetes
vals when atrioventricular conduction is not impaired;
Figure 17).600,614 Recommendations Classa Levelb
In patients with diabetes and established AF, controlling the ventricu-
Screening
lar rate is recommended to decrease symptoms and prevent AF-related
complications, while asymptomatic patients mainly need thrombo- Opportunistic screening for AF by pulse taking or
embolic prevention. In those with persistent symptoms despite ad- ECG is recommended in patients ≥65 years of I B
equate rate control, or in those with LV dysfunction attributable to
age.577,611,630,631
poorly controlled high ventricular rate, rhythm-control strategies Opportunistic screening for AF by pulse taking or
should be attempted, including cardioversion, antiarrhythmic drug use, ECG is recommended in patients with diabetes <65
and catheter ablation, which is the general management in this setting years of age (particularly when other risk factors are I C
whether diabetes is present or not.600,615–617For details on managing present) because patients with diabetes exhibit a
AF, please refer to the 2020 ESC/EACTS Guidelines for the diagnosis higher AF frequency at a younger age.577,611,631,632
and management of atrial fibrillation and recent European Heart
Systematic ECG screening should be considered to
Rhythm Association scientific documents.577,600,613
detect AF in patients aged ≥75 years, or those at high IIa B
risk of stroke.577,633–635
8.1.3. Preventing stroke in patients with atrial Anticoagulation
fibrillation and diabetes
Oral anticoagulation is recommended for preventing
Stratifying AF stroke risk with diabetes should use the established stroke in patients with AF and diabetes and with at
I A
CHA 2DS 2-VASc (Congestive HF, Hypertension, Age ≥75 years [2 least one additional (CHA 2DS 2-VASc) risk factor for
points], Diabetes mellitus, Stroke/transient ischaemic attack [2 points], stroke.636
Vascular disease, Age [65–74 years], Sex category [female]) score; fol-
For preventing stroke in AF, NOACs are
lowing stratification, stroke prevention (i.e. OAC) should be started in
recommended in preference to VKAs, with the
patients with >1 risk factor.600,618The score is likely higher in patients I A
exception of patients with mechanical valve
with diabetes due to the common association with other risk factors
prostheses or moderate to severe mitral stenosis.637
for stroke, such as arterial hypertension, age over 65 or 75 years, asso-
Oral anticoagulation should be considered for
ciated vascular disease, or HF. Several studies found that diabetes inde-
pendently predicted stroke in patients with AF.619However, diabetes preventing stroke in patients with AF and diabetes
may not be a significant risk factor for stroke in the elderly.620 The but no other CHA 2DS 2-VASc risk factor for stroke. IIa B
Stroke in AF Working Group attributed a RR of 1.7 (95% CI, 1.4– This includes patients with T1DM or T2DM <65
2.0) for stroke in patients with AF and diabetes, as well as an absolute years old.638–640
stroke risk of 2–3.5% per year for non-anticoagulated patients in the Use of a formal, structured, bleeding risk score
same population.621 Diabetes is probably not the most potent inde- (HAS-BLED score) should be considered to identify
pendent risk factor for stroke in AF compared with the other items modifiable and non-modifiable risk factors for IIa B
in the CHA 2DS 2-VASc score, but it is included in this risk-stratification bleeding in patients with diabetes and AF, and to
tool, giving a point alongside most other items.600,618,622–624 The in- identify patients in need of closer follow-up.641–643
creased risk of stroke associated with AF and diabetes is similar in
T1DM and T2DM except perhaps a slightly increased risk in T2DM
AF, atrial fibrillation; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥ 75
years (2 points), Diabetes mellitus, Stroke or transient ischaemic attack (2 points),
compared with T1DM in patients <65 years of age. The risk of stroke Vascular disease, Age 65–74 years, Sex category (female); ECG, electrocardiogram;
in patients with diabetes and AF may increase with longer diabetes dur- HAS-BLED, Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or
ation, increasing levels of HbA1c, and more diabetes-related comorbid- predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol
ities, such as nephropathy and retinopathy.625,626 concomitantly; NOAC, non-vitamin K antagonist oral anticoagulant; T1DM, type 1
diabetes mellitus; T2DM, type 2 diabetes mellitus; VKA, vitamin K antagonist.
As an OAC is being initiated, a clinical bleeding risk score, such as the aClass of recommendation.
HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, bLevel of evidence.
Bleeding history or predisposition, Labile international normalized ra-
tio, Elderly [>65 years], Drugs/alcohol concomitantly) score, should
8.2. Ventricular arrhythmias and risk of
be used to identify patients at risk of bleeding, and importantly, to ad-
sudden cardiac death and diabetes
dress the potentially reversible bleeding risk factors (that should be
considered in all patients, irrespective of HAS-BLED score).600 Due Compared with the general population, patients with diabetes have an
to the increased risk of several CV adverse events in patients with dia- increased risk of both SCD and non-SCD.575,615,644–646 In a
betes, a similar RR reduction with OACs generally translates into great- meta-analysis of 14 studies involving 346 356 participants and 5647
er ARR in the diabetes population.577The beneficial efficacy and safety SCD cases, the risk of SCD was two-fold higher in patients with dia-
of NOACs compared with warfarin seem conserved in patients with betes compared with patients without diabetes (adjusted HR 2.25;
AF and diabetes, irrespective of their baseline stroke risk or the pres- 95% CI, 1.70–2.97).647However, patients with diabetes also exhibited
ence of other CV risk factors.577,627–629 a nearly three-fold greater risk of non-SCD than patients without
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4099
diabetes (adjusted HR 2.90; 95% CI, 1.89–4.46).646Men at all ages have patients with HFrEF, compared with placebo.673The benefit was mainly
a higher risk of SCD than women, but in the presence of diabetes, the observed >9 months post-randomization, suggesting that the beneficial
risk of SCD is higher in both men and women.575,615,644–646,648 effects of dapagliflozin require time to develop and may involve cellular
Both hyperglycaemia and hypoglycaemia are independently asso- mechanisms that slow the progression of HFrEF.674However, a recent
ciated with increased risk of ventricular arrhythmias.649 meta-analysis indicated that SGLT2 inhibition was not associated with
Insulin-induced hypoglycaemia has been associated with nocturnal an overall lower risk of SCD or ventricular arrhythmias in patients
death (also called ‘dead-in-bed syndrome’) in T1DM, and arrhythmic with T2DM and/or HF and/or CKD, although the point estimates sug-
deaths were reported in several T2DM trials.187,576,650–654Diabetic kid- gested potential benefits.675
ney disease might also play a role in the arrhythmia-associated mechan-
ism of sudden death in this setting.655
Hypoglycaemia-associated arrhythmias are difficult to document, but
9. Chronic kidney disease and
observational studies using CGM and Holter monitoring in small T2DM
cohorts showed that hypoglycaemic episodes were common, often diabetes
asymptomatic, and associated with various arrhythmias.656,657
Compared with daytime hypoglycaemia, nocturnal episodes were 9.1. Chronic kidney disease definitions,
more common and associated with a greater risk of bradycardia or at- staging, and screening
rial ectopy, while ventricular arrhythmias were equally common.656,657 Chronic kidney disease has a major effect on global morbidity and mor-
The use of antiarrhythmic drugs should follow the general principles tality.676CKD is defined as abnormalities of kidney structure or func-
and precautions related to pharmacological treatment of cardiac ar-
tion, present for >3 months, with implications for health. It is staged
rhythmias.600,658In patients with diabetes and an ICD, there is an in-
primarily by categories of glomerular filtration rate (GFR) and albumin-
creased risk of death in those who have appropriate therapy uria.677 The CKD Epidemiology Collaboration (CKD-EPI) has devel-
compared to those who do not.659In contrast, patients with diabetes
oped accurate eGFR equations based on creatinine ± cystatin C
may have a lower risk of inappropriate therapy or ICD shock, since measurements.678An eGFR ≥60 mL/min/1.73 m2 does not constitute
they may be more sedentary with consequently less frequent
CKD unless there is albuminuria or other evidence of kidney disease
exercise-induced sinus tachycardia and also lower incidence of lead (Table 11).677 A persistent decrease in eGFR <60 mL/min/1.73 m2
fracture.600,658,659
(i.e. stages G3–5), however, is sufficient to confirm CKD. This level
Observational studies have reported significant corrected QT (QTc)
of eGFR is associated with increased risk of CKD progression and
interval prolongation possibly associated with microvascular complica- CVD.43,679,680 The most advanced stage of CKD is characterized by
tions, atypical patterns of microvolt T-wave alternans, altered heart an eGFR <15 mL/min/1.73 m2, and recently implemented nomencla-
rate variability, or heart rate turbulence in patients with diabetes, but ture refers to this as ‘kidney failure’.681Such low levels of eGFR may
none of these tests should routinely be used to stratify the risk of ven-
tricular arrhythmias or SCD in clinical practice.658,660–668 There may
also be a direct effect of both hyper- and hypoglycaemia on QTc inter-
val.669–671The mechanisms by which hyperglycaemia may produce ven- Table 11 KDIGO staging by glomerular filtration rate
tricular instability may be increased sympathetic activity, increased and urinary albumin-to-creatinine ratio categories with
cytosolic calcium content in myocytes, or both.672The risk of cardiac colour chart for risk of initiation of maintenance kidney
replacement therapy
events is usually related to the underlying heart disease rather than ven-
tricular premature beats.669–671
Albuminuria stage
There is no diabetes-specific protocol for SCD screening, but all pa-
tients diagnosed with diabetes should undergo regular evaluation for
eGFR stage A1 <3 mg/ A2 3–30 A3
CV risk factors or structural heart disease.48,576,658Patients with dia-
(mL/min/ mmol mg/mmol >30 mg/
betes and symptoms suggestive of cardiac arrhythmias (e.g. palpitations, 1.73 m2) (<30 mg/g) (30– mmol
pre-syncope, or syncope) should undergo further detailed diagnostic
300 mg/g) (>300 mg/g)
assessment.576Patients with diabetes and frequent premature ventricu-
lar beats, episodes of non-sustained ventricular tachycardia, or symp- G1 (≥90)
toms suggestive of HF should be examined for the presence of an G2 (60–89)
underlying structural heart disease and their eligibility for an ICD should
G3a (45–59)
be assessed; this is a general principle in managing patients with HF, ir-
G3b (30–44)
respective of diabetes status.658In case of sustained ventricular arrhyth-
G4 (15–29)
mias, diagnosing underlying structural heart disease with imaging
techniques and coronary angiography is usually needed if no obvious G5 (<15)
trigger factors, such as electrolyte imbalance, can be identified.48,576,658
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; KDIGO, Kidney
Although cardiac arrhythmias were not specifically investigated in ei- Disease: Improving Global Outcomes.
ther the LEADER or the EMPA-REG OUTCOME trials, an antiarrhyth- Note that this staging uses a ratio 1:10 to convert the urinary albumin-to-creatinine ratio
from mg/mmol to mg/g, but the precise ratio is 1:8.84.
mic effect of these drugs (perhaps mediated by glucagon-release
Green is low risk (and represents no CKD if there is no structural or histological evidence
stimulation or increased blood ketone bodies, which may have of kidney disease). Relative to low risk (estimated at 0.04/1000 patient-years), yellow is
sympathico-suppressive effects) has been hypothesized to contribute moderately increased risk (at least ∼5×), orange is high risk (at least ∼20×), and red is
to the reduced risk of CV death.71,72In the DAPA-HF trial, dapagliflozin very high risk (at least ∼150×). Risk of cardiovascular death approximately mirrors the
same pattern.
reduced the risk of the composite outcome of serious ventricular ar-
Table adapted from the KDIGO 2012 Clinical Practice Guideline for the Evaluation and
rhythmia, resuscitated cardiac arrest, or sudden death by 21% in Management of Chronic Kidney Disease. Reprinted with permission from Elsevier.677
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

4100 E S C G u id e l in e s
necessitate the need to start maintenance kidney replacement therapy increasing evidence that these interventions should be started early
(KRT).677 to prevent end-organ damage in at-risk patients.
Albuminuria is an early marker of nephropathy and predicts both risk Blocking RAS with an ACE-I (captopril) or ARBs (irbesartan/losar-
of kidney failure and CVD independently of eGFR.43,682Nephropathy tan) prevented kidney failure in patients with diabetes and overt ne-
caused by diabetes is a leading cause of CKD globally, and screening pa- phropathy in dedicated clinical outcomes trials.705–707 ARBs
tients with diabetes for CKD is recommended at least annually.676,677A (irbesartan/telmisartan) also slowed progression from microalbumi-
spot urine sample measuring UACR is an efficient method to identify nuria (albuminuria stage A2) to overt nephropathy.708,709 These
and quantify albuminuria.677,683 Changes in UACR or GFR slope are RAS inhibitors are therefore recommended in patients with diabetes
used as surrogate trial endpoints for nephroprotection, but more de- as soon as CKD is clinically diagnosed. Combining an ARB with an
finitive evidence for reducing risk of kidney failure in patients with dia- ACE-I, however, is not recommended, as large trials have identified
betes generally requires categorical endpoints based on a ≥40% an increased risk of hyperkalaemia and acute kidney injury, without
sustained decline in GFR.684,685 demonstrable additional benefits of such ‘dual-blockade’ on risk of
kidney failure or CVD.710
9.2. Management of cardiovascular disease In contrast, combining an SGLT2 inhibitor with an ACE-I or ARB has
clear beneficial effects on risk of kidney failure and hospitalization for HF
risk and kidney failure in patients with
in patients with CKD and T2DM.153,542The CREDENCE, DAPA-CKD,
chronic kidney disease and diabetes
and EMPA-KIDNEY placebo-controlled trials were all stopped early for
Risk of CVD increases progressively with lower levels of eGFR and, in efficacy while testing canagliflozin, dapagliflozin, and empagliflozin, re-
those with advanced CKD, structural abnormalities of the heart, HF, spectively.153,543,711All three trials found the RR reductions for kidney
and sudden death are particular features.679,680,686–688 Increased risk disease progression were unmodified by baseline eGFR, with
of CAD also accompanies CKD, often with calcification of atheroscler- EMPA-KIDNEY reporting clear benefits in patients with eGFR 20–
otic plaques.679,689 Accelerated vascular media calcification with in- 30 mL/min/1.73 m2.153,542,543,712,713 EMPA-KIDNEY included 254 pa-
creased vascular stiffness is also a feature of CKD and attributed to tients with an eGFR <20 mL/min/1.73 m2 at randomization, and once in-
disordered calcium–phosphate metabolism, referred to as itiated, SGLT2 inhibitors could be continued until the need of KRT. As
CKD-mineral bone disorder (CKD-MBD).690,691 Managing CVD risk patients with decreased eGFR are at the highest absolute risk of kidney
in patients with CKD and diabetes may, therefore, need to consider mul- disease progression, these trials’ results should encourage the initiation
tiple interventions and both traditional and CKD-specific risk fac- of SGLT2 inhibitors in patients with CKD down to at least an eGFR of
tors.361,692–694 20 mL/min/1.73 m2 with continued use until the need for KRT (despite
All patients with diabetes and CKD should be offered standard ad- low eGFR substantially attenuating their HbA1c-lowering effect).
vice on smoking, nutrition, and exercise.45A raised BMI is independent- Meta-analysis of all the large SGLT2 inhibitor trials shows benefits of
ly associated with risk of CKD, and behavioural interventions to SGLT2 inhibitors on the risk of HF hospitalization or CV death are
promote weight loss in people with T2DM reduce the risk of develop- also unmodified by eGFR (at a trial level; Figure 19).714The combined
ing very high-risk CKD over the long-term.57,695,696 Management of SGLT1/2 inhibitor sotagliflozin was analysed vs. placebo in the
people with diabetes and CKD is then based on sequentially initiating SCORED trial in patients with T2DM and CKD (eGFR 25–60 mL/min/
and titrating doses of pharmacological interventions with proven effi- 1.73 m2); sotagliflozin reduced the primary composite of the total num-
cacy (Figure 18). ber of CV deaths, hospitalizations for HF, and urgent visits for HF by 26%
Statin-based therapy reduces the risk of major atherosclerotic events vs. placebo (HR 0.74; 95% CI, 0.63–0.88; P < 0.001).150 Initiating an
(i.e. coronary death, non-fatal MI, ischaemic stroke, and coronary revascu- SGLT2 inhibitor alongside an ACE-I or ARB is therefore recommended
larization) in patients with CKD, but does not meaningfully slow progres- in patients with T2DM following the first clinical evidence of CKD. In pa-
sion of CKD.248,697–699 Trials of statin-based therapy, combined in tients with T1DM and CKD, the absence of large trials with sufficient
collaborative meta-analyses, show a trend towards smaller relative reduc- follow-up means it is unclear whether the absolute benefits of SGLT2
tions per mmol/L reduction in LDL-C on major atherosclerotic events as inhibitors on kidney failure and CVD outcomes are outweighed by the
eGFR declines, with uncertainty about benefits among patients on dialy- high absolute risk of ketoacidosis with SGLT2 inhibitors.715,716
sis.697This diminution in RR reduction at decreased eGFR implies that MRAs reduce BP and albuminuria in patients with CKD.717 The
more intensive LDL-C-lowering regimens are required to maximize ben- placebo-controlled FIDELIO-DKD (Efficacy and Safety of Finerenone
efits.697The goal in patients with CKD and diabetes should be to achieve in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney
the largest possible absolute reduction in LDL-C safely.697,700 Disease) and FIGARO-DKD (Efficacy and Safety of Finerenone in
Four large trials recruiting different types of patients with CKD have Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of
confirmed the safety of intensive LDL-C lowering with statins alone Diabetic Kidney Disease) trials demonstrated for the non-steroidal
(atorvastatin, rosuvastatin, fluvastatin), or combining a moderate dose MRA finerenone that these effects translate into reduced risk of kidney
of simvastatin with ezetimibe.698,701–704Although there is no dedicated, failure and a reduction of the combined CV outcome of CV death, non-
large-scale trial of a PCSK9 inhibitor in patients with CKD, sub-group fatal MI, non-fatal stroke, or hospitalization for HF in patients with CKD
analyses by CKD stage from the FOURIER trial of the PCSK9 inhibitor and T2DM who are already on maximum ACE-I or ARB.718–720
evolocumab found its LDL-C-lowering effect was preserved in patients FIDELIO-DKD demonstrated reduced risk of a categorical kidney out-
with stage G3 CKD, and CV benefits on atherosclerotic events ap- come, a primary composite outcome combining kidney failure, a sus-
peared unmodified by baseline eGFR.699 tained decline in eGFR of at least 40%, or death from renal causes, in
Several drugs developed to manage CVD risk or hyperglycaemia patients with eGFR 25–60 mL/min/1.73 m2 and UACR of 34–
have been shown to reduce the risk of CKD progression in large trials 567 mg/mmol (30–5000 mg/g), or eGFR 60–75 mL/min/1.73 m2 with
that recruited patients with T2DM and CKD (Figure 18). These in- UACR of 34–567 mg/mmol (300–5000 mg/g; mean eGFR 43 ±
clude RAS inhibitors, SGLT2 inhibitors, and finerenone. There is 13 mL/min/1.73 m2; median UACR 96 mg/mmol [852 mg/g]).719
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4101
Treatment of patients with T2DM and CKDa
To reduce cardiovascular risk To reduce kidney failure risk
Statin-based regimen ACE-I or ARB
(Class I) (Class I)
To reduce cardiovascular and kidney failure risk
SGLT2 inhibitorb BP control Finerenone
(Class I) (Class I) (Class I)
For additional glucose control
Glucose-lowering medications with suggested cardiovascular benefit
GLP-1 RA
Glucose-lowering medications with neutral or no proven cardiovascular benefit
Metformin (if eGFR >30 mL/min/1.73 m2)
DPP-4 inhibitor
Insulin
Figure 18 Pharmacological management to reduce cardiovascular or kidney failure risk in patients with type 2 diabetes and chronic kidney disease. ACE-I,
angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; BP, blood pressure; CKD, chronic kidney disease; CV, cardiovascular; CVD,
cardiovascular disease; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; RAS,
renin–angiotensin system; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus; UACR, urinary albumin-to-creatinine ratio. aA statin-
based regimen reduces CV risk in CKD while ACE-I or ARBs reduce kidney failure risk; SGLT2 inhibitors, BP control, and finerenone reduce both CV risk and
kidney failure risk. SGLT2 inhibitors, RAS inhibitors, and finerenone are particularly effective at reducing risk of kidney failure when albuminuria is present [e.g.
UACR ≥3 mg/mmol (30 mg/g); stage A2 and A3]. bCanagliflozin, empagliflozin, or dapagliflozin.
Information on the safety and efficacy of combining MRAs with FIDELIO-DKD and FIGARO-DKD excluded patients with a potas-
SGLT2 inhibitors in CKD is limited as only ∼4% of FIDELIO-DKD, sium of >4.8 mmol/L, as MRAs cause hyperkalaemia.718,719
∼8% of FIGARO-DKD, ∼5% of DAPA-CKD, and no CREDENCE par- Combining RAS and SGLT2 inhibitors does not appear to cause hyper-
ticipants were prescribed such a combination.153,718,719,721Sub-group kalaemia, and a hypothesis has been raised that SGLT2 inhibitors re-
analyses considering those co-prescribed MRA and SGLT2 inhibitors duce the risk of severe hyperkalaemia among MRA users with
suggest their combined use does not modify safety findings from the HF.153,542,710,723,724,727,728 Finerenone is therefore recommended in
key trials.150,189,722–726 addition to an RAS inhibitor in patients with T2DM and eGFR
Downloaded
from

by
guest
on
22
January
2026

4102 E S C G u id e l in e s
Diabetes No diabetes
High atherosclerotic cardiovascular riska
Mean eGFR: 80 mL/min/1.73m2
Kidney disease progression
5 0.3 0.6 Acute kidney injury
0 Cardiovascular death or hospitalization
-5 -2 -1 for heart failure
-10 -5
Events avoided or -15 Ketoacidosis
caused per 1000 -20 Lower limb amputationb
patient-years in
-25
SGLT2i groups
-30
-35
-40
-45
Placebo population
4 4 21 0.2 4
mean event rate
Stable heart failure
Mean eGFR: 61 mL/min/1.73m2 Mean eGFR: 64 mL/min/1.73m2
5 0.5 1.0 c 0.0
0
-5 -2
-10 -6 -4 -5
Events avoided or -15
caused per 1000 -20
patient-years in -25
SGLT2i groups -30 -23
-35
-40 -34
-45
Placebo population
16 23 148 0.5 6 7 17 104 1.0
mean event rate
Chronic kidney disease
Mean eGFR: 45 mL/min/1.73m2 Mean eGFR: 40 mL/min/1.73m2
5 1.3 1.1 c 0.0
0
-5 -2
-10 -4 -5
Events avoided or -15 -11 -11
caused per 1000 -20
-15
patient-years in -25
SGLT2i groups
-30
-35
-40
-45
Placebo population
29 19 47 1.2 7 48 16 11 0.6
mean event rate
Figure 19 Absolute benefits and harms of sodium–glucose co-transporter-2 inhibitors in patients with and without diabetes. eGFR, estimated glomerular
filtration rate; RR, relative risk; SE, standard error; SGLT2i, sodium–glucose co-transporter-2 inhibitor. Patient group-specific absolute effects estimated by
applying the diabetes sub-group-specific RR to the average event rate in the placebo arms (first event only). Negative numbers indicate events avoided by
SGLT2 inhibition per 1000 patient-years. Error bars represent SE in the numbers of events avoided or caused, estimated from uncertainty in the RRs. Mean
eGFR values are given for combined trial populations by patient group and diabetes status. Placebo population mean event rates are the absolute numbers of
events per 1000 patient-years in the placebo groups of all trials in the relevant subpopulation. aAdditionally, two (SE 0.5) fewer myocardial infarctions per
1000 patient-years of SGLT2i treatment were observed in the diabetes and high atherosclerotic cardiovascular risk group. bRRs to determine absolute effects
for lower-limb amputation included the CANVAS trial. cToo few ketoacidosis events to estimate absolute effects. Figure adapted from the Nuffield
Department of Population Health Renal Studies Group and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. This is an open access article
distributed under the terms of the Creative Commons CC-BY License. 
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4103
>60 mL/min/1.73 m2 with UACR ≥34 mg/mmol (≥300 mg/g), or counterbalanced.291,292,325,735 CKD is associated with both increased
eGFR 25–60 mL/min/1.73 m2 and UACR ≥3 mg/mmol (≥30 mg/g), ASCVD and bleeding risk, and so the net effects of low-dose ASA
with appropriate potassium monitoring.718,719 (75 mg o.d.) in CKD (stages G3–G4 or G1–2 with albuminuria) without
ASCVD is being tested in the large, open-label, ATTACK (Aspirin to
9.3. Blood pressure and glycaemic control Target Arterial Events in Chronic Kidney Disease) trial.679,736,737The net
in patients with diabetes and chronic benefit of low-dose rivaroxaban (2.5 mg b.i.d.) on atherothrombotic vs.
bleeding risk is also being tested in the large, placebo-controlled,
kidney disease
TRACK (Treatment of Cardiovascular Disease with Low Dose
In patients with T2DM, BP lowering reduces CV risk, with relative ben- Rivaroxaban in Advanced Chronic Kidney Disease) trial in people with
efits similar in people with and without CKD.196,693,729RR reductions CKD stage G4–5 who are at high CVD risk due to diabetes, age >65 years,
for CVD per 10 mmHg of lower SBP are greater in patients with a start- or prior ASCVD.738
ing SBP of ≥140 mmHg, but a reduced risk of stroke and albuminuria is
Invasive vs. medical management strategies for stable moderate or se-
evident with a further reduction in SBP in those with an SBP
vere CAD in CKD have been assessed in the ISCHEMIA-CKD
<140 mmHg.196 Whether intensively lowering moderately elevated
(International Study of Comparative Health Effectiveness with Medical
SBP prevents kidney failure, however, is uncertain. and Invasive Approaches–Chronic Kidney Disease) trial, in which 57%
The effect of tight glycaemic control, as compared with standard con- (444/777) of participants had diabetes.739The trial was conducted in
trol, on risk of kidney failure is also uncertain, but such an approach reduces parallel with the large ISCHEMIA trial.740When results from both these
risk of developing or worsening of diabetic nephropathy based on mea-
trials are considered alongside one another, ISCHEMIA-CKD suggests
sures of albuminuria.132,133,730Personalized HbA1c targets of 6.5−8.0% that an initial conservative approach using intensive medical therapies
(48−64 mmol/mol) are suggested for people with diabetes and CKD,
to manage stable CAD is appropriate for patients with diabetes and
with a target <7.0% (<53 mmol/mol) still recommended to reduce micro- an eGFR <30 mL/min/1.73 m2.739 ISCHEMIA-CKD did not replicate
vascular complications, wherever possible.132,133Above eGFR 30 mL/min/ the anti-anginal benefits of an invasive strategy observed in
1.73 m2, metformin with appropriate dose adjustment can be used, but
ISCHEMIA, but such benefits should not be ruled out due to lower
below eGFR 30 mL/min/1.73 m2, metformin should generally be stopped power.739,740It should also be noted that patients with acute MI, un-
to avoid risk of lactic acidosis due to its accumulation.731,732
stable CAD, or unacceptable levels of angina were excluded from
In CKD, HbA1c monitoring may be less reliable when eGFR is
both trials, meaning optimal management of such conditions in patients
<30 mL/min/1.73 m2, and self-monitoring or CGM may help safely with CKD may still include an intensive strategy (Section 6).
achieve tight glycaemic control in such patients.45 Serum phosphate may increase in advanced CKD (e.g. eGFR <30 mL/
Another potential strategy to help achieve glycaemic targets in pa- min/1.73 m2) and is associated with an increased risk of CVD.694Lowering
tients with CKD is use of GLP-1 RAs. Extrapolating evidence from
phosphate, controlling parathyroid hormone, and maintaining normal cal-
trials in patients with T2DM suggest GLP-1 RAs safely improve gly-
cium levels is common practice in nephrology despite a lack of definitive
caemic control and may reduce weight and CV risk in patients with evidence that it modifies risk of CVD.691,741Some evidence suggests the
CKD.164Meta-analysis of the GLP-1 RAs trials (lixisenatide, liraglutide, dose of calcium-based phosphate binders should be restricted.742,743In pa-
semaglutide, exenatide, albiglutide, dulaglutide, efpeglenatide) showed tients with T2DM and CKD, correcting renal anaemia improves quality of
they favourably lower levels of albuminuria in T2DM, with some life, but does not reduce the risk of CVD and may increase the risk of
GLP-1 RAs reducing MACE in those with prior CVD or at high CV stroke.744Renal specialist advice should be sought for managing a raised
risk.164The size of RR reductions on MACE appears similar in people serum phosphate (>1.5 mmol/L) or other evidence of CKD-MBD, and re-
with or without reduced eGFR.164Dulaglutide has been tested in pa- nal anaemia (e.g. haemoglobin <10 g/dL).
tients with T2DM and CKD stages G3–4. It was as effective at lower-
ing HbA1c as insulin glargine, but it reduced weight, had lower rates of Recommendation Table 24 — Recommendations for
patients with chronic kidney disease and diabetes
symptomatic hypoglycaemia, and slowed eGFR decline compared
with insulin glargine.733The benefits of GLP-1 RAs on risk of kidney
Recommendations Classa Levelb
failure have yet to be confirmed, and a definitive assessment of sema-
glutide in the FLOW (Effect of Semaglutide Versus Placebo on the Intensive LDL-C lowering with statins or a statin/
I A
Progression of Renal Impairment in Subjects With Type 2 Diabetes ezetimibe combination is recommended.c,697,698
and Chronic Kidney Disease) trial of 3535 patients with T2DM and A BP target of ≤130/80 mmHg is recommended to
albuminuric CKD is ongoing.734 reduce risk of CVD and albuminuria.196 I A
An alternative to GLP-1 RAs in CKD is a DPP-4 inhibitor. Linagliptin
Personalized HbA1c targets 6.5–8.0% (48–64 mmol/
safely lowers HbA1c in patients with T2DM and CKD but does not re-
mol) are recommended, with a target <7.0%
duce risk of CVD or kidney failure.180 I A
(<53 mmol/mol) to reduce microvascular
9.4. Roles for antithrombotic therapy and complications, wherever possible.132,133
The maximum tolerated dose of an ACE-I or ARB is
invasive strategies in managing I A
recommended.705–709
atherosclerotic cardiovascular disease in
A SGLT2 inhibitor (canagliflozin, empagliflozin, or
patients with diabetes and chronic kidney dapagliflozin)d is recommended in patients with
disease T2DM and CKD with an eGFR ≥20 mL/min/1.73 m2 I A
Low-dose ASA (75–100 mg o.d.) is indicated in patients with diabetes and/ to reduce the risk of CVD and kidney
or CKD and ASCVD.325 In primary ASCVD prevention in T2DM and failure.150,153,542,543,711,714,715
CKD, the benefits and risks of low-dose ASA may be finely Continued
Downloaded
from

by
guest
on
22
January
2026

4104 E S C G u id e l in e s
Finerenone is recommended in addition to an ACE-I patients with chronic limb-threatening ischaemia (CLTI) have dia-
or ARB in patients with T2DM and eGFR >60 mL/ betes.750,752 Patients with diabetes and LEAD show specific anatomic
min/1.73 m2 with a UACR ≥30 mg/mmol (≥300 mg/ and morphologic characteristics, which are important for further man-
g), or eGFR 25–60 mL/min/1.73 m2 and UACR I A agement.753In addition, patients with diabetes have occlusions of arteries
≥3 mg/mmol (≥30 mg/g) to reduce CV events and below the knee more often than do patients without diabetes. Moreover,
kidney failure.718–720 severe calcification, such as media sclerosis and development of collateral
A GLP-1 RA is recommended at eGFR >15 mL/min/ circulation, is typical for these patients.753
1.73 m2 to achieve adequate glycaemic control, due Compared with patients without diabetes, those with diabetes de-
I A velop LEAD at a younger age and have faster LEAD progression,
to low risk of hypoglycaemia and beneficial effects on
with more patients having CLTI. Prolonged diabetes duration, sub-
weight, CV risk, and albuminuria.164
optimal glycaemic control, co-existing CV risk factors, and other
Low-dose ASA (75–100 mg o.d.) is recommended in
I A end-organ damage (e.g. proteinuria) increase the prevalence of
patients with CKD and ASCVD.325,735 LEAD.751 Moreover, patients with microangiopathy are at increased
It is recommended that patients with diabetes are risk of CLTI and major amputation.754,755In a cohort study with 125
routinely screened for kidney disease by assessing I B 674 participants, the presence of microvascular disease such as retinop-
eGFR defined by CKD-EPI and UACR.43,678,745 athy, nephropathy, or neuropathy independently increased the risk of
Treatment with intensive medical or an initial invasive amputation.754
strategy is recommended in people with CKD, For patients with a diabetic foot ulcer (diabetic foot disease), the
I B diabetes, and stable moderate or severe CAD, due to risk of death at 5 years is 2.5 times higher than for patients with dia-
similar outcomes.e,740,746 betes but no foot ulcer.752,756In patients with diabetes, pain is often
Kidney specialist advice may be considered for masked because of peripheral neuropathy with decreased pain sensi-
managing a raised serum phosphate, other evidence IIb C tivity. Therefore, atherosclerosis is often advanced when diagnosed.
CLTI is the clinical presentation of advanced disease, characterized
of CKD-MBD, and renal anaemia.
by ischaemic rest pain; however, pain may be absent in patients
Combined use of an ARB with an ACE-I is not
III B with diabetes. The 2017 ESC Guidelines on the diagnosis and treat-
recommended.710
ment of peripheral arterial diseases and the 2019 Global Vascular
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; ASA, Guidelines on the management of chronic limb-threatening ischaemia
acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; proposed the Wound, Ischaemia, and foot Infection (WIfI) classifica-
CAD, coronary artery disease; CKD, chronic kidney disease; CKD-EPI, chronic kidney
tion to stratify amputation risk and the potential benefits of revascu-
disease epidemiology; CKD-MBD, chronic kidney-mineral bone disorder; CV,
cardiovascular; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; larization (Supplementary data online, Table S17).747,757,758 Patients
GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; with diabetes and critical limb ischaemia are at very high risk of lower-
LDL-C, low-density lipoprotein-cholesterol; o.d., once daily; SGLT2, sodium–glucose limb amputation and recurrent wounds. All of these factors increase
co-transporter-2; T2DM, type 2 diabetes mellitus; UACR, urinary albumin-to-creatinine
the risk of limb infection.
ratio.
aClass of recommendation. Although 20–30% of patients with diabetes have LEAD, more than
bLevel of evidence. half of these have no clinical symptoms.760 Therefore, screening and
cLittle evidence of benefit in patients on dialysis.
early diagnosis is important to allow early treatment and prevent major
dSotagliflozin reduces CV risk but has not demonstrated a reduction in the risk of kidney
failure. amputation. Clinical evaluation includes medical history, assessing
eISCHEMIA-CKD trial primary and key secondary outcomes were a composite of ‘death or symptoms, palpating peripheral pulses, and evaluating skin colour and
non-fatal myocardial infarction’ and ‘death, non-fatal myocardial infarction, or temperature. In addition, examination for neuropathy is important;
hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest’, respectively. however, the sensitivity of clinical examination is limited.761
Therefore, screening for LEAD is indicated in patients with diabetes
and foot ulceration.747,761There is a lack of evidence concerning the
10. Aortic and peripheral arterial
frequency of screening for LEAD in patients with diabetes, but it seems
diseases and diabetes plausible to assess leg perfusion regularly.
An ankle–brachial index (ABI) ≤0.90 is diagnostic for LEAD, with
10.1. The impact of diabetes on peripheral 80% sensitivity and 95% specificity in all populations.760,762However,
the accuracy of ABI is lower in patients with diabetes.762,763 Beyond
atherosclerosis
LEAD, an ABI ≤0.90 (or >1.40) is associated with an increased risk
Diabetes is one of the most important risk factors for the develop- of death and CV events.762,763 Measuring ABI can be difficult due to
ment and progression of atherosclerosis.747–751 The number of pa-
medial calcinosis (ABI >1.40), in which case, other tests are useful for
tients with atherosclerosis associated with diabetes is steadily
diagnosing LEAD, including Doppler waveform analysis of the ankle ar-
increasing alongside the increasing number of patients with diabetes
teries, or the toe–brachial index (TBI), which may be helpful because
worldwide. Peripheral atherosclerosis summarizes LEAD and carotid
medial calcinosis barely affects digital arteries. A TBI <0.70 is diagnostic
atherosclerosis. for LEAD.747,763
In patients with intermittent claudication, a treadmill test is useful for
10.1.1. Diabetes and lower-extremity artery disease assessing walking distance.747Duplex scan is the first-line imaging for
The impact of diabetes differs between vascular territories.747The strong confirming LEAD and should be performed at least when revasculariza-
correlation between LEAD and diabetes is well established.747–749Up to tion is indicated. Magnetic resonance angiography or CT angiography
30% of all patients with intermittent claudication and ∼50–70% of can also help to plan further treatment (Figure 20).
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4105
Patients with diabetes
Regular screening
Clinical symptoms for LEAD N
Y
Aetiology for LEAD Clinical examination ABI
Intermittent
Ulcer or wound ≤0.9 or >1.4
claudication
Y N
Clinical examination Clinical examination
ABI (TBIa), TcPO2 ABI (TBIa)
TBIa
Duplex sonography
Duplex sonography Duplex sonography
Treadmill test
WIfI score Treadmill test
Wound healing without
LEAD LEAD
revascularization likely
Y N N Y Y N
Wound Search for other causes
Exercise trainingb
managementb for limited walking distance
Wound Limited daily practice
Regular screening
healing despite exercise training
Y N Y N
(Additional MRA or CTAc)
Revascularization
Regular screening / follow-up
Figure 20 Screening for and managing lower-extremity artery disease in patients with diabetes. ABI, ankle–brachial index; CTA, computed tomography
angiography; LEAD, lower-extremity artery disease; MRA, magnet resonance angiography; TBI, toe–brachial index; TcPO , transcutaneous oxygen pressure;
2
WlfI, Wound, Ischaemia, foot Infection. aTBI when ABI >1.4. bFurther information regarding wound management and exercise training can be found in the
2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases.747cMRA or CTA when duplex sonography is not sufficient for planning
revascularization.
Downloaded
from

by
guest
on
22
January
2026

4106 E S C G u id e l in e s
Due to the high burden of comorbidities in patients with diabetes, With respect to the impact of diabetes on carotid revascularization, a
interdisciplinary co-operation is crucial. The medical management of meta-analysis of 14 observational studies involving 16 264 patients
LEAD in patients with diabetes does not differ from that recommended showed that patients with diabetes had a higher risk of peri-operative
for patients with ASCVD in general including SGLT2 inhibitors and stroke and death versus those without diabetes.773 The CREST
GLP-1 RAs.747,757,764,765Still, it should be noted that for the SGLT2 in- (Carotid Revascularization Endarterectomy versus Stenting) trial was
hibitor canagliflozin, the risk of amputation was increased in the the only trial comparing carotid endarterectomy and carotid artery
CANVAS study, a finding that has not been repeated in the stenting to enrol enough patients with diabetes (n = 759) for sub-group
CREDENCE trial comparing canagliflozin with placebo in patients analysis.774Although re-stenosis rates were low at 2 years after carotid
with T2DM and CKD, nor in CVOTs with other SGLT2 inhibitors.151 stenting (6.0%) and carotid endarterectomy (6.3%), diabetes predicted
Still, according to US Food and Drug Administration requirements, re-stenosis with both techniques.
the amputation risk with canagliflozin is described in the Warnings Details on revascularization strategies can be found in the 2017 ESC
and Precautions section of the prescribing information. There are Guidelines on the diagnosis and treatment of peripheral arterial diseases.747
some discussions as to whether the use of GLP-1 RAs could be prefer-
able in patients with LEAD. Ongoing studies may help to clarify this
10.2. Diabetes and aortic aneurysm
question in the future.
Recent data showed that the combination of low-dose ASA and riv- Current evidence shows a lower risk of developing aortic aneurysm in
aroxaban 2.5 mg b.i.d. reduces MACE and major adverse limb events patients with diabetes compared with persons without dia-
including amputation (MALE) compared with ASA and placebo, par- betes.759,775,776There are different mechanisms under discussion includ-
ticularly in patients with PAD.766 A sub-group analysis of patients ing effects on extracellular matrix volume, extracellular matrix glycation,
with LEAD showed a significantly higher MACE and MALE rate com- the formation of advanced glycation end-products, inflammation, oxida-
pared with patients with CAD and a higher benefit of the combination tive stress, and intraluminal thrombus biology.777Moreover, some med-
therapy.767 Improvement of prognosis was similar in patients with ications, such as metformin used to treat diabetes, seem to have
(44%) and without diabetes. The total number of major bleeding events protective effects on the development of abdominal aortic aneurysms.
was increased but fatal or critical organ bleeding did not. Nevertheless, aortic aneurysm is associated with atherosclerosis and
Patients with intermittent claudication should take part in exercise general secondary prevention is recommended based on expert
training programmes (30–45 min, at least three times per week), as consensus.
regular intensive exercise improves walking distance.747
In patients with CLTI, revascularization must be attempted when pos- Recommendation Table 25 — Recommendations for
peripheral arterial and aortic diseases in patients with
sible, and amputation should only be considered when revascularization
diabetes
options fail.768With respect to the revascularization modality of choice,
we refer to dedicated guidelines. There has not been a specific trial on Recommendation Classa Levelb
revascularization strategies in patients with diabetes; however, a review
of 56 studies including patients with diabetes suggested higher limb- Lower-extremity arterial disease
salvage rates after revascularization (78–85% at 1 year) compared with
In patients with diabetes and symptomatic LEAD,
conservative management.768 Due to disease progression, long-term antiplatelet therapy is recommended.325 I A
follow-up is very important in patients with diabetes and LEAD.769
In patients with diabetes and CLTI, it is
recommended to assess the risk of amputation; the I B
10.1.2. Diabetes and carotid artery disease WIfI score is useful for this purpose.747,758
As patients with diabetes and LEAD are at very high
According to the results of a recent community-based study, the preva-
lence of diabetes linearly correlated with carotid plaques, and patients CV risk, a LDL-C target of <1.4 mmol/L (<55 mg/dL) I B
with diabetes had more advanced carotid atherosclerosis than indivi- and a LDL-C reduction of at least 50% is
duals without diabetes.770 Based on a prospective cohort study with recommended.778,779
300 patients, which showed a high prevalence of carotid atherosclerosis Screening for LEAD is recommended on a regular
especially in men, screening of male patients with diabetes and a history basis, with clinical assessment and/or ABI I C
of CAD or ABI <0.85 has been suggested.771Nevertheless, in patients measurement.
with diabetes without a history of cerebrovascular disease, there is only Patient education about foot care is recommended in
limited evidence that carotid screening improves outcomes, and regular patients with diabetes, and especially those with
screening is not recommended.747,772Asymptomatic carotid artery dis-
LEAD, even if asymptomatic. Early recognition of
ease is frequently treated conservatively, and the patient is followed up I C
tissue loss and/or infection, and referral to a
with duplex ultrasound.
multidisciplinary team, is mandatory to improve limb
Carotid revascularization should be considered in asymptomatic pa-
salvage.
tients with one or more indicators of increased stroke risk (previous
An ABI ≤0.90 is diagnostic of LEAD, irrespective of
transient ischaemic attack/stroke, ipsilateral silent infarction, stenosis
symptoms. In symptomatic cases, further assessment I C
progression, or high-risk plaques), and if the estimated peri-operative
including duplex ultrasound is recommended.
stroke or death rate is <3% and the patient’s life expectancy is >5 years.
In symptomatic patients, carotid revascularization is indicated if the When ABI is elevated (>1.40), other non-invasive
stenosis is >70%, and should be considered if the stenosis is >50%, as- tests, including TBI or duplex ultrasound, are I C
suming that the estimated peri-operative stroke or death rate is recommended.
<6%.747 Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4107
Duplex ultrasound is recommended as the first-line Recently, a mediation analysis and multi-variable models of the EDIC
imaging method to assess the anatomy and I C trial showed that the quality of adjustment of traditional risk factors ac-
counts for only ∼50% of the cardio-protective effect of improved
haemodynamic status of lower-extremity arteries.
metabolic control.787 About 40% of the cardio-protective effect re-
In case of CLTI, revascularization is recommended
I C mains for HbA1c or elevated glucose concentrations per se.
whenever feasible for limb salvage.747,758
Accordingly, recent analyses from the Swedish National Diabetes
In patients with chronic, symptomatic LEAD without
Register evaluated the prognostic significance of 17 risk factors for
high bleeding risk, a combination of low-dose
IIa B death, acute MI, or stroke. Of the 32 611 patients with T1DM in this
rivaroxaban (2.5 mg b.i.d.) and ASA (100 mg o.d.)
Swedish registry cohort, 5.5% died over the course of 10.4 years.
should be considered.766
The strongest predictors of death and CV endpoints were HbA1c, al-
Carotid artery disease buminuria, diabetes duration, systolic BP, and LDL-C concentration.788
In patients with diabetes and carotid artery disease, it Thus, reducing CV risk in patients with T1DM relates to both low-
ering HbA1c and controlling other classical CV risk factors, including is recommended to implement the same diagnostic
I C BP and LDL-C. Therefore, glucose control target values are recom-
work-up and therapeutic strategies (medical, surgical,
mended for most adults with T1DM by the joint consensus report of
or endovascular) as in patients without diabetes.
the ADA and EASD: HbA1c <53 mmol/mol or <7.0%; pre-prandial glu-
Aortic aneurysm
cose 4.4–7.2 mmol/L or 80–130 mg/dL; and 1–2 h post-prandial glu-
In patients with diabetes and aortic aneurysm, it is cose <10.0 mmol/L or <180 mg/dL.13 Hypoglycaemia should be
recommended to implement the same diagnostic avoided, especially in patients with CV complications.
I C
work-up and therapeutic strategies (medical, surgical, Advances in diabetes technologies have started a new era in clinical
or endovascular) as in patients without diabetes. practice, and the use of CGM has now become widespread. CGM can
significantly improve glycaemic control in T1DM, providing more de-
ABI, ankle–brachial index; ASA, acetylsalicylic acid; b.i.d., twice a day; CLTI, chronic
tailed information and introducing new outcome variables including
limb-threatening ischaemia; CV, cardiovascular; LDL-C, low-density lipoprotein-cholesterol;
LEAD, lower-extremity artery disease; o.d., once a day; TBI, toe–brachial index; WIfI, time-in-range and glycaemic variability.138
Wound, Ischaemia, foot Infection. Management strategies should adapt new therapies and technologies
aClass of recommendation.
as they become available, according to the wishes and desires of the
bLevel of evidence.
person with diabetes.
11.1. Cardiovascular risk assessment in
11. Type 1 diabetes and
type 1 diabetes
cardiovascular disease
With respect to treatment targets and thresholds for other CV risk fac-
tors, a critical question is predicting CV risk in patients with T1DM
This section summarizes evidence-based recommendations to effect-
without CVD. Determining ASCVD risk in patients with T1DM is
ively manage CV risk factors in patients with T1DM; the section does
less well studied than in patients with T2DM.
not address the control of glucose levels, which must follow the prin-
In 2011, an observational study using the data from 3661 patients in the
ciples of patient self-management under the guidance of the diabetes
Swedish National Diabetes Register proposed a 5-year CVD risk model for
healthcare multidisciplinary team according to clinical recommenda-
tions by EASD/ADA.1 use in patients with T1DM.789More recently, the Steno Type 1 Risk Engine
was externally validated at 5 years but lacks validation at 10 years.790Age at
People with T1DM face a three-fold increase in mortality compared
the onset and duration of diabetes are two risk factors that lead the estima-
with the general population, which translates into an 11-year reduction
tion of CV risk. Thus, patients diagnosed with T1DM at an early age show an
in life expectancy; CVD mortality accounts for 30–44% of all deaths in
patients with T1DM.780–784 increased incidence of CVD. In addition, excess mortality in patients diag-
nosed with T1DM under the age of 10 years, compared with those aged
The DCCT prospectively investigated not only the impact of an in- 26–30 years at diagnosis, has been highlighted by a Swedish study.791
tensified glucose-lowering treatment strategy on microvascular compli-
This concept has been underlined by the Pittsburgh Epidemiology of
cations in patients with T1DM, but also the rate of macrovascular
Diabetes Complications (EDC) study, which showed duration of diabetes events at long-term follow-up. This study showed that intensified insu-
to be an independent risk factor for MACE.791,792Several other risk factors
lin therapy lasting over a mean of 6.5 years halved the incidence and
related to diabetes management, including glycaemic control, insulin re-
progression of microvascular sequelae, which was associated with a sig-
nificant decrease in HbA1c, compared with conventional therapy.126 quirements, smoking, cardiac autonomic neuropathy, dysfunctional im-
mune response, and insulin resistance, are to be taken into account.788
After a mean follow-up of 17 years in >90% of the initially enrolled pa-
A recent risk tool, developed based on the Scottish/Swedish
tients, CV risk was also significantly reduced by 42% in the intensified-
Diabetes Registry and validated in the Swedish National Diabetes
treatment group, and the reduction in HbA1c over the first 6.5 years
was significantly associated with a reduction in CV risk.785 In the Register can provide individualized risk predictions.793 This 10-year
ASCVD risk prediction tool 
EDIC (Epidemiology of Diabetes Interventions and Complications)
facilitate risk estimation and discussions with patients with T1DM.
study, patients were followed up for over 30 years and the following
was concluded: (i) hyperglycaemia is the primary modifiable mediator
11.2. Managing cardiovascular risk
of late complications in T1DM; (ii) near-normal glucose control reduces
the incidence and progression of microvascular complications, such as Analogies of recommendations for risk-factor modifications in patients
retinopathy, nephropathy, and neuropathy; and (iii) intensive diabetes with T1DM derive from the fact that there is no direct evidence that
therapy reduces CV complications in T1DM.786 CV risk reduction by lowering causal CV risk factors, like LDL-C or
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

4108 E S C G u id e l in e s
BP, differs in patients with T1DM or T2DM. However, the recommen- 11.4. Renal protection in type 1 diabetes
dations are given in the awareness that, in most CVOTs for lipids, BP,
As in patients with T2DM, patients with T1DM should be regularly
antiplatelet agents, and anticoagulation, patients with T1DM were ex-
screened for kidney disease by assessing eGFR defined by CKD-EPI
cluded or recruited in small groups. In the following, we summarize re- and UACR.677RAS blockade with an ACE-I prevents kidney failure in
commendations of the respective sections with focus on specific patients with T1DM and overt nephropathy (Section 9).705,805RAS in-
aspects or caveats that should be considered in patients with T1DM.794
hibitors are therefore recommended in patients with T1DM as soon as
kidney damage is first clinically evident.
11.2.1. Exercise and lifestyle
Data on the effects of exercise on T1DM are inconclusive. Aerobic fit- Recommendation Table 26 — Recommendations for
ness improved HbA1c in patients with T1DM, but did not affect BMI, patients with type 1 diabetes
BP, and lipids.795
Recommendation Classa Levelb
In patients with T1DM, it is recommended that
11.2.2. Lipid lowering
adjustment of glucose-lowering medication follows
Statins remain the cornerstone of lipid-lowering treatment. In patients
principles of patient self-management under the I C
with T1DM at a younger age, starting statins early might be justified
guidance of the diabetes healthcare multidisciplinary
with long duration of disease, two additional risk factors, or microalbu-
team.
minuria. In the Cholesterol Treatment Trialists’ Collaboration
meta-analysis, 1466 patients with T1DM were also included.248 Avoiding hypoglycaemic episodes is recommended,
I C
Increased cholesterol absorption in T1DM compared with T2DM particularly in those with established CVD.780–782
may explain why ezetimibe, a drug that directly decreases cholesterol Statins should be considered for LDL-C lowering in
absorption, may reduce LDL-C more in T1DM than in T2DM.796,797 adults older than 40 years with T1DM without a IIa B
history of CVD to reduce CV risk.787
Statins should be considered for use in adults
11.2.3. Blood pressure
younger than 40 years with T1DM and other risk
People with T1DM may benefit from stringent BP-lowering strategies.
factors of CVD or microvascular end-organ damage IIa B
A recent analysis of the EDC study in patients without known CAD
or 10-year CVD risk ≥10% to reduce CVD
showed that the optimal BP threshold associated with reduced CVD
risk.787,788
risk was 120/80 mmHg in young adults with childhood-onset
T1DM.798Routine ambulatory BP monitoring is recommended to iden- The use of the Scottish/Swedish risk prediction
tify subjects with masked hypertension, as demonstrated in a Finnish model may be considered to estimate 10-year CVD IIb B
study in which one-quarter of patients with T1DM had underlying risk in patients with T1DM.793
hypertension and increased arterial stiffness.799
CV, cardiovascular; CVD, cardiovascular disease; LDL-C, low-density lipoprotein-cholesterol;
T1DM, type 1 diabetes mellitus.
aClass of recommendation.
11.2.4. Antiplatelet therapy bLevel of evidence.
Antiplatelet agents may be beneficial in individuals with T1DM without
symptomatic ASCVD who have at least one additional major CV risk
factor.800 12. Person-centred care
A person-centred approach that encourages and empowers patients to
11.3. Glucose-lowering agents beyond actively take part in finding solutions to their problems is suggested.806
insulin Person-centred care, including shared decision-making, goes beyond
maintaining active person consent to decisions and the person’s partici-
Glucagon-like peptide-1 receptor agonists or SGLT2 inhibitors are cur-
pation to the development of the therapeutic plan. It shapes disease
rently not indicated for T1DM.
management to advance the life and health-related quality of life of
Although GLP-1 RAs and SGLT2 inhibitors reduce CV risk in patients
the person.806,807 It helps people make better healthcare decisions
with T2DM in large CVOTs, no such data are available for patients with
based on their informed preferences in collaboration with their health-
T1DM. For GLP-1 RAs, despite showing potential in reducing HbA1c
care professionals (HCPs). 806Person-centred care requires:
and weight in patients with T1DM in the ADJUNCT ONE (The Efficacy
and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment
of Type 1 Diabetes) Treat-To-Target trial, concerns have been raised • Identifying and integrating patient needs, background, and culture
about increased rates of symptomatic hypoglycaemia and hyperglycaemia into decisions regarding health practices.808–812
with ketosis.801Another RCT in patients with T1DM also showed no sig- • Active person participation as a key factor for successful self-
nificant overall reduction in HbA1c by liraglutide compared with pla- management.808 This encompasses all kinds of preferences, as well
cebo.802Adding SGLT2 inhibitors at a lower than usual dose to insulin as physical, psychosocial, behavioural, and financial needs in the devel-
therapy in T1DM may reduce glucose variability and facilitate glucose con- opment of the therapeutic plan.808,813It also refers to meal planning,
trol, thereby reducing insulin doses and hypoglycaemia.803However, ke- planned physical activity, managing symptoms, blood glucose moni-
toacidosis at lower glucose levels, so called ‘euglycaemic ketoacidosis’, toring, medical treatments, and managing episodes of illness and of
has been reported in 2–3% of patients with T1DM taking SGLT2 inhibi- low and high blood glucose, as well as psychosocial, cultural, and spir-
tors.804This is a potentially lethal complication. itual consequences of health conditions.814–816
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4109
• Motivation and support of people with diabetes, such as: support to models of preventive care are those that adopt a total risk-
stop smoking; adopt a healthy diet; increase PA and exercise; man- management approach (i.e. those that address all of the risk factors
age other comorbidities, such as arthritis, renal failure, frailty, and that impact CV health) using behavioural counselling with action
cognitive impairment, which increase risk of drug interactions; plans, education, comprehensive, goal-setting, and problem-solving
and manage body weight, taking psychosocial factors into ac- approaches, and proven therapeutics supported by frequent follow-
count.817–826 up, either face to face or by telephone and/or digital health
• Interdisciplinary teams comprising the person (including caregivers/ interventions.820,829,830
family), physicians, nurses, social workers, physiotherapists, occupa-
tional therapists, dieticians, pharmacists, physical activity specialists, Figure 21 summarizes the model of person-centred care approach
and psychologists are effective for enhancing effective communica- for patients with diabetes with or without CVD, considering sex and
tion, collaboration, and preventing CVD.827,828 The most effective cultural and socioeconomic factors.
Frequent follow-up
Face-to-face meetings
Telemedicine
Person-centred care
Persons with Interdisciplinary
diabetes team
Family/caregivers
Cultural, gender, physical, Physicians, nurses,
psychological, socio- dietologists, psychologists,
economic, spiritual physiotherapists, etc
perspectives
Communication,
relationship development,
education, empowerment,
support, holistic, comprehensive
& problem-solving care,
self-management
Figure 21 Person-centred care approach for patients with diabetes with or without cardiovascular disease.
Downloaded
from

by
guest
on
22
January
2026

4110 E S C G u id e l in e s
Recommendation Table 27 — Recommendations for with symptoms, while two abnormal tests are usually required with-
person-centred care in diabetes out symptoms.
• Undiagnosed diabetes is common, particularly in individuals with
Recommendations Classa Levelb CVD. Therefore, screening for diabetes in all individuals with CVD,
including HF, is recommended using HbA1c and/or fasting glucose.
Structured education programmes are
recommended in patients with diabetes to improve
I A Cardiovascular risk assessment
diabetes knowledge, glycaemic control, disease
management, and patient empowerment.811,812,821 • All patients with diabetes should be evaluated for the presence of
Person-centred care is recommended to facilitate ASCVD and severe TOD.
shared control and decision-making within the I C • In patients with T2DM without symptomatic ASCVD or severe
context of person priorities and goals.822–824 TOD, 10-year CVD risk via SCORE2-Diabetes should be calculated.
Providing individual empowerment strategies should
be considered to enhance self-efficacy, self-care, and IIa B Lifestyle
motivation in patients with diabetes.825,826,831–834
• For smokers, smoking cessation is a primary target of lifestyle inter-
aClass of recommendation. vention in patients with CVD and diabetes.
bLevel of evidence. • Exercise should be introduced in all patients with CVD and T2DM,
following the paradigm ‘every step counts’.
13. Practical guidance
• In patients with obesity and T2DM with or without CVD, reducing
weight combined with increasing daily PA through structured exer-
New guidelines and clinical recommendations for treating T2DM are pa-
cise sessions are key lifestyle components to improve metabolic con-
tient centred and evidence based; the clinical picture and risk of
trol, improve exercise capacity, and reduce clinical outcomes.
cardio-renal complications, rather than HbA1c alone, are the forefront
• A Mediterranean diet supplemented with olive oil and/or nuts re-
of personalized treatment decisions. The primary therapeutic goals in pa-
duces the incidence of major CV events in patients with CVD.
tients with diabetes and ASCVD or increased risk of CV complications is
protecting organs and improving prognosis (Figure 1). Accordingly, these
ESC Guidelines on CVD and diabetes are based on the extensive data Glycaemic targets
from large CVOTs of recent years. For patients with T2DM and
• Tight glycaemic control reduces short- and long-term microvascular
ASCVD, a wealth of data exists but CV risk reduction in those without
disease.
ASCVD is less clear. Thus, to provide recommendations for treatment
• Tight glycaemic control reduces long-term macrovascular complica-
strategies to lower CV risk in patients with T2DM but without
tions (over 20 years).
ASCVD or severe TOD, an appropriate tool for stratifying risk in these
• Hypoglycaemia is associated with adverse CV outcomes and is best
patients is of major importance. Therefore, an extension of SCORE2 for
avoided.
T2DM, named SCORE2-Diabetes, is provided to predict 10-year risk of
fatal and non-fatal CVD events (MI, stroke) across four European risk re-
Glucose-lowering therapy
gions in patients without ASCVD or severe TOD.63
Implementation of the current Guidelines should be fostered not only • ASCVD complications are common in patients with T2DM.
by using respective educational tools developed by the ESC including the • Glycaemic status should be systematically evaluated in all patients
ESC Clinical Practice Guideline, but also by integrating it into national elec- with or at high risk of CVD, as diabetes status informs many clinical
tronic health-record systems and digital-based healthcare solutions. decisions in cardiology.
The evidence-based concept of the current Guidelines, its key messages, • Independent of baseline HbA1c or additional glucose-lowering
and gaps of evidence as medical needs for future research must be distrib- agents, selected SGLT2 inhibitors and GLP-1 RAs reduce CV events
uted to all healthcare stakeholders, policymakers, politicians, and the gen- in patients with T2DM with ASCVD and/or severe TOD.
eral public. Awareness should be raised, respectively, on national and
European levels, including in European Union (EU) parliament and respon- Blood pressure
sible commissions.
• BP targets should be individualized for hypertensive patients.
From our point of view, the current Guidelines might provide a blue-
• Optimal BP control reduces the risk of micro- and macrovascular
print for approaching multimorbid patients with common, chronic,
complications.
non-communicable diseases such as ASCVD, HF, diabetes, and CKD.
• Controlling BP often requires multiple drug therapies with an RAS in-
Non-communicable diseases are one of the greatest burdens on health-
hibitor, and a CCB or diuretic. Dual therapy is recommended as first-
care systems and societies in Europe and many other areas of the
line treatment.
world. Therefore, we hope that the current Guidelines will contribute
• All hypertensive patients with diabetes, irrespective of their anti-
to the ultimate goal of managing CVD and CV risk in patients with dia-
hypertensive treatments, should monitor their BP at home.
betes: to improve patients’ prognosis and health-related quality of life.
14. Key messages Lipids
• Statins remain the first-line and state-of-the-art therapy to decrease
Diagnosis of diabetes
LDL-C levels.
• Raised fasting or random glucose, elevated HbA1c, or an abnormal • Ezetimibe and PCSK9 inhibitors in addition to statins (if treatment
OGTT is diagnostic of diabetes; a single abnormal test is sufficient targets have not been achieved)—or alone (in case of documented
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4111
intolerance to statins)—significantly reduce LDL-C levels, thus im- Aortic and peripheral arterial diseases
proving CV outcomes.
• LEAD is a common complication in patients with diabetes and asso-
ciated with poorer prognosis.
Antithrombotic therapy
• Patients with diabetes are at higher risk of CLTI as the first clinical
• Based on the presence of ASCVD and individual CV risk, antiplatelet manifestation of LEAD, supporting regular screening with ABI meas-
agents are a cornerstone of preventing CV events in patients with urement for early diagnosis.
diabetes. • The management of patients with LEAD and indications for different
• Shortening or scaling down DAPT to clopidogrel should be treatment strategies are similar in patients with or without diabetes,
avoided in patients with diabetes post-ACS, given their high back- although the options for revascularization may be poorer in patients
ground CV risk, the lack of efficacy data, and the poor bio-activation with diabetes because of diffuse and distal lesions.
of clopidogrel.
• Platelet-function testing guided de-escalation should be avoided Type 1 diabetes
based on lack of evidence and poor bio-activation of clopidogrel.
• Glucose-lowering therapy in T1DM should follow principles of pa-
tient self-management under the guidance of the diabetes healthcare
Multifactorial approach
multidisciplinary team.
• Continuous, multidisciplinary counselling is necessary to achieve
Person-centred care
long-term lifestyle changes.
• A person-centred approach is a key factor in successful self-
Management of coronary artery disease management, resulting in greater patient satisfaction, adherence to
therapeutic plans, and improved health outcomes.
• In patients with CAD, SGLT2 inhibitors and/or GLP-1 RAs reduce
• Important factors for self-management of diabetes and comorbidities
the risk of CV events.
are education, motivation, empowerment, and continuing supportive
• In patients with diabetes and multivessel CAD, suitable coronary
care of individuals.
anatomy for revascularization, and low predicted surgical mortality,
CABG is superior to PCI.
15. Gaps in evidence
Heart failure
Diagnosis of diabetes
• The prognosis of patients with diabetes and HF is worse compared
with patients with HF without diabetes. • Global screening programmes for diabetes, adjusted for regional
• Beta-blockers, ARNI/ACE-Is, MRAs, and SGLT2 inhibitors are recom- demographics and ethnic groups, are required to establish the
mended as cornerstone therapies for patients with HFrEF and diabetes. most accurate and cost-effective screening test.
• Empagliflozin and dapagliflozin reduce the combined endpoint of CV
death or HF hospitalization in patients with HF and a LVEF >40%. Lifestyle
• Glucose-lowering treatment with SGLT2 inhibitors in patients with
• RCTs of long-term exercise intervention to reduce CV outcomes are
diabetes and HF reduces HF-related endpoints.
needed in different patient groups with diabetes and CVD, e.g. CAD,
• Saxagliptin and pioglitazone increase the risk of HF hospitalization in
HFpEF, HFrEF, AF, or PAD.
patients with diabetes and HF.
• Large RCTs assessing the benefit of a multidisciplinary team to in-
crease adherence to lifestyle interventions and optimal medication
Arrhythmias
are needed in patients with T2DM and CVD.
• AF is common in patients with diabetes, and increases mortality, risk • The applicability and best practice of telehealth needs to be evaluated
of stroke, and risk of HF. in elderly and frail patients with T2DM and CVD.
• Opportunistic screening for AF is recommended for patients with
diabetes aged ≥65 years by palpating pulse (or using wearable de- Glycaemic targets
vices) and systematic ECG screening when age is ≥75 years. AF
• The independent role of hypoglycaemia, glycaemic variability,
should always be confirmed by ECG.
time-in-range, and post-prandial hyperglycaemia in CV pathology re-
• Opportunistic screening for AF by pulse taking or ECG is recom-
quires further research.
mended in patients with diabetes aged <65 years in view of their
• Large-scale studies are required to understand the role of modern
risk of AF and the possibly associated risk of ischaemic stroke.
glucose-monitoring strategies (CGM) in improving macrovascular
and HF outcomes.
Chronic kidney disease
• CKD in patients with diabetes is associated with high risk of develop- Glucose-lowering therapy
ing kidney failure and CVD. • It remains unclear if the combination therapy of GLP-1 RAs and
• Patients with diabetes should be regularly screened for CKD, or have SGLT2 inhibitors is complementary in cardio-renal outcomes in pa-
their CKD staged, by assessing eGFR and UACR. tients with T2DM.
• Certain ACE-I/ARBs, SGLT2 inhibitors, and finerenone reduce the risk • It needs to be examined if more intensive glycaemic control, achieved
of kidney failure and the risk of CVD in patients with T2DM and CKD. with novel medications, might prove to have incremental CV efficacy.
Downloaded
from

by
guest
on
22
January
2026

4112 E S C G u id e l in e s
Blood pressure • Robust data on patients with CAD and T1DM are missing.
• The effect of anti-inflammatory strategies in patients with diabetes
• High-quality data on managing BP in T1DM are lacking.
should be assessed in dedicated trials.
• Optimal targets for (isolated) DBP in patients with diabetes and
hypertension remain inconclusive.
Heart failure
• More information on optimizing CV protection in diabetes by man-
aging BP based on out-of-office BP levels should be provided by ran- • The effect of finerenone on cardio-renal endpoints in patients with
domized intervention trials. diabetes and HFrEF or HFpEF needs to be examined.
• More mechanistic studies are warranted to better understand how
Lipids SGLT2 inhibitors improve HF outcomes.
• Research is needed to guide OMT in patients with HF and T1DM.
• Optimal LDL-C target levels for patients with diabetes need to
• The prognostic benefit of HF screening with BNP/NT-proBNP in
be established; good scientific evidence is especially missing in
asymptomatic patients with diabetes needs to be determined.
T1DM.
• Novel lipid-lowering drugs, such as inclisiran need efficacy data on CV
Arrhythmias
endpoints both in the general population and in patients with
diabetes. • Better evidence is needed regarding the risks of atrial and ventricular
arrhythmias associated with T1DM and how they should be optimally
Antithrombotic therapy managed.
• Optimal screening methods and treatment for patients with diabetes
• More data on primary CV prevention are needed for patients with
still need to be defined in RCTs.
T1DM.
• The role of AF in diabetes needs to be evaluated in CVOTs.
• Future phase 3 RCTs testing antithrombotic drugs in CV prevention
• Whether SGLT2 inhibitors reduce the risk of CV death by reducing the
should share homogeneous classifications of bleeding to make the
risk of ventricular tachyarrhythmias should be more precisely evaluated.
benefit-risk profile of mono- or combined therapy comparable
across different studies.
Chronic kidney disease
• The benefit-risk profile of ASA in CV prevention in patients with dia-
betes, documented significant atherosclerotic lesions (peripheral or • CV and renal effects of using non-steroidal MRAs in patients with CKD on
coronary), or high CAC score but without history of stroke or MI a combined ACE-I/ARB + SGLT2-inhibitor regimen need to be explored.
should be further investigated in RCTs. • Net benefits of antiplatelet therapy in patients with diabetes and
• Since documented kidney and/or eye microvascular disease inde- CKD with and without ASCVD need to be examined.
pendently predict future CV events, it needs to be assessed whether
patients with diabetes with microvascular disease and no history of Aortic and peripheral arterial diseases
MACE would benefit from early primary prophylaxis.
• The frequency and mode of vascular screening in patients with dia-
• It needs to be demonstrated in adequately powered, superiority,
betes needs to be assessed.
efficacy-based RCTs whether 12-month DAPT post-ACS can be re-
• Specific trials are needed to help clinicians choose different pharma-
duced to a shorter period in patients with diabetes using SAPT with
cological strategies according to the presence of PAD.
ASA or with a P2Y inhibitor.
12
• The optimal duration of TAT post-ACS in patients with diabetes and
Type 1 diabetes
AF needs to be established.
• Comprehensive cardio-protection management in patients with
Multifactorial approach early-onset T1DM needs to be evaluated.
• The role of ameliorating insulin resistance and using adjunctive ther-
• An optimal intervention protocol to improve adherence remains to
apies to reduce CV risk remains to be elucidated.
be established, particularly addressing patients with diabetes and co-
• Lifestyle intervention trials in patients with T1DM and CVD are lacking.
morbidities, and the elderly population.
• Sex and ethnicity differences regarding efficacy of multifactorial inter-
Person-centred care
ventions need to be evaluated.
• Evaluation of E-health applications to improve adherence to lifestyle • Better CVD management of women with diabetes is needed.
intervention and medication also assessing clinical outcomes is • Effective interdisciplinary approaches to better manage glycaemic
needed in patients with CVD and diabetes. control and minimize the risk of complications are required.
• Data are lacking on personalization of mobile Health (mHealth) by
Management of coronary artery disease assessing how individual factors, such as health literacy, culture, socio-
economic status, ageing, behaviours, and treatment plan, impact pa-
• Optimal glycaemic control and in-hospital anti-glycaemic strategies
tient engagement with mHealth tools and clinical outcomes.
for the outcomes of ACS and stable CAD, as well as after coronary
revascularization, remain to be established.
• Although newer-generation DES have improved outcomes in pa- 16. Sex differences
tients with diabetes, RCTs are needed to determine whether they
can reduce the gap in outcomes between CABG and PCI. Epidemiological studies suggest that diabetes is a stronger risk factor for
• No direct comparison RCT has focused on revascularization in pa- CVD in women compared with men. Data from large CVOTs do not sug-
tients with diabetes and left main disease. gest sex differences with respect to the benefit of CV risk-reducing
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4113
strategies in T2DM, i.e. treatment with SGLT2 inhibitors or GLP-1 RAs. with men.835–837This should be explored in future studies. Therefore,
Although women are under-represented in clinical trials, there is no evi- we recommend implementing sex-balanced recruitment strategies for fu-
dence for sex-specific recommendations for managing CVD in patients ture CVOTs. In addition, pre-specified analyses addressing sex differences
with diabetes. However, epidemiological and real-world data suggest that are needed. Most importantly, every effort should be made to ensure wo-
guideline-directed therapy in women is less likely to be applied compared men receive equal healthcare opportunities in managing CVD in diabetes.
17. ‘What to do’ and ‘What not to do’ messages from the Guidelines
Table 12 ‘What to do’ and ‘What not to do’
Recommendations Classa Levelb
Recommendations for diagnosis of diabetes
Screening for diabetes is recommended in all individuals with CVD, using fasting glucose and/or HbA1c. I A
It is recommended that the diagnosis of diabetes is based on HbA1c and/or fasting plasma glucose, or on an OGTT if still in doubt. I B
Recommendations for assessing cardiovascular risk in patients with diabetes
It is recommended to screen patients with diabetes for the presence of severe TOD. I A
It is recommended to assess medical history and the presence of symptoms suggestive of ASCVD in patients with diabetes. I B
In patients with T2DM without symptomatic ASCVD or severe TOD, it is recommended to estimate 10-year CVD risk via
I B
SCORE2-Diabetes.
Recommendations for weight reduction in patients with diabetes
It is recommended that individuals living with overweight or obesity aim to reduce weight and increase physical exercise to improve
I A
metabolic control and overall CVD risk profile.
Recommendations for nutrition in patients with diabetes
It is recommended to adopt a Mediterranean or plant-based diet with high unsaturated fat content to lower cardiovascular risk. I A
Recommendation for physical activity/exercise in patients with diabetes
It is recommended to increase any physical activity (e.g. 10 min daily walking) in all patients with T2DM with and without CVD. Optimal is a
I A
weekly activity of 150 min of moderate intensity or 75 min of vigorous endurance intensity.
It is recommended to adapt exercise interventions to T2DM-associated comorbidities, e.g. frailty, neuropathy, or retinopathy. I B
It is recommended to introduce structured exercise training in patients with T2DM and established CVD, e.g. CAD, HFpEF, HFmrEF,
I B
HFrEF, or AF to improve metabolic control, exercise capacity and quality of life, and to reduce CV events.
It is recommended to perform resistance exercise in addition to endurance exercise at least twice a week. I B
Recommendation for smoking cessation in patients with diabetes
It is recommended to stop smoking to reduce cardiovascular risk. I A
Recommendations for glycaemic targets
It is recommended to apply tight glycaemic control (HbA1c <7%) to reduce microvascular complications. I A
It is recommended to avoid hypoglycaemia, particularly in patients with CVD. I B
It is recommended to individualize HbA1c targets according to comorbidities, diabetes duration, and life expectancy. I C
Recommendations for glucose-lowering treatment for patients with type 2 diabetes and atherosclerotic cardiovascular disease to
reduce cardiovascular risk
It is recommended to prioritize the use of glucose-lowering agents with proven CV benefits followed by agents with proven CV safety over
I C
agents without proven CV benefit or proven CV safety.
Sodium–glucose co-transporter-2 inhibitors
SGLT2 inhibitors with proven CV benefit are recommended in patients with T2DM and ASCVD to reduce CV events, independent of
I A
baseline or target HbA1c and independent of concomitant glucose-lowering medication.
Glucagon-like peptide-1 receptor agonists
GLP-1 RAs with proven CV benefit are recommended in patients with T2DM and ASCVD to reduce CV events, independent of baseline or
I A
target HbA1c and independent of concomitant glucose-lowering medication.
Continued
Downloaded
from

by
guest
on
22
January
2026

4114 E S C G u id e l in e s
Recommendations for blood pressure in patients with diabetes
Screening for hypertension
Regular BP measurements are recommended in all patients with diabetes to detect and treat hypertension to reduce CV risk. I A
Treatment targets
Anti-hypertensive drug treatment is recommended for people with diabetes when office BP is ≥140/90 mmHg. I A
It is recommended to treat hypertension in patients with diabetes in an individualized manner. The BP goal is to target SBP to 130 mmHg
I A
and <130 mmHg if tolerated, but not <120 mmHg. In older people (age >65 years), it is recommended to target SBP to 130–139 mmHg.
Treatment and evaluation
Lifestyle changes (weight loss if overweight, physical activity, alcohol restriction, sodium restriction, increased consumption of vegetables,
I A
using low-fat dairy products) are recommended in patients with diabetes and hypertension.
It is recommended to initiate treatment with a combination of an RAS inhibitor and a CCB or thiazide/thiazide-like diuretic. I A
Recommendations for lipids and diabetes
Lipid targets in patients with diabetes
In patients with T2DM at moderate CV risk, an LDL-C target of <2.6 mmol/L (<100 mg/dL) is recommended. I A
In patients with T2DM at high CV risk, an LDL-C target of <1.8 mmol/L (<70 mg/dL) and LDL-C reduction of at least 50% is recommended. I A
In patients with T2DM at very high CV risk, an LDL-C target of <1.4 mmol/L (<55 mg/dL) and LDL-C reduction of at least 50% is
I B
recommended.
In patients with T2DM, a secondary goal of a non-HDL-C target of <2.2 mmol/L (<85 mg/dL) in very high CV risk patients, and <2.6 mmol/
I B
L (<100 mg/dL) in high CV risk patients, is recommended.
Lipid-lowering treatment in patients with diabetes
Statins are recommended as the first-choice LDL-C-lowering treatment in patients with diabetes and above-target LDL-C levels.
I A
Administration of statins is defined based on the CV risk profile of the patients and the recommended LDL-C (or non-HDL-C) target levels.
A PCSK9 inhibitor is recommended in patients at very high CV risk, with persistently high LDL-C levels above target despite treatment with
I A
a maximum tolerated statin dose, in combination with ezetimibe, or in patients with statin intolerance.
If the target LDL-C is not reached with statins, combination therapy with ezetimibe is recommended. I B
Recommendations for antithrombotic therapy in patients with diabetes and acute or chronic coronary syndrome without indications
for long-term oral anticoagulation
ASA at a dose of 75–100 mg o.d. is recommended in patients with diabetes and previous MI or revascularization (CABG or stenting). I A
In patients with ACS and diabetes who undergo PCI, a P2Y receptor inhibitor (ticagrelor or prasugrel) is recommended in addition to ASA
12 I A
(75–100 mg o.d.), maintained over 12 months.
Clopidogrel 75 mg o.d. following appropriate loading (e.g. 600 mg or at least 5 days already on maintenance therapy) is recommended in
addition to ASA for 6 months following coronary stenting in patients with CCS, irrespective of stent type, unless a shorter duration is I A
indicated due to the risk or occurrence of life-threatening bleeding.
Clopidogrel is recommended as an alternative in case of ASA intolerance. I B
In patients with diabetes and ACS treated with DAPT who are undergoing CABG and do not require long-term OAC therapy, resuming a
I C
P2Y receptor inhibitor as soon as deemed safe after surgery and continuing it up to 12 months is recommended.
12
Recommendations for antithrombotic therapy in patients with diabetes and acute or chronic coronary syndrome and/or
post-percutaneous coronary intervention requiring long-term oral anticoagulation
In patients with AF and receiving antiplatelet therapy, eligible for anticoagulation, and without a contraindication, NOACs are
I A
recommended in preference to a VKA.
In patients with ACS or CCS and diabetes undergoing coronary stent implantation and having an indication for anticoagulation, triple
therapy with low-dose ASA, clopidogrel, and an OAC is recommended for at least 1 week, followed by dual therapy with an OAC and a I A
single, oral, antiplatelet agent.
Recommendations for gastric protection
When antithrombotic drugs are used in combination, proton pump inhibitors are recommended to prevent gastrointestinal bleeding. I A
When clopidogrel is used, omeprazole and esomeprazole are not recommended for gastric protection. III B
Recommendations for a multifactorial approach in patients with diabetes
Identifying and treating risk factors and comorbidities early is recommended. I A
A multifactorial approach to managing T2DM with treatment targets is recommended. I B
Multidisciplinary behavioural approaches that combine the knowledge and skills of different caregivers are recommended. I C
Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4115
Recommendations for revascularization in patients with diabetes
It is recommended that similar revascularization techniques are implemented (e.g. the use of DES and the radial approach for PCI, and the
I A
use of the left internal mammary artery as the graft for CABG) in patients with and without diabetes.
Myocardial revascularization in CCS is recommended when angina persists despite treatment with anti-anginal drugs or in patients with a
I A
documented large area of ischaemia (>10% LV).
Complete revascularization is recommended in patients with STEMI without cardiogenic shock and with multivessel CAD. I A
Routine immediate revascularization of non-culprit lesions in patients with MI with multivessel disease presenting with cardiogenic shock is
III B
not recommended.
Recommendations for glycaemic control in patients with diabetes and acute coronary syndrome
It is recommended to assess glycaemic status at initial evaluation in all patients with ACS. I B
It is recommended to frequently monitor blood glucose levels in patients with known diabetes or hyperglycaemia (defined as glucose levels
I C
≥11.1 mmol/L or ≥200 mg/dL).
Recommendations for heart failure screening and diagnosis in patients with diabetes
Evaluation for heart failure
If HF is suspected, it is recommended to measure BNP/NT-proBNP. I B
Systematic survey for HF symptoms and/or signs of HF is recommended at each clinical encounter in all patients with diabetes. I C
Diagnostic tests in all patients with suspected heart failure
12-lead ECG is recommended. I C
Transthoracic echocardiography is recommended. I C
Chest radiography (X-ray) is recommended. I C
Routine blood tests for comorbidities are recommended, including full blood count, urea, creatinine and electrolytes, thyroid function,
I C
lipids, and iron status (ferritin and TSAT).
Recommendations for heart failure treatments in patients with heart failure with reduced ejection fraction and diabetes
Recommendations for pharmacological treatment indicated in patients with HFrEF (NYHA class II–IV) and diabetes
SGLT2 inhibitors (dapagliflozin, empagliflozin, or sotagliflozin) are recommended in all patients with HFrEF and T2DM to reduce the risk of
I A
HF hospitalization and death.
Sacubitril/valsartan or an ACE-I is recommended in all patients with HFrEF and diabetes to reduce the risk of HF hospitalization and death. I A
Beta-blockers are recommended in patients with HFrEF and diabetes to reduce the risk of HF hospitalization and death. I A
MRAs are recommended in patients with HFrEF and diabetes to reduce the risk of HF hospitalization and death. I A
An intensive strategy of early initiation of evidence-based treatment (SGLT2 inhibitors, ARNI/ACE-Is, beta-blockers, and MRAs), with rapid
up-titration to trial-defined target doses starting before discharge and with frequent follow-up visits in the first 6 weeks following a HF I B
hospitalization is recommended to reduce re-admissions or mortality.
Recommendations for other treatments indicated in selected patients with HFrEF (NYHA class II–IV) and diabetes
Device therapy with an ICD, CRT-P, or CRT-D is recommended in patients with diabetes, as in the general population with HFrEF. I A
ARBs are recommended in symptomatic patients with HFrEF and diabetes who do not tolerate sacubitril/valsartan or ACE-Is, to reduce the
I A
risk of HF hospitalization and death.
Diuretics are recommended in patients with HFrEF and diabetes with signs and/or symptoms of fluid congestion to improve symptoms,
I C
exercise capacity, and HF hospitalization.
Recommendations for the treatment of heart failure patients with left ventricular ejection fraction >40% and diabetes
Empagliflozin or dapagliflozin are recommended in patients with T2DM and LVEF >40% (HFmrEF and HFpEF) to reduce the risk of HF
I A
hospitalization or CV death.
Diuretics are recommended in patients with HFpEF or HFmrEF and diabetes with signs and/or symptoms of fluid congestion to improve
I C
symptoms, exercise capacity, and HF hospitalization.
Recommendations for glucose-lowering medications in patients with type 2 diabetes with and without heart failure
Recommendations for glucose-lowering medications to reduce heart failure hospitalization in patients with type 2 diabetes with or
without existing heart failure
SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, or sotagliflozin) are recommended in patients with T2DM with
I A
multiple ASCVD risk factors or established ASCVD to reduce the risk of HF hospitalization.
SGLT2 inhibitors (dapagliflozin, empagliflozin, or sotagliflozin) are recommended in patients with T2DM and HFrEF to reduce the risk of HF
I A
hospitalization and death.
Continued
Downloaded
from

by
guest
on
22
January
2026

4116 E S C G u id e l in e s
Empagliflozin or dapagliflozin are recommended in patients with T2DM and LVEF >40% (HFmrEF and HFpEF) to reduce the risk of HF
I A
hospitalization or CV death.
Recommendations for glucose-lowering medications with an increased risk of heart failure hospitalization in patients with type 2
diabetes
Pioglitazone is associated with an increased risk of incident HF in patients with diabetes and is not recommended for glucose-lowering
III A
treatment in patients at risk of HF (or with previous HF).
The DPP-4 inhibitor saxagliptin is associated with an increased risk of HF hospitalization in patients with diabetes and is not recommended
III B
for glucose-lowering treatment in patients at risk of HF (or with previous HF).
Recommendations for special consideration in patients with heart failure and diabetes
It is recommended to switch glucose-lowering treatment from agents without proven CV benefit or proven safety to agents with proven
I C
CV benefit.
Recommendations for atrial fibrillation in patients with diabetes
Screening for atrial fibrillation in diabetes
Opportunistic screening for AF by pulse taking or ECG is recommended in patients ≥65 years of age. I B
Opportunistic screening for AF by pulse taking or ECG is recommended in patients with diabetes <65 years of age (particularly when other
I C
risk factors are present) because patients with diabetes exhibit a higher AF frequency at a younger age.
Anticoagulation for atrial fibrillation in patients with diabetes
Oral anticoagulation is recommended for preventing stroke in patients with AF and diabetes and with at least one additional
I A
(CHA DS-VASc) risk factor for stroke.
2 2
For preventing stroke in AF, NOACs are recommended in preference to VKAs, with the exception of patients with mechanical valve
I A
prostheses or moderate to severe mitral stenosis.
Recommendations for patients with chronic kidney disease and diabetes
Intensive LDL-C lowering with statins or a statin/ezetimibe combination is recommended. I A
A BP target of ≤130/80 mmHg is recommended to reduce risk of CVD and albuminuria. I A
Personalized HbA1c targets 6.5–8.0% (48–64 mmol/mol) are recommended, with a target <7.0% (<53 mmol/mol) to reduce
I A
microvascular complications, wherever possible.
The maximum tolerated dose of an ACE-I or ARB is recommended. I A
A SGLT2 inhibitor (canagliflozin, empagliflozin, or dapagliflozin) is recommended in patients with T2DM and CKD with an eGFR ≥20 mL/
I A
min/1.73 m2 to reduce the risk of CVD and kidney failure.
Finerenone is recommended in addition to an ACE-I or ARB in patients with T2DM and eGFR >60 mL/min/1.73 m2 with a UACR ≥30 mg/
I A
mmol (≥300 mg/g), or eGFR 25–60 mL/min/1.73 m2 and UACR ≥3 mg/mmol (≥30 mg/g) to reduce CV events and kidney failure.
A GLP-1 RA is recommended at eGFR >15 mL/min/1.73 m2 to achieve adequate glycaemic control, due to low risk of hypoglycaemia and
I A
beneficial effects on weight, CV risk, and albuminuria.
Low-dose ASA (75–100 mg o.d.) is recommended in patients with CKD and ASCVD. I A
It is recommended that patients with diabetes are routinely screened for kidney disease by assessing eGFR defined by CKD-EPI and UACR. I B
Treatment with intensive medical or an initial invasive strategy is recommended in people with CKD, diabetes, and stable moderate or
I B
severe CAD, due to similar outcomes.
Combined use of an ARB with an ACE-I is not recommended. III B
Recommendations for aortic and peripheral arterial diseases and diabetes
Lower-extremity artery disease in patients with diabetes
In patients with diabetes and symptomatic LEAD, antiplatelet therapy is recommended. I A
In patients with diabetes and CLTI, it is recommended to assess the risk of amputation; the WIfI score is useful for this purpose. I B
As patients with diabetes and LEAD are at very high CV risk, an LDL-C target of <1.4 mmol/L (<55 mg/dL) and an LDL-C reduction of at
I B
least 50% is recommended.
Screening for LEAD is recommended on a regular basis, with clinical assessment and/or ABI measurement. I C
Patient education about foot care is recommended in patients with diabetes, and especially those with LEAD, even if asymptomatic. Early
I C
recognition of tissue loss and/or infection, and referral to a multidisciplinary team, is mandatory to improve limb salvage.
An ABI ≤0.90 is diagnostic of LEAD, irrespective of symptoms. In symptomatic cases, further assessment including duplex ultrasound is
I C
recommended.
When ABI is elevated (>1.40), other non-invasive tests, including TBI or duplex ultrasound, are recommended. I C
Duplex ultrasound is recommended as the first-line imaging method to assess the anatomy and haemodynamic status of lower-extremity
I C
arteries.
Continued
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4117
In case of CLTI, revascularization is recommended whenever feasible for limb salvage. I C
Carotid artery disease in patients with diabetes
In patients with diabetes and carotid artery disease, it is recommended to implement the same diagnostic work-up and therapeutic
I C
strategies (medical, surgical, or endovascular) as in patients without diabetes.
Aortic aneurysm in patients with diabetes
In patients with diabetes and aortic aneurysm, it is recommended to implement the same diagnostic work-up and therapeutic strategies
I C
(medical, surgical, or endovascular) as in patients without diabetes.
Recommendations for type 1 diabetes and cardiovascular disease
In patients with T1DM, it is recommended that adjustment of glucose-lowering medication follows principles of patient self-management
I C
under the guidance of the diabetes healthcare multidisciplinary team.
Avoiding hypoglycaemic episodes is recommended, particularly in those with established CVD. I C
Recommendations for person-centred care in diabetes
Structured education programmes are recommended in patients with diabetes to improve diabetes knowledge, glycaemic control, disease
I A
management, and patient empowerment.
Person-centred care is recommended to facilitate shared control and decision-making within the context of person priorities and goals. I C
ABI, ankle–brachial index; ACE-I, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; AF, atrial fibrillation; ARB, angiotensin-II receptor blocker; ARNI, angiotensin
receptor–neprilysin inhibitor; ASA, acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; BNP, B-type natriuretic peptide; BP, blood pressure; CABG, coronary artery
bypass graft; CAD, coronary artery disease; CCB, calcium channel blocker; CCS, chronic coronary syndrome; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75 years (2
points), Diabetes mellitus, Stroke or transient ischaemic attack (2 points), Vascular disease, Age 65–74 years, Sex category (female); CKD, chronic kidney disease; CKD-EPI, chronic
kidney disease epidemiology; CLTI, chronic limb-threatening ischaemia; CRT-D, cardiac resynchronization therapy with an implantable defibrillator; CRT-P, cardiac resynchronization
therapy-pacemaker; CV, cardiovascular; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; DES, drug-eluting stents; DPP-4, dipeptidyl peptidase-4; ECG, electrocardiogram;
eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein-cholesterol; HF, heart
failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICD,
implantable cardioverter defibrillator; LEAD, lower-extremity artery disease; LDL-C, low-density lipoprotein-cholesterol; LV, left ventricle; LVEF, left ventricular ejection fraction; MI,
myocardial infarction; MRA, mineralocorticoid receptor antagonist; NOAC, non-vitamin K antagonist oral anticoagulant; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA,
New York Heart Association; OAC, oral anticoagulant; o.d., once daily; OGTT, oral glucose tolerance test; PCI, percutaneous coronary intervention; PCSK9, proprotein convertase
subtilisin/kexin type 9; RAS, renin–angiotensin system; SBP, systolic blood pressure; SCORE2-Diabetes, type 2 diabetes-specific 10-year CVD risk score; SGLT2, sodium–glucose
co-transporter-2; STEMI, ST-elevation myocardial infarction; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TBI, toe–brachial index; TOD, target-organ damage; TSAT,
transferrin saturation; UACR, urinary albumin-to-creatinine ratio; VKA, vitamin K antagonist; WIfI, Wound, Ischaemia, foot Infection.
aClass of recommendation.
bLevel of evidence.
18. Quality indicators 21. Author information
Quality indicators (QIs) are tools that may be used to evaluate care qual- Author/Task Force Member Affiliations: Katharina Schütt,
ity, including structural, process, and outcomes of care.838They may also Department of Internal Medicine I Cardiology, RWTH Aachen
serve as a mechanism for enhancing adherence to Guideline recommen- University, Aachen, Germany; Dirk Müller-Wieland, Department of
dations, through associated quality-improvement initiatives and bench- Internal Medicine I Cardiology, RWTH Aachen University, Aachen,
marking of care clinicians.839,840As such, the role of QIs in improving Germany; Ramzi A. Ajjan, Clinical Population and Sciences
care and outcomes for CVD is increasingly recognized by healthcare au- Department, Leeds Institute of Cardiovascular and Metabolic Medicine,
thorities, professional organizations, payers, and the public.838 University of Leeds, Leeds, United Kingdom, Department of Diabetes
The ESC understands the need for measuring and reporting quality and Endocrinology, Leeds Teaching Hospitals Trust, Leeds, United
and outcomes of CV care and has established methods for developing Kingdom; Manuel J. Antunes, Faculty of Medicine, University of
the ESC QIs for quantifying care and outcomes for CVDs.838To date, Coimbra, Coimbra, Portugal; Ruxandra M. Christodorescu,
the ESC has developed QI suites for a number of CVDs in parallel with Department V Internal Medicine, University of Medicine and Pharmacy
writing the ESC Clinical Practice Guidelines.841–844 V. Babeș, Timișoara, Romania, Research Center Institute of
The ESC aims to harmonize its QIs for various CV conditions and in- Cardiovascular Diseases, Timișoara, Romania; Carolyn Crawford
tegrate them with ESC registries, providing real-world data about the (United Kingdom), ESC Patient Forum, Sophia Antipolis, France;
patterns and outcomes of care for CVD across Europe.845 Emanuele Di Angelantonio, Department of Public Health and
Primary Care University of Cambridge, Cambridge, United Kingdom,
Health Data Science Centre, Human Technopole, Milan, Italy; Björn
19. Supplementary data
Eliasson, Institute of Medicine, Sahlgrenska University Hospital,
Gothenburg, Sweden; Christine Espinola-Klein, Department of
Supplementary datais available at European Heart Journal online.
Angiology, Center of Cardiology, University Medical Center of the
Johannes Gutenberg University Mainz, Mainz, Germany; Laurent
20. Data availability statement Fauchier, Cardiology Department Centre Hospitalier Universitaire
Trousseau, Université de Tours, Tours, France; Martin Halle,
No new data were generated or analysed in support of this research. Preventive Sports Medicine and Sports Cardiology, Technical University
3202CSE©
Downloaded
from

by
guest
on
22
January
2026

4118 E S C G u id e l in e s
of Munich, Muenchen, Germany; William G. Herrington, Nuffield Czechia: Czech Society of Cardiology, Michal Vrablík; Denmark:
Department of Population Health, University of Oxford, Oxford, Danish Society of Cardiology, Morten Schou; Egypt: Egyptian
United Kingdom; Alexandra Kautzky-Willer, Department of Society of Cardiology, Hosam Hasan-Ali; Estonia: Estonian Society
Medicine III, Medical University of Vienna, Vienna, Austria, Institute for of Cardiology, Margus Viigimaa; Finland: Finnish Cardiac Society,
Gender Medicine, La pura women’s health resort Kamptal, Gars am Riikka Lautamäki; France: French Society of Cardiology, Victor
Kamp, Austria; Ekaterini Lambrinou, Department of Nursing, Aboyans; Georgia: Georgian Society of Cardiology, Zurab
Cyprus University of Technology, Limassol, Cyprus; Maciej Lesiak, Klimiashvili; Germany: German Cardiac Society, Malte Kelm;
1st Department of Cardiology, Poznan University of Medical Sciences, Greece: Hellenic Society of Cardiology, Gerasimos Siasos;
Poznan, Poland; Maddalena Lettino, Cardiothoracic and Vascular Hungary: Hungarian Society of Cardiology, Róbert Gábor Kiss;
Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; Iceland: Icelandic Society of Cardiology, Berglind Libungan; Ireland:
Darren K. McGuire, Department of Internal Medicine, Division of Irish Cardiac Society, Maeve Durkan; Israel: Israel Heart Society,
Cardiology, University of Texas Southwestern Medical Center, Dallas, Barak Zafrir; Italy: Italian Federation of Cardiology, Furio Colivicchi;
United States of America, Parkland Health and Hospital System, Dallas, Kazakhstan: Association of Cardiologists of Kazakhstan, Meiramgul
United States of America; Wilfried Mullens, Cardiology, Ziekenhuis Tundybayeva; Kosovo (Republic of): Kosovo Society of
Oost Limburg, Genk, Belgium, Faculty of Medicine and Life Sciences, Cardiology, Ibadete Bytyçi; Kyrgyzstan: Kyrgyz Society of
University Hasselt, Hasselt, Belgium; Bianca Rocca, Section of Cardiology, Erkin Mirrakhimov; Latvia: Latvian Society
Pharmacology, Catholic University School of Medicine, Rome, Italy; and of Cardiology, Karlis Trusinskis; Lebanon: Lebanese Society of
Naveed Sattar, School of Cardiovascular and Metabolic Health, Cardiology, Georges Saadé; Lithuania: Lithuanian Society of
University of Glasgow, Glasgow, United Kingdom. Cardiology, Jolita Badarienė; Luxembourg: Luxembourg Society
of Cardiology, Cristiana-Astra Banu; Malta: Maltese Cardiac Society,
Caroline Jane Magri; Montenegro: Montenegro Society of
22. Appendix Cardiology, Aneta Boskovic; Morocco: Moroccan Society of
Cardiology, Mustapha El Hattaoui; Netherlands: Netherlands
ESC Scientific Document Group Society of Cardiology, Fabrice Martens; North Macedonia: The
Includes Document Reviewers and ESC National Cardiac Societies. National Society of Cardiology of North Macedonia, Marijan
Bosevski; Norway: Norwegian Society of Cardiology, Eva Cecilie
Document Reviewers: Eva Prescott (CPG Review Co-ordinator)
Knudsen; Poland: Polish Cardiac Society, Paweł Burchardt;
(Denmark), Francesco Cosentino (CPG Review Co-ordinator)
Portugal: Portuguese Society of Cardiology, Ricardo
(Sweden), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Sotiris
Fontes-Carvalho; Romania: Romanian Society of Cardiology,
Antoniou (United Kingdom), Riccardo Asteggiano (Italy), Iris
Dragos Vinereanu; San Marino: San Marino Society of Cardiology,
Baumgartner (Switzerland), Sergio Buccheri (Sweden), Hector Bueno
Tatiana Mancini; Serbia: Cardiology Society of Serbia, Branko
(Spain), Jelena Čelutkienė (Lithuania), Alaide Chieffo (Italy), Christina
Beleslin; Slovakia: Slovak Society of Cardiology, Emil Martinka;
Christersson (Sweden), Andrew Coats (United Kingdom), Bernard
Slovenia: Slovenian Society of Cardiology, Zlatko Fras; Spain:
Cosyns (Belgium), Martin Czerny (Germany), Christi Deaton (United
Spanish Society of Cardiology, Almudena Castro Conde; Sweden:
Kingdom), Volkmar Falk (Germany), Brian A. Ference
Swedish Society of Cardiology, Linda Mellbin; Switzerland: Swiss
(United Kingdom), Gerasimos Filippatos (Greece), Miles Fisher (United
Society of Cardiology, David Carballo; Syrian Arab Republic:
Kingdom), Heikki Huikuri (Finland), Borja Ibanez (Spain), Tiny Jaarsma
Syrian Cardiovascular Association, Walid Bsata; Tunisia: Tunisian
(Sweden), Stefan James (Sweden), Kamlesh Khunti (United Kingdom),
Society of Cardiology and Cardiovascular Surgery, Fathia Mghaieth;
Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Basil
Türkiye: Turkish Society of Cardiology, Baris Gungor; Ukraine:
S. Lewis (Israel), Maja-Lisa Løchen (Norway), John William McEvoy
Ukrainian Association of Cardiology, Olena Mitchenko; United
(Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham
Kingdom of Great Britain and Northern Ireland: British
(United Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis
Cardiovascular Society, Stephen Wheatcroft; and Uzbekistan: Nielsen (Denmark), Gianfranco Parati (Italy), Agnes A. Pasquet
Association of Cardiologists of Uzbekistan, Raisa Trigulova.
(Belgium), Carlo Patrono (Italy), Steffen E. Petersen (United Kingdom),
Massimo F. Piepoli (Italy), Amina Rakisheva (Kazakhstan), Xavier ESC Clinical Practice Guidelines (CPG) Committee: Eva
Rossello (Spain), Peter Rossing (Denmark), Lars Ryden (Sweden), Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson)
Eberard Standl (Germany), Lale Tokgozoglu (Türkiye), Rhian M. Touyz (Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom),
(Canada/United Kingdom), Frank Visseren (Netherlands), Massimo Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja
Volpe (Italy), Christiaan Vrints (Belgium), and Adam Witkowski (Poland). Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova
ESC National Cardiac Societies actively involved in the review
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck
process of the 2023 ESC Guidelines for the management of cardiovas-
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes
cular disease in patients with diabetes: Armenia: Armenian
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca
Cardiologists Association, Lusine Hazarapetyan; Austria: Austrian
(Italy), Xavier Rosselló (Spain), Ilonca Vaartjes (Netherlands),
Society of Cardiology, Andreas Zirlik; Azerbaijan: Azerbaijan
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja
Society of Cardiology, Yasmin Rustamova; Belgium: Belgian Society
Zeppenfeld (Netherlands).
of Cardiology, Philippe van de Borne; Bosnia and Herzegovina:
Association of Cardiologists of Bosnia and Herzegovina, Šekib
23. Acknowledgements
Sokolović; Bulgaria: Bulgarian Society of Cardiology, Nina
Gotcheva; Croatia: Croatian Cardiac Society, Davor Milicic; The Task Force Chairs thank Marlo Verket for her support in the
Cyprus: Cyprus Society of Cardiology, Petros Agathangelou; co-ordination of this document.
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4119
24. References on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care
2010;33:676–682. 
1.Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. 23.Harreiter J, Fadl H, Kautzky-Willer A, Simmons D. Do women with diabetes need
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the more intensive action for cardiovascular reduction than men with diabetes? Curr
American Diabetes Association (ADA) and the European Association for the Study Diab Rep 2020;20:61. 
of Diabetes (EASD). Diabetologia 2022;65:1925–1966.  24.Vounzoulaki E, Khunti K, Abner SC, Tan BK, Davies MJ, Gillies CL. Progression to type
s00125-022-05787-2 2 diabetes in women with a known history of gestational diabetes: systematic review
2.Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF and meta-analysis. BMJ 2020;369:m1361. 
Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 25.Lowe WL, Scholtens DM, Lowe LP, Kuang A, Nodzenski M, Talbot O, et al.
2021 and projections for 2045. Diabetes Res Clin Pract 2022;183:109119.  Association of gestational diabetes with maternal disorders of glucose metabolism
org/10.1016/j.diabres.2021.109119 and childhood adiposity. JAMA 2018;320:1005–1016. 
3.Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes 2018.11628
in adults. Diabetes Res Clin Pract 2014;103:150–160.  26.Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovas-
2013.11.001 cular disease in women: a systematic review and meta-analysis. Diabetologia 2019;62:
4.International Expert Committee. International Expert Committee report on the role 905–914. 
of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327–1334. 27.Tobias DK, Stuart JJ, Li S, Chavarro J, Rimm EB, Rich-Edwards J, et al. Association of
 history of gestational diabetes with long-term cardiovascular disease risk in a large pro-
5.World Health Organization. Classification of Diabetes Mellitus 2019. Geneva, spective cohort of US women. JAMA Intern Med 2017;177:1735–1742. 
Switzerland, 1–36. 10.1001/jamainternmed.2017.2790
6.WHO Guidelines Approved by the Guidelines Review Committee. Use of glycated 28.McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P. Gestational
Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a diabetes mellitus. Nat Rev Dis Primers 2019;5:47. 
WHO Consultation. Geneva, Switzerland, 2011.
019-0098-8
7.American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care
29.Daly B, Toulis KA, Thomas N, Gokhale K, Martin J, Webber J, et al. Increased risk of
2021;44(Suppl 1):S15–S33. 
ischemic heart disease, hypertension, and type 2 diabetes in women with previous ges-
8.Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of
tational diabetes mellitus, a target group in general practice for preventive interven-
the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes
tions: a population-based cohort study. PLoS Med 2018;15:e1002488. 
Care 2003;26:S5–S20. 
org/10.1371/journal.pmed.1002488
9.Pareek M, Bhatt DL, Nielsen ML, Jagannathan R, Eriksson K-F, Nilsson PM, et al.
30.O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, De Lemos JA, et al. 2013
Enhanced predictive capability of a 1-hour oral glucose tolerance test: a prospective
ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a re-
population-based cohort study. Diabetes Care 2018;41:171–177. 
port of the American College of Cardiology Foundation/American Heart Association
2337/dc17-1351
Task Force on Practice Guidelines. J Am College Cardiol 2013;61:e78–e140. 
10.Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS, et al. Prevalence of
diabetes and high risk for diabetes using A1C criteria in the US population in 1988– org/10.1016/j.jacc.2012.11.019
2006. Diabetes Care 2010;33:562–568.  31.Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC
11.Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and man- Guidelines for the management of acute coronary syndromes in patients presenting
agement of youth-onset type 2 diabetes: a position statement by the American without persistent ST-segment elevation: Task Force for the management of acute
Diabetes Association. Diabetes Care 2018;41:2648–2668.  coronary syndromes in patients presenting without persistent ST-segment elevation
dci18-0052 of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267–315. https://
12.Krhač M, Lovrenčić MV. Update on biomarkers of glycemic control. World J Diabetes doi.org/10.1093/eurheartj/ehv320
2019;10:1–15.  32.Zhou M, Liu J, Hao Y, Liu J, Huo Y, Smith SC, et al. Prevalence and in-hospital outcomes
13.Holt RI, DeVries JH, Hess-Fischl A, Hirsch IB, Kirkman MS, Klupa T, et al. The manage- of diabetes among patients with acute coronary syndrome in China: findings from the
ment of type 1 diabetes in adults. A consensus report by the American Diabetes Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome
Association (ADA) and the European Association for the Study of Diabetes Project. Cardiovasc Diabetol 2018;17:147. 
(EASD). Diabetes Care 2021;44:2589–2625.  33.Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 diabetes
14.Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, Kaptoge S, et al. mellitus and heart failure: a scientific statement from the American Heart Association
Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA and the Heart Failure Society of America: this statement does not represent an update
2014;311:1225–1233.  of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation 2019;140:
15.Foteinopoulou E, Clarke CA, Pattenden RJ, Ritchie SA, McMurray EM, Reynolds RM, e294–e324. 
et al. Impact of routine clinic measurement of serum C-peptide in people with a 34.Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, Mellbin L, et al. Patients
clinician-diagnosis of type 1 diabetes. Diabet Med 2021;38:e14449.  with coronary artery disease and diabetes need improved management: a report from
1111/dme.14449 the EUROASPIRE IV survey: a registry from the EuroObservational Research
16.Kietsiriroje N, Pearson S, Campbell M, Ariëns RA, Ajjan RA. Double diabetes: a distinct Programme of the European Society of Cardiology. Cardiovasc Diabetol 2015;14:
high-risk group? Diabetes Obes Metab 2019;21:2609–2618.  133. 
dom.13848
35.Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of
17.Riddle MC, Philipson LH, Rich SS, Carlsson A, Franks PW, Greeley SAW, et al.
glycemia and implications for the classification of diabetes. Arch Intern Med 2007;167:
Monogenic diabetes: from genetic insights to population-based precision in care.
1545–1551. 
Reflections from a diabetes care editors’ expert forum. Diabetes Care 2020;43:
36.Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K, et al. Glycemic
3117–3128. 
thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for dia-
18.Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM,
betes. Diabetes Care 2011;34:145–150. 
et al. Management of hyperglycemia in hospitalized patients in non-critical care setting:
37.Preiss D, Sattar N. Diabetic microvascular complications as simple indicators of risk for
an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012;97:16–38.
cardiovascular outcomes and heart failure. Lancet Diabetes Endocrinol 2016;4:555–556.

19.Bellis A, Mauro C, Barbato E, Ceriello A, Cittadini A, Morisco C. Stress-induced hyper-
38.Tabák AG, Brunner EJ, Lindbohm JV, Singh-Manoux A, Shipley MJ, Sattar N, et al. Risk of
glycaemia in non-diabetic patients with acute coronary syndrome: from molecular me-
macrovascular and microvascular disease in diabetes diagnosed using oral glucose tol-
chanisms to new therapeutic perspectives. Int J Mol Sci 2021;22:775. 
3390/ijms22020775 erance test with and without confirmation by hemoglobin A1c: the Whitehall II cohort
20.Norhammar A, Tenerz Å, Nilsson G, Hamsten A, Efendíc S, Rydén L, et al. Glucose study. Circulation 2022;146:995–1005. 
metabolism in patients with acute myocardial infarction and no previous diagnosis 122.059430
of diabetes mellitus: a prospective study. Lancet 2002;359:2140–2144.  39.Mak K-H, Vidal-Petiot E, Young R, Sorbets E, Greenlaw N, Ford I, et al. Prevalence of
org/10.1016/S0140-6736(02)09089-X diabetes and impact on cardiovascular events and mortality in patients with chronic
21.Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, et al. The prevalence coronary syndromes, across multiple geographical regions and ethnicities. Eur J Prev
of abnormal glucose regulation in patients with coronary artery disease across Europe: Cardiol 2021;28:1795–1806. 
the Euro Heart Survey on diabetes and the heart. Eur Heart J 2004;25:1880–1890. 40.Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes
 mellitus, fasting blood glucose concentration, and risk of vascular disease: a collabora-
22.International Association of Diabetes Pregnancy Study Groups Consensus Panel. tive meta-analysis of 102 prospective studies. Lancet 2010;375:2215–2222. 
International association of diabetes and pregnancy study groups recommendations org/10.1016/S0140-6736(10)60484-9
Downloaded
from

by
guest
on
22
January
2026

4120 E S C G u id e l in e s
41.Chan JC, Lim L-L, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, et al. The Lancet 60.Wills AC, Arreola EV, Olaiya MT, Curtis JM, Hellgren MI, Hanson RL, et al.
Commission on diabetes: using data to transform diabetes care and patient lives. Cardiorespiratory fitness, BMI, mortality, and cardiovascular disease in adults with
Lancet 2020;396:2019–2082.  overweight/obesity and type 2 diabetes. Med Sci Sports Exerc 2022;54:994–1001.
42.Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N, et al. 
Association of cardiometabolic multimorbidity with mortality. JAMA 2015;314:52–60. 61.Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary
 care-led weight management for remission of type 2 diabetes (DiRECT): an open-
43.Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJL, et al. label, cluster-randomised trial. Lancet 2018;391:541–551. 
Associations of kidney disease measures with mortality and end-stage renal disease S0140-6736(17)33102-1
in individuals with and without diabetes: a meta-analysis. Lancet 2012;380: 62.Karjalainen JJ, Kiviniemi AM, Hautala AJ, Piira O-P, Lepojärvi ES, Perkiömäki JS, et al.
1662–1673.  Effects of physical activity and exercise training on cardiovascular risk in coronary ar-
44.Brownrigg JR, Hughes CO, Burleigh D, Karthikesalingam A, Patterson BO, Holt PJ, et al. tery disease patients with and without type 2 diabetes. Diabetes Care 2015;38:
Microvascular disease and risk of cardiovascular events among individuals with type 2 706–715. 
diabetes: a population-level cohort study. Lancet Diabetes Endocrinol 2016;4:588–597. 63.Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC
 Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collab-
45.Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. oration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular
KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney dis- diseases of the European Society of Cardiology (ESC) and the European Association
ease. Kidney Int 2022;102(Suppl 5S):S1–S127.  for the Study of Diabetes (EASD). Eur Heart J 2020;41:255–323. 
008 1093/eurheartj/ehz486
46.Kengne AP, Patel A, Marre M, Travert F, Lievre M, Zoungas S, et al. Contemporary mod- 64.Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss interven-
el for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc tion outcomes in overweight and obese adults with type 2 diabetes: a systematic re-
Prevent Rehabil 2011;18:393–398.  view and meta-analysis of randomized clinical trials. J Acad Nutr Diet 2015;115:
47.Berkelmans GF, Gudbjörnsdottir S, Visseren FL, Wild SH, Franzen S, Chalmers J, et al. 1447–1463. 
Prediction of individual life-years gained without cardiovascular events from lipid, 65.Galaviz KI, Weber MB, Straus A, Haw JS, Narayan KV, Ali MK. Global diabetes preven-
blood pressure, glucose, and aspirin treatment based on data of more than 500 000 tion interventions: a systematic review and network meta-analysis of the real-world
patients with type 2 diabetes mellitus. Eur Heart J 2019;40:2899–2906.  impact on incidence, weight, and glucose. Diabetes Care 2018;41:1526–1534. https://
doi.org/10.2337/dc17-2222
org/10.1093/eurheartj/ehy839
48.Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC 66.Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, et al. Effects of
weight-loss medications on cardiometabolic risk profiles: a systematic review and net-
Guidelines on cardiovascular disease prevention in clinical practice: developed by the
work meta-analysis. Gastroenterology 2018;154:1309–1319.e7. 
Task Force for cardiovascular disease prevention in clinical practice with representa-
1053/j.gastro.2017.12.024
tives of the European Society of Cardiology and 12 medical societies With the special
67.Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose co-
contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart
transporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) recep-
J 2021;42:3227–3337. 
tor agonists for type 2 diabetes: systematic review and network meta-analysis of
49.SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk
randomised controlled trials. BMJ 2021;372:m4573. 
prediction algorithms: new models to estimate 10-year risk of cardiovascular dis-
m4573
ease in Europe. Eur Heart J 2021;42:2439–2454. 
68.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al.
ehab309
Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:
50.SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration.
205–216. 
SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in
69.Lundgren JR, Janus C, Jensen SB, Juhl CR, Olsen LM, Christensen RM, et al. Healthy
Europe. Eur Heart J 2023;44:2544–2556. 
weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med
51.SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP
2021;384:1719–1730. 
risk prediction algorithms: estimating incident cardiovascular event risk in older per-
70.Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al.
sons in four geographical risk regions. Eur Heart J 2021;42:2455–2467. 
Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:
org/10.1093/eurheartj/ehab312
311–322. 
52.Østergaard HB, Hageman SHJ, Read SH, Taylor O, Pennells L, Kaptoge S, et al.
71.Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin,
Estimating individual lifetime risk of incident cardiovascular events in adults with
cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:
type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime per-
2117–2128. 
spective model (DIAL2). Eur J Prev Cardiol 2023;30:61–69. 
72.Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide
eurjpc/zwac232
and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;
53.Ling J, Koye D, Buizen L, Khunti K, Montvida O, Paul SK. Temporal trends in co- 375:1834–1844. 
morbidities and cardiometabolic risk factors at the time of type 2 diabetes diagnosis
73.Ikramuddin S, Korner J, Lee W-J, Thomas AJ, Connett JE, Bantle JP, et al. Lifestyle inter-
in the UK. Diabetes Obes Metab 2021;23:1150–1161.  vention and medical management with vs without Roux-en-Y gastric bypass and con-
14323 trol of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the
54.Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes diabetes surgery study. JAMA 2018;319:266–278. 
on cardiovascular disease risk and all-cause mortality in older men: influence of age at 20813
onset, diabetes duration, and established and novel risk factors. Arch Intern Med 2011; 74.Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial–a
171:404–410.  prospective controlled intervention study of bariatric surgery. J Intern Med 2013;273:
55.Nelson AJ, Peterson ED, Pagidipati NJ. Atherosclerotic cardiovascular disease and 219–234. 
heart failure: determinants of risk and outcomes in patients with diabetes. Progr 75.Carlsson LM, Sjöholm K, Jacobson P, Andersson-Assarsson JC, Svensson P-A, Taube
Cardiovasc Dis 2019;62:306–314.  M, et al. Life expectancy after bariatric surgery in the Swedish obese subjects study.
56.Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular ef- N Engl J Med 2020;383:1535–1543. 
fects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369: 76.Syn NL, Cummings DE, Wang LZ, Lin DJ, Zhao JJ, Loh M, et al. Association of meta-
145–154.  bolic–bariatric surgery with long-term survival in adults with and without diabetes: a
57.Look AHEAD Research Group. Effect of a long-term behavioural weight loss interven- one-stage meta-analysis of matched cohort and prospective controlled studies with
tion on nephropathy in overweight or obese adults with type 2 diabetes: a secondary 174 772 participants. Lancet 2021;397:1830–1841. 
analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2014; 6736(21)00591-2
2:801–809.  77.Doumouras AG, Wong JA, Paterson JM, Lee Y, Sivapathasundaram B, Tarride J-E, et al.
58.Look AHEAD Research Group. Effects of intensive lifestyle intervention on all-cause Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovas-
mortality in older adults with type 2 diabetes and overweight/obesity: results from the cular disease: a population-based retrospective cohort study. Circulation 2021;143:
Look AHEAD Study. Diabetes Care 2022;45:1252–1259.  1468–1480. 
1805 78.Liakopoulos V, Franzén S, Svensson A-M, Miftaraj M, Ottosson J, Näslund I, et al. Pros
59.Patel KV, Bahnson JL, Gaussoin SA, Johnson KC, Pi-Sunyer X, White U, et al. and cons of gastric bypass surgery in individuals with obesity and type 2 diabetes: na-
Association of baseline and longitudinal changes in body composition measures with tionwide, matched, observational cohort study. BMJ Open 2019;9:e023882. 
risk of heart failure and myocardial infarction in type 2 diabetes: findings from the org/10.1136/bmjopen-2018-023882
Look AHEAD Trial. Circulation 2020;142:2420–2430.  79.Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Durability
CIRCULATIONAHA.120.050941 of a primary care-led weight-management intervention for remission of type 2
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4121
diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet aged≥ 60 years: a systematic review and meta-analysis. Br J Sports Med 2015;49:
Diabetes Endocrinol 2019;7:344–355.  1262–1267. 
80.Bloomfield HE, Koeller E, Greer N, MacDonald R, Kane R, Wilt TJ. Effects on health 101. Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, et al. Effects of
outcomes of a Mediterranean diet with no restriction on fat intake: a systematic review aerobic and resistance training on hemoglobin A1c levels in patients with type 2 dia-
and meta-analysis. Ann Intern Med 2016;165:491–500.  betes: a randomized controlled trial. JAMA 2010;304:2253–2262. 
0361 1001/jama.2010.1710
81.Sacks FM, Lichtenstein AH, Wu JH, Appel LJ, Creager MA, Kris-Etherton PM, et al. 102. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines
Dietary fats and cardiovascular disease: a presidential advisory from the American on sports cardiology and exercise in patients with cardiovascular disease: the Task
Heart Association. Circulation 2017;136:e1–e23.  Force on sports cardiology and exercise in patients with cardiovascular disease of
0000000000000510 the European Society of Cardiology (ESC). Eur Heart J 2021;42:17–96. 
82.Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, et al. Primary preven- org/10.1093/eurheartj/ehaa605
tion of cardiovascular disease with a Mediterranean diet supplemented with extra- 103. Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical
virgin olive oil or nuts. N Engl J Med 2018;378:e34.  activity/exercise and diabetes: a position statement of the American Diabetes
NEJMoa1800389 Association. Diabetes Care 2016;39:2065–2079. 
83.Qian F, Liu G, Hu FB, Bhupathiraju SN, Sun Q. Association between plant-based diet- 104. Ambrosetti M, Abreu A, Corrà U, Davos CH, Hansen D, Frederix I, et al. Secondary
ary patterns and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA prevention through comprehensive cardiovascular rehabilitation: from knowledge to
Intern Med 2019;179:1335–1344.  implementation. 2020 update. A position paper from the Secondary Prevention and
84.Willett W, Rockström J, Loken B, Springmann M, Lang T, Vermeulen S, et al. Food in Rehabilitation Section of the European Association of Preventive Cardiology. Eur J
the Anthropocene: the EAT–Lancet Commission on healthy diets from sustainable Prev Cardiol 2021;28:460–495. 
food systems. Lancet 2019;393:447–492.  105. Karstoft K, Winding K, Knudsen SH, Nielsen JS, Thomsen C, Pedersen BK, et al. The
31788-4 effects of free-living interval-walking training on glycemic control, body composition,
85.Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, Quintana-Navarro GM, Fuentes F, and physical fitness in type 2 diabetic patients: a randomized, controlled trial.
Garcia-Rios A, et al. Long-term secondary prevention of cardiovascular disease with Diabetes Care 2013;36:228–236. 
a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled 106. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee I-M, et al.
trial. Lancet 2022;399:1876–1885.  American College of Sports Medicine position stand. Quantity and quality of exercise
86.Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, et al. n–3 Fatty acids and for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor
cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367: fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports
309–318.  Exerc 2011;43:1334–1359. 
87.ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes 107. Hansen D, Abreu A, Ambrosetti M, Cornelissen V, Gevaert A, Kemps H, et al. Exercise
mellitus. N Engl J Med 2018;379:1540–1550.  intensity assessment and prescription in cardiovascular rehabilitation and beyond: why
88.Malik VS, Li Y, Pan A, De Koning L, Schernhammer E, Willett WC, et al. Long-term and how: a position statement from the Secondary Prevention and Rehabilitation
consumption of sugar-sweetened and artificially sweetened beverages and risk of mor- Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol
tality in US adults. Circulation 2019;139:2113–2125.  2022;29:230–245. 
CIRCULATIONAHA.118.037401 108. Kemps H, Kränkel N, Dörr M, Moholdt T, Wilhelm M, Paneni F, et al. Exercise training
89.Mullee A, Romaguera D, Pearson-Stuttard J, Viallon V, Stepien M, Freisling H, et al. for patients with type 2 diabetes and cardiovascular disease: what to pursue and how to
Association between soft drink consumption and mortality in 10 European countries. do it. A Position Paper of the European Association of Preventive Cardiology (EAPC).
JAMA Intern Med 2019;179:1479–1490.  Eur J Prev Cardiol 2019;26:709–727. 
2478 109. Scherr J, Wolfarth B, Christle JW, Pressler A, Wagenpfeil S, Halle M. Associations be-
90.Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, et al. Risk tween Borg’s rating of perceived exertion and physiological measures of exercise inten-
thresholds for alcohol consumption: combined analysis of individual-participant data sity. Eur J Appl Physiol 2013;113:147–155. 
for 599 912 current drinkers in 83 prospective studies. Lancet 2018;391: 110. Kraus WE, Powell KE, Haskell WL, Janz KF, Campbell WW, Jakicic JM, et al. Physical
1513–1523.  activity, all-cause and cardiovascular mortality, and cardiovascular disease. Med Sci
91.Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, et al. Conventional and gen- Sports Exerc 2019;51:1270. 
etic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 111. Jakicic JM, Kraus WE, Powell KE, Campbell WW, Janz KF, Troiano RP, et al. Association
men and women in China. Lancet 2019;393:1831–1842.  between bout duration of physical activity and health: systematic review. Med Sci Sports
S0140-6736(18)31772-0 Exerc 2019;51:1213. 
92.Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. Association be- 112. Cradock KA, ÓLaighin G, Finucane FM, Gainforth HL, Quinlan LR, Ginis KAM.
tween alcohol and cardiovascular disease: Mendelian randomisation analysis based Behaviour change techniques targeting both diet and physical activity in type 2 dia-
on individual participant data. BMJ 2014;349:g4164.  betes: a systematic review and meta-analysis. Int J Behav Nutr Phys Act 2017;14:18.
93.Evangelista LS, Jose MM, Sallam H, Serag H, Golovko G, Khanipov K, et al. High-protein 
vs. standard-protein diets in overweight and obese patients with heart failure and dia- 113. Howlett N, Trivedi D, Troop NA, Chater AM. Are physical activity interventions for
betes mellitus: findings of the Pro-HEART trial. ESC Heart Fail 2021;8:1342–1348. healthy inactive adults effective in promoting behavior change and maintenance, and
 which behavior change techniques are effective? A systematic review and
94.Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition meta-analysis. Transl Behav Med 2019;9:147–157. 
therapy recommendations for the management of adults with diabetes. Diabetes Care 114. Brickwood K-J, Watson G, O’Brien J, Williams AD. Consumer-based wearable activity
2014;37(Suppl 1):S120–S143.  trackers increase physical activity participation: systematic review and meta-analysis.
95.He FJ, Tan M, Ma Y, MacGregor GA. Salt reduction to prevent hypertension and car- JMIR mHealth uHealth 2019;7:e11819. 
diovascular disease: JACC state-of-the-art review. J Am College Cardiol 2020;75: 115. Mannucci E, Bonifazi A, Monami M. Comparison between different types of exercise
632–647.  training in patients with type 2 diabetes mellitus: a systematic review and network me-
96.Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. Effect of salt substitution on car- tanalysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 2021;31:
diovascular events and death. N Engl J Med 2021;385:1067–1077.  1985–1992. 
1056/NEJMoa2105675 116. Murray EM, Whellan DJ, Chen H, Bertoni AG, Duncan P, Pastva AM, et al. Physical re-
97.Sluik D, Buijsse B, Muckelbauer R, Kaaks R, Teucher B, Tj A, et al. Physical activity and habilitation in older patients hospitalized with acute heart failure and diabetes: insights
mortality in individuals with diabetes mellitus: a prospective study and meta-analysis. from REHAB-HF. Am J Med 2022;135:82–90. 
Arch Intern Med 2012;172:1285–1295.  08.001
3130 117. Yang Z, Scott CA, Mao C, Tang J, Farmer AJ. Resistance exercise versus aerobic exer-
98.Wahid A, Manek N, Nichols M, Kelly P, Foster C, Webster P, et al. Quantifying the cise for type 2 diabetes: a systematic review and meta-analysis. Sports Med 2014;44:
association between physical activity and cardiovascular disease and diabetes: a sys- 487–499. 
tematic review and meta-analysis. J Am Heart Assoc 2016;5:e002495.  118. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in
10.1161/JAHA.115.002495 patients with coronary heart disease: a systematic review. JAMA 2003;290:86–97.
99.Arem H, Moore SC, Patel A, Hartge P, De Gonzalez AB, Visvanathan K, et al. Leisure time 
physical activity and mortality: a detailed pooled analysis of the dose-response relationship. 119. Choi JW, Han E, Kim TH. Association of smoking cessation after new-onset type 2 dia-
JAMA Intern Med 2015;175:959–967.  betes with overall and cause-specific mortality among Korean men: a nationwide
100. Hupin D, Roche F, Gremeaux V, Chatard J-C, Oriol M, Gaspoz J-M, et al. Even a low- population-based cohort study. BMJ Open Diabetes Res Care 2020;8:e001249.
dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults 
Downloaded
from

by
guest
on
22
January
2026

4122 E S C G u id e l in e s
120. Kim MK, Han K, Kim B, Kim J, Kwon H-S. Effects of exercise initiation and smoking ces- patients with coronary artery disease: a report from EUROASPIRE IV: a survey
sation after new-onset type 2 diabetes mellitus on risk of mortality and cardiovascular from the European Society of Cardiology. Diabetes Care 2017;40:1233–1240.
outcomes. Sci Rep 2022;12:1–9.  
121. Jennings C, Kotseva K, De Bacquer D, Hoes A, de Velasco J, Brusaferro S, et al. 142. Hanssen NM, Kraakman MJ, Flynn MC, Nagareddy PR, Schalkwijk CG, Murphy AJ.
Effectiveness of a preventive cardiology programme for high CVD risk persistent smo- Postprandial glucose spikes, an important contributor to cardiovascular disease in dia-
kers: the EUROACTION PLUS varenicline trial. Eur Heart J 2014;35:1411–1420. betes? Front Cardiovasc Med 2020;7:570553. 
 570553
122. Suissa K, Larivière J, Eisenberg MJ, Eberg M, Gore GC, Grad R, et al. Efficacy and safety 143. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, et al. Effects of prandial
of smoking cessation interventions in patients with cardiovascular disease: a network versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D
meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2017;10: trial. Diabetes Care 2009;32:381–386. 
e002458.  144. Kosiborod M. Hyperglycemia in acute coronary syndromes: from mechanisms to
123. Gotts JE, Jordt S-E, McConnell R, Tarran R. What are the respiratory effects of prognostic implications. Endocrinol Metab Clin North Am 2018;47:185–202. https://
e-cigarettes? BMJ 2019;366:l5275. 
doi.org/10.1016/j.ecl.2017.11.002
124. Skotsimara G, Antonopoulos AS, Oikonomou E, Siasos G, Ioakeimidis N, Tsalamandris
145. Malmberg K, Ryden L, Hamstent A, Herlitz J, Waldenström A, Wedel H. Effects of in-
S, et al. Cardiovascular effects of electronic cigarettes: a systematic review and
sulin treatment on cause-specific one-year mortality and morbidity in diabetic patients
meta-analysis. Eur J Prev Cardiol 2019;26:1219–1228. 
with acute myocardial infarction. Eur Heart J 1996;17:1337–1344. 
2047487319832975
1093/oxfordjournals.eurheartj.a015067
125. Franck C, Filion KB, Eisenberg MJ. Smoking cessation in patients with acute coronary
146. Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense
syndrome. Am J Cardiol 2018;121:1105–1111. 
metabolic control by means of insulin in patients with diabetes mellitus and acute myo-
01.017
cardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:
126. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of in-
650–661. 
tensive treatment of diabetes on the development and progression of long-term com-
147. Caturano A, Galiero R, Pafundi PC, Cesaro A, Vetrano E, Palmiero G, et al. Does a
plications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.
strict glycemic control during acute coronary syndrome play a cardioprotective effect?

Pathophysiology and clinical evidence. Diabetes Res Clin Practice 2021;178:108959.
127. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulpho-
nylureas or insulin compared with conventional treatment and risk of complications in 
patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.  148. Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson A-M, Miftaraj M, et al.
10.1016/S0140-6736(98)07019-6 Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med
128. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood 2017;376:1407–1418. 
glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 149. Stancoven A, McGuire DK. Preventing macrovascular complications in type 2 diabetes
2008;358:2560–2572.  mellitus: glucose control and beyond. Am J Cardiol 2007;99:S5–S11. 
129. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of inten- 1016/j.amjcard.2007.04.005
sive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an 150. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in
analysis of the ACCORD randomised trial. Lancet 2010;376:419–430.  patients with diabetes and chronic kidney disease. N Engl J Med 2021;384:129–139.
org/10.1016/S0140-6736(10)60576-4 
130. Nathan DM, DCCT/EDIC Research Group. The diabetes control and complications 151. Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al.
trial/epidemiology of diabetes interventions and complications study at 30 years: over- Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med
view. Diabetes Care 2014;37:9–16.  2017;377:644–657. 
131. Writing Group for the DCCT/EDIC Research Group. Coprogression of cardiovascu- 152. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and
lar risk factors in type 1 diabetes during 30 years of follow-up in the DCCT/EDIC cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–357. https://
study. Diabetes Care 2016;39:1621–1630.  doi.org/10.1056/NEJMoa1812389
132. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of in- 153. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al.
tensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–1589. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med
 2019;380:2295–2306. 
133. Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects 154. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al.
of intensive glucose control on microvascular outcomes in patients with type 2 dia- Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020;
betes: a meta-analysis of individual participant data from randomised controlled trials. 383:1425–1435. 
Lancet Diabetes Endocrinol 2017;5:431–437.  155. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZ, Dagogo-Jack S, et al.
30104-3 Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients
134. Turnbull F, Abraira C, Anderson R, Byington R, Chalmers J, Duckworth W, et al. with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021;6:148–158. 
Intensive glucose control and macrovascular outcomes in type 2 diabetes. 1001/jamacardio.2020.4511
Diabetologia 2009;52:2288–2298.  156. Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL, et al. 2018 ACC
135. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function expert consensus decision pathway on novel therapies for cardiovascular risk reduc-
of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;
tion in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a re-
375:481–489. 
port of the American College of Cardiology Task Force on Expert Consensus Decision
136. Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper M, Colagiuri S, et al. Association of
Pathways. J Am College Cardiol 2018;72:3200–3223. 
HbA1c levels with vascular complications and death in patients with type 2 diabetes:
09.020
evidence of glycaemic thresholds. Diabetologia 2012;55:636–643. 
157. American Diabetes Association Professional Practice Committee. 10. Cardiovascular
1007/s00125-011-2404-1
Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes
137. International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and
Care 2022;45(Suppl 1):S144–S174. 
mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes
158. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide
Endocrinol 2019;7:385–396. 
in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:
138. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets
2247–2257. 
for continuous glucose monitoring data interpretation: recommendations from the
159. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects
international consensus on time in range. Diabetes Care 2019;42:1593–1603. https://
doi.org/10.2337/dci19-0028 of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med
139. Standl E, Stevens SR, Armstrong PW, Buse JB, Chan JC, Green JB, et al. Increased risk of 2017;377:1228–1239. 
severe hypoglycemic events before and after cardiovascular outcomes in TECOS sug- 160. Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP,
gests an at-risk type 2 diabetes frail patient phenotype. Diabetes Care 2018;41: et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and
596–603.  cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-
140. Standl E, Stevens SR, Lokhnygina Y, Bethel MA, Buse JB, Gustavson SM, et al. controlled trial. Lancet 2018;392:1519–1529. 
Confirming the bidirectional nature of the association between severe hypoglycemic 6736(18)32261-X
and cardiovascular events in type 2 diabetes: insights from EXSCEL. Diabetes Care 161. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al.
2020;43:643–652.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-
141. Shahim B, De Bacquer D, De Backer G, Gyberg V, Kotseva K, Mellbin L, et al. The prog- blind, randomised placebo-controlled trial. Lancet 2019;394:121–130. 
nostic value of fasting plasma glucose, two-hour postload glucose, and HbA1c in org/10.1016/S0140-6736(19)31149-3
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4123
162. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. 182. Gore MO, McGuire DK. Resolving drug effects from class effects among drugs for type
Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J 2 diabetes mellitus: more support for cardiovascular outcome assessments. Eur Heart J
Med 2019;381:841–851.  2011;32:1832–1834. 
163. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, 183. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with
et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
Engl J Med 2021;385:896–907.  Lancet 1998;352:854–865. 
164. Sattar N, Lee MM, Kristensen SL, Branch KR, Del Prato S, Khurmi NS, et al. 184. Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in pa- meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia
tients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. 2017;60:1620–1629. 
Lancet Diabetes Endocrinol 2021;9:653–662.  185. Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and car-
00203-5 diovascular mortality in patients with coronary artery diseases: a systematic review and
165. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, an updated meta-analysis. Cardiovasc Diabetol 2019;18:1–16. 
et al. Secondary prevention of macrovascular events in patients with type 2 diabetes s12933-019-0900-7
in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular 186. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality
Events): a randomised controlled trial. Lancet 2005;366:1279–1289.  and cardiovascular risk associated with different insulin secretagogues compared with
10.1016/S0140-6736(05)67528-9 metformin in type 2 diabetes, with or without a previous myocardial infarction: a na-
166. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular tionwide study. Eur Heart J 2011;32:1900–1908. 
events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. ehr077
JAMA 2007;298:1180–1188.  187. Mellbin LG, Rydén L, Riddle MC, Probstfield J, Rosenstock J, Díaz R, et al. Does hypo-
167. Zhou Y, Huang Y, Ji X, Wang X, Shen L, Wang Y. Pioglitazone for the primary and sec- glycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial.
ondary prevention of cardiovascular and renal outcomes in patients with or at high risk Eur Heart J 2013;34:3137–3144. 
of type 2 diabetes mellitus: a meta-analysis. J Clin Endocrinol Metab 2020;105: 188. ORIGIN Trial Investigators. Predictors of nonsevere and severe hypoglycemia during
1670–1681.  glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial.
168. de Jong M, van der Worp HB, van der Graaf Y, Visseren FL, Westerink J. Pioglitazone Diabetes Care 2015;38:22–28. 
189. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in
and the secondary prevention of cardiovascular disease. A meta-analysis of
patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:
randomized-controlled trials. Cardiovasc Diabetol 2017;16:134. 
117–128. 
1186/s12933-017-0617-4
190. Tuttle KR, Brosius FC III, Cavender MA, Fioretto P, Fowler KJ, Heerspink HJ, et al.
169. Lin M-H, Yang H-Y, Yen C-L, Wu C-Y, Jenq C-C, Kuo G, et al. Pioglitazone is associated
SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a
with lower major adverse cardiovascular and cerebrovascular events than
scientific workshop sponsored by the National Kidney Foundation. Diabetes 2021;
DPP4-inhibitors in diabetic patients with end-stage renal disease: a Taiwan
70:1–16. 
Nationwide Cohort Study, 2006–2016. J Clin Med 2020;9:3578. 
191. Ferrannini G, De Bacquer D, Vynckier P, De Backer G, Gyberg V, Kotseva K, et al.
3390/jcm9113578
Gender differences in screening for glucose perturbations, cardiovascular risk factor
170. Rydén L, Thráinsdóttir I, Swedberg K. Adjudication of serious heart failure in patients
management and prognosis in patients with dysglycaemia and coronary artery disease:
from PROactive. Lancet 2007;369:189–190. 
results from the ESC-EORP EUROASPIRE surveys. Cardiovasc Diabetol 2021;20:1–12.
60106-8

171. McGuire DK, Abdullah SM, See R, Snell PG, McGavock J, Szczepaniak LS, et al.
192. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020
Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated
International Society of Hypertension global hypertension practice guidelines.
cardiovascular performance, cardiac structure, and function. Eur Heart J 2010;31:
Hypertension 2020;75:1334–1357. 
2262–70. 
120.15026
172. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin
193. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/
and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med
ESH Guidelines for the management of arterial hypertension: the Task Force for the
2013;369:1317–1326. 
management of arterial hypertension of the European Society of Cardiology (ESC) and
173. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al.
the European Society of Hypertension (ESH). Eur Heart J 2018;39:3021–3104. https://
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J
doi.org/10.1093/eurheartj/ehy339
Med 2013;369:1327–1335. 
194. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with
174. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin
type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and
on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232–242.
Bayesian random-effects meta-analyses of randomized trials. Circulation 2011;123:

2799–2810. 
175. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of 195. Grenet G, Le H, Bejan-Angoulvant T, Erpeldinger S, Boussageon R, Kassaï B, et al.
linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and
Association between difference in blood pressure reduction and risk of cardiovascular
high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA
events in a type 2 diabetes population: a meta-regression analysis. Diabetes Metab
2019;321:69–79.  2019;45:550–556. 
176. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart fail- 196. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering
ure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 rando- in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015;313:603–615.
mized trial. Circulation 2014;130:1579–1588.  
CIRCULATIONAHA.114.010389 197. Arima H, Anderson C, Omae T, Woodward M, MacMahon S, Mancia G, et al. Degree
177. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart fail- of blood pressure reduction and recurrent stroke: the PROGRESS trial. J Neurol
ure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus Neurosurg Psychiatry 2014;85:1284–1285. 
placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015; 198. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al. Safety and efficacy of
385:2067–2076.  low blood pressures among patients with diabetes: subgroup analyses from the
178. McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, et al. ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global
Association between sitagliptin use and heart failure hospitalization and related out- Endpoint Trial). J Am College Cardiol 2012;59:74–83. 
comes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. 2011.09.040
JAMA Cardiol 2016;1:126–135.  199. Margolis KL, O’Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, et al.
179. McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 dia-
Linagliptin effects on heart failure and related outcomes in individuals with type 2 dia- betes: the ACCORD randomized trial. Diabetes Care 2014;37:1721–1728. 
betes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation 2019; org/10.2337/dc13-2334
139:351–361.  200. Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, et al. Effects of com-
180. Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect bination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563–1574.
of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with 
type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 2019;322:1155–1166. 201. Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Emrich I, et al. Renal outcomes and
 blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. J
181. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy Hypertension 2021;39:766–774. 
and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017;377: 202. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment
723–732.  on outcome incidence in hypertension: 10–should blood pressure management differ
Downloaded
from

by
guest
on
22
January
2026

4124 E S C G u id e l in e s
in hypertensive patients with and without diabetes mellitus? Overview and failure and preserved ejection fraction. Eur Heart J 2021;42:3741–3752. 
meta-analyses of randomized trials. J Hypertension 2017;35:922–944.  org/10.1093/eurheartj/ehab499
10.1097/HJH.0000000000001276 221. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, et al. Blood pressure-lowering effects of
203. Ilkun OL, Greene T, Cheung AK, Whelton PK, Wei G, Boucher RE, et al. The influence GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
of baseline diastolic blood pressure on the effects of intensive blood pressure lowering Diabetes Obes Metab 2013;15:737–749. 
on cardiovascular outcomes and all-cause mortality in type 2 diabetes. Diabetes Care 222. Liakos CI, Papadopoulos DP, Sanidas EA, Markou MI, Hatziagelaki EE, Grassos CA,
2020;43:1878–1884.  et al. Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhi-
204. Blood Pressure Lowering Treatment Trialists’ Collaboration. Age-stratified and bitors, GLP-1 receptor agonists, and DPP-4 inhibitors). Am J Cardiovasc Drugs 2021;21:
blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for 123–137. 
the prevention of cardiovascular disease and death: an individual participant-level 223. Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhi-
data meta-analysis. Lancet 2021;398:1053–1064.  bitors on blood pressure in people with type 2 diabetes mellitus: a systematic review
6736(21)01921-8 and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart
205. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on
Assoc 2017;6:e004007. 
blood pressure of reduced dietary sodium and the Dietary Approaches to Stop 224. Ye N, Jardine MJ, Oshima M, Hockham C, Heerspink HJ, Agarwal R, et al. Blood pres-
Hypertension (DASH) diet. N Engl J Med 2001;344:3–10. 
sure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney
NEJM200101043440101
disease: insights from the CREDENCE trial. Circulation 2021;143:1735–1749. https://
206. Kastorini C-M, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB.
doi.org/10.1161/CIRCULATIONAHA.120.048740
The effect of Mediterranean diet on metabolic syndrome and its components: a
225. Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al. 24-hour blood
meta-analysis of 50 studies and 534,906 individuals. J Am College Cardiol 2011;57:
pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncon-
1299–1313. 
trolled nocturnal hypertension: results from the randomized, placebo-controlled
207. Toledo E, Hu FB, Estruch R, Buil-Cosiales P, Corella D, Salas-Salvadó J, et al. Effect of
SACRA study. Circulation 2019;139:2089–2097. 
the Mediterranean diet on blood pressure in the PREDIMED trial: results from a ran-
CIRCULATIONAHA.118.037076
domized controlled trial. BMC Med 2013;11:207. 
226. Georgianos PI, Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibi-
11-207
tors: dose-response meta-analysis and comparative evaluation with low-dose hydro-
208. Hansen D, Niebauer J, Cornelissen V, Barna O, Neunhäuserer D, Stettler C, et al.
chlorothiazide. Diabetes Care 2019;42:693–700. 
Exercise prescription in patients with different combinations of cardiovascular disease
227. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cifkova
risk factors: a consensus statement from the EXPERT Working Group. Sports Med
2018;48:1781–1797.  R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular dis-
209. Beamish AJ, Olbers T, Kelly AS, Inge TH. Cardiovascular effects of bariatric surgery. eases during pregnancy: the task force for the management of cardiovascular diseases
Nat Rev Cardiol 2016;13:730–743.  during pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2018;39:
210. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of 3165–3241. 
modest weight loss in improving cardiovascular risk factors in overweight and obese 228. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al.
individuals with type 2 diabetes. Diabetes Care 2011;34:1481–1486.  Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management
10.2337/dc10-2415 recommendations for international practice. Hypertension 2018;72:24–43. 
211. Allhat Officers and Coordinators for the Allhat Collaborative Research Group, The org/10.1161/HYPERTENSIONAHA.117.10803
Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major out- 229. Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, et al. Treatment for
comes in high-risk hypertensive patients randomized to angiotensin-converting en- mild chronic hypertension during pregnancy. N Engl J Med 2022;386:1781–1792.
zyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and 
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 230. Wright AK, Welsh P, Gill JM, Kontopantelis E, Emsley R, Buchan I, et al. Age-, sex-and
288:2981–2997.  ethnicity-related differences in body weight, blood pressure, HbA1c and lipid levels at
212. Wright JT, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, et al. the diagnosis of type 2 diabetes relative to people without diabetes. Diabetologia 2020;
Clinical outcomes by race in hypertensive patients with and without the metabolic syn- 63:1542–1553. 
drome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 231. Gerdts E, Sudano I, Brouwers S, Borghi C, Bruno RM, Ceconi C, et al. Sex differences in
(ALLHAT). Arch Intern Med 2008;168:207–217.  arterial hypertension: a scientific statement from the ESC Council on Hypertension,
archinternmed.2007.66 the European Association of Preventive Cardiology, Association of Cardiovascular
213. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Nursing and Allied Professions, the ESC Council for Cardiology Practice, and the
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan ESC Working Group on Cardiovascular Pharmacotherapy. Eur Heart J 2022;43:
Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial 4777–4788. 
against atenolol. Lancet 2002;359:1004–1010.  232. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, aware-
6736(02)08090-X ness, treatment, and control of hypertension in rural and urban communities in high-,
214. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A; CAPPP Study Group. Reduced
middle-, and low-income countries. JAMA 2013;310:959–968. 
cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line jama.2013.184182
therapy with an ACE inhibitor compared with a diuretic/β-blocker–based treatment 233. Lindholt JS, Søgaard R. Population screening and intervention for vascular disease in
regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001;24:
Danish men (VIVA): a randomised controlled trial. Lancet 2017;390:2256–2265.
2091–2096. 

215. Östergren J, Poulter NR, Sever PS, Dahlöf B, Wedel H, Beevers G, et al. The
234. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on out-
Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects
come incidence in hypertension: 7. Effects of more vs. less intensive blood pressure
in patients with type II diabetes. J Hypertension 2008;26:2103–2111. 
lowering and different achieved blood pressure levels–updated overview and
10.1097/HJH.0b013e328310e0d9
meta-analyses of randomized trials. J Hypertension 2016;34:613–622. 
216. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al.
10.1097/HJH.0000000000000881
Cardiovascular events during differing hypertension therapies in patients with dia-
235. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on out-
betes. J Am College Cardiol 2010;56:77–85. 
come incidence in hypertension: 1. Overview, meta-analyses, and meta-regression
217. Kunimura A, Himuro N, Fujiyoshi A, Segawa H, Ohnishi H, Saitoh S. The effects of re-
nin–angiotensin system inhibitors on mortality, cardiovascular events, and renal events analyses of randomized trials. J Hypertension 2014;32:2285–2295. 
in hypertensive patients with diabetes: a systematic review and meta-analysis of rando- 1097/HJH.0000000000000378
mized controlled trials. Hypertension Res 2019;42:669–680.  236. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, et al. Follow-up of blood-
s41440-019-0234-6 pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014;371:
218. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus mono- 1392–1406. 
therapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 237. McBrien K, Rabi DM, Campbell N, Barnieh L, Clement F, Hemmelgarn BR, et al.
trials. Am J Med 2009;122:290–300.  Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus:
219. Bahiru E, de Cates AN, Farr MR, Jarvis MC, Palla M, Rees K, et al. Fixed-dose combin- systematic review and meta-analysis. Arch Intern Med 2012;172:1296–1303. 
ation therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane org/10.1001/archinternmed.2012.3147
Database Syst Rev 2017;3:CD009868.  238. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood
pub3 pressure lowering on cardiovascular and renal outcomes: updated systematic review
220. Jackson AM, Jhund PS, Anand IS, Düngen H-D, Lam CS, Lefkowitz MP, et al. Sacubitril– and meta-analysis. Lancet 2016;387:435–443. 
valsartan as a treatment for apparent resistant hypertension in patients with heart 00805-3
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4125
239. Mancia G, Grassi G. Blood pressure targets in type 2 diabetes. Evidence against or in antibodies. Curr Med Chem 2021;28:7427–7445. 
favour of an aggressive approach. Diabetologia 2018;61:517–525.  0929867328666210222092628
1007/s00125-017-4537-3 259. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al.
240. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2015;372:2387–2397. 
2010;362:1575–1585.  260. Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, et al. Benefit of
241. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, et al. Renal outcomes adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients
with different fixed-dose combination therapies in patients with hypertension at high with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction
risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a of Outcomes: Vytorin Efficacy International Trial). Circulation 2018;137:1571–1582.
randomised controlled trial. Lancet 2010;375:1173–1181.  
S0140-6736(09)62100-0 261. Semova I, Levenson AE, Krawczyk J, Bullock K, Williams KA, Wadwa RP, et al. Type 1
242. McManus RJ, Mant J, Franssen M, Nickless A, Schwartz C, Hodgkinson J, et al. Efficacy of diabetes is associated with an increase in cholesterol absorption markers but a de-
self-monitored blood pressure, with or without telemonitoring, for titration of antihy- crease in cholesterol synthesis markers in a young adult population. J Clin Lipidol
pertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet 2019;13:940–946. 
2018;391:949–959.  262. Durairaj A, Sabates A, Nieves J, Moraes B, Baum S. Proprotein convertase subtilisin/
243. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated kexin type 9 (PCSK9) and its inhibitors: a review of physiology, biology, and clinical
with selective and combined elevation in office, home, and ambulatory blood pressure. data. Curr Treat Options Cardiovasc Med 2017;19:58. 
Hypertension 2006;47:846–853.  017-0556-0
244. Chiesa ST, Charakida M, McLoughlin E, Nguyen HC, Georgiopoulos G, Motran L, et al. 263. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al.
Elevated high-density lipoprotein in adolescents with type 1 diabetes is associated with Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J
endothelial dysfunction in the presence of systemic inflammation. Eur Heart J 2019;40: Med 2017;376:1713–1722. 
3559–3566.  264. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and
245. Chait A, Goldberg I. Treatment of dyslipidemia in diabetes: recent advances and re- cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:
maining questions. Curr Diab Rep 2017;17:112. 
2097–2107. 
0942-8 265. Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, Monsalvo ML, et al.
246. Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, De Boer IH, et al. Update on
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary
prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light
results of the randomised controlled BANTING study. Diabetologia 2019;62:948–958.
of recent evidence: a scientific statement from the American Heart Association and

the American Diabetes Association. Circulation 2015;132:691–718. 
266. Lorenzatti AJ, Monsalvo ML, López JAG, Wang H, Rosenson RS. Effects of evolocumab
10.1161/CIR.0000000000000230
in individuals with type 2 diabetes with and without atherogenic dyslipidemia: an ana-
247. Cholesterol Treatment Trialists’ (CTT) Collaboration. The effects of lowering LDL
lysis from BANTING and BERSON. Cardiovasc Diabetol 2021;20:94. 
cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis
1186/s12933-021-01287-6
of individual data from 27 randomised trials. Lancet 2012;380:581–590. 
267. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and
10.1016/S0140-6736(12)60367-5
efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019;380:
248. Cholesterol Treatment Trialists’ (CTT) Collaboration; Kearney P, Blackwell L, Collins
1022–1032. 
R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18 686 people
268. Colhoun HM, Leiter LA, Müller-Wieland D, Cariou B, Ray KK, Tinahones FJ, et al.
with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:
Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low
117–125. 
high-density lipoprotein cholesterol. Cardiovasc Diabetol 2020;19:14. 
249. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of
10.1186/s12933-020-0991-1
LDL-lowering therapy among men and women: meta-analysis of individual data
269. Khan SU, Rahman H, Okunrintemi V, Riaz H, Khan MS, Sattur S, et al. Association of
from 174 000 participants in 27 randomised trials. Lancet 2015;385:1397–1405.
lowering low-density lipoprotein cholesterol with contemporary lipid-lowering ther-

apies and risk of diabetes mellitus: a systematic review and meta-analysis. J Am Heart
250. Jones P, Kafonek S, Hunninghake D. Comparative dose efficacy study of atorvastatin
Assoc 2019;8:e011581. 
versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholes-
270. Scott R, O’Brien R, Fulcher G, Pardy C, d’Emden M, Tse D, et al. Effects of fenofibrate
terolemia (the CURVES study). Am J Cardiol 1998;81:582–587. 
treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and
S0002-9149(97)00965-X
various components of the metabolic syndrome: the Fenofibrate Intervention and
251. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk
Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493–498. https:// of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet
doi.org/10.2337/dc08-1543
2010;375:735–742. 
271. Bruckert E, Labreuche J, Deplanque D, Touboul P-J, Amarenco P. Fibrates effect on
252. Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, et al. Statin use
and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dys-
Open Diabetes Res Care 2017;5:e000438.  lipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol 2011;
000438 57:267–272. 
253. Hero C, Rawshani A, Svensson A-M, Franzén S, Eliasson B, Eeg-Olofsson K, et al. 272. Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPARα modulator:
Association between use of lipid-lowering therapy and cardiovascular diseases and drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr
death in individuals with type 1 diabetes. Diabetes Care 2016;39:996–1003. https:// Atheroscler Rep 2020;22:5. 
doi.org/10.2337/dc15-2450 273. Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, et al. Rationale
254. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing
Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J 2018;206:
5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: 80–93. 
2005–2016.  274. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al.
255. Marcovecchio ML, Chiesa ST, Bond S, Daneman D, Dawson S, Donaghue KC, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J
ACE inhibitors and statins in adolescents with type 1 diabetes. N Engl J Med 2017; Med 2019;380:11–22. 
377:1733–1745.  275. Olshansky B, Chung MK, Budoff MJ, Philip S, Jiao L, Doyle J, et al. Mineral oil: safety and
256. Moon J, Cohen Sedgh R, Jackevicius CA. Examining the nocebo effect of statins use as placebo in REDUCE-IT and other clinical studies. Eur Heart J Suppl 2020;22-
through statin adverse events reported in the food and drug administration adverse (Suppl J):J34–J48. 
event reporting system. Circ Cardiovasc Quality Outcomes 2021;14:e007480. https:// 276. Steg PG, Bhatt DL. The reduction in cardiovascular risk in REDUCE-IT is due to eicosa-
doi.org/10.1161/CIRCOUTCOMES.120.007480 pentaenoic acid in icosapent ethyl. Eur Heart J 2021;42:4865–4866. 
257. Reston JT, Buelt A, Donahue MP, Neubauer B, Vagichev E, McShea K. Interventions to 1093/eurheartj/ehab760
improve statin tolerance and adherence in patients at risk for cardiovascular disease: a 277. Warden BA, Duell PB. Inclisiran: a novel agent for lowering apolipoprotein B–contain-
systematic review for the 2020 US Department of Veterans Affairs and US ing lipoproteins. J Cardiovasc Pharmacol 2021;78:e157–e174. 
Department of Defense Guidelines for Management of Dyslipidemia. Ann Intern FJC.0000000000001053
Med 2020;173:806–812.  278. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of
258. Ali AH, Younis N, Abdallah R, Shaer F, Dakroub A, Ayoub MA, et al. Lipid-lowering inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382:1507–1519.
therapies for atherosclerosis: statins, fibrates, ezetimibe and PCSK9 monoclonal 
Downloaded
from

by
guest
on
22
January
2026

4126 E S C G u id e l in e s
279. ClinicalTrials.gov. A Randomized Trial Assessing the Effects of Inclisiran on Clinical European Society of Cardiology (ESC). Eur Heart J 2020;41:407–477. 
Outcomes among People with Cardiovascular Disease (ORION-4).  10.1093/eurheartj/ehz425
gov/ct2/show/NCT03705234(19 April 2022) 300. Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Muñoz D, et al. Comparative
280. Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med 2021;384:
ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates ath- 1981–1990. 
erosclerosis. Nat Commun 2016;7:13457.  301. Current-Oasis 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute
281. Masson W, Lobo M, Lavalle-Cobo A, Masson G, Molinero G. Effect of bempedoic acid coronary syndromes. N Engl J Med 2010;363:930–942. 
on new onset or worsening diabetes: a meta-analysis. Diabetes Res Clin Practice 2020; NEJMoa0909475
168:108369.  302. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in pa-
282. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJ, et al. Bempedoic acid tients with stable coronary disease and diabetes. N Engl J Med 2019;381:1309–1320.
and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023;388: 
1353–1364.  303. Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, et al. Ticagrelor in patients
283. Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, et al. with diabetes and stable coronary artery disease with a history of previous percutan-
Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein eous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised
B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin trial. Lancet 2019;394:1169–1180. 
Chem 2009;55:473–480.  304. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al.
284. Thanassoulis G, Williams K, Ye K, Brook R, Couture P, Lawler PR, et al. Relations of Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med
change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from sta- 2017;377:1319–1330. 
tin therapy: a meta-analysis of randomized trials. J Am Heart Assoc 2014;3:e000759. 305. Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, et al. Role of com-
 bination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascu-
285. Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B lar disease: insights from the COMPASS trial. Circulation 2020;141:1841–1854. https://
and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin- doi.org/10.1161/CIRCULATIONAHA.120.046448
treated patients. J Am College Cardiol 2021;77:1439–1450.  306. Lu H, Guan W, Zhou Y, Tang Z, Bao H. Cangrelor or clopidogrel in patients with type
jacc.2021.01.027 2 diabetes mellitus undergoing percutaneous coronary intervention: a meta-analysis of
286. Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, et al. Effects randomized controlled trials. Diabetes Ther 2019;10:937–950. 
of alirocumab on cardiovascular and metabolic outcomes after acute coronary syn- s13300-019-0593-7
drome in patients with or without diabetes: a prespecified analysis of the ODYSSEY 307. Abtan J, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW, et al. Efficacy and
OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol 2019;7:
safety of cangrelor in preventing periprocedural complications in patients with stable
618–628. 
angina and acute coronary syndromes undergoing percutaneous coronary interven-
287. Nissen SE, Dent-Acosta RE, Rosenson RS, Stroes E, Sattar N, Preiss D, et al.
tion: the CHAMPION PHOENIX trial. JACC Cardiovasc Interv 2016;9:1905–1913.
Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients:

design of the goal achievement after utilizing an anti-PCSK9 antibody in
308. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al.
statin-intolerant subjects 3 (GAUSS-3) trial. Clin Cardiol 2016;39:137–144. https://
2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40:
doi.org/10.1002/clc.22518
87–165. 
288. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy
309. James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, et al. Ticagrelor vs.
and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechal-
clopidogrel in patients with acute coronary syndromes and diabetes: a substudy
lenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 2015;9:
from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J
758–769. 
2010;31:3006–3016. 
289. Kearney K, Tomlinson D, Smith K, Ajjan R. Hypofibrinolysis in diabetes: a therapeutic
310. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al.
target for the reduction of cardiovascular risk. Cardiovasc Diabetol 2017;16:1–17.
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J

Med 2007;357:2001–2015. 
290. Rocca B, Patrono C. Aspirin in the primary prevention of cardiovascular disease in dia-
311. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor
betes mellitus: a new perspective. Diabetes Res Clin Practice 2020;160:108008. https://
versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:
doi.org/10.1016/j.diabres.2020.108008
1045–1057. 
291. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the
312. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, et al. Greater
primary and secondary prevention of vascular disease: collaborative meta-analysis of
clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients
individual participant data from randomised trials. Lancet 2009;373:1849–1860.
with diabetes mellitus in the trial to assess improvement in therapeutic outcomes

by optimizing platelet inhibition with prasugrel–Thrombolysis in Myocardial
292. ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in per-
Infarction 38. Circulation 2008;118:1626–1636.  sons with diabetes mellitus. N Engl J Med 2018;379:1529–1539. 
CIRCULATIONAHA.108.791061
1056/NEJMoa1804988
313. Schüpke S, Neumann F-J, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, et al.
293. Joseph P, Roshandel G, Gao P, Pais P, Lonn E, Xavier D, et al. Fixed-dose combination
Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med
therapies with and without aspirin for primary prevention of cardiovascular disease: an
individual participant data meta-analysis. Lancet 2021;398:1133–1146.  2019;381:1524–1534. 
10.1016/S0140-6736(21)01827-4 314. Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, et al.
294. Parish S, Mafham M, Offer A, Barton J, Wallendszus K, Stevens W, et al. Effects of as- Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome
pirin on dementia and cognitive function in diabetic patients: the ASCEND trial. Eur with or without revascularization: results from the PLATO trial. Eur Heart J 2014;35:
Heart J 2022;43:2010–2019.  2083–2093. 
295. Cainzos-Achirica M, Miedema MD, McEvoy JW, Al Rifai M, Greenland P, Dardari Z, 315. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al. Benefits and risks of the
et al. Coronary artery calcium for personalized allocation of aspirin in primary preven- combination of clopidogrel and aspirin in patients undergoing surgical revascularization
tion of cardiovascular disease in 2019: the MESA Study (Multi-Ethnic Study of for non–ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to
Atherosclerosis). Circulation 2020;141:1541–1553.  prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110:1202–1208.
CIRCULATIONAHA.119.045010 
296. Lindholt JS, Søgaard R, Rasmussen LM, Mejldal A, Lambrechtsen J, Steffensen FH, et al. 316. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin
Five-year outcomes of the Danish Cardiovascular Screening (DANCAVAS) trial. N for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopi-
Engl J Med 2022;387:1385–1394.  dogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months
297. Denissen SJ, Van Der Aalst CM, Vonder M, Gratama JWC, Adriaansen HJ, Kuijpers D, after implantation of a drug-eluting stent: a multicentre, open-label, randomised
et al. Screening for coronary artery calcium in a high-risk population: the ROBINSCA superiority trial. Lancet 2018;392:940–949. 
trial. Eur J Prev Cardiol 2021;28:1155–1159.  31858-0
2263 317. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of
298. Marwick TH, Whitmore K, Nicholls SJ, Stanton T, Mitchell G, Tonkin A, et al. Rationale ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:
and design of a trial to personalize risk assessment in familial coronary artery disease. 1791–1800. 
Am Heart J 2018;199:22–30.  318. Khan SU, Singh M, Valavoor S, Khan MU, Lone AN, Khan MZ, et al. Dual antiplatelet
299. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 therapy after percutaneous coronary intervention and drug-eluting stents: a systemat-
ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the ic review and network meta-analysis. Circulation 2020;142:1425–1436. 
Task Force for the diagnosis and management of chronic coronary syndromes of the 10.1161/CIRCULATIONAHA.120.046308
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4127
319. Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, et al. Reduction in 336. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve
ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;
PEGASUS–TIMI 54. J Am College Cardiol 2016;67:2732–2740.  371:2155–2166. 
jacc.2016.03.529 337. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, et al. Use of single and
320. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. Guided de- combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding:
escalation of antiplatelet treatment in patients with acute coronary syndrome under- population based case-control study. BMJ 2006;333:726. 
going percutaneous coronary intervention (TROPICAL-ACS): a randomised, open- 38947.697558.AE
label, multicentre trial. Lancet 2017;390:1747–1757.  338. Han Y, Liao Z, Li Y, Zhao X, Ma S, Bao D, et al. Magnetically controlled capsule endos-
6736(17)32155-4 copy for assessment of antiplatelet therapy-induced gastrointestinal injury. J Am College
321. Hein R, Gross L, Aradi D, Rieber J, Hadamitzky M, Merkely B, et al. Diabetes and out- Cardiol 2022;79:116–128. 
comes following guided de-escalation of antiplatelet treatment in acute coronary syn- 339. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic
drome patients undergoing percutaneous coronary intervention: a pre-specified therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019;
analysis from the randomised TROPICAL-ACS trial. EuroIntervention 2019;15: 380:1509–1524. 
e513–e521.  340. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al.
322. Collet J-P, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J
to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367: Med 2016;375:2423–2434. 
2100–2109.  341. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al.
322a. Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, et al.; Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after suc-
ANTARCTIC investigators. Platelet function monitoring to adjust antiplatelet ther- cessful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a ran-
apy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an domised, open-label, phase 3b trial. Lancet 2019;394:1335–1343. 
open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 2016; 1016/S0140-6736(19)31872-0
388:2015–2022.  342. Cannon CP, Bhatt DL, Oldgren J, Lip GY, Ellis SG, Kimura T, et al. Dual antithrombotic
323. Erlinge D, Varenhorst C, Braun OÖ, James S, Winters KJ, Jakubowski JA, et al. Patients therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:
with poor responsiveness to thienopyridine treatment or with diabetes have lower le- 1513–1524. 
vels of circulating active metabolite, but their platelets respond normally to active me- 343. Potpara TS, Mujovic N, Proietti M, Dagres N, Hindricks G, Collet J-P, et al. Revisiting
tabolite added ex vivo. J Am College Cardiol 2008;52:1968–1977.  the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrilla-
1016/j.jacc.2008.07.068 tion and acute coronary syndromes or percutaneous coronary interventions:
324. Wallentin L, Varenhorst C, James S, Erlinge D, Braun OÖ, Jakubowski JA, et al.
meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and
Prasugrel achieves greater and faster P2Y 12 receptor-mediated platelet inhibition
AUGUSTUS trials. Europace 2020;22:33–46. 
than clopidogrel due to more efficient generation of its active metabolite in aspirin-
euz259
treated patients with coronary artery disease. Eur Heart J 2008;29:21–30. https://
344. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, et al. Safety and ef-
doi.org/10.1093/eurheartj/ehm545
ficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fib-
325. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised
rillation following percutaneous coronary intervention: a systematic review and
trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke
meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical
in high risk patients. BMJ 2002;324:71–86. 
trials. Eur Heart J 2019;40:3757–3767. 
326. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of
345. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman J-P, et al. Use
antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by pro-
of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and
longed antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.
undergoing percutaneous coronary intervention: an open-label, randomised, con-

trolled trial. Lancet 2013;381:1107–1115. 
327. Gwon H-C, Hahn J-Y, Park KW, Song YB, Chae I-H, Lim D-S, et al. Six-month versus
62177-1
12-month dual antiplatelet therapy after implantation of drug-eluting stents: the
346. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et al.
Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting
Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med
(EXCELLENT) randomized, multicenter study. Circulation 2012;125:505–513.
2016;375:35–43. 

347. Soriano LC, Fowkes FGR, Allum AM, Johansson S, Rodriguez LAG. Predictors of
328. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al.
bleeding in patients with symptomatic peripheral artery disease: a cohort study using
Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting:
the health improvement network in the United Kingdom. Thromb Haemost 2018;118:
a randomized multicenter trial. Circulation 2012;125:2015–2026. 
1101–1112. 
1161/CIRCULATIONAHA.111.071589
348. Lanas A, García-Rodríguez L-A, Arroyo M-T, Gomollón F, Feu F, González-Pérez A,
329. Schulz-Schüpke S, Byrne RA, Ten Berg JM, Neumann F-J, Han Y, Adriaenssens T, et al.
et al. Risk of upper gastrointestinal ulcer bleeding associated with selective ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of
cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory
clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015;36:1252–1263. https://
doi.org/10.1093/eurheartj/ehu523 drugs, aspirin and combinations. Gut 2006;55:1731–1738. 
330. Han Y, Xu B, Xu K, Guan C, Jing Q, Zheng Q, et al. Six versus 12 months of dual anti- gut.2005.080754
platelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: 349. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable
randomized substudy of the I-LOVE-IT 2 trial. Circ Cardiovasc Interv 2016;9:e003145. Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of clopidogrel
 in addition to aspirin in patients with acute coronary syndromes without ST-segment
331. Hong S-J, Shin D-H, Kim J-S, Kim B-K, Ko Y-G, Choi D, et al. 6-month versus 12-month elevation. N Engl J Med 2001;345:494–502. 
dual-antiplatelet therapy following long everolimus-eluting stent implantation: the 350. Gaist D, Rodríguez LAG, Hellfritzsch M, Poulsen FR, Halle B, Hallas J, et al. Association
IVUS-XPL randomized clinical trial. JACC Cardiovasc Interv 2016;9:1438–1446. https:// of antithrombotic drug use with subdural hematoma risk. JAMA 2017;317:836–846.
doi.org/10.1016/j.jcin.2016.04.036 
332. Byrne RA, Neumann F-J, Mehilli J, Pinieck S, Wolff B, Tiroch K, et al. Paclitaxel-eluting 351. Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, et al. Effects of gastropro-
balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis tectant drugs for the prevention and treatment of peptic ulcer disease and its compli-
after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label cations: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018;3:
trial. Lancet 2013;381:461–467.  231–241. 
333. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin 352. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al.
in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–1339. https:// Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban
doi.org/10.1016/S0140-6736(96)09457-3 and/or aspirin in a randomized, double-blind, placebo-controlled trial.
334. Zhao Q, Zhu Y, Xu Z, Cheng Z, Mei J, Chen X, et al. Effect of ticagrelor plus aspirin, Gastroenterology 2019;157:403–412. 
ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary 353. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, et al.
artery bypass grafting: a randomized clinical trial. JAMA 2018;319:1677–1686. https:// Association of proton pump inhibitors with reduced risk of warfarin-related serious
doi.org/10.1001/jama.2018.3197 upper gastrointestinal bleeding. Gastroenterology 2016;151:1105–1112.e10. https://
335. Held C, Åsenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, et al. Ticagrelor doi.org/10.1053/j.gastro.2016.08.054
versus clopidogrel in patients with acute coronary syndromes undergoing coronary ar- 354. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Safety
tery bypass surgery: results from the PLATO (Platelet Inhibition and Patient of proton pump inhibitors based on a large, multi-year, randomized trial of patients
Outcomes) trial. J Am College Cardiol 2011;57:672–684.  receiving rivaroxaban or aspirin. Gastroenterology 2019;157:682–691.e2. 
2010.10.029 org/10.1053/j.gastro.2019.05.056
Downloaded
from

by
guest
on
22
January
2026

4128 E S C G u id e l in e s
355. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, et al. 375. Kim J, Hur M-H. The effects of dietary education interventions on individuals with type
Association of oral anticoagulants and proton pump inhibitor cotherapy with hospital- 2 diabetes: a systematic review and meta-analysis. Int J Environ Res Public Health 2021;
ization for upper gastrointestinal tract bleeding. JAMA 2018;320:2221–2230. https:// 18:8439. 
doi.org/10.1001/jama.2018.17242 376. Hennein R, Hwang SJ, Au R, Levy D, Muntner P, Fox CS, et al. Barriers to medication
356. Niu Q, Wang Z, Zhang Y, Wang J, Zhang P, Wang C, et al. Combination use of clopi- adherence and links to cardiovascular disease risk factor control: the Framingham
dogrel and proton pump inhibitors increases major adverse cardiovascular events in Heart Study. Intern Med J 2018;48:414–421. 
patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Therap 377. Goldstein CM, Gathright EC, Garcia S. Relationship between depression and medica-
2017;22:142–152.  tion adherence in cardiovascular disease: the perfect challenge for the integrated care
357. Yang R, Xu H, Pedersen NL, Li X, Yu J, Bao C, et al. A healthy lifestyle mitigates the risk team. Patient Prefer Adherence 2017;11:547–559. 
of heart disease related to type 2 diabetes: a prospective nested case-control study in a S127277
nationwide Swedish twin cohort. Diabetologia 2021;64:530–539.  378. Palmer MJ, Machiyama K, Woodd S, Gubijev A, Barnard S, Russell S, et al. Mobile
1007/s00125-020-05324-z phone-based interventions for improving adherence to medication prescribed for
358. Mancini GJ, Maron DJ, Hartigan PM, Spertus JA, Kostuk WJ, Berman DS, et al. Lifestyle, the primary prevention of cardiovascular disease in adults. Cochrane Database Syst
glycosylated hemoglobin A1c, and survival among patients with stable ischemic heart Rev 2021;3:CD012675. 
disease and diabetes. J Am College Cardiol 2019;73:2049–2058.  379. Dobson R, Whittaker R, Jiang Y, Maddison R, Shepherd M, McNamara C, et al.
j.jacc.2018.11.067 Effectiveness of text message based, diabetes self management support programme
359. Magliano DJ, Chen L, Carstensen B, Gregg EW, Pavkov ME, Salim A, et al. Trends in (SMS4BG): two arm, parallel randomised controlled trial. BMJ 2018;361:k1959.
all-cause mortality among people with diagnosed diabetes in high-income settings: a 
multicountry analysis of aggregate data. Lancet Diabetes Endocrinol 2022;10: 380. Wändell PE, de Waard A-KM, Holzmann MJ, Gornitzki C, Lionis C, de Wit N, et al.
112–119.  Barriers and facilitators among health professionals in primary care to prevention of
360. Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson A-M, et al. Risk fac- cardiometabolic diseases: a systematic review. Family Practice 2018;35:383–398.
tors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J 
381. Krempf M, Parhofer KG, Steg PG, Bhatt DL, Ohman EM, Röther J, et al. Cardiovascular Med 2018;379:633–644. 
361. Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial inter- event rates in diabetic and nondiabetic individuals with and without established ather-
othrombosis (from the REduction of Atherothrombosis for Continued Health
vention on mortality in type 2 diabetes. N Engl J Med 2008;358:580–591. 
[REACH] Registry). Am J Cardiol 2010;105:667–671. 
org/10.1056/NEJMoa0706245
amjcard.2009.10.048
362. Oellgaard J, Gæde P, Rossing P, Rørth R, Køber L, Parving H-H, et al. Reduced risk of
382. BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coron-
heart failure with intensified multifactorial intervention in individuals with type 2 dia-
ary artery disease. N Engl J Med 2009;360:2503–2515. 
betes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study.
NEJMoa0805796
Diabetologia 2018;61:1724–1733. 
383. Krishnaswami A, Hardison R, Nesto RW, Sobel B, BARI 2D Investigators. Presentation
363. Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving H-H, et al.
in patients with angiographically documented coronary artery disease and type II dia-
Years of life gained by multifactorial intervention in patients with type 2 diabetes mel-
betes mellitus (from the BARI 2D Clinical Trial). Am J Cardiol 2012;109:36–41. https://
litus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.
doi.org/10.1016/j.amjcard.2011.08.004
Diabetologia 2016;59:2298–2307. 
384. Anand DV, Lim E, Hopkins D, Corder R, Shaw LJ, Sharp P, et al. Risk stratification in
364. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbæk A, et al. Effect of
uncomplicated type 2 diabetes: prospective evaluation of the combined use of coron-
early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals
ary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J
with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-
2006;27:713–721. 
randomised trial. Lancet 2011;378:156–167. 
385. Goraya TY, Leibson CL, Palumbo PJ, Weston SA, Killian JM, Pfeifer EA, et al. Coronary
60698-3
atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am College
365. Griffin SJ, Rutten GE, Khunti K, Witte DR, Lauritzen T, Sharp SJ, et al. Long-term effects
Cardiol 2002;40:946–953. 
of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in
386. Lièvre MM, Moulin P, Thivolet C, Rodier M, Rigalleau V, Penfornis A, et al. Detection of
primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial.
silent myocardial ischemia in asymptomatic patients with diabetes: results of a rando-
Lancet Diabetes Endocrinol 2019;7:925–937. 
mized trial and meta-analysis assessing the effectiveness of systematic screening. Trials
30349-3
2011;12:23. 
366. Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, et al. Effect of an in-
387. Muhlestein JB, Lappé DL, Lima JA, Rosen BD, May HT, Knight S, et al. Effect of screen-
tensified multifactorial intervention on cardiovascular outcomes and mortality in
ing for coronary artery disease using CT angiography on mortality and cardiac events in
type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA 2014;
Diabetes Endocrinol 2017;5:951–964.  312:2234–2243. 
367. Ferrannini G, De Bacquer D, De Backer G, Kotseva K, Mellbin L, Wood D, et al. 388. Young LH, Frans JT, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et al. Cardiac out-
Screening for glucose perturbations and risk factor management in dysglycemic pa- comes after screening for asymptomatic coronary artery disease in patients with
tients with coronary artery disease—a persistent challenge in need of substantial im- type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009;301:
provement: a report from ESC EORP EUROASPIRE V. Diabetes Care 2020;43: 1547–1555. 
726–733.  389. Clerc OF, Fuchs TA, Stehli J, Benz DC, Gräni C, Messerli M, et al. Non-invasive screen-
368. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. ing for coronary artery disease in asymptomatic diabetic patients: a systematic review
Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022;387: and meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Imaging 2018;
967–977.  19:838–846. 
369. Cersosimo E, Johnson EL, Chovanes C, Skolnik N. Initiating therapy in patients newly 390. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic
diagnosed with type 2 diabetes: combination therapy vs a stepwise approach. Diabetes effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hyper-
Obes Metab 2018;20:497–507.  tension: a randomized controlled trial. JAMA 2004;292:2227–2236. 
370. Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification 1001/jama.292.18.2227
with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus 391. Schmidt AC, Graf C, Brixius K, Scholze J. Blood pressure-lowering effect of nebivolol in
therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes hypertensive patients with type 2 diabetes mellitus. Clin Drug Invest 2007;27:841–849.
Endocrinol 2014;2:30–37.  
371. Balducci S, D’Errico V, Haxhi J, Sacchetti M, Orlando G, Cardelli P, et al. Effect of a be- 392. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients
havioral intervention strategy on sustained change in physical activity and sedentary be- with hypertension treated with beta blockers to determine the risk of new-onset dia-
havior in patients with type 2 diabetes: the IDES_2 randomized clinical trial. JAMA 2019; betes mellitus. Am J Cardiol 2007;100:1254–1262. 
321:880–890.  2007.05.057
372. Astin F, Lucock M, Jennings CS. Heart and mind: behavioural cardiology demystified for 393. Arnold SV, McGuire DK, Spertus JA, Li Y, Yue P, Ben-Yehuda O, et al. Effectiveness of
the clinician. Heart 2019;105:881–888.  ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according
373. Zulman DM, Haverfield MC, Shaw JG, Brown-Johnson CG, Schwartz R, Tierney AA, to baseline hemoglobin A1c. Am Heart J 2014;168:457–465.e2. 
et al. Practices to foster physician presence and connection with patients in the clinical 1016/j.ahj.2014.06.020
encounter. JAMA 2020;323:70–81.  394. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and
374. Miller WR, Rose GS. Toward a theory of motivational interviewing. Am Psychol 2009; HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006;27:42–48. https://
64:527.  doi.org/10.1093/eurheartj/ehi495
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4129
395. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardio- 414. Alabas O, Hall M, Dondo T, Rutherford MJ, Timmis A, Batin P, et al. Long-term excess
vascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor mortality associated with diabetes following acute myocardial infarction: a population-
blocker telmisartan on cardiovascular events in high-risk patients intolerant to based cohort study. J Epidemiol Community Health 2017;71:25–32. 
angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 1136/jech-2016-207402
2008;372:1174–1183.  415. Niedziela JT, Hiczkiewicz J, Kleinrok A, Pączek P, Leszek P, Lelonek M, et al. Prevalence,
396. Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indica- characteristics, and prognostic implications of type 2 diabetes in patients with myocar-
tion for use of renin angiotensin system blockers: systematic review and meta-analysis dial infarction: the Polish Registry of Acute Coronary Syndromes (PL-ACS) annual
of randomized trials. BMJ 2016;352:i438.  2018 report. Kardiol Pol 2020;78:243–246. 
397. Arnold SV, Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE, et al. 416. Canto JG, Fincher C, Kiefe CI, Allison JJ, Li Q, Funkhouser E, et al. Atypical presenta-
Clinical management of stable coronary artery disease in patients with type 2 diabetes tions among Medicare beneficiaries with unstable angina pectoris. Am J Cardiol 2002;
mellitus: a scientific statement from the American Heart Association. Circulation 2020; 90:248–253. 
141:e779–e806.  417. O’Donoghue ML, Vaidya A, Afsal R, Alfredsson J, Boden WE, Braunwald E, et al. An
398. Taggart DP, Audisio K, Gerry S, Robinson NB, Rahouma M, Soletti G Jr, et al. Single invasive or conservative strategy in patients with diabetes mellitus and
versus multiple arterial grafting in diabetic patients at 10 years: the Arterial non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis
Revascularization Trial. Eur Heart J 2022;43:4644–4652.  of randomized trials. J Am College Cardiol 2012;60:106–111. 
eurheartj/ehac199 jacc.2012.02.059
399. Nyström T, Sartipy U, Franzén S, Eliasson B, Gudbjörnsdottir S, Miftaraj M, et al. PCI 418. Angeli F, Verdecchia P, Karthikeyan G, Mazzotta G, Pinto MD, Repaci S, et al.
Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease. J Am Coll New-onset hyperglycemia and acute coronary syndrome: a systematic overview and
Cardiol 2017;70:1441–1451. meta-analysis. Curr Diabetes Rev 2010;6:102–110. 
400. Navarese EP, Lansky AJ, Kereiakes DJ, Kubica J, Gurbel PA, Gorog DA, et al. Cardiac 10790909413
mortality in patients randomised to elective coronary revascularisation plus medical 419. Goyal A, Mehta SR, Gerstein HC, Díaz R, Afzal R, Xavier D, et al. Glucose levels com-
therapy or medical therapy alone: a systematic review and meta-analysis. Eur Heart J pared with diabetes history in the risk assessment of patients with acute myocardial
2021;42:4638–4651.  infarction. Am Heart J 2009;157:763–770. 
401. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery 420. Kosiborod M, Inzucchi SE, Krumholz HM, Xiao L, Jones PG, Fiske S, et al. Glucometrics
bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364: in patients hospitalized with acute myocardial infarction: defining the optimal
1607–1616.  outcomes-based measure of risk. Circulation 2008;117:1018–1027. 
402. Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, et al. Percutaneous
10.1161/CIRCULATIONAHA.107.740498
coronary intervention versus optimal medical therapy in stable coronary artery dis-
421. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al. Randomized
ease: a systematic review and meta-analysis of randomized clinical trials. Circ
trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic
Cardiovasc Interv 2012;5:476–490. 
patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1
112.970954
year. J Am College Cardiol 1995;26:57–65. 
402a. Newman JD, Anthopolos R, Mancini GJ, Bangalore S, Reynolds HR, Kunichoff DF,
00126-K
et al. Outcomes of participants with diabetes in the ISCHEMIA trials. Circulation
422. Zhao Y-T, Weng C-L, Chen M-L, Li K-B, Ge Y-G, Lin X-M, et al. Comparison of
2021;144:1380–1395. 
glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial
403. Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, et al.
infarction: a contemporary meta-analysis of randomised controlled trials. Heart 2010;
Randomized trial of complete versus lesion-only revascularization in patients undergo-
96:1622–1626. 
ing primary percutaneous coronary intervention for STEMI and multivessel disease:
423. Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, et al.
the CvLPRIT trial. J Am College Cardiol 2015;65:963–972. 
U-shaped relationship of blood glucose with adverse outcomes among patients with
jacc.2014.12.038
ST-segment elevation myocardial infarction. J Am College Cardiol 2005;46:178–180.
404. Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, et al.

Complete revascularisation versus treatment of the culprit lesion only in patients
424. Svensson A-M, McGuire DK, Abrahamsson P, Dellborg M. Association between
with ST-segment elevation myocardial infarction and multivessel disease
hyper-and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with
(DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet 2015;
acute coronary events. Eur Heart J 2005;26:1255–1261. 
386:665–671. 
eurheartj/ehi230
405. Smits PC, Abdel-Wahab M, Neumann F-J, Boxma-de Klerk BM, Lunde K, Schotborgh
425. The NICE-SUGAR Study Investigators. Intensive versus conventional glucose control
CE, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarc-
in critically ill patients. N Engl J Med 2009;360:1283–1297. 
tion. N Engl J Med 2017;376:1234–1244. 
NEJMoa0810625 406. Rathod KS, Koganti S, Jain AK, Astroulakis Z, Lim P, Rakhit R, et al. Complete versus
426. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC
culprit-only lesion intervention in patients with acute coronary syndromes. J Am
Guidelines for the management of acute coronary syndromes in patients presenting
College Cardiol 2018;72:1989–1999. 
without persistent ST-segment elevation: the Task Force for the management of acute
407. Sardella G, Lucisano L, Garbo R, Pennacchi M, Cavallo E, Stio RE, et al. Single-staged
coronary syndromes in patients presenting without persistent ST-segment elevation
compared with multi-staged PCI in multivessel NSTEMI patients: the SMILE trial. J
Am College Cardiol 2016;67:264–272.  of the European Society of Cardiology (ESC). Eur Heart J 2021;42:1289–1367.
408. Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, et al. PCI strategies 
in patients with acute myocardial infarction and cardiogenic shock. N Eng J Med 2017; 427. Malcolm J, Halperin I, Miller DB, Moore S, Nerenberg KA, Woo V, et al. In-hospital
377:2419–2432.  management of diabetes. Can J Diabetes 2018;42:S115–S123. 
409. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 1016/j.jcjd.2017.10.014
2 diabetes: a systematic literature review of scientific evidence from across the world 428. Ajjan RA, Heller SR, Everett CC, Vargas-Palacios A, Higham R, Sharples L, et al.
in 2007–2017. Cardiovasc Diabetol 2018;17:83.  Multicenter randomized trial of intermittently scanned continuous glucose monitoring
0728-6 versus self-monitoring of blood glucose in individuals with type 2 diabetes and
410. Aggarwal B, Shah GK, Randhawa M, Ellis SG, Lincoff AM, Menon V. Utility of glycated recent-onset acute myocardial infarction: results of the LIBERATES trial. Diabetes
hemoglobin for assessment of glucose metabolism in patients with ST-segment eleva- Care 2023;46:441–449. 
tion myocardial infarction. Am J Cardiol 2016;117:749–753.  429. von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al.
amjcard.2015.11.060 Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J 2022;43:
411. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibi- 4421–4432. 
tors in the early treatment of acute myocardial infarction: systematic overview of in- 430. Ritsinger V, Tanoglidi E, Malmberg K, Näsman P, Rydén L, Tenerz Å, et al. Sustained
dividual data from 100 000 patients in randomized trials. Circulation 1998;97: prognostic implications of newly detected glucose abnormalities in patients with acute
2202–2212.  myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with
412. Yahagi K, Kolodgie FD, Lutter C, Mori H, Romero ME, Finn AV, et al. Pathology of hu- Acute Myocardial Infarction cohort. Diabetes Vasc Dis Res 2015;12:23–32. 
man coronary and carotid artery atherosclerosis and vascular calcification in diabetes org/10.1177/1479164114551746
mellitus. Arterioscler Thromb Vasc Biol 2017;37:191–204.  431. Timmer JR, Ottervanger JP, de Boer M-J, Boersma E, Grines CL, Westerhout CM, et al.
ATVBAHA.116.306256 Primary percutaneous coronary intervention compared with fibrinolysis for myocar-
413. Henriksen EJ. A radical concept on caveolae and endothelial dysfunction in coronary dial infarction in diabetes mellitus: results from the primary coronary angioplasty vs
microvascular disease in diabetes. Diabetes 2014;63:1200–1202.  thrombolysis–2 trial. Arch Intern Med 2007;167:1353–1359. 
2337/db14-0057 archinte.167.13.1353
Downloaded
from

by
guest
on
22
January
2026

4130 E S C G u id e l in e s
432. Megaly M, Schmidt CW, Dworak MW, Garberich R, Stanberry L, Sharkey S, et al. 452. Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, et al.
Diabetic patients who present with ST-elevation myocardial infarction. Cardiovasc Hospitalizations for new heart failure among subjects with diabetes mellitus in the
Revasc Med 2022;38:89–93.  RENAAL and LIFE studies. Am J Cardiol 2005;96:1530–1536. 
433. Burgess S, Juergens CP, Yang W, Shugman IM, Idris H, Nguyen T, et al. Cardiac mor- j.amjcard.2005.07.061
tality, diabetes mellitus, and multivessel disease in ST elevation myocardial infarction. 453. Maack C, Lehrke M, Backs J, Heinzel FR, Hulot J-S, Marx N, et al. Heart failure and dia-
Int J Cardiol 2021;323:13–18.  betes: metabolic alterations and therapeutic interventions: a state-of-the-art review
434. Burgess SN, Juergens CP, Nguyen T, Leung M, Robledo KP, Thomas L, et al. Diabetes from the Translational Research Committee of the Heart Failure Association–
and incomplete revascularisation in ST elevation myocardial infarction. Heart Lung Circ European Society of Cardiology. Eur Heart J 2018;39:4243–4254. 
2021;30:471–480.  1093/eurheartj/ehy596
435. Ullah W, Saleem S, Zahid S, Sattar Y, Mukhtar M, Younas S, et al. Clinical outcomes of 454. Pham I, Cosson E, Nguyen MT, Banu I, Genevois I, Poignard P, et al. Evidence for a spe-
patients with diabetes mellitus and acute ST-elevation myocardial infarction following cific diabetic cardiomyopathy: an observational retrospective echocardiographic study
fibrinolytic therapy: a nationwide inpatient sample (NIS) database analysis. Expert Rev in 656 asymptomatic type 2 diabetic patients. Int J Endocrinol 2015;2015:743503.
Cardiovasc Ther 2021;19:357–362.  
436. Rakowski T, De Luca G, Siudak Z, Plens K, Dziewierz A, Kleczyński P, et al. 455. Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, et al. Serum levels
Characteristics of patients presenting with myocardial infarction with non-obstructive of advanced glycation end products are associated with left ventricular diastolic func-
coronary arteries (MINOCA) in Poland: data from the ORPKI national registry. J tion in patients with type 1 diabetes. Diabetes Care 1999;22:1186–1190. 
Thromb Thrombol 2019;47:462–466.  org/10.2337/diacare.22.7.1186
437. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC 456. Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ. Advanced glycation end-
Guidelines for the management of acute myocardial infarction in patients presenting products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart
with ST-segment elevation: the Task Force for the management of acute myocardial Fail 2007;9:1146–1155. 
infarction in patients presenting with ST-segment elevation of the European Society 457. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, et al.
of Cardiology (ESC). Eur Heart J 2018;39:119–177.  Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 dia-
eurheartj/ehx393 betes mellitus. J Am College Cardiol 2008;52:1793–1799. 
438. Tardif J-C, L’Allier PL, Fitchett DH. Management of acute coronary syndromes. Can J
2008.07.062
Diabetes 2018;42:S190–S195.  458. Shenouda SM, Widlansky ME, Chen K, Xu G, Holbrook M, Tabit CE, et al. Altered
439. Mehta SR, Granger CB, Boden WE, Steg PG, Bassand J-P, Faxon DP, et al. Early versus
mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus.
delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009;360:
Circulation 2011;124:444–453. 
2165–2175. 
014506
440. Kofoed KF, Kelbæk H, Hansen PR, Torp-Pedersen C, Høfsten D, Kløvgaard L, et al.
459. Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K,
Early versus standard care invasive examination and treatment of patients with
et al. The association between glucose abnormalities and heart failure in the
non-ST-segment elevation acute coronary syndrome: VERDICT randomized con-
population-based Reykjavik study. Diabetes Care 2005;28:612–616. 
trolled trial. Circulation 2018;138:2741–2750. 
10.2337/diacare.28.3.612
CIRCULATIONAHA.118.037152
460. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study.
441. Bonello L, Laine M, Puymirat E, Lemesle G, Thuny F, Paganelli F, et al. Timing of cor-
JAMA 1979;241:2035–2038. 
onary invasive strategy in non-ST-segment elevation acute coronary syndromes and
461. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, et al.
clinical outcomes: an updated meta-analysis. JACC Cardiovasc Interv 2016;9:
Predictors of congestive heart failure in the elderly: the Cardiovascular Health
2267–2276. 
Study. J Am College Cardiol 2000;35:1628–1637. 
442. Martinón-Martínez J, Alvarez Alvarez B, Gonzalez Ferrero T, Garcia-Rodeja Arias F,
1097(00)00582-9
Otero Garcia O, Cacho Antonio C, et al. Prognostic benefit from an early invasive
462. van Melle JP, Bot M, De Jonge P, De Boer RA, van Veldhuisen DJ, Whooley MA.
strategy in patients with non-ST elevation acute coronary syndrome (NSTEACS):
Diabetes, glycemic control, and new-onset heart failure in patients with stable coron-
evaluation of the new risk stratification in the NSTEACS European guidelines. Clin
ary artery disease: data from the heart and soul study. Diabetes Care 2010;33:
Res Cardiol 2021;110:1464–1472. 
2084–2089. 
443. Jobs A, Mehta SR, Montalescot G, Vicaut E, Van’t Hof AW, Badings EA, et al. Optimal
463. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive
timing of an invasive strategy in patients with non-ST-elevation acute coronary syn-
heart failure in type 2 diabetes: an update. Diabetes Care 2004;27:1879–1884. https://
drome: a meta-analysis of randomised trials. Lancet 2017;390:737–746. 
doi.org/10.2337/diacare.27.8.1879
org/10.1016/S0140-6736(17)31490-3
464. Boonman-de Winter L, Rutten F, Cramer M, Landman M, Liem A, Rutten G, et al. High
444. Li Y, Wang C, Nan Y, Zhao H, Cao Z, Du X, et al. Early invasive strategy for non-ST
prevalence of previously unknown heart failure and left ventricular dysfunction in pa- elevation acute coronary syndrome: a meta-analysis of randomized, controlled trials. J
tients with type 2 diabetes. Diabetologia 2012;55:2154–2162. 
Int Med Res 2020;48:300060520966500. 
s00125-012-2579-0
445. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021
465. Zareini B, Rørth R, Holt A, Mogensen UM, Selmer C, Gislason G, et al. Heart failure and
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: de-
the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide
veloped by the Task Force for the diagnosis and treatment of acute and chronic heart
cohort study. Cardiovasc Diabetol 2019;18:79. 
failure of the European Society of Cardiology (ESC) with the special contribution of
the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599–3726. 0883-4
466. Centers for Disease Control and Prevention. Incidence of Newly Diagnosed Diabetes.

446. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, 
et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 (21 April 2022)
million people. Lancet Diabetes Endocrinol 2015;3:105–113.  467. Dauriz M, Targher G, Laroche C, Temporelli PL, Ferrari R, Anker S, et al. Association
S2213-8587(14)70219-0 between diabetes and 1-year adverse clinical outcomes in a multinational cohort of
447. Seferović PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with ambulatory patients with chronic heart failure: results from the ESC-HFA heart failure
restrictive and dilated phenotypes. Eur Heart J 2015;36:1718–1727.  long-term registry. Diabetes Care 2017;40:671–678. 
10.1093/eurheartj/ehv134 2016
448. Sattar N, McGuire DK. Pathways to cardiorenal complications in type 2 diabetes mel- 468. Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM, et al.
litus: a need to rethink. Circulation 2018;138:7–9.  In-hospital and 1-year mortality associated with diabetes in patients with acute heart
CIRCULATIONAHA.118.035083 failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail
449. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: 2017;19:54–65. 
prevalence, incidence, and risk factors. Diabetes Care 2001;24:1614–1619.  469. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al.
org/10.2337/diacare.24.9.1614 Epidemiology and one-year outcomes in patients with chronic heart failure and pre-
450. Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA, et al. Association served, mid-range and reduced ejection fraction: an analysis of the ESC Heart
of systolic blood pressure with macrovascular and microvascular complications of type Failure Long-Term Registry. Eur J Heart Fail 2017;19:1574–1585. 
2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412–419. 1002/ejhf.813
 470. Johansson I, Dahlström U, Edner M, Näsman P, Ryden L, Norhammar A. Type 2 dia-
451. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart fail- betes and heart failure: characteristics and prognosis in preserved, mid-range and re-
ure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care duced ventricular function. Diab Vasc Dis Res 2018;15:494–503. 
2004;27:699–703.  1177/1479164118794619
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4131
471. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin– 489. Mant J, Doust J, Roalfe A, Barton P, Cowie M, Glasziou P, et al. Systematic review and
neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004. individual patient data meta-analysis of diagnosis of heart failure, with modelling of im-
 plications of different diagnostic strategies in primary care. Health Technol Assess 2009;
472. Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, et al. Impact of dia- 13:1–207. 
betes mellitus on hospitalization for heart failure, cardiovascular events, and death: 490. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety,
outcomes at 4 years from the Reduction of Atherothrombosis for Continued tolerability and efficacy of up-titration of guideline-directed medical therapies for acute
Health (REACH) registry. Circulation 2015;132:923–931.  heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet
CIRCULATIONAHA.114.014796 2022;400:1938–1952. 
473. Johansson I, Dahlström U, Edner M, Näsman P, Rydén L, Norhammar A. Prognostic 491. McMurray JJ, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al.
implications of type 2 diabetes mellitus in ischemic and nonischemic heart failure. J Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J
Am College Cardiol 2016;68:1404–1416.  Med 2019;381:1995–2008. 
474. Kristensen SL, Jhund PS, Lee MM, Køber L, Solomon SD, Granger CB, et al. Prevalence 492. Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, et al. Effects of
of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and asso- dapagliflozin on symptoms, function, and quality of life in patients with heart failure and
ciated clinical outcomes. Cardiovasc Drugs Ther 2017;31:545–549.  reduced ejection fraction: results from the DAPA-HF trial. Circulation 2020;141:
1007/s10557-017-6754-x 90–99. 
475. MacDonald MR, Petrie MC, Varyani F, Östergren J, Michelson EL, Young JB, et al. 493. Docherty KF, Jhund PS, Bengtsson O, DeMets DL, Inzucchi SE, Køber L, et al. Effect of
Impact of diabetes on outcomes in patients with low and preserved ejection fraction dapagliflozin in DAPA-HF according to background glucose-lowering therapy. Diabetes
heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction Care 2020;43:2878–2881. 
in Mortality and morbidity (CHARM) programme. Eur Heart J 2008;29:1377–1385. 494. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular
 and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:
476. Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, et al. Clinical and 1413–1424. 
echocardiographic characteristics and cardiovascular outcomes according to diabetes 495. Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CS, et al. Effect of empagliflozin
status in patients with heart failure and preserved ejection fraction: a report from the on cardiovascular and renal outcomes in patients with heart failure by baseline dia-
I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). betes status: results from the EMPEROR-reduced trial. Circulation 2021;143:
337–349. 
Circulation 2017;135:724–735. 
496. Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, et al. Empagliflozin and
024593
health-related quality of life outcomes in patients with heart failure with reduced ejec-
477. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of
tion fraction: the EMPEROR-Reduced trial. Eur Heart J 2021;42:1203–1212. 
candesartan in patients with chronic heart failure and preserved left-ventricular ejec-
org/10.1093/eurheartj/ehaa1007
tion fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–781. 
497. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibi-
10.1016/S0140-6736(03)14285-7
tors in patients with heart failure with reduced ejection fraction: a meta-analysis of the
478. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al.
EMPEROR-Reduced and DAPA-HF trials. Lancet 2020;396:819–829. 
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT):
10.1016/S0140-6736(20)31824-9
1-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016;18:
498. Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TD, Elvan A, et al.
613–625. 
Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects
479. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al.
of empagliflozin on clinical outcomes in patients with acute decompensated heart fail-
Universal definition and classification of heart failure: a report of the Heart Failure
ure (EMPA-RESPONSE-AHF). Eur J Heart Fail 2020;22:713–722. 
Society of America, Heart Failure Association of the European Society of
1002/ejhf.1713
Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal
499. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The
Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart
SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multi-
Failure Association of India, Cardiac Society of Australia and New Zealand, and
national randomized trial. Nat Med 2022;28:568–574. 
Chinese Heart Failure Association. Eur J Heart Fail 2021;23:352–380. 
021-01659-1
10.1002/ejhf.2115
500. Garg R, Yusuf S, Bussmann W, Sleight P, Uprichard A, Massie B, et al. Overview of ran-
480. Segar MW, Vaduganathan M, Patel KV, McGuire DK, Butler J, Fonarow GC, et al.
domized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity
Machine learning to predict the risk of incident heart failure hospitalization among pa-
in patients with heart failure. JAMA 1995;273:1450–1456. 
tients with diabetes: the WATCH-DM risk score. Diabetes Care 2019;42:2298–2306.
jama.1995.03520420066040

501. Gustafsson I, Torp-Pedersen C, Køber L, Gustafsson F, Hildebrandt P, Group TS.
481. Pandey A, Vaduganathan M, Patel KV, Ayers C, Ballantyne CM, Kosiborod MN, et al.
Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and
Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes.
morbidity in diabetic patients with left ventricular dysfunction after acute myocardial
Heart Fail 2021;9:215–223.  infarction. J Am College Cardiol 1999;34:83–89. 
482. Seferović P, Farmakis D, Bayes-Genis A, Gal TB, Böhm M, Chioncel O, et al.
1097(99)00146-1
Biomarkers for the prediction of heart failure and cardiovascular events in patients 502. Moye L, Pfeffer M, Wun C, Davis B, Geltman E, Hayes D, et al. Uniformity of captopril
with type 2 diabetes: a position statement from the Heart Failure Association of the benefit in the SAVE study: subgroup analysis. Eur Heart J 1994;15(Suppl B):2–8. https://
European Society of Cardiology. Eur J Heart Fail 2022;24:1162–1170.  doi.org/10.1093/eurheartj/15.suppl_B.2
10.1002/ejhf.2575 503. Shekelle PG, Rich MW, Morton SC, Atkinson CSW, Tu W, Maglione M, et al. Efficacy
483. Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, et al. State of of angiotensin-converting enzyme inhibitors and beta-blockers in the management of
the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10: left ventricular systolic dysfunction according to race, gender, and diabetic status: a
824–839.  meta-analysis of major clinical trials. J Am College Cardiol 2003;41:1529–1538. https://
484. Hildebrandt P, Collinson PO. Amino-terminal pro-B-type natriuretic peptide testing to doi.org/10.1016/S0735-1097(03)00262-6
assist the diagnostic evaluation of heart failure in symptomatic primary care patients. 504. Vijayakumar S, Butler J, Bakris GL. Barriers to guideline mandated renin–angiotensin
Am J Cardiol 2008;101:S25–S28.  inhibitor use: focus on hyperkalaemia. Eur Heart J Suppl 2019;21(Suppl A):A20–A27.
485. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T, et al. The 
diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary 505. Beldhuis IE, Streng KW, Ter Maaten JM, Voors AA, van der Meer P, Rossignol P, et al.
care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Renin–angiotensin system inhibition, worsening renal function, and outcome in heart
Heart Fail 2005;7:537–541.  failure patients with reduced and preserved ejection fraction: a meta-analysis of pub-
486. Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, lished study data. Circ Heart Fail 2017;10:e003588. 
BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J CIRCHEARTFAILURE.116.003588
Cardiol 2014;176:611–617.  506. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of
487. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JG, Kozhuharov N, et al. Heart kidney function throughout the heart failure trajectory–a position statement from the
Failure Association of the European Society of Cardiology practical guidance on the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020;
use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715–731. https:// 22:584–603. 
doi.org/10.1002/ejhf.1494 507. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spir-
488. Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJ, et al. onolactone on morbidity and mortality in patients with severe heart failure. N Engl J
The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review Med 1999;341:709–717. 
and diagnostic meta-analysis in the acute care setting. BMJ 2015;350:h910.  508. Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, et al.
org/10.1136/bmj.h910 Eplerenone and atrial fibrillation in mild systolic heart failure: results from the
Downloaded
from

by
guest
on
22
January
2026

4132 E S C G u id e l in e s
EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in 528. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, et al.
Heart Failure) study. J Am College Cardiol 2012;59:1598–1603.  The effect of diabetes on outcomes of patients with advanced heart failure in the BEST
1016/j.jacc.2011.11.063 trial. J Am College Cardiol 2003;42:914–922. 
509. Bobbio M, Ferrua S, Opasich C, Porcu M, Lucci D, Scherillo M, et al. Survival and hos- 00856-8
pitalization in heart failure patients with or without diabetes treated with β-blockers. J 529. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al.
Cardiac Fail 2003;9:192–202.  Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med
510. Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, et al. Efficacy, 2011;364:11–21. 
safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart 530. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in
failure: experiences from MERIT-HF. Am Heart J 2005;149:159–167.  heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–1461.
1016/j.ahj.2004.05.056 
511. Erdmann E, Philippe L, Patricia V, Hermann W. Results from post-hoc analyses of the 531. Filippatos G, Butler J, Farmakis D, Zannad F, Pernille Ofstad A, Pedro Ferreira J, et al.
CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and
Eur J Heart Fail 2001;3:469–479.  without diabetes. Circulation 2022;146:676–686. 
512. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of car- CIRCULATIONAHA.122.059785
vedilol on the morbidity of patients with severe chronic heart failure: results of the car- 532. Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al.
vedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N
2002;106:2194–2199.  Engl J Med 2022;387:1089–1098. 
513. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of 533. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF,
candesartan in patients with chronic heart failure and reduced left-ventricular systolic et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis
function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM- of five randomised controlled trials. Lancet 2022;400:757–767. 
Alternative trial. Lancet 2003;362:772–776.  1016/S0140-6736(22)01429-5
14284-5 534. Solomon SD, McMurray JJ, Anand IS, Ge J, Lam CS, Maggioni AP, et al. Angiotensin–
514. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with 2019;381:1609–1620. 
heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374: 535. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone
1840–1848.  for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–1392.
515. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN, et al. Effects of val-

sartan on morbidity and mortality in patients with heart failure not receiving
536. Cleland JG, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, et al. Perindopril for
angiotensin-converting enzyme inhibitors. J Am College Cardiol 2002;40:1414–1421.
elderly people with chronic heart failure: the PEP-CHF study. Eur J Heart Fail 1999;1:

211–217. 
516. Komajda M, Tavazzi L, Francq BG, Böhm M, Borer JS, Ford I, et al. Efficacy and safety of
537. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan
ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from
in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:
the SHIFT trial. Eur J Heart Fail 2015;17:1294–1301. 
2456–2467. 
517. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R Jr, Ferdinand K, et al.
538. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, et al. Effects of digoxin
African-American Heart Failure Trial Investigators. Combination of isosorbide dini-
on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation
trate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:
group trial. Circulation 2006;114:397–403. 
2049–2057. 
106.628347
518. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, et al. Early and sus-
539. Butler J, Anker SD, Filippatos G, Usman MS, Ferreira JP, Zannad F, et al. Sodium glucose
tained benefit on event-free survival and heart failure hospitalization from fixed-dose
co-transporter inhibitors and heart failure outcomes across different patient popula-
combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the
tions. Eur Heart J 2021;42:4887–4890. 
African-American Heart Failure Trial. Circulation 2007;115:1747–1753. 
540. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RH, et al. Effect of
org/10.1161/CIRCULATIONAHA.106.644013
dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019;
519. Abdul-Rahim AH, MacIsaac RL, Jhund PS, Petrie MC, Lees KR, McMurray JJ, et al.
139:2528–2536. 
Efficacy and safety of digoxin in patients with heart failure and reduced ejection frac-
541. Cosentino F, Cannon CP, Cherney DZ, Masiukiewicz U, Pratley R, Dagogo-Jack S, et al.
tion according to diabetes status: an analysis of the Digitalis Investigation Group (DIG)
Efficacy of ertugliflozin on heart failure–related events in patients with type 2 diabetes
trial. Int J Cardiol 2016;209:310–316. 
mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS
520. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence
CV Trial. Circulation 2020;142:2205–2215. 
supporting the role of diuretics in heart failure: a meta analysis of randomised con-
120.050255
trolled trials. Int J Cardiol 2002;82:149–158. 
542. Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, 00600-3
et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:
521. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al.
1436–1446. 
The use of diuretics in heart failure with congestion—a position statement from the
543. EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney
Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail
disease. N Engl J Med 2023;388:117–127. 
2019;21:137–155. 
544. Marso SP, Baeres FM, Bain SC, Goldman B, Husain M, Nauck MA, et al. Effects of lir-
522. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al.
Cardiac-resynchronization therapy with or without an implantable defibrillator in ad- aglutide on cardiovascular outcomes in patients with diabetes with or without heart
vanced chronic heart failure. N Engl J Med 2004;350:2140–2150.  failure. J Am College Cardiol 2020;75:1128–1141. 
1056/NEJMoa032423 12.063
523. Ghali JK, Boehmer J, Feldman AM, Saxon LA, Demarco T, Carson P, et al. Influence of 545. Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al. GLP-1
diabetes on cardiac resynchronization therapy with or without defibrillator in patients receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated
with advanced heart failure. J Cardiac Fail 2007;13:769–773.  meta-analysis of eight CVOTs. Cardiovasc Diabetol 2021;20:189. 
cardfail.2007.06.723 1186/s12933-021-01366-8
524. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator im- 546. Lam CS, Ramasundarahettige C, Branch KR, Sattar N, Rosenstock J, Pratley R, et al.
plantation in patients with nonischemic systolic heart failure. N Engl J Med 2016; Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose
375:1221–1230.  co-transporter-2 inhibition use in type 2 diabetes: exploratory analysis of the
525. Rørth R, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. The effect of implan- AMPLITUDE-O trial. Circulation 2021;145:565–574. 
table cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic CIRCULATIONAHA.121.057934
heart failure. Europace 2019;21:1203–1210.  547. Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J,
526. Kilic A, Weiss ES, George TJ, Arnaoutakis GJ, Yuh DD, Shah AS, et al. What predicts et al. Glucagon-like peptide 1 receptor agonists and heart failure: the need for further
long-term survival after heart transplantation? An analysis of 9,400 ten-year survivors. evidence generation and practice guidelines optimization. Circulation 2020;142:
Ann Thorac Surg 2012;93:699–704.  1205–1218. 
527. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, et al. Risk related to 548. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of
pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection frac- liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable
tion: insights from prospective comparison of ARNI with ACEI to determine impact chronic heart failure patients with and without diabetes (LIVE)—a multicentre,
on global mortality and morbidity in heart failure trial. Circ Heart Fail 2016;9: double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19:69–77.
e002560.  
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4133
549. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. 569. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al. Impact of diabetes
Effects of liraglutide on clinical stability among patients with advanced heart failure on long-term prognosis in patients with unstable angina and non-Q-wave myocardial
and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500–508. infarction: results of the OASIS (Organization to Assess Strategies for Ischemic
 Syndromes) Registry. Circulation 2000;102:1014–1019. 
550. Lepore JJ, Olson E, Demopoulos L, Haws T, Fang Z, Barbour AM, et al. Effects of the CIR.102.9.1014
novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, 570. Scirica BM, Bhatt DL, Braunwald E, Raz I, Cavender MA, Im K, et al. Prognostic implica-
and exercise capacity in patients with chronic heart failure and reduced ejection frac- tions of biomarker assessments in patients with type 2 diabetes at high cardiovascular
tion. JACC Heart Fail 2016;4:559–566.  risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol 2016;1:989–998.
551. McMurray JJ, Ponikowski P, Bolli GB, Lukashevich V, Kozlovski P, Kothny W, et al. 
Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus 571. Tse G, Lai ETH, Tse V, Yeo JM. Molecular and electrophysiological mechanisms under-
and heart failure: a randomized placebo-controlled trial. JACC Heart Fail 2018;6: lying cardiac arrhythmogenesis in diabetes mellitus. J Diabetes Res 2016;2016:
8–17. 
2848759. 
552. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a
572. Koektuerk B, Aksoy M, Horlitz M, Bozdag-Turan I, Turan RG. Role of diabetes in heart
marked increase in mortality in patients with advanced heart failure. Am Heart J
rhythm disorders. World J Diabetes 2016;7:45. 
2005;149:168–174. 
573. Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D’Agostino RB, et al. Trends in cardio-
553. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, et al. Basal insulin and
vascular complications of diabetes. JAMA 2004;292:2495–2499. 
cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319–328.
1001/jama.292.20.2495

574. Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB. The impact of diabetes mellitus and
554. Pratley RE, Husain M, Lingvay I, Pieber TR, Mark T, Saevereid HA, et al. Heart failure
prior myocardial infarction on mortality from all causes and from coronary heart dis-
with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk
ease in men. J Am College Cardiol 2002;40:954–960. 
of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol 2019;18:156. 
1097(02)02044-2
org/10.1186/s12933-019-0960-8
575. Balkau B, Jouven X, Ducimetière P, Eschwège E. Diabetes as a risk factor for sudden
555. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical out-
death. Lancet 1999;354:1968–1969. 
comes associated with metformin in patients with diabetes and heart failure. Diabetes
576. Gorenek B, Boriani G, Dan G-A, Fauchier L, Fenelon G, Huang H, et al. European Heart
Care 2005;28:2345–2351. 
Rhythm Association (EHRA) position paper on arrhythmia management and device
556. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM.
therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society
Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart
failure: an observational study. Circulation 2005;111:583–590.  (APHRS) and Latin American Heart Rhythm Society (LAHRS). Europace 2018;20:
01.CIR.0000154542.13412.B1 895–896. 
557. Ekström N, Schiöler L, Svensson A-M, Eeg-Olofsson K, Jonasson JM, Zethelius B, et al. 577. Fauchier L, Boriani G, de Groot JR, Kreutz R, Rossing P, Camm AJ. Medical therapies
Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and dif- for prevention of cardiovascular and renal events in patients with atrial fibrillation and
ferent levels of renal function: a cohort study from the Swedish National Diabetes diabetes mellitus. Europace 2021;23:1873–1891. 
Register. BMJ Open 2012;2:e001076.  euab184
558. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. 578. Rautio E, Gadler F, Gudbjörnsdottir S, Franzén S, Rydén L, Svensson A-M, et al. Patients
Comparative safety and effectiveness of metformin in patients with diabetes mellitus with type 2 diabetes have an increased demand for pacemaker treatment: a compari-
and heart failure: systematic review of observational studies involving 34000 patients. son with age-and sex-matched control subjects from the general population. Diabetes
Circ Heart Fail 2013;6:395–402.  Care 2020;43:2853–2858. 
000162 579. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021
559. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: developed by
2 diabetes and kidney disease: a systematic review. JAMA 2014;312:2668–2675. https:// the Task Force on cardiac pacing and cardiac resynchronization therapy of the
doi.org/10.1001/jama.2014.15298 European Society of Cardiology (ESC) with the special contribution of the
560. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. The risk of devel- European Heart Rhythm Association (EHRA). Eur Heart J 2022;24:71–164. https://
oping coronary artery disease or congestive heart failure, and overall mortality, in type doi.org/10.1093/eurheartj/ehab364
2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulphonylureas: 580. Jansen HJ, Bohne LJ, Gillis AM, Rose RA. Atrial remodeling and atrial fibrillation in ac-
a retrospective analysis. Acta Diabetol 2009;46:145–154.  quired forms of cardiovascular disease. Heart Rhythm O2 2020;1:147–159. 
s00592-008-0090-3 org/10.1016/j.hroo.2020.05.002
561. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular 581. Reuter H, Grönke S, Adam C, Ribati M, Brabender J, Zobel C, et al. Sarcoplasmic Ca2
disease and all cause mortality among patients with type 2 diabetes prescribed oral + release is prolonged in nonfailing myocardium of diabetic patients. Mol Cell Biochem
antidiabetes drugs: retrospective cohort study using UK general practice research 2008;308:141–149. 
database. BMJ 2009;339:b4731.  582. Lamberts RR, Lingam SJ, Wang H-Y, Bollen IA, Hughes G, Galvin IF, et al. Impaired re-
562. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, et al. A Diabetes
laxation despite upregulated calcium-handling protein atrial myocardium from type 2
Outcome Progression Trial (ADOPT). An international multicenter study of the com- diabetic patients with preserved ejection fraction. Cardiovasc Diabetol 2014;13:72.
parative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 
diabetes. Diabetes Care 2002;25:1737–1743. 
583. Sedgwick B, Riches K, Bageghni SA, O’Regan DJ, Porter KE, Turner NA. Investigating
1737
inherent functional differences between human cardiac fibroblasts cultured from non-
563. Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, et al. Effect of
diabetic and type 2 diabetic donors. Cardiovasc Pathol 2014;23:204–210. 
nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;
org/10.1016/j.carpath.2014.03.004
362:1463–1476. 
584. Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, Crow R, et al. A
564. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of
clinical risk score for atrial fibrillation in a biracial prospective cohort (from the
macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ
Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2011;107:85–91.
1998;317:703–713. 

565. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosigli-
585. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and pre-
tazone on the frequency of diabetes in patients with impaired glucose tolerance or im-
paired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096–1105. disposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol
 1998;82:2N–9N. 
566. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of 586. Dahlqvist S, Rosengren A, Gudbjörnsdottir S, Pivodic A, Wedel H, Kosiborod M, et al.
heart failure in patients with or at high risk of type 2 diabetes mellitus. Am J Cardiovasc Risk of atrial fibrillation in people with type 1 diabetes compared with matched con-
Drugs 2011;11:115–128.  trols from the general population: a prospective case-control study. Lancet Diabetes
567. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Endocrinol 2017;5:799–807. 
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination ther- 587. Lee Y-B, Han K, Kim B, Lee S-E, Jun JE, Ahn J, et al. Risk of early mortality and cardio-
apy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. vascular disease in type 1 diabetes: a comparison with type 2 diabetes, a nationwide
Lancet 2009;373:2125–2135.  study. Cardiovasc Diabetol 2019;18:157. 
568. Fitchett D, Inzucchi SE, Wanner C, Mattheus M, George JT, Vedin O, et al. Relationship 588. Bisson A, Bodin A, Fauchier G, Herbert J, Angoulvant D, Ducluzeau PH, et al. Sex, age,
between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a
EMPA-REG OUTCOME® trial. Eur Heart J 2020;41:209–217.  nationwide analysis. Cardiovasc Diabetol 2021;20:1–11. 
eurheartj/ehz621 s12933-021-01216-7
Downloaded
from

by
guest
on
22
January
2026

4134 E S C G u id e l in e s
589. Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, et al. Diabetes melli- 609. Gallagher C, Hendriks JM, Mahajan R, Middeldorp ME, Elliott AD, Pathak RK, et al.
tus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med 2010;25:853–858. Lifestyle management to prevent and treat atrial fibrillation. Expert Rev Cardiovas
 Ther 2016;14:799–809. 
590. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case–control 610. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation
studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011; of risk stratification schemes for predicting stroke and thromboembolism in patients
108:56–62.  with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124. 
591. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for 1136/bmj.d124
stroke: the Framingham Study. Stroke 1991;22:983–988.  611. Nichols GA, Reinier K, Chugh SS. Independent contribution of diabetes to increased
str.22.8.983 prevalence and incidence of atrial fibrillation. Diabetes Care 2009;32:1851–1856.
592. Mahmoodi BK, Yatsuya H, Matsushita K, Sang Y, Gottesman RF, Astor BC, et al. 
Association of kidney disease measures with ischemic versus hemorrhagic strokes: 612. Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J, et al. Screening for
pooled analyses of 4 prospective community-based cohorts. Stroke 2014;45: atrial fibrillation: a report of the AF-SCREEN International Collaboration. Circulation
1925–1931.  2017;135:1851–1867. 
593. Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. Circ 613. Svennberg E, Tjong F, Goette A, Akoum N, Di Biase L, Bordachar P, et al. How to use
Res 2017;120:472–495.  digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace
594. Patlolla SH, Lee H-C, Noseworthy PA, Wysokinski WE, Hodge DO, Greene EL, et al. 2022;24:979–1005. 
Impact of diabetes mellitus on stroke and survival in patients with atrial fibrillation. Am J 614. Mairesse GH, Moran P, Van Gelder IC, Elsner C, Rosenqvist M, Mant J, et al. Screening
Cardiol 2020;131:33–39.  for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus docu-
595. Melduni RM, Lee H-C, Bailey KR, Miller FA Jr, Hodge DO, Seward JB, et al. Real-time ment endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society
physiologic biomarker for prediction of atrial fibrillation recurrence, stroke, and mor- (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia
tality after electrical cardioversion: a prospective observational study. Am Heart J 2015; (SOLAECE). Europace 2017;19:1589–1623. 
170:914–922.  615. Forleo GB, Mantica M, De Luca L, Leo R, Santini L, Panigada S, et al. Catheter ablation
596. Karayiannides S, Norhammar A, Landstedt-Hallin L, Friberg L, Lundman P. Prognostic of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized
impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J
hypoglycaemia: a nationwide cohort study. Eur J Prev Cardiol 2022;29:1759–1769. Cardiovasc Electrophysiol 2009;20:22–28. 
 01275.x
597. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial 616. Anselmino M, Matta M, D’ascenzo F, Pappone C, Santinelli V, Bunch TJ, et al. Catheter
ablation of atrial fibrillation in patients with diabetes mellitus: a systematic review and
fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J
meta-analysis. Europace 2015;17:1518–1525. 
Med 1995;98:476–484. 
euv214
598. Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, et al. Metabolic
617. Bogossian H, Frommeyer G, Brachmann J, Lewalter T, Hoffmann E, Kuck KH, et al.
syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine
Catheter ablation of atrial fibrillation and atrial flutter in patients with diabetes mellitus:
study. Circulation 2008;117:1255–1260. 
who benefits and who does not? Data from the German ablation registry. Int J Cardiol
107.744466
2016;214:25–30. 
599. Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk of in-
618. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification
cident atrial fibrillation in women. J Am College Cardiol 2012;60:1421–1428. 
for predicting stroke and thromboembolism in atrial fibrillation using a novel risk
org/10.1016/j.jacc.2012.06.030
factor-based approach: the Euro heart survey on atrial fibrillation. Chest 2010;137:
600. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020
263–272. 
ESC Guidelines for the diagnosis and management of atrial fibrillation developed in col-
619. Hughes M, Lip GY. Guideline Development Group for the NICE National Clinical
laboration with the European Association for Cardio-Thoracic Surgery (EACTS): the
Guideline for Management of Atrial Fibrillation in Primary Secondary Care. Stroke
Task Force for the diagnosis and management of atrial fibrillation of the European
and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors,
Society of Cardiology (ESC) developed with the special contribution of the
risk stratification schema and cost effectiveness data. Thromb Haemost 2008;99:
European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:
295–304. 
373–498. 
620. Aronow WS, Ahn C, Kronzon I, Gutstein H. Risk factors for new thromboembolic
601. Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, et al. Impact of in-
stroke in patients ≥62 years of age with chronic atrial fibrillation. Am J Cardiol 1998;
tensive glycemic control on the incidence of atrial fibrillation and associated cardiovas-
82:A9. 
cular outcomes in patients with type 2 diabetes mellitus (from the Action to Control
621. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in
Cardiovascular Risk in Diabetes Study). Am J Cardiol 2014;114:1217–1222. 
patients with atrial fibrillation: a systematic review. Neurology 2007;69:546–554.
org/10.1016/j.amjcard.2014.07.045

602. Liou Y-S, Yang F-Y, Chen H-Y, Jong G-P. Antihyperglycemic drugs use and new-onset 622. Wang A, Green JB, Halperin JL, Piccini JP. Atrial fibrillation and diabetes mellitus: JACC
atrial fibrillation: a population-based nested case control study. PLoS One 2018;13:
review topic of the week. J Am College Cardiol 2019;74:1107–1115. 
e0197245. 
1016/j.jacc.2019.07.020
603. Zelniker TA, Bonaca MP, Furtado RH, Mosenzon O, Kuder JF, Murphy SA, et al. Effect
623. Proietti M, Lane DA, Boriani G, Lip GY. Stroke prevention, evaluation of bleeding risk,
of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights and anticoagulant treatment management in atrial fibrillation contemporary inter-
from the DECLARE-TIMI 58 trial. Circulation 2020;141:1227–1234.  national guidelines. Can J Cardiol 2019;35:619–633. 
10.1161/CIRCULATIONAHA.119.044183 2019.02.009
604. Böhm M, Slawik J, Brueckmann M, Mattheus M, George JT, Ofstad AP, et al. Efficacy of 624. Fauchier L, Bodin A, Bisson A. Editorial commentary: the CHA2DS2VASc score and its
empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data black and white items. Trends Cardiovasc Med 2019;29:392–393. 
from the EMPA-REG OUTCOME trial. Eur J Heart Fail 2020;22:126–135.  1016/j.tcm.2018.11.012
org/10.1002/ejhf.1663 625. Fangel MV, Nielsen PB, Kristensen JK, Larsen TB, Overvad TF, Lip GY, et al. Glycemic
605. Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, et al. Finerenone re- status and thromboembolic risk in patients with atrial fibrillation and type 2 diabetes
duces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 mellitus: a Danish cohort study. Circ Arrhythm Electrophysiol 2019;12:e007030. https://
diabetes. J Am College Cardiol 2021;78:142–152.  doi.org/10.1161/CIRCEP.118.007030
04.079 626. Lip GY, Clementy N, Pierre B, Boyer M, Fauchier L. The impact of associated diabetic
606. Neefs J, Van den Berg N, Limpens J, Berger W, Boekholdt S, Sanders P, et al. retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrilla-
Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and tion: the Loire Valley Atrial Fibrillation Project. Chest 2015;147:1103–1110. https://
meta-analysis. Int J Cardiol 2017;231:155–161.  doi.org/10.1378/chest.14-2096
12.029 627. Itzhaki Ben Zadok O, Eisen A. Use of non-vitamin K oral anticoagulants in people with
607. Du X, Ninomiya T, De Galan B, Abadir E, Chalmers J, Pillai A, et al. Risks of cardiovas- atrial fibrillation and diabetes mellitus. Diabet Med 2018;35:548–556. 
cular events and effects of routine blood pressure lowering among patients with type 2 10.1111/dme.13600
diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009;30: 628. Plitt A, McGuire DK, Giugliano RP. Atrial fibrillation, type 2 diabetes, and non–vitamin
1128–1135.  K antagonist oral anticoagulants: a review. JAMA Cardiol 2017;2:442–448. 
608. Aksnes TA, Schmieder RE, Kjeldsen SE, Ghani S, Hua TA, Julius S. Impact of new-onset org/10.1001/jamacardio.2016.5224
diabetes mellitus on development of atrial fibrillation and heart failure in high-risk 629. Plitt A, Zelniker TA, Park J-G, McGuire DK, Ruff CT, Antman EM, et al. Patients with
hypertension (from the VALUE Trial). Am J Cardiol 2008;101:634–638.  diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral antic-
org/10.1016/j.amjcard.2007.10.025 oagulants: meta-analysis of eight outcomes in 58634 patients across four randomized
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4135
controlled trials. Eur Heart J Cardiovasc Pharmacother 2021;7:f40–f49.  651. Tanenberg RJ, Newton CA, Drake AJ III. Confirmation of hypoglycemia in the
10.1093/ehjcvp/pvaa120 “dead-in-bed” syndrome, as captured by a retrospective continuous glucose monitor-
630. Fitzmaurice DA, Hobbs FR, Jowett S, Mant J, Murray ET, Holder R, et al. Screening ver- ing system. Endocr Pract 2010;16:244–248. 
sus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster 652. NICE-Sugar Study Investigators. Hypoglycemia and risk of death in critically ill patients.
randomised controlled trial. BMJ 2007;335:383.  N Engl J Med 2012;367:1108–1118. 
660567.55 653. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al.
631. Pallisgaard JL, Schjerning A-M, Lindhardt TB, Procida K, Hansen ML, Torp-Pedersen C, Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl
et al. Risk of atrial fibrillation in diabetes mellitus: a nationwide cohort study. Eur J Prev J Med 2011;364:818–828. 
Cardiol 2016;23:621–627.  654. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of
632. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559.
factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. 
JAMA 1994;271:840–844.  655. Laurita KR, Khan S, McMahon T, Dennis AT, Li V, Gaivin R, et al. Ventricular arrhyth-
633. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial mias in mouse models of diabetic kidney disease. Sci Rep 2021;11:20570. 
fibrillation. Thromb Haemost 2013;110:213–222.  org/10.1038/s41598-021-99891-9
0165 656. Chow E, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J, et al. Risk of cardiac
634. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibril- arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular
lation in a 75-year-old population: implications for stroke prevention. Circulation 2013; risk. Diabetes 2014;63:1738–1747. 
127:930–937.  657. Hay L, Wilmshurst E, Fulcher G. Unrecognized hypo- and hyperglycemia in well-
635. Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M. Clinical out- controlled patients with type 2 diabetes mellitus: the results of continuous glucose
comes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, monitoring. Diab Technol Therap 2003;5:19–26. 
parallel group, unmasked, randomised controlled trial. Lancet 2021;398:1498–1506. 763816427
658. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al.

636. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and
stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146: the prevention of sudden cardiac death: the Task Force for the management of pa-
tients with ventricular arrhythmias and the prevention of sudden cardiac death of
857–867. 
637. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. the European Society of Cardiology (ESC) endorsed by: association for European
Paediatric and Congenital Cardiology (AEPC). Europace 2015;17:1601–1687. https://
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in pa-
doi.org/10.1093/europace/euv319
tients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:
659. Ruwald MH, Zareba W, Jons C, Zhang C, Ruwald A-CH, Olshansky B, et al. Influence of
955–962. 
diabetes mellitus on inappropriate and appropriate implantable cardioverter-
638. Nielsen PB, Larsen TB, Skjøth F, Overvad TF, Lip GY. Stroke and thromboembolic
defibrillator therapy and mortality in the Multicenter Automatic Defibrillator
event rates in atrial fibrillation according to different guideline treatment thresholds:
Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) Trial. Circulation
a nationwide cohort study. Sci Rep 2016;6:27410. 
2013;128:694–701. 
639. Fauchier L, Clementy N, Bisson A, Ivanes F, Angoulvant D, Babuty D, et al. Should atrial
660. Cardoso CR, Salles GF, Deccache W. Prognostic value of QT interval parameters in
fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be an-
type 2 diabetes mellitus: results of a long-term follow-up prospective study. J
ticoagulated? Stroke 2016;47:1831–1836. 
Diabetes Complications 2003;17:169–178. 
013253
00206-4
640. Shin SY, Han S-J, Kim J-S, Im SI, Shim J, Ahn J, et al. Identification of markers associated
661. Kobayashi S, Nagao M, Asai A, Fukuda I, Oikawa S, Sugihara H. Severity and multiplicity
with development of stroke in “clinically low-risk” atrial fibrillation patients. J Am Heart
of microvascular complications are associated with QT interval prolongation in pa-
Assoc 2019;8:e012697. 
tients with type 2 diabetes. J Diabetes Invest 2018;9:946–951. 
641. Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJ, Lip GY. A novel user-friendly
1111/jdi.12772
score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibril-
662. Molon G, Costa A, Bertolini L, Zenari L, Arcaro G, Barbieri E, et al. Relationship be-
lation: the Euro Heart Survey. Chest 2010;138:1093–1100. 
tween abnormal microvolt T-wave alternans and poor glycemic control in type 2 dia-
chest.10-0134
betic patients. Pacing Clin Electrophysiol 2007;30:1267–1272. 
642. Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R, et al. Predicting
1540-8159.2007.00849.x
thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation:
663. O’Brien I, O’Hare J, Lewin I, Corrall R. The prevalence of autonomic neuropathy in
a systematic review. Thromb Haemost 2018;118:2171–2187. 
insulin-dependent diabetes mellitus: a controlled study based on heart rate variability.
0038-1675400 Q J Med 1986;61:957–967. 
643. Chang G, Xie Q, Ma L, Hu K, Zhang Z, Mu G, et al. Accuracy of HAS-BLED and other
664. Tsuji H, Venditti Jr FJ, Manders ES, Evans JC, Larson MG, Feldman CL, et al. Reduced
bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation: a
heart rate variability and mortality risk in an elderly cohort. The Framingham Heart
network meta-analysis. J Thromb Haemost 2020;18:791–801. 
Study. Circulation 1994;90:878–883. 
jth.14692 665. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007;
644. Jouven X, Lemaître RN, Rea TD, Sotoodehnia N, Empana J-P, Siscovick DS. Diabetes, 115:387–397. 
glucose level, and risk of sudden cardiac death. Eur Heart J 2005;26:2142–2147. https:// 666. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, et al. The ef-
doi.org/10.1093/eurheartj/ehi376 fect of empagliflozin on arterial stiffness and heart rate variability in subjects with un-
645. Kucharska-Newton AM, Couper DJ, Pankow JS, Prineas RJ, Rea TD, Sotoodehnia N, complicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014;13:28. 
et al. Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in 10.1186/1475-2840-13-28
Communities study. Acta Diabetol 2010;47:161–168.  667. Balcıoğlu S, Arslan U, Türkoğlu S, Özdemir M, Çengel A. Heart rate variability and heart
009-0157-9 rate turbulence in patients with type 2 diabetes mellitus with versus without cardiac
646. Eranti A, Kerola T, Aro AL, Tikkanen JT, Rissanen HA, Anttonen O, et al. Diabetes, autonomic neuropathy. Am J Cardiol 2007;100:890–893. 
glucose tolerance, and the risk of sudden cardiac death. BMC Cardiovasc Disord amjcard.2007.03.106
2016;16:51.  668. Bissinger A, Ruxer J, Ahmed RB, Lubinski A. Heart rate turbulence in patients with
647. Zaccardi F, Khan H, Laukkanen JA. Diabetes mellitus and risk of sudden cardiac death: a poorly controlled diabetes mellitus type 2. Arch Med Sci 2014;10:1073–1077. https://
systematic review and meta-analysis. Int J Cardiol 2014;177:535–537.  doi.org/10.5114/aoms.2014.47819
10.1016/j.ijcard.2014.08.105 669. Kuppermann N, Park J, Glatter K, Marcin JP, Glaser NS. Prolonged QT interval cor-
648. Kannel WB, Wilson PW, D’Agostino RB, Cobb J. Sudden coronary death in women. rected for heart rate during diabetic ketoacidosis in children. Arch Pediatr Adolesc
Am Heart J 1998;136:205–212.  Med 2008;162:544–549. 
649. Chen-Scarabelli C, Scarabelli TM. Suboptimal glycemic control, independently of QT 670. Murphy N, Ford-Adams M, Ong K, Harris N, Keane S, Davies C, et al. Prolonged car-
interval duration, is associated with increased risk of ventricular arrhythmias in a high- diac repolarisation during spontaneous nocturnal hypoglycaemia in children and ado-
risk population. Pacing Clin Electrophysiol 2006;29:9–14.  lescents with type 1 diabetes. Diabetologia 2004;47:1940–1947. 
8159.2006.00298.x 1007/s00125-004-1552-y
650. Secrest A, Becker D, Kelsey S, Laporte R, Orchard T. Characterizing sudden death and 671. Ninkovic VM, Ninkovic SM, Miloradovic V, Stanojevic D, Babic M, Giga V, et al.
dead-in-bed syndrome in type 1 diabetes: analysis from two childhood-onset type 1 Prevalence and risk factors for prolonged QT interval and QT dispersion in patients
diabetes registries. Diabet Med 2011;28:293–300.  with type 2 diabetes. Acta Diabetol 2016;53:737–744. 
5491.2010.03154.x s00592-016-0864-y
Downloaded
from

by
guest
on
22
January
2026

4136 E S C G u id e l in e s
672. Marfella R, Rossi F, Giugliano D. Hyperglycemia and QT interval: time for re-evaluation. 694. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of
Diabetes Nutr Metab 2001;14:63–65. phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular
673. Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, et al. Effect of da- disease in individuals with chronic kidney disease: a systematic review and
pagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in meta-analysis. JAMA 2011;305:1119–1127. 
DAPA-HF. Eur Heart J 2021;42:3727–3738.  695. Zhu P, Herrington WG, Haynes R, Emberson J, Landray MJ, Sudlow CL, et al.
ehab560 Conventional and genetic evidence on the association between adiposity and CKD.
674. Light PE. Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart fail- J Am Soc Nephrol 2021;32:127–137. 
ure. Eur Heart J 2021;42:3739–3740.  696. Herrington WG, Smith M, Bankhead C, Matsushita K, Stevens S, Holt T, et al.
675. Sfairopoulos D, Zhang N, Wang Y, Chen Z, Letsas KP, Tse G, et al. Association be- Body-mass index and risk of advanced chronic kidney disease: prospective analyses
tween sodium–glucose cotransporter-2 inhibitors and risk of sudden cardiac death from a primary care cohort of 1.4 million adults in England. PLoS One 2017;12:
or ventricular arrhythmias: a meta-analysis of randomized controlled trials. Europace e0173515. 
2022;24:20–30.  697. Cholesterol Treatment Trialists’ (CTT) Collaboration. Impact of renal function on the
676. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of in-
chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of dividual participant data from 28 randomised trials. Lancet Diab Endocrinol 2016;4:
Disease Study 2017. Lancet 2020;395:709–733.  829–839. 
6736(20)30045-3 698. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects
677. Kidney Disease: Improving Global Outcomes, CKD Work Group. KDIGO 2012 clin- of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic
ical practice guideline for the evaluation and management of chronic kidney disease. kidney disease (Study of Heart and Renal Protection): a randomised placebo-
Kidney Int 2013;3:1–150.  controlled trial. Lancet 2011;377:2181–2192. 
678. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- 6736(11)60739-3
and cystatin C-based equations to estimate GFR without race. N Engl J Med 2021;385: 699. Charytan DM, Sabatine MS, Pedersen TR, Im K, Park J-G, Pineda AL, et al. Efficacy and
1737–1749.  safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am College
679. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary Cardiol 2019;73:2961–2970. 
events in people with chronic kidney disease compared with those with diabetes: a 700. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/
population-level cohort study. Lancet 2012;380:807–814.  EAS guidelines for the management of dyslipidaemias: lipid modification to reduce car-
diovascular risk. Atherosclerosis 2019;290:140–205. 
S0140-6736(12)60572-8
680. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y. Chronic kidney disease and the atherosclerosis.2019.08.014
701. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al.
risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J
1296–1305. 
Med 2009;360:1395–1407. 
681. Levey AS, Eckardt K-U, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, et al.
702. Wanner C, Krane V, März W, Olschewski M, Asmus H-G, Krämer W, et al.
Nomenclature for kidney function and disease: report of a Kidney Disease:
Randomized controlled trial on the efficacy and safety of atorvastatin in patients
Improving Global Outcomes (KDIGO) consensus conference. Kidney Int 2020;97:
with type 2 diabetes on hemodialysis (4D study): demographic and baseline character-
1117–1129. 
istics. Kidney Blood Pressure Res 2004;27:259–266. 
682. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular
703. Reith C, Staplin N, Herrington W, Stevens W, Emberson J, Haynes R, et al. Effect on
filtration rate and albuminuria with all-cause and cardiovascular mortality in general
non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney
population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073–2081.
disease: results from the Study of Heart and Renal Protection. BMC Nephrol 2017;

18:147. 
683. Park JI, Baek H, Kim BR, Jung HH. Comparison of urine dipstick and albumin: creatinine
704. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of flu-
ratio for chronic kidney disease screening: a population-based study. PLoS One 2017;
vastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised,
12:e0171106. 
placebo-controlled trial. Lancet 2003;361:2024–2031. 
684. Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change
6736(03)13638-0
in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific
705. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-
workshop sponsored by the National Kidney Foundation in collaboration with the US
enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456–1462.
Food and Drug Administration and European Medicines Agency. Am J Kidney Dis 2020;

75:84–104. 
706. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving H-H, et al.
685. Levin A, Agarwal R, Herrington WG, Heerspink HL, Mann JF, Shahinfar S, et al.
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 dia-
International consensus definitions of clinical trial outcomes for kidney failure: 2020.
betes and nephropathy. N Engl J Med 2001;345:861–869. 
Kidney Int 2020;98:849–859. 
NEJMoa011161
686. Park M, Hsu C-Y, Li Y, Mishra RK, Keane M, Rosas SE, et al. Associations between kid- 707. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective
ney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol 2012;23:
effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy
1725–1734.  due to type 2 diabetes. N Engl J Med 2001;345:851–860. 
687. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Long-term evolu-
NEJMoa011303
tion of cardiomyopathy in dialysis patients. Kidney Int 1998;54:1720–1725.  708. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al.
org/10.1046/j.1523-1755.1998.00154.x The effect of irbesartan on the development of diabetic nephropathy in patients with
688. Suzuki T, Agarwal SK, Deo R, Sotoodehnia N, Grams ME, Selvin E, et al. Kidney func- type 2 diabetes. N Engl J Med 2001;345:870–878. 
tion and sudden cardiac death in the community: the Atherosclerosis Risk in 011489
Communities (ARIC) Study. Am Heart J 2016;180:46–53.  709. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Prevention of
ahj.2016.07.004 transition from incipient to overt nephropathy with telmisartan in patients with
689. Kono K, Fujii H, Nakai K, Goto S, Shite J, Hirata K-I, et al. Composition and plaque pat- type 2 diabetes. Diabetes Care 2007;30:1577–1578. 
terns of coronary culprit lesions and clinical characteristics of patients with chronic kid- 710. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al.
ney disease. Kidney Int 2012;82:344–351.  Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J
690. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media cal- Med 2013;369:1892–1903. 
cification in end-stage renal disease: impact on all-cause and cardiovascular mortality. 711. Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, et al. Effects of
Nephrol Dial Transplant 2003;18:1731–1740.  dapagliflozin on major adverse kidney and cardiovascular events in patients with dia-
691. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work betic and non-diabetic chronic kidney disease: a prespecified analysis from the
Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, DAPA-CKD trial. Lancet Diabetes Endocrinol 2021;9:22–31. 
prevention, and treatment of chronic kidney disease–Mineral and Bone Disorder S2213-8587(20)30369-7
(CKD-MBD). Kidney Int Suppl 2017;7:1–59.  712. Cherney DZ, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, et al. Pooled
692. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular analysis of Phase III trials indicate contrasting influences of renal function on blood
system. Circulation 2007;116:85–97.  pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int 2018;
106.678342 93:231–244. 
693. Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, Cass A, et al. Blood pressure low- 713. Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, et al.
ering and major cardiovascular events in people with and without chronic kidney dis- Relative and absolute risk reductions in cardiovascular and kidney outcomes with ca-
ease: meta-analysis of randomised controlled trials. BMJ 2013;347:f5680.  nagliflozin across KDIGO risk categories: findings from the CANVAS program. Am J
org/10.1136/bmj.f5680 Kidney Dis 2021;77:23–34.e1. 
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4137
714. The Nuffield Department of Population Health Renal Studies Group, SGLT2 Inhibitor randomised trial. Lancet Diabetes Endocrinol 2018;6:605–617. 
Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of 1016/S2213-8587(18)30104-9
sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collabora- 734. ClinicalTrials.gov. FLOW: A Research Study to See How Semaglutide Works Compared to
tive meta-analysis of large placebo-controlled trials. Lancet 2022;400:1788–1801. Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW). https://
 clinicaltrials.gov/ct2/show/NCT03819153(4 March 2023)
715. Staplin N, Roddick AJ, Emberson J, Reith C, Riding A, Wonnacott A, et al. Net effects of 735. Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, et al.
sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2022;2:
of large placebo-controlled randomized trials. EClinicalMedicine 2021;41:101163. CD008834. 
 736. Molnar AO, Bota SE, Garg AX, Harel Z, Lam N, McArthur E, et al. The risk of major
716. Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, et al. Effects of sotagli- hemorrhage with CKD. J Am Soc Nephrol 2016;27:2825–2832. 
flozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017;377: ASN.2015050535
2337–2348.  737. ClinicalTrials.gov. Aspirin to Target Arterial Events in Chronic Kidney Disease (ATTACK).
717. Currie G, Taylor AH, Fujita T, Ohtsu H, Lindhardt M, Rossing P, et al. Effect of min-  April 2022)
eralocorticoid receptor antagonists on proteinuria and progression of chronic kidney 738. ClinicalTrials.gov. Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in
disease: a systematic review and meta-analysis. BMC Nephrol 2016;17:127.  Advanced Chronic Kidney Disease (TRACK). 
org/10.1186/s12882-016-0337-0 NCT03969953(19 April 2022)
718. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finere- 739. Bangalore S, Maron DJ, O’Brien SM, Fleg JL, Kretov EI, Briguori C, et al. Management of
none on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383: coronary disease in patients with advanced kidney disease. N Engl J Med 2020;382:
2219–2229.  1608–1618. 
719. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular 740. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE, et al. Initial
events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021; invasive or conservative strategy for stable coronary disease. N Engl J Med 2020;382:
385:2252–2263.  1395–1407. 
720. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and 741. Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, et al.
kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J
Med 2012;367:2482–2494. 
disease: the FIDELITY pooled analysis. Eur Heart J 2022;43:474–484. 
742. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al.
1093/eurheartj/ehab777
Effect of calcium-based versus non-calcium-based phosphate binders on mortality in
721. Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZ, Chertow GM,
patients with chronic kidney disease: an updated systematic review and meta-analysis.
et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease
Lancet 2013;382:1268–1277. 
(DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant 2020;35:
743. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Benefits and harms of
1700–1711. 
phosphate binders in CKD: a systematic review of randomized controlled trials. Am
722. Docherty KF, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Effects
J Kidney Dis 2009;54:619–637. 
of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J
744. Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, De Zeeuw D, Eckardt K-U, et al. A
2020;41:2379–2392. 
trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med
723. Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. Interplay of min-
2009;361:2019–2032. 
eralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-
745. George C, Echouffo-Tcheugui JB, Jaar BG, Okpechi IG, Kengne AP. The need for
Reduced. J Am College Cardiol 2021;77:1397–1407. 
screening, early diagnosis, and prediction of chronic kidney disease in people with dia-
2021.01.044
betes in low- and middle-income countries—a review of the current literature. BMC
724. Shen L, Kristensen SL, Bengtsson O, Böhm M, de Boer RA, Docherty KF, et al.
Med 2022;20:1–12. 
Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists:
746. Spertus JA, Jones PG, Maron DJ, Mark DB, O’Brien SM, Fleg JL, et al. Health status after
an analysis of DAPA-HF. Heart Fail 2021;9:254–264. 
invasive or conservative care in coronary and advanced kidney disease. N Engl J Med
2020.11.009
2020;382:1619–1628. 
725. Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, et al. Finerenone in
747. Aboyans V, Ricco J-B, Bartelink M-L, Björck M, Brodmann M, Cohner T, et al. 2017 ESC
predominantly advanced CKD and type 2 diabetes with or without sodium-glucose
Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collabor-
cotransporter-2 inhibitor therapy. Kidney Int Rep 2022;7:36–45. 
ation with the European Society for Vascular Surgery (ESVS). Eur Heart J 2017;39:
1016/j.ekir.2021.10.008
763–816. 
726. Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, et al. Finerenone in
748. Keller K, Schmitt VH, Vosseler M, Brochhausen C, Münzel T, Hobohm L, et al. Diabetes
patients with chronic kidney disease and type 2 diabetes by sodium–glucose cotran-
mellitus and its impact on patient-profile and in-hospital outcomes in peripheral artery
sporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care 2022;45:
disease. J Clin Med 2021;10:5033. 
2991–2998.  749. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al.
727. Weir MR, Slee A, Sun T, Balis D, Oh R, de Zeeuw D, et al. Effects of canagliflozin on
Comparison of global estimates of prevalence and risk factors for peripheral artery dis-
serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS)
ease in 2000 and 2010: a systematic review and analysis. Lancet 2013;382:1329–1340.
Program. Clin Kidney J 2021;14:1396–1402.  
728. Seidu S, Kunutsor SK, Topsever P, Khunti K. Benefits and harms of sodium-glucose 750. Malyar NM, Freisinger E, Meyborg M, Lüders F, Gebauer K, Reinecke H, et al.
co-transporter-2 inhibitors (SGLT2-I) and renin–angiotensin–aldosterone system inhi- Amputations and mortality in in-hospital treated patients with peripheral artery dis-
bitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: a systematic ease and diabetic foot syndrome. J Diabetes Complications 2016;30:1117–1122.
review and meta-analysis of randomized controlled trials. Endocrinol Diabetes Metab 
2022;5:e00303.  751. American Diabetes Association. Peripheral arterial disease in people with diabetes.
729. Nazarzadeh M, Bidel Z, Canoy D, Copland E, Bennett DA, Dehghan A, et al. Blood Diabetes Care 2003;26:3333–3341. 
pressure-lowering treatment for prevention of major cardiovascular diseases in peo- 752. Armstrong DG, Boulton AJ, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J
ple with and without type 2 diabetes: an individual participant-level data meta-analysis. Med 2017;376:2367–2375. 
Lancet Diabetes Endocrinol 2022;10:645–654.  753. Buso G, Aboyans V, Mazzolai L. Lower extremity artery disease in patients with type 2
00172-3 diabetes. Eur J Prev Cardiol 2019;26(2_suppl):114–124. 
730. Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, et al. Long-term 2047487319880044
benefits of intensive glucose control for preventing end-stage kidney disease: 754. Beckman JA, Duncan MS, Damrauer SM, Wells QS, Barnett JV, Wasserman DH, et al.
ADVANCE-ON. Diabetes Care 2016;39:694–700.  Microvascular disease, peripheral artery disease, and amputation. Circulation 2019;140:
731. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong J, et al. Clinical pharmaco- 449–458. 
kinetics of metformin. Clin Pharmacokinet 2011;50:81–98.  755. Behroozian A, Beckman JA. Microvascular disease increases amputation in patients
11534750-000000000-00000 with peripheral artery disease. Arterioscler Thromb Vasc Biol 2020;40:534–540.
732. Duong JK, Kumar SS, Kirkpatrick CM, Greenup LC, Arora M, Lee TC, et al. Population 
pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes 756. Walsh J, Hoffstad O, Sullivan M, Margolis D. Association of diabetic foot ulcer and
mellitus: simulation of doses according to renal function. Clin Pharmacokinet 2013; death in a population-based cohort from the United Kingdom. Diabet Med 2016;33:
52:373–384.  1493–1498. 
733. Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, 757. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular
et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc
moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, Endovasc Surg 2019;58:S1–S109.e33. 
Downloaded
from

by
guest
on
22
January
2026

4138 E S C G u id e l in e s
758. Mills JL Sr, Conte MS, Armstrong DG, Pomposelli FB, Schanzer A, Sidawy AN, et al. patients with peripheral artery disease: insights from the FOURIER trial (Further
The society for vascular surgery lower extremity threatened limb classification system: Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With
risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg 2014; Elevated Risk). Circulation 2018;137:338–350. 
59:220–234.  CIRCULATIONAHA.117.032235
759. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. 2014 779. Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, et al. Alirocumab in
ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY
acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The OUTCOMES trial. J Am College Cardiol 2019;74:1167–1176. 
Task Force for the Diagnosis and Treatment of Aortic Diseases of the European j.jacc.2019.03.013
Society of Cardiology (ESC). Eur Heart J 2014;35:2873–2926.  780. Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and
1093/eurheartj/ehu281 risk of cardiovascular disease and all-cause mortality in insulin-treated people with type
760. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015;116: 1 and type 2 diabetes: a cohort study. Diabetes Care 2015;38:316–322. 
1509–1526.  10.2337/dc14-0920
761. Hinchliffe RJ, Forsythe RO, Apelqvist J, Boyko EJ, Fitridge R, Hong JP, et al. Guidelines 781. Vergès B. Cardiovascular disease in type 1 diabetes: a review of epidemiological data
on diagnosis, prognosis, and management of peripheral artery disease in patients with and underlying mechanisms. Diabetes Metab 2020;46:442–449. 
foot ulcers and diabetes (IWGDF 2019 update). Diabetes/Metab Res Rev 2020;36: 1016/j.diabet.2020.09.001
e3276.  782. Jørgensen ME, Almdal TP, Carstensen B. Time trends in mortality rates in type 1 dia-
762. Tehan PE, Barwick AL, Sebastian M, Chuter VH. Diagnostic accuracy of the postexer- betes from 2002 to 2011. Diabetologia 2013;56:2401–2404. 
cise ankle–brachial index for detecting peripheral artery disease in suspected claudi- s00125-013-3025-7
cants with and without diabetes. Vasc Med 2018;23:116–125.  783. Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, Chalmers J, et al. Risk of
1177/1358863X17751259 cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish regis-
763. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. try linkage study. PLoS One 2012;9:e1001321. 
Measurement and interpretation of the ankle-brachial index: a scientific statement 1001321
from the American Heart Association. Circulation 2012;126:2890–2909.  784. Lind M, Svensson A-M, Rosengren A. Glycemic control and excess mortality in type 1
org/10.1161/CIR.0b013e318276fbcb diabetes. N Engl J Med 2015;372:880–881. 
764. Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, et al. 785. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and
diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J
peripheral artery disease. Diabetes Obes Metab 2022;24:1288–1299. 
Med 2005;353:2643–2653. 
10.1111/dom.14700
786. Zinman B, Genuth S, Nathan DM. The diabetes control and complications trial/epi-
765. Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, et al.
demiology of diabetes interventions and complications study: 30th anniversary presen-
Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes
tations. Diabetes Care 2014;37:8. 
mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME.
787. Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, Lachin JM, DCCT/EDIC Research Group.
Circulation 2018;137:405–407. 
Mediation of the effect of glycemia on the risk of CVD outcomes in type 1 diabetes: the
032031
DCCT/EDIC study. Diabetes Care 2019;42:1284–1289. 
766. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban
1613
with or without aspirin in patients with stable peripheral or carotid artery disease: an
788. Rawshani A, Rawshani A, Sattar N, Franzén S, McGuire DK, Eliasson B, et al. Relative
international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:
prognostic importance and optimal levels of risk factors for mortality and cardiovas-
219–229. 
cular outcomes in type 1 diabetes mellitus. Circulation 2019;139:1900–1912. https://
767. Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V, et al. Major adverse limb
doi.org/10.1161/CIRCULATIONAHA.118.037454
events and mortality in patients with peripheral artery disease: the COMPASS trial. J
789. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Gudbjörnsdottir S; Swedish
Am College Cardiol 2018;71:2306–2315. 
National Diabetes Register. A new model for 5-year risk of cardiovascular disease in
768. Hinchliffe RJ, Brownrigg J, Andros G, Apelqvist J, Boyko EJ, Fitridge R, et al. Effectiveness
Type 1 diabetes; from the Swedish National Diabetes Register (NDR). Diabet Med
of revascularization of the ulcerated foot in patients with diabetes and peripheral ar-
2011;28:1213–1220. 
tery disease: a systematic review. Diabetes Metab Res Rev 2016;32:136–144. 
790. Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, et al.
org/10.1002/dmrr.2705
Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the Steno
769. Venermo M, Sprynger M, Desormais I, Björck M, Brodmann M, Cohnert T, et al.
Type 1 Risk Engine. Circulation 2016;133:1058–1066. 
Follow-up of patients after revascularisation for peripheral arterial diseases: a consen-
CIRCULATIONAHA.115.018844
sus document from the European Society of Cardiology Working Group on Aorta and
791. Rawshani A, Sattar N, Franzén S, Rawshani A, Hattersley AT, Svensson A-M, et al.
Peripheral Vascular Diseases and the European Society for Vascular Surgery. Eur J Prev
Excess mortality and cardiovascular disease in young adults with type 1 diabetes in re-
Cardiol 2019;26:1971–1984. 
lation to age at onset: a nationwide, register-based cohort study. Lancet 2018;392: 770. Wu T-W, Chou C-L, Cheng C-F, Lu S-X, Wang L-Y. Prevalences of diabetes mellitus
and carotid atherosclerosis and their relationships in middle-aged adults and elders: a 477–486. 
792. Miller RG, Costacou T, Orchard TJ. Risk factor modeling for cardiovascular disease in
community-based study. J Formosan Med Assoc 2021;121:1133–1140. 
10.1016/j.jfma.2021.10.005 type 1 diabetes in the Pittsburgh epidemiology of diabetes complications (EDC) study:
771. Lacroix P, Aboyans V, Criqui M, Bertin F, Bouhamed T, Archambeaud F, et al. Type-2 a comparison with the diabetes control and complications trial/epidemiology of dia-
diabetes and carotid stenosis: a proposal for a screening strategy in asymptomatic pa- betes interventions and complications study (DCCT/EDIC). Diabetes 2019;68:
tients. Vasc Med 2006;11:93–99.  409–419. 
772. Weyer GW, Davis AM. Screening for asymptomatic carotid artery stenosis. JAMA 793. McGurnaghan SJ, McKeigue PM, Read SH, Franzen S, Svensson A-M, Colombo M, et al.
2015;313:192–194.  Development and validation of a cardiovascular risk prediction model in type 1 dia-
773. Hussain MA, Bin-Ayeed SA, Saeed OQ, Verma S, Al-Omran M. Impact of diabetes on betes. Diabetologia 2021;64:2001–2011. 
carotid artery revascularization. J Vasc Surg 2016;63:1099–1107.  794. Teoh I, Elisaus P, Schofield J. Cardiovascular risk management in type 1 diabetes. Curr
1016/j.jvs.2015.12.041 Diabetes Rep 2021;21:29. 
774. Lal BK, Beach KW, Roubin GS, Lutsep HL, Moore WS, Malas MB, et al. Restenosis after 795. Wu N, Bredin SS, Guan Y, Dickinson K, Kim DD, Chua Z, et al. Cardiovascular health
carotid artery stenting and endarterectomy: a secondary analysis of CREST, a rando- benefits of exercise training in persons living with type 1 diabetes: a systematic review
mised controlled trial. Lancet Neurol 2012;11:755–763.  and meta-analysis. J Clin Med 2019;8:253. 
4422(12)70159-X 796. Ciriacks K, Coly G, Krishnaswami S, Patel SB, Kidambi S. Effects of simvastatin and eze-
775. Pafili K, Gouni-Berthold I, Papanas N, Mikhailidis DP. Abdominal aortic aneurysms and timibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type
diabetes mellitus. J Diabetes Complications 2015;29:1330–1336.  2 diabetes mellitus. Metab Syndr Relat Disord 2015;13:84–90. 
1016/j.jdiacomp.2015.08.011 met.2014.0114
776. Nikol S, Mathias K, Olinic DM, Blinc A, Espinola-Klein C. Aneurysms and dissections – 797. Tell S, Nadeau KJ, Eckel RH. Lipid management for cardiovascular risk reduction in type
what is new in the literature of 2019/2020 – a European Society of Vascular Medicine 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2020;27:207. 
annual review. Vasa 2020;49:1–36.  MED.0000000000000551
777. Dattani N, Sayers RD, Bown MJ. Diabetes mellitus and abdominal aortic aneurysms: a 798. Guo J, Brooks MM, Muldoon MF, Naimi AI, Orchard TJ, Costacou T. Optimal blood
review of the mechanisms underlying the negative relationship. Diab Vasc Dis Res 2018; pressure thresholds for minimal coronary artery disease risk in type 1 diabetes.
15:367–374.  Diabetes Care 2019;42:1692–1699. 
778. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. 799. Lithovius R, Gordin D, Forsblom C, Saraheimo M, Harjutsalo V, Groop P-H; FinnDiane
Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in Study Group. Ambulatory blood pressure and arterial stiffness in individuals with type
Downloaded
from

by
guest
on
22
January
2026

ESC Guidelines 4139
1 diabetes. Diabetologia 2018;61:1935–1945.  821. Odgers-Jewell K, Ball L, Kelly J, Isenring E, Reidlinger D, Thomas R. Effectiveness of
4648-5 group-based self-management education for individuals with type 2 diabetes: a system-
800. Kalyani RR, Cannon CP, Cherrington AL, Coustan DR, De Boer IH, Feldman H, et al. atic review with meta-analyses and meta-regression. Diabet Med 2017;34:1027–1039.
Professional practice committee: standards of medical care in Diabetes-2018. Diabetes 
Care 2018;41:S3.  822. Coulter A, Entwistle VA, Eccles A, Ryan S, Shepperd S, Perera R. Personalised care
801. Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, et al. planning for adults with chronic or long-term health conditions. Cochrane Database
Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the Syst Rev 2015;2015:CD010523. 
ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 2016;39: 823. Lewin S, Skea Z, Entwistle VA, Zwarenstein M, Dick J. Interventions for providers to
1702–1710.  promote a patient-centred approach in clinical consultations. Cochrane Database Syst
802. Frandsen CS, Dejgaard TF, Holst JJ, Andersen HU, Thorsteinsson B, Madsbad S. Rev 2001;4:CD003267. 
Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients 824. Ekman I, Swedberg K, Taft C, Lindseth A, Norberg A, Brink E, et al. Person-centered
with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double- care—ready for prime time. Eur J Cardiovasc Nursing 2011;10:248–251. 
blind parallel study. Diabetes Care 2015;38:2250–2257.  10.1016/j.ejcnurse.2011.06.008
1037 825. Aquino JA, Baldoni NR, Flôr CR, Sanches C, Oliveira CDL, Alves GCS, et al.
803. Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Sodium-glucose Effectiveness of individual strategies for the empowerment of patients with diabetes
co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: mellitus: a systematic review with meta-analysis. Primary Care Diabetes 2018;12:
systematic review and meta-analysis of randomized controlled trials. Diabetes Obes 97–110. 
Metab 2018;20:1755–1761.  826. Cox DJ, Taylor AG, Singh H, Moncrief M, Diamond A, Yancy WS Jr, et al. Glycemic
804. Fattah H, Vallon V. The potential role of SGLT2 inhibitors in the treatment of type 1 load, exercise, and monitoring blood glucose (GEM): a paradigm shift in the treatment
diabetes mellitus. Drugs 2018;78:717–726.  of type 2 diabetes mellitus. Diabetes Res Clin Pract 2016;111:28–35. 
805. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 1016/j.diabres.2015.10.021
diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibi- 827. Schulman-Green D, Jaser SS, Park C, Whittemore R. A metasynthesis of factors affect-
tors? A meta-analysis of individual patient data. Ann Intern Med 2001;134:370–379. ing self-management of chronic illness. J Adv Nursing 2016;72:1469–1489. 
 org/10.1111/jan.12902
806. Lambrinou E, Hansen TB, Beulens JW. Lifestyle factors, self-management and patient 828. Dunn JA, Chokron Garneau H, Filipowicz H, Mahoney M, Seay-Morrison T, Dent K,
empowerment in diabetes care. Eur J Prev Cardiol 2019;26(2_suppl):55–63.  et al. What are patient preferences for integrated behavioral health in primary care?
org/10.1177/2047487319885455 J Primary Care Community Health 2021;12:21501327211049053. 
807. Lambrinou E, Kyriakou M, Lakatamitou I, Angus N, Khatib R, Vellone E, et al. An inte- 1177/21501327211049053
grative review on facilitators and barriers in delivering and managing injectable therap- 829. Piepoli MF, Villani GQ. Lifestyle modification in secondary prevention. Eur J Prev Cardiol
ies in chronic conditions: a part of the ACNAP project ‘injectable medicines among 2017;24(3_suppl):101–107. 
patients with cardiovascular conditions’. Eur J Cardiovasc Nursing 2020;19:663–680. 830. Kyriakou M, Samara A, Philippou K, Lakatamitou I, Lambrinou E. A qualitative meta-
 synthesis of patients with heart failure perceived needs. Rev Cardiovasc Med 2021;
808. Jennings C, Astin F. A multidisciplinary approach to prevention. Eur J Prev Cardiol 2017; 22:853–864. 
24(3_suppl):77–87.  831. Greenwood DA, Blozis SA, Young HM, Nesbitt TS, Quinn CC. Overcoming clinical
809. Chen Y, Tian Y, Sun X, Wang B, Huang X. Effectiveness of empowerment-based inter- inertia: a randomized clinical trial of a telehealth remote monitoring intervention using
vention on HbA1c and self-efficacy among cases with type 2 diabetes mellitus: a paired glucose testing in adults with type 2 diabetes. J Med Internet Res 2015;17:e4112.
meta-analysis of randomized controlled trials. Medicine (Baltimore) 2021;100: 
e27353.  832. McCarrier KP, Ralston JD, Hirsch IB, Lewis G, Martin DP, Zimmerman FJ, et al.
810. Galati G, Sabouret P, Germanova O, Bhatt DL. Women and diabetes: preventing heart Web-based collaborative care for type 1 diabetes: a pilot randomized trial. Diabetes
disease in a new era of therapies. Eur Cardiol 2021;16:e40.  Technol Ther 2009;11:211–217. 
2021.22 833. Sigurdardottir AK, Benediktsson R, Jonsdottir H. Instruments to tailor care of people
811. Deakin TA, McShane CE, Cade JE, Williams R. Group based training for self- with type 2 diabetes. J Adv Nursing 2009;65:2118–2130. 
management strategies in people with type 2 diabetes mellitus. Cochrane Database 2648.2009.05040.x
Syst Rev 2005;2:CD003417.  834. Wu H-C, Tan S, Yeh C, Wu S. A study on efficacy of empowerment training among
812. Steinsbekk A, Rygg L, Lisulo M, Rise MB, Fretheim A. Group based diabetes self- diabetes patients. Life Sci J 2011;8:215–219. 
management education compared to routine treatment for people with type 2 dia- 835. Clayton JA, Gaugh MD. Sex as a biological variable in cardiovascular diseases: JACC
betes mellitus. A systematic review with meta-analysis. BMC Health Services Res focus seminar 1/7. J Am College Cardiol 2022;79:1388–1397. 
2012;12:213.  jacc.2021.10.050
813. Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, et al. Insulin and glucose-lowering 836. Nussbaum SS, Henry S, Yong CM, Daugherty SL, Mehran R, Poppas A. Sex-specific
agents for treating people with diabetes and chronic kidney disease. Cochrane Database considerations in the presentation, diagnosis, and management of ischemic heart dis-
Syst Rev 2018;9:CD011798.  ease: JACC focus seminar 2/7. J Am College Cardiol 2022;79:1398–1406. 
814. Tan SM, Han E, Quek RYC, Singh SR, Gea-Sánchez M, Legido-Quigley H. A systematic 10.1016/j.jacc.2021.11.065
review of community nursing interventions focusing on improving outcomes for indi- 837. Gaudino M, Di Franco A, Cao D, Giustino G, Bairey Merz CN, Fremes SE, et al.
viduals exhibiting risk factors of cardiovascular disease. J Adv Nursing 2020;76:47–61. Sex-related outcomes of medical, percutaneous, and surgical interventions for coron-
 ary artery disease: JACC focus seminar 3/7. J Am College Cardiol 2022;79:1407–1425.
815. Snaterse M, Dobber J, Jepma P, Peters RJ, Ter Riet G, Boekholdt SM, et al. Effective 
components of nurse-coordinated care to prevent recurrent coronary events: a sys- 838. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, et al. European Society of
tematic review and meta-analysis. Heart 2016;102:50–56.  Cardiology methodology for the development of quality indicators for the quantifica-
heartjnl-2015-308050 tion of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes 2022;8:
816. Carrington MJ, Zimmet PZ. Nurse co-ordinated health and lifestyle modification for 4–13. 
reducing multiple cardio-metabolic risk factors in regional adults: outcomes from 839. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of care in the United
the MODERN randomized controlled trial. Eur J Cardiovasc Nursing 2022;21:26–35. Kingdom after removal of financial incentives. N Engl J Med 2018;379:948–957. https://
 doi.org/10.1056/NEJMsa1801495
817. Seidu S, Cos X, Brunton S, Harris S, Jansson SP, Mata-Cases M, et al. A disease state 840. Song Z, Ji Y, Safran DG, Chernew ME. Health care spending, utilization, and quality 8
approach to the pharmacological management of type 2 diabetes in primary care: a years into global payment. N Engl J Med 2019;381:252–263. 
position statement by Primary Care Diabetes Europe. Primary Care Diabetes 2021; NEJMsa1813621
15:31–51.  841. Arbelo EC, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, et al. Quality indica-
818. Goldwater D, Wenger NK. Patient-centered care in geriatric cardiology. Trends tors for the care and outcomes of adults with atrial fibrillation: Task Force for the de-
Cardiovasc Med 2023;33:13–20. doi:10.1016/j.tcm.2021.11.001 velopment of quality indicators in atrial fibrillation of the European Heart Rhythm
819. Ekman I, Wolf A, Olsson L-E, Taft C, Dudas K, Schaufelberger M, et al. Effects of Association (EHRA) of the European Society of Cardiology (ESC): developed in collab-
person-centred care in patients with chronic heart failure: the PCC-HF study. Eur oration with the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society
Heart J 2012;33:1112–1119.  (APHRS), and the Latin-American Heart Rhythm Society (LAHRS). Europace 2021;23:
820. Elissen AM, Hertroijs DF, Schaper NC, Bosma H, Dagnelie PC, Henry RM, et al. 494–495. 
Differences in biopsychosocial profiles of diabetes patients by level of glycaemic con- 842. Schiele F, Aktaa S, Rossello X, Ahrens I, Claeys MJ, Collet J-P, et al. 2020 update of the
trol and health-related quality of life: the Maastricht Study. PLoS One 2017;12: quality indicators for acute myocardial infarction: a position paper of the Association
e0182053.  for Acute Cardiovascular Care: the study group for quality indicators from the ACVC
Downloaded
from

by
guest
on
22
January
2026

4140 E S C G u id e l in e s
and the NSTE-ACS guideline group. Eur Heart J Acute Cardiovasc Care 2021;10: developed by the working group for cardiovascular disease prevention quality indica-
224–233.  tors in collaboration with the European Association for Preventive Cardiology of the
843. Aktaa S, Abdin A, Arbelo E, Burri H, Vernooy K, Blomström-Lundqvist C, et al.
European Society of Cardiology. Eur J Prev Cardiol 2022;29:1060–1071. 
European Society of Cardiology Quality Indicators for the care and outcomes of car-
10.1093/eurjpc/zwab160
diac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in
845. Aktaa S, Yadegarfar ME, Wu J, Rashid M, de Belder M, Deanfield J, et al. Quality of acute
collaboration with the European Heart Rhythm Association of the European Society
myocardial infarction care in England and Wales during the COVID-19 pandemic:
of Cardiology. Europace 2022;24:165–172. 
844. Aktaa S, Gencer B, Arbelo E, Davos CH, Désormais I, Hollander M, et al. European linked nationwide cohort study. BMJ Qual Saf 2022;31:116–122. 
Society of Cardiology Quality Indicators for cardiovascular disease prevention: 1136/bmjqs-2021-013040
Downloaded
from

by
guest
on
22
January
2026
